,direction,relation,relex_relcos,sentence,term1,term2
0,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.824163383692134,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.824163383692134,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
2,HYPERTENSION diagnosis PHEOCHROMOCYTOMA,diagnosis,0.824163383692134,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
3,no_relation,diagnosis,0.824163383692134,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
4,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.824163383692134,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
5,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.824163383692134,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
6,HYPERTENSION diagnosis PHEOCHROMOCYTOMA,diagnosis,0.824163383692134,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
7,HEMOPTYSIS causes BRONCHIAL CARCINOMA,causes,0.7715167498104591,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
8,no_relation,causes,0.7715167498104591,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
9,no_relation,causes,0.7715167498104591,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
10,no_relation,causes,0.7715167498104591,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
11,no_relation,causes,0.7715167498104591,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
12,BRONCHIAL CARCINOMA causes HEMOPTYSIS,causes,0.7715167498104591,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
13,no_relation,causes,0.7715167498104591,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
14,SEIZURES causes EPILEPSY,causes,0.936329177569044,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
15,EPILEPSY causes SEIZURES,causes,0.936329177569044,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
16,EPILEPSY causes SEIZURES,causes,0.936329177569044,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
17,no_relation,causes,0.936329177569044,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
18,EPILEPSY causes SEIZURES,causes,0.936329177569044,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
19,SEIZURES causes EPILEPSY,causes,0.936329177569044,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
20,EPILEPSY causes SEIZURES,causes,0.936329177569044,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
21,FUNGI causes FUNGAL INFECTIONS,causes,0.9931270663228408,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
22,FUNGI causes FUNGAL INFECTIONS,causes,0.9931270663228408,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
23,FUNGI causes FUNGAL INFECTIONS,causes,0.9931270663228408,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
24,FUNGI causes FUNGAL INFECTIONS,causes,0.9931270663228408,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
25,FUNGI causes FUNGAL INFECTIONS,causes,0.9931270663228408,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
26,FUNGAL INFECTIONS causes FUNGI,causes,0.9931270663228408,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
27,FUNGI causes FUNGAL INFECTIONS,causes,0.9931270663228408,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
28,LYMPHOMA PATIENTS WITHOUT IPSID causes WEIGHT LOSS,causes,0.9901475429766742,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
29,LYMPHOMA PATIENTS WITHOUT IPSID causes WEIGHT LOSS,causes,0.9901475429766742,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
30,LYMPHOMA PATIENTS WITHOUT IPSID causes WEIGHT LOSS,causes,0.9901475429766742,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
31,LYMPHOMA PATIENTS WITHOUT IPSID causes WEIGHT LOSS,causes,0.9901475429766742,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
32,LYMPHOMA PATIENTS WITHOUT IPSID causes WEIGHT LOSS,causes,0.9901475429766742,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
33,LYMPHOMA PATIENTS WITHOUT IPSID causes WEIGHT LOSS,causes,0.9901475429766742,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
34,LYMPHOMA PATIENTS WITHOUT IPSID causes WEIGHT LOSS,causes,0.9901475429766742,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
35,BACTERIA causes BACTERIURIA,causes,0.34815531191139604,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
36,BACTERIURIA causes BACTERIA,causes,0.34815531191139604,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
37,no_relation,causes,0.34815531191139604,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
38,BACTERIA causes BACTERIURIA,causes,0.34815531191139604,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
39,BACTERIA causes BACTERIURIA,causes,0.34815531191139604,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
40,no_relation,causes,0.34815531191139604,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
41,BACTERIA causes BACTERIURIA,causes,0.34815531191139604,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
42,no_relation,treats,0.38490017945975,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
43,STATUS EPILEPTICUS treats SEIZURES,treats,0.38490017945975,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
44,no_relation,treats,0.38490017945975,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
45,no_relation,treats,0.38490017945975,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
46,no_relation,treats,0.38490017945975,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
47,no_relation,treats,0.38490017945975,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
48,no_relation,treats,0.38490017945975,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
49,CHRONIC HEPATITIS C VIRUS INFECTION treats CHRONIC HEPATITIS B VIRUS INFECTIONS,treats,0.609994281330419,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
50,no_relation,treats,0.609994281330419,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
51,no_relation,treats,0.609994281330419,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
52,no_relation,treats,0.609994281330419,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
53,no_relation,treats,0.609994281330419,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
54,no_relation,treats,0.609994281330419,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
55,no_relation,treats,0.609994281330419,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
56,MIGRAINE causes HEADACHE,causes,0.7453559924999301,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
57,MIGRAINE causes HEADACHE,causes,0.7453559924999301,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
58,no_relation,causes,0.7453559924999301,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
59,MIGRAINE causes HEADACHE,causes,0.7453559924999301,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
60,MIGRAINE causes HEADACHE,causes,0.7453559924999301,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
61,HEADACHE causes MIGRAINE,causes,0.7453559924999301,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
62,no_relation,causes,0.7453559924999301,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE
63,no_relation,treats,0.35921060405355,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
64,FLUORIDE treats DENTAL FLUOROSIS,treats,0.35921060405355,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
65,DENTAL FLUOROSIS treats FLUORIDE,treats,0.35921060405355,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
66,FLUORIDE treats DENTAL FLUOROSIS,treats,0.35921060405355,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
67,FLUORIDE treats DENTAL FLUOROSIS,treats,0.35921060405355,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
68,no_relation,treats,0.35921060405355,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
69,FLUORIDE treats DENTAL FLUOROSIS,treats,0.35921060405355,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS
70,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.811107105653813,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
71,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.811107105653813,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
72,PREGNANCY COMPLICATIONS causes PREECLAMPSIA,causes,0.811107105653813,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
73,PREGNANCY COMPLICATIONS causes PREECLAMPSIA,causes,0.811107105653813,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
74,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.811107105653813,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
75,PREGNANCY COMPLICATIONS causes PREECLAMPSIA,causes,0.811107105653813,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
76,no_relation,causes,0.811107105653813,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA
77,no_relation,causes,0.8838834764831841,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
78,OVERDOSE causes DRUGS,causes,0.8838834764831841,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
79,DRUGS causes OVERDOSE,causes,0.8838834764831841,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
80,DRUGS causes OVERDOSE,causes,0.8838834764831841,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
81,DRUGS causes OVERDOSE,causes,0.8838834764831841,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
82,DRUGS causes OVERDOSE,causes,0.8838834764831841,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
83,OVERDOSE causes DRUGS,causes,0.8838834764831841,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE
84,ISCHEMIA location BLOOD VESSELS,location,0.8219949365267859,"Similarly, HNE was determined during ischemia in the brain BLOOD VESSELS of rats exposed to ISCHEMIA/reperfusion injury of the brain.",BLOOD VESSELS,ISCHEMIA
85,no_relation,location,0.8219949365267859,"Similarly, HNE was determined during ischemia in the brain BLOOD VESSELS of rats exposed to ISCHEMIA/reperfusion injury of the brain.",BLOOD VESSELS,ISCHEMIA
86,ISCHEMIA location BLOOD VESSELS,location,0.8219949365267859,"Similarly, HNE was determined during ischemia in the brain BLOOD VESSELS of rats exposed to ISCHEMIA/reperfusion injury of the brain.",BLOOD VESSELS,ISCHEMIA
87,no_relation,location,0.8219949365267859,"Similarly, HNE was determined during ischemia in the brain BLOOD VESSELS of rats exposed to ISCHEMIA/reperfusion injury of the brain.",BLOOD VESSELS,ISCHEMIA
88,no_relation,location,0.8219949365267859,"Similarly, HNE was determined during ischemia in the brain BLOOD VESSELS of rats exposed to ISCHEMIA/reperfusion injury of the brain.",BLOOD VESSELS,ISCHEMIA
89,no_relation,location,0.8219949365267859,"Similarly, HNE was determined during ischemia in the brain BLOOD VESSELS of rats exposed to ISCHEMIA/reperfusion injury of the brain.",BLOOD VESSELS,ISCHEMIA
90,BLOOD VESSELS location ISCHEMIA,location,0.8219949365267859,"Similarly, HNE was determined during ischemia in the brain BLOOD VESSELS of rats exposed to ISCHEMIA/reperfusion injury of the brain.",BLOOD VESSELS,ISCHEMIA
91,PHEOCHROMOCYTOMA diagnosis MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,diagnosis,0.8427009716003839,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
92,PHEOCHROMOCYTOMA diagnosis MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,diagnosis,0.8427009716003839,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
93,PHEOCHROMOCYTOMA diagnosis MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,diagnosis,0.8427009716003839,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
94,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 diagnosis PHEOCHROMOCYTOMA,diagnosis,0.8427009716003839,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
95,PHEOCHROMOCYTOMA diagnosis MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,diagnosis,0.8427009716003839,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
96,PHEOCHROMOCYTOMA diagnosis MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,diagnosis,0.8427009716003839,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
97,PHEOCHROMOCYTOMA diagnosis MULTIPLE ENDOCRINE NEOPLASIA TYPE 2,diagnosis,0.8427009716003839,Analysis of hereditary PHEOCHROMOCYTOMA two gene tests are established: detection of MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 (MEN 2) using mutational analysis of RET gene and detection of von Hippel Lindau syndrome using mutational analysis of VHL gene.,PHEOCHROMOCYTOMA,MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
98,MAGNESIUM MALABSORPTION causes MAGNESIUM DEFICIENCY,causes,0.995893206467704,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest MAGNESIUM DEFICIENCY in post menoposal osteoporosis, probably caused by MAGNESIUM MALABSORPTION.",MAGNESIUM DEFICIENCY,MAGNESIUM MALABSORPTION
99,MAGNESIUM DEFICIENCY causes MAGNESIUM MALABSORPTION,causes,0.995893206467704,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest MAGNESIUM DEFICIENCY in post menoposal osteoporosis, probably caused by MAGNESIUM MALABSORPTION.",MAGNESIUM DEFICIENCY,MAGNESIUM MALABSORPTION
100,MAGNESIUM MALABSORPTION causes MAGNESIUM DEFICIENCY,causes,0.995893206467704,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest MAGNESIUM DEFICIENCY in post menoposal osteoporosis, probably caused by MAGNESIUM MALABSORPTION.",MAGNESIUM DEFICIENCY,MAGNESIUM MALABSORPTION
101,MAGNESIUM MALABSORPTION causes MAGNESIUM DEFICIENCY,causes,0.995893206467704,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest MAGNESIUM DEFICIENCY in post menoposal osteoporosis, probably caused by MAGNESIUM MALABSORPTION.",MAGNESIUM DEFICIENCY,MAGNESIUM MALABSORPTION
102,MAGNESIUM MALABSORPTION causes MAGNESIUM DEFICIENCY,causes,0.995893206467704,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest MAGNESIUM DEFICIENCY in post menoposal osteoporosis, probably caused by MAGNESIUM MALABSORPTION.",MAGNESIUM DEFICIENCY,MAGNESIUM MALABSORPTION
103,MAGNESIUM MALABSORPTION causes MAGNESIUM DEFICIENCY,causes,0.995893206467704,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest MAGNESIUM DEFICIENCY in post menoposal osteoporosis, probably caused by MAGNESIUM MALABSORPTION.",MAGNESIUM DEFICIENCY,MAGNESIUM MALABSORPTION
104,MAGNESIUM MALABSORPTION causes MAGNESIUM DEFICIENCY,causes,0.995893206467704,"The decreased bone magnesium concentration and the increased retention of magnesium in the magnesium load test suggest MAGNESIUM DEFICIENCY in post menoposal osteoporosis, probably caused by MAGNESIUM MALABSORPTION.",MAGNESIUM DEFICIENCY,MAGNESIUM MALABSORPTION
105,OVARIES location EPITHELIAL OVARIAN CANCER,location,0.911684611677103,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
106,OVARIES location EPITHELIAL OVARIAN CANCER,location,0.911684611677103,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
107,EPITHELIAL OVARIAN CANCER location OVARIES,location,0.911684611677103,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
108,OVARIES location EPITHELIAL OVARIAN CANCER,location,0.911684611677103,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
109,no_relation,location,0.911684611677103,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
110,OVARIES location EPITHELIAL OVARIAN CANCER,location,0.911684611677103,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
111,OVARIES location EPITHELIAL OVARIAN CANCER,location,0.911684611677103,EPITHELIAL OVARIAN CANCER (EOC) arises from the epithelial layer covering the surface of OVARIES and i.p.,OVARIES,EPITHELIAL OVARIAN CANCER
112,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
113,no_relation,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
114,no_relation,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
115,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
116,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
117,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
118,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.99654575824488,The results of the MRC Vitamin Study have established the specific role of FOLIC ACID in the prevention of NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
119,BIPOLAR DISORDER treats OLANZAPINE,treats,0.995893206467704,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et alOLANZAPINE versus lithium in the maintenance treatment of BIPOLAR DISORDER: a 12 month, randomized, double blind, controlled clinical trial.",BIPOLAR DISORDER,OLANZAPINE
120,OLANZAPINE treats BIPOLAR DISORDER,treats,0.995893206467704,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et alOLANZAPINE versus lithium in the maintenance treatment of BIPOLAR DISORDER: a 12 month, randomized, double blind, controlled clinical trial.",BIPOLAR DISORDER,OLANZAPINE
121,no_relation,treats,0.995893206467704,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et alOLANZAPINE versus lithium in the maintenance treatment of BIPOLAR DISORDER: a 12 month, randomized, double blind, controlled clinical trial.",BIPOLAR DISORDER,OLANZAPINE
122,OLANZAPINE treats BIPOLAR DISORDER,treats,0.995893206467704,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et alOLANZAPINE versus lithium in the maintenance treatment of BIPOLAR DISORDER: a 12 month, randomized, double blind, controlled clinical trial.",BIPOLAR DISORDER,OLANZAPINE
123,OLANZAPINE treats BIPOLAR DISORDER,treats,0.995893206467704,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et alOLANZAPINE versus lithium in the maintenance treatment of BIPOLAR DISORDER: a 12 month, randomized, double blind, controlled clinical trial.",BIPOLAR DISORDER,OLANZAPINE
124,OLANZAPINE treats BIPOLAR DISORDER,treats,0.995893206467704,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et alOLANZAPINE versus lithium in the maintenance treatment of BIPOLAR DISORDER: a 12 month, randomized, double blind, controlled clinical trial.",BIPOLAR DISORDER,OLANZAPINE
125,OLANZAPINE treats BIPOLAR DISORDER,treats,0.995893206467704,"1]  Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et alOLANZAPINE versus lithium in the maintenance treatment of BIPOLAR DISORDER: a 12 month, randomized, double blind, controlled clinical trial.",BIPOLAR DISORDER,OLANZAPINE
126,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
127,no_relation,diagnosis,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
128,no_relation,diagnosis,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
129,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
130,no_relation,diagnosis,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
131,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
132,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
133,TUBERCULIN causes TUBERCULOSIS,causes,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
134,no_relation,causes,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
135,no_relation,causes,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
136,TUBERCULIN causes TUBERCULOSIS,causes,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
137,no_relation,causes,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
138,TUBERCULIN causes TUBERCULOSIS,causes,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
139,no_relation,causes,0.308606699924184,Depletion of T gamma cells from in vitro cell culture consistently and selectively increased TUBERCULIN responsiveness of T cells from patients with TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
140,VERNAL KERATOCONJUNCTIVITIS treats TYPE I ALLERGIC REACTIONS,treats,0.328797974610715,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
141,TYPE I ALLERGIC REACTIONS treats VERNAL KERATOCONJUNCTIVITIS,treats,0.328797974610715,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
142,no_relation,treats,0.328797974610715,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
143,VERNAL KERATOCONJUNCTIVITIS treats TYPE I ALLERGIC REACTIONS,treats,0.328797974610715,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
144,no_relation,treats,0.328797974610715,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
145,no_relation,treats,0.328797974610715,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
146,no_relation,treats,0.328797974610715,"When topically applied to the eye before allergen exposure, ocular sodium cromoglycate prevents many of the signs and symptoms associated with TYPE I ALLERGIC REACTIONS (which includes hayfever, acute allergic and chronic allergic conjunctivitis, and VERNAL KERATOCONJUNCTIVITIS) and giant papillary conjunctivitis.",VERNAL KERATOCONJUNCTIVITIS,TYPE I ALLERGIC REACTIONS
147,GYRATE ATROPHY diagnosis HYPERORNITHINEMIA,diagnosis,0.544331053951817,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
148,no_relation,diagnosis,0.544331053951817,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
149,no_relation,diagnosis,0.544331053951817,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
150,no_relation,diagnosis,0.544331053951817,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
151,GYRATE ATROPHY diagnosis HYPERORNITHINEMIA,diagnosis,0.544331053951817,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
152,no_relation,diagnosis,0.544331053951817,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
153,GYRATE ATROPHY diagnosis HYPERORNITHINEMIA,diagnosis,0.544331053951817,The diagnosis of GYRATE ATROPHY was confirmed biochemically and clinically; HYPERORNITHINEMIA and a deficiency of ornithine ketoacid transaminase were confirmed biochemically.,GYRATE ATROPHY,HYPERORNITHINEMIA
154,ABDOMINAL MASS causes WILMS' TUMOR,causes,0.923380516876639,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
155,WILMS' TUMOR causes ABDOMINAL MASS,causes,0.923380516876639,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
156,WILMS' TUMOR causes ABDOMINAL MASS,causes,0.923380516876639,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
157,no_relation,causes,0.923380516876639,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
158,WILMS' TUMOR causes ABDOMINAL MASS,causes,0.923380516876639,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
159,no_relation,causes,0.923380516876639,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
160,WILMS' TUMOR causes ABDOMINAL MASS,causes,0.923380516876639,In comparison to WILMS' TUMOR renal cell carcinoma in childhood and adolescence usually presents with a smaller ABDOMINAL MASS which is frequently not palpable or visible on plain abdominal radiographs.,ABDOMINAL MASS,WILMS' TUMOR
161,CUSHING'S SYNDROME causes DEXAMETHASONE AND METYRAPONE TESTS,causes,0.577350269189626,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
162,no_relation,causes,0.577350269189626,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
163,no_relation,causes,0.577350269189626,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
164,DEXAMETHASONE AND METYRAPONE TESTS causes CUSHING'S SYNDROME,causes,0.577350269189626,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
165,no_relation,causes,0.577350269189626,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
166,no_relation,causes,0.577350269189626,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
167,no_relation,causes,0.577350269189626,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
168,VARICELLA ZOSTER VIRUS causes ZOSTER (SHINGLES),causes,1.0,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
169,VARICELLA ZOSTER VIRUS causes ZOSTER (SHINGLES),causes,1.0,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
170,VARICELLA ZOSTER VIRUS causes ZOSTER (SHINGLES),causes,1.0,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
171,VARICELLA ZOSTER VIRUS causes ZOSTER (SHINGLES),causes,1.0,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
172,VARICELLA ZOSTER VIRUS causes ZOSTER (SHINGLES),causes,1.0,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
173,VARICELLA ZOSTER VIRUS causes ZOSTER (SHINGLES),causes,1.0,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
174,VARICELLA ZOSTER VIRUS causes ZOSTER (SHINGLES),causes,1.0,Herpes ZOSTER (SHINGLES) is caused when the VARICELLA ZOSTER VIRUS that has remained latent since an earlier varicella infection (chicken pox) is reactivated.,VARICELLA ZOSTER VIRUS,ZOSTER (SHINGLES)
175,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
176,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
177,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
178,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
179,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
180,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
181,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
182,CUSHING'S SYNDROME diagnosis DEXAMETHASONE AND METYRAPONE TESTS,diagnosis,0.8082903768654759,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
183,CUSHING'S SYNDROME diagnosis DEXAMETHASONE AND METYRAPONE TESTS,diagnosis,0.8082903768654759,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
184,CUSHING'S SYNDROME diagnosis DEXAMETHASONE AND METYRAPONE TESTS,diagnosis,0.8082903768654759,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
185,DEXAMETHASONE AND METYRAPONE TESTS diagnosis CUSHING'S SYNDROME,diagnosis,0.8082903768654759,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
186,CUSHING'S SYNDROME diagnosis DEXAMETHASONE AND METYRAPONE TESTS,diagnosis,0.8082903768654759,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
187,DEXAMETHASONE AND METYRAPONE TESTS diagnosis CUSHING'S SYNDROME,diagnosis,0.8082903768654759,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
188,CUSHING'S SYNDROME diagnosis DEXAMETHASONE AND METYRAPONE TESTS,diagnosis,0.8082903768654759,This study prospectively evaluated the accuracy of the DEXAMETHASONE AND METYRAPONE TESTS in determining the cause of CUSHING'S SYNDROME in a series of 25 unselected patients.,CUSHING'S SYNDROME,DEXAMETHASONE AND METYRAPONE TESTS
189,EXPERIMENTAL FORMS OF HYPERTENSION causes BLOOD PRESSURE ELEVATION,causes,0.98058067569092,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
190,BLOOD PRESSURE ELEVATION causes EXPERIMENTAL FORMS OF HYPERTENSION,causes,0.98058067569092,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
191,no_relation,causes,0.98058067569092,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
192,EXPERIMENTAL FORMS OF HYPERTENSION causes BLOOD PRESSURE ELEVATION,causes,0.98058067569092,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
193,BLOOD PRESSURE ELEVATION causes EXPERIMENTAL FORMS OF HYPERTENSION,causes,0.98058067569092,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
194,EXPERIMENTAL FORMS OF HYPERTENSION causes BLOOD PRESSURE ELEVATION,causes,0.98058067569092,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
195,EXPERIMENTAL FORMS OF HYPERTENSION causes BLOOD PRESSURE ELEVATION,causes,0.98058067569092,"There is some evidence for a role of ET 1 in blood pressure elevation in some EXPERIMENTAL FORMS OF HYPERTENSION particularly severe, sodium sensitive hypertension, in which it may play a role in accentuating rather than initiating BLOOD PRESSURE ELEVATION.",BLOOD PRESSURE ELEVATION,EXPERIMENTAL FORMS OF HYPERTENSION
196,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER causes VITAMIN A DEFICIENCY,causes,0.5303300858899109,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
197,no_relation,causes,0.5303300858899109,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
198,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER causes VITAMIN A DEFICIENCY,causes,0.5303300858899109,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
199,no_relation,causes,0.5303300858899109,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
200,no_relation,causes,0.5303300858899109,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
201,no_relation,causes,0.5303300858899109,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
202,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER causes VITAMIN A DEFICIENCY,causes,0.5303300858899109,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
203,PALMAR LICHEN NITIDUS causes NORMAL PALMAR SKIN,causes,0.881917103688197,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
204,no_relation,causes,0.881917103688197,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
205,no_relation,causes,0.881917103688197,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
206,NORMAL PALMAR SKIN causes PALMAR LICHEN NITIDUS,causes,0.881917103688197,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
207,no_relation,causes,0.881917103688197,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
208,NORMAL PALMAR SKIN causes PALMAR LICHEN NITIDUS,causes,0.881917103688197,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
209,NORMAL PALMAR SKIN causes PALMAR LICHEN NITIDUS,causes,0.881917103688197,We conclude that this histopathologic feature in PALMAR LICHEN NITIDUS could be the result of the superimposition of lichen nitidus on NORMAL PALMAR SKIN resulting in a picture resembling hypertrophic lichen planus.,NORMAL PALMAR SKIN,PALMAR LICHEN NITIDUS
210,no_relation,causes,0.547722557505166,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
211,no_relation,causes,0.547722557505166,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
212,no_relation,causes,0.547722557505166,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
213,NECROSIS causes SCLC,causes,0.547722557505166,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
214,no_relation,causes,0.547722557505166,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
215,NECROSIS causes SCLC,causes,0.547722557505166,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
216,no_relation,causes,0.547722557505166,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
217,OSTEOARTHRITIS treats PIROXICAM,treats,0.7559289460184542,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
218,PIROXICAM treats OSTEOARTHRITIS,treats,0.7559289460184542,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
219,OSTEOARTHRITIS treats PIROXICAM,treats,0.7559289460184542,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
220,PIROXICAM treats OSTEOARTHRITIS,treats,0.7559289460184542,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
221,PIROXICAM treats OSTEOARTHRITIS,treats,0.7559289460184542,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
222,no_relation,treats,0.7559289460184542,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
223,no_relation,treats,0.7559289460184542,PIROXICAM in 211 patients with rheumatoid arthritis (RA) (n = 95) or OSTEOARTHRITIS (OA) (n = 116.,OSTEOARTHRITIS,PIROXICAM
224,NECROSIS location SCLC,location,0.3651483716701111,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
225,no_relation,location,0.3651483716701111,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
226,SCLC location NECROSIS,location,0.3651483716701111,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
227,no_relation,location,0.3651483716701111,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
228,SCLC location NECROSIS,location,0.3651483716701111,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
229,no_relation,location,0.3651483716701111,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
230,NECROSIS location SCLC,location,0.3651483716701111,Xenograft histology following radioimmunotherapy showed large areas of NECROSIS fibrosis and very few residual cells of SCLC origin.,NECROSIS,SCLC
231,BONE location BONE LOSS,location,0.609994281330419,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS
232,no_relation,location,0.609994281330419,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS
233,BONE location BONE LOSS,location,0.609994281330419,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS
234,BONE location BONE LOSS,location,0.609994281330419,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS
235,no_relation,location,0.609994281330419,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS
236,BONE location BONE LOSS,location,0.609994281330419,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS
237,BONE location BONE LOSS,location,0.609994281330419,"In contrast, all ITAM adapter deficient mice responded to OVX with BONE LOSS in both femur and tibia of approximately 40%, relative to basal BONE volumes.",BONE,BONE LOSS
238,no_relation,causes,0.643267520902677,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
239,no_relation,causes,0.643267520902677,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
240,no_relation,causes,0.643267520902677,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
241,no_relation,causes,0.643267520902677,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
242,no_relation,causes,0.643267520902677,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
243,ANENCEPHALY causes BRAIN,causes,0.643267520902677,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
244,no_relation,causes,0.643267520902677,Infants with ANENCEPHALY are born without all or most of their BRAIN and die within a few days of life.,BRAIN,ANENCEPHALY
245,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,causes,0.8,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
246,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,causes,0.8,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
247,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,causes,0.8,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
248,GLIOBLASTOMA MULTIFORME causes MICROVASCULAR PROLIFERATION,causes,0.8,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
249,MICROVASCULAR PROLIFERATION causes GLIOBLASTOMA MULTIFORME,causes,0.8,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
250,GLIOBLASTOMA MULTIFORME causes MICROVASCULAR PROLIFERATION,causes,0.8,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
251,no_relation,causes,0.8,The presence of MICROVASCULAR PROLIFERATION leads to the histological diagnosis of GLIOBLASTOMA MULTIFORME.,MICROVASCULAR PROLIFERATION,GLIOBLASTOMA MULTIFORME
252,HYPERTENSION causes INCREASED BLOOD PRESSURE,causes,0.610847221781526,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
253,INCREASED BLOOD PRESSURE causes HYPERTENSION,causes,0.610847221781526,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
254,INCREASED BLOOD PRESSURE causes HYPERTENSION,causes,0.610847221781526,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
255,HYPERTENSION causes INCREASED BLOOD PRESSURE,causes,0.610847221781526,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
256,no_relation,causes,0.610847221781526,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
257,INCREASED BLOOD PRESSURE causes HYPERTENSION,causes,0.610847221781526,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
258,HYPERTENSION causes INCREASED BLOOD PRESSURE,causes,0.610847221781526,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
259,MULTIPLE SCLEROSIS treats ORAL CLADRIBINE,treats,0.9594032236002472,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE
260,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,treats,0.9594032236002472,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE
261,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,treats,0.9594032236002472,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE
262,MULTIPLE SCLEROSIS treats ORAL CLADRIBINE,treats,0.9594032236002472,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE
263,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,treats,0.9594032236002472,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE
264,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,treats,0.9594032236002472,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE
265,ORAL CLADRIBINE treats MULTIPLE SCLEROSIS,treats,0.9594032236002472,New Reference of Interest  2010 02 04  A placebo controlled trial of ORAL CLADRIBINE for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,ORAL CLADRIBINE
266,NEPHROBLASTOMA diagnosis HYPERTENSION,diagnosis,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
267,HYPERTENSION diagnosis NEPHROBLASTOMA,diagnosis,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
268,NEPHROBLASTOMA diagnosis HYPERTENSION,diagnosis,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
269,no_relation,diagnosis,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
270,HYPERTENSION diagnosis NEPHROBLASTOMA,diagnosis,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
271,NEPHROBLASTOMA diagnosis HYPERTENSION,diagnosis,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
272,no_relation,diagnosis,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
273,GLIOBLASTOMA diagnosis DEDIFFERENTIATION,diagnosis,0.301511344577764,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
274,no_relation,diagnosis,0.301511344577764,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
275,GLIOBLASTOMA diagnosis DEDIFFERENTIATION,diagnosis,0.301511344577764,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
276,DEDIFFERENTIATION diagnosis GLIOBLASTOMA,diagnosis,0.301511344577764,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
277,GLIOBLASTOMA diagnosis DEDIFFERENTIATION,diagnosis,0.301511344577764,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
278,GLIOBLASTOMA diagnosis DEDIFFERENTIATION,diagnosis,0.301511344577764,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
279,no_relation,diagnosis,0.301511344577764,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
280,GLIOBLASTOMA causes DEDIFFERENTIATION,causes,0.9045340337332908,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
281,DEDIFFERENTIATION causes GLIOBLASTOMA,causes,0.9045340337332908,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
282,DEDIFFERENTIATION causes GLIOBLASTOMA,causes,0.9045340337332908,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
283,GLIOBLASTOMA causes DEDIFFERENTIATION,causes,0.9045340337332908,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
284,DEDIFFERENTIATION causes GLIOBLASTOMA,causes,0.9045340337332908,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
285,GLIOBLASTOMA causes DEDIFFERENTIATION,causes,0.9045340337332908,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
286,DEDIFFERENTIATION causes GLIOBLASTOMA,causes,0.9045340337332908,The results of modern neuro oncology support the pathogenetic view that GLIOBLASTOMA results from neoplastic transformation of glial elements with continuing DEDIFFERENTIATION,DEDIFFERENTIATION,GLIOBLASTOMA
287,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
288,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
289,HYPERTENSION treats INCREASED BLOOD PRESSURE,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
290,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
291,INCREASED BLOOD PRESSURE treats HYPERTENSION,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
292,HYPERTENSION treats INCREASED BLOOD PRESSURE,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
293,no_relation,treats,0.7330166661378309,The number of patients with well controlled HYPERTENSION is alarmingly low worldwide and new approaches to treatment of INCREASED BLOOD PRESSURE (BP) are being sought.,INCREASED BLOOD PRESSURE,HYPERTENSION
294,GLUTEN FREE DIET treats COELIAC DISEASE,treats,1.0,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
295,GLUTEN FREE DIET treats COELIAC DISEASE,treats,1.0,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
296,GLUTEN FREE DIET treats COELIAC DISEASE,treats,1.0,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
297,GLUTEN FREE DIET treats COELIAC DISEASE,treats,1.0,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
298,GLUTEN FREE DIET treats COELIAC DISEASE,treats,1.0,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
299,GLUTEN FREE DIET treats COELIAC DISEASE,treats,1.0,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
300,GLUTEN FREE DIET treats COELIAC DISEASE,treats,1.0,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
301,no_relation,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
302,no_relation,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
303,NSAID ASSOCIATED DUODENAL ULCERS treats SUCRALFATE,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
304,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
305,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
306,SUCRALFATE treats NSAID ASSOCIATED DUODENAL ULCERS,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
307,no_relation,treats,1.0,"Misoprostol, H2 antagonists and SUCRALFATE are of similar efficacy in prevention of NSAID ASSOCIATED DUODENAL ULCERS but misoprostol is more effective in prevention of gastric ulcers.",NSAID ASSOCIATED DUODENAL ULCERS,SUCRALFATE
308,TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS causes HEPATOCELLULAR CARCINOMA,causes,1.0,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
309,HEPATOCELLULAR CARCINOMA causes TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,causes,1.0,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
310,no_relation,causes,1.0,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
311,no_relation,causes,1.0,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
312,HEPATOCELLULAR CARCINOMA causes TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,causes,1.0,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
313,TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS causes HEPATOCELLULAR CARCINOMA,causes,1.0,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
314,HEPATOCELLULAR CARCINOMA causes TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,causes,1.0,"Occasionally, hemorrhage of the TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS which may be the first manifestation of HEPATOCELLULAR CARCINOMA",TUMOR CAUSES BLOODY ASCITES SHOCK OR PERITONITIS,HEPATOCELLULAR CARCINOMA
315,no_relation,causes,0.4170288281141501,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
316,SARS COV RECEPTOR causes SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV,causes,0.4170288281141501,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
317,no_relation,causes,0.4170288281141501,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
318,SARS COV RECEPTOR causes SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV,causes,0.4170288281141501,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
319,no_relation,causes,0.4170288281141501,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
320,no_relation,causes,0.4170288281141501,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
321,SARS COV RECEPTOR causes SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV,causes,0.4170288281141501,"To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV a gene coding for the SARS COV RECEPTOR or the genes coding for an antibody shown to bind and neutralize SARS CoV (SARS AB.",SARS COV RECEPTOR,SEVERE ACUTE RESPIRATORY SYNDROME (SARS COV
322,BONE MINERAL METABOLISM diagnosis OSTEOPOROSIS,diagnosis,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
323,BONE MINERAL METABOLISM diagnosis OSTEOPOROSIS,diagnosis,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
324,OSTEOPOROSIS diagnosis BONE MINERAL METABOLISM,diagnosis,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
325,OSTEOPOROSIS diagnosis BONE MINERAL METABOLISM,diagnosis,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
326,BONE MINERAL METABOLISM diagnosis OSTEOPOROSIS,diagnosis,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
327,OSTEOPOROSIS diagnosis BONE MINERAL METABOLISM,diagnosis,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
328,OSTEOPOROSIS diagnosis BONE MINERAL METABOLISM,diagnosis,0.577350269189626,"Our results indicate, for the first time, an association between Graves' disease and a VDR polymorphism in the Japanese and suggest that a VDR FokI polymorphism may affect BONE MINERAL METABOLISM and can predict risk of OSTEOPOROSIS as a complication of Graves' disease in patients in remission.",BONE MINERAL METABOLISM,OSTEOPOROSIS
329,EXERCISE INDUCED ANGINA causes PAINS,causes,0.9284766908852592,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
330,EXERCISE INDUCED ANGINA causes PAINS,causes,0.9284766908852592,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
331,EXERCISE INDUCED ANGINA causes PAINS,causes,0.9284766908852592,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
332,EXERCISE INDUCED ANGINA causes PAINS,causes,0.9284766908852592,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
333,EXERCISE INDUCED ANGINA causes PAINS,causes,0.9284766908852592,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
334,EXERCISE INDUCED ANGINA causes PAINS,causes,0.9284766908852592,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
335,EXERCISE INDUCED ANGINA causes PAINS,causes,0.9284766908852592,"Results showed near zero correlations between measures of heat, cold, ischemic, and electrical laboratory pains, as well as between these laboratory PAINS and an idiopathic pain, the latency to EXERCISE INDUCED ANGINA in the patients.",PAINS,EXERCISE INDUCED ANGINA
336,no_relation,causes,0.790569415042095,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
337,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.790569415042095,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
338,DIABETIC KETOACIDOSIS causes DIABETES MELLITUS,causes,0.790569415042095,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
339,no_relation,causes,0.790569415042095,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
340,no_relation,causes,0.790569415042095,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
341,no_relation,causes,0.790569415042095,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
342,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.790569415042095,"Hyperglycemic Effects  Hyperglycemia, new onset diabetes mellitus, or exacerbation of preexisting DIABETES MELLITUS reported with use of PIs; DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
343,USDA TUBERCULIN diagnosis TUBERCULOSIS,diagnosis,0.549442255794756,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
344,TUBERCULOSIS diagnosis USDA TUBERCULIN,diagnosis,0.549442255794756,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
345,TUBERCULOSIS diagnosis USDA TUBERCULIN,diagnosis,0.549442255794756,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
346,no_relation,diagnosis,0.549442255794756,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
347,TUBERCULOSIS diagnosis USDA TUBERCULIN,diagnosis,0.549442255794756,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
348,TUBERCULOSIS diagnosis USDA TUBERCULIN,diagnosis,0.549442255794756,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
349,TUBERCULOSIS diagnosis USDA TUBERCULIN,diagnosis,0.549442255794756,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
350,ACUTE MYELOCYTIC LEUKEMIA diagnosis CYTOSINE ARABINOSIDE,diagnosis,0.312347523777212,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
351,no_relation,diagnosis,0.312347523777212,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
352,no_relation,diagnosis,0.312347523777212,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
353,no_relation,diagnosis,0.312347523777212,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
354,ACUTE MYELOCYTIC LEUKEMIA diagnosis CYTOSINE ARABINOSIDE,diagnosis,0.312347523777212,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
355,no_relation,diagnosis,0.312347523777212,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
356,no_relation,diagnosis,0.312347523777212,"CASE SCENARIO  A 30 year old man with ACUTE MYELOCYTIC LEUKEMIA failed to respond to induction therapy with cytosine arabinoside and idarubicin and received salvage chemotherapy with fludarabine, CYTOSINE ARABINOSIDE, G CSF, and idarubicin.",ACUTE MYELOCYTIC LEUKEMIA,CYTOSINE ARABINOSIDE
357,GASTRO INTESTINAL POLYPS causes POLYPOID LESION,causes,0.577350269189626,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
358,no_relation,causes,0.577350269189626,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
359,no_relation,causes,0.577350269189626,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
360,GASTRO INTESTINAL POLYPS causes POLYPOID LESION,causes,0.577350269189626,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
361,no_relation,causes,0.577350269189626,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
362,no_relation,causes,0.577350269189626,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
363,no_relation,causes,0.577350269189626,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
364,TUMOR (NEUROFIBROMA causes NEUROFIBROMATOSIS TYPE 1,causes,0.987878339907213,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
365,no_relation,causes,0.987878339907213,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
366,TUMOR (NEUROFIBROMA causes NEUROFIBROMATOSIS TYPE 1,causes,0.987878339907213,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
367,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,causes,0.987878339907213,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
368,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,causes,0.987878339907213,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
369,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,causes,0.987878339907213,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
370,NEUROFIBROMATOSIS TYPE 1 causes TUMOR (NEUROFIBROMA,causes,0.987878339907213,NEUROFIBROMATOSIS TYPE 1 (NF1) is a common autosomal dominant condition characterized by benign TUMOR (NEUROFIBROMA) growth and increased risk of malignancy.,TUMOR (NEUROFIBROMA,NEUROFIBROMATOSIS TYPE 1
371,MIGRAINE causes TENSION TYPE HEADACHE,causes,0.557086014531156,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
372,TENSION TYPE HEADACHE causes MIGRAINE,causes,0.557086014531156,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
373,MIGRAINE causes TENSION TYPE HEADACHE,causes,0.557086014531156,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
374,no_relation,causes,0.557086014531156,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
375,TENSION TYPE HEADACHE causes MIGRAINE,causes,0.557086014531156,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
376,TENSION TYPE HEADACHE causes MIGRAINE,causes,0.557086014531156,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
377,no_relation,causes,0.557086014531156,"Migraine with TENSION TYPE HEADACHE differs from pure migraine in respect of more numerous attacks within 1 year among females, and of more frequent occurrence of MIGRAINE with sensory aura among males.",TENSION TYPE HEADACHE,MIGRAINE
378,DRUG RESISTANT EPILEPSY causes ANTIEPILEPTIC DRUGS (AEDS),causes,0.404519917477945,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
379,ANTIEPILEPTIC DRUGS (AEDS) causes DRUG RESISTANT EPILEPSY,causes,0.404519917477945,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
380,ANTIEPILEPTIC DRUGS (AEDS) causes DRUG RESISTANT EPILEPSY,causes,0.404519917477945,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
381,ANTIEPILEPTIC DRUGS (AEDS) causes DRUG RESISTANT EPILEPSY,causes,0.404519917477945,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
382,no_relation,causes,0.404519917477945,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
383,no_relation,causes,0.404519917477945,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
384,no_relation,causes,0.404519917477945,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
385,no_relation,causes,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
386,no_relation,causes,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
387,POLYCYTHAEMIA VERA causes THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,causes,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
388,no_relation,causes,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
389,no_relation,causes,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
390,POLYCYTHAEMIA VERA causes THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,causes,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
391,no_relation,causes,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
392,OCA2 causes SKIN AND HAIR PIGMENTATION,causes,0.31622776601683805,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
393,OCA2 causes SKIN AND HAIR PIGMENTATION,causes,0.31622776601683805,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
394,OCA2 causes SKIN AND HAIR PIGMENTATION,causes,0.31622776601683805,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
395,no_relation,causes,0.31622776601683805,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
396,OCA2 causes SKIN AND HAIR PIGMENTATION,causes,0.31622776601683805,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
397,OCA2 causes SKIN AND HAIR PIGMENTATION,causes,0.31622776601683805,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
398,SKIN AND HAIR PIGMENTATION causes OCA2,causes,0.31622776601683805,"Although the function of the OCA2 gene product has not been totally clarified, variation in OCA2 has been associated with SKIN AND HAIR PIGMENTATION in human and mouse.",SKIN AND HAIR PIGMENTATION,OCA2
399,BRONCHIAL HYPERREACTIVITY treats SINGLE METHACHOLINE STIMULATION,treats,0.32444284226152503,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
400,no_relation,treats,0.32444284226152503,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
401,no_relation,treats,0.32444284226152503,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
402,SINGLE METHACHOLINE STIMULATION treats BRONCHIAL HYPERREACTIVITY,treats,0.32444284226152503,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
403,no_relation,treats,0.32444284226152503,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
404,SINGLE METHACHOLINE STIMULATION treats BRONCHIAL HYPERREACTIVITY,treats,0.32444284226152503,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
405,SINGLE METHACHOLINE STIMULATION treats BRONCHIAL HYPERREACTIVITY,treats,0.32444284226152503,"In the presence of extracellular Ca(2+), simultaneous exposure to TDI and methacholine led a higher level of [Ca(2+)](c) compared to SINGLE METHACHOLINE STIMULATION that might explain that TDI induces BRONCHIAL HYPERREACTIVITY to methacholine.",BRONCHIAL HYPERREACTIVITY,SINGLE METHACHOLINE STIMULATION
406,END STAGE RENAL DISEASE causes RENAL OSTEODYSTROPHY,causes,0.964901281354015,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
407,RENAL OSTEODYSTROPHY causes END STAGE RENAL DISEASE,causes,0.964901281354015,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
408,no_relation,causes,0.964901281354015,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
409,no_relation,causes,0.964901281354015,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
410,RENAL OSTEODYSTROPHY causes END STAGE RENAL DISEASE,causes,0.964901281354015,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
411,END STAGE RENAL DISEASE causes RENAL OSTEODYSTROPHY,causes,0.964901281354015,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
412,END STAGE RENAL DISEASE causes RENAL OSTEODYSTROPHY,causes,0.964901281354015,RENAL OSTEODYSTROPHY is a general complication of chronic renal failure and END STAGE RENAL DISEASE,RENAL OSTEODYSTROPHY,END STAGE RENAL DISEASE
413,no_relation,causes,0.4472135954999579,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
414,CRANIOFACIAL DYSOSTOSIS causes DIVERGENT SQUINT,causes,0.4472135954999579,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
415,no_relation,causes,0.4472135954999579,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
416,DIVERGENT SQUINT causes CRANIOFACIAL DYSOSTOSIS,causes,0.4472135954999579,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
417,no_relation,causes,0.4472135954999579,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
418,no_relation,causes,0.4472135954999579,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
419,no_relation,causes,0.4472135954999579,"Crouzon's disease    (              audio )  [Octave Crouzon, Fr. neurologist, 1874 1938] An autosomal dominantly inherited congenital disease characterized by hypertelorism (widely spaced eyes), CRANIOFACIAL DYSOSTOSIS exophthalmos, optic atrophy, and DIVERGENT SQUINT",DIVERGENT SQUINT,CRANIOFACIAL DYSOSTOSIS
420,INTRAVENOUS DANTROLENE causes MALIGNANT HYPERTHERMIA,causes,0.371390676354104,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
421,MALIGNANT HYPERTHERMIA causes INTRAVENOUS DANTROLENE,causes,0.371390676354104,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
422,no_relation,causes,0.371390676354104,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
423,no_relation,causes,0.371390676354104,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
424,INTRAVENOUS DANTROLENE causes MALIGNANT HYPERTHERMIA,causes,0.371390676354104,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
425,MALIGNANT HYPERTHERMIA causes INTRAVENOUS DANTROLENE,causes,0.371390676354104,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
426,no_relation,causes,0.371390676354104,In one group of four pigs sensitive to MALIGNANT HYPERTHERMIA (MHS) a dose response to INTRAVENOUS DANTROLENE was determined by quantitation of toe twitch tension.,MALIGNANT HYPERTHERMIA,INTRAVENOUS DANTROLENE
427,ACETAMINOPHEN treats PAIN,treats,0.993883734673619,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
428,PAIN treats ACETAMINOPHEN,treats,0.993883734673619,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
429,ACETAMINOPHEN treats PAIN,treats,0.993883734673619,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
430,ACETAMINOPHEN treats PAIN,treats,0.993883734673619,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
431,ACETAMINOPHEN treats PAIN,treats,0.993883734673619,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
432,ACETAMINOPHEN treats PAIN,treats,0.993883734673619,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
433,PAIN treats ACETAMINOPHEN,treats,0.993883734673619,"She is given a prescription for ACETAMINOPHEN with codeine to take as needed for PAIN the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",PAIN,ACETAMINOPHEN
434,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,1.0,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
435,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,1.0,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
436,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,1.0,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
437,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,1.0,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
438,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,1.0,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
439,no_relation,treats,1.0,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
440,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,1.0,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
441,OSTEOARTHRITIS THAT INVOLVES JOINTS location OSTEOARTHRITIS,location,0.480384461415261,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
442,OSTEOARTHRITIS THAT INVOLVES JOINTS location OSTEOARTHRITIS,location,0.480384461415261,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
443,no_relation,location,0.480384461415261,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
444,OSTEOARTHRITIS THAT INVOLVES JOINTS location OSTEOARTHRITIS,location,0.480384461415261,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
445,OSTEOARTHRITIS location OSTEOARTHRITIS THAT INVOLVES JOINTS,location,0.480384461415261,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
446,no_relation,location,0.480384461415261,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
447,no_relation,location,0.480384461415261,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? OSTEOARTHRITIS THAT INVOLVES JOINTS that are not usually affected by OSTEOARTHRITIS ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,OSTEOARTHRITIS THAT INVOLVES JOINTS,OSTEOARTHRITIS
448,no_relation,diagnosis,0.937042571331636,"In conclusion, NSE was considered to be very useful as a tumor MARKER OF THE LUNG especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non SMALL CELL CARCINOMA for the evaluation of treatment effectiveness.",MARKER OF THE LUNG,SMALL CELL CARCINOMA
449,SMALL CELL CARCINOMA diagnosis MARKER OF THE LUNG,diagnosis,0.937042571331636,"In conclusion, NSE was considered to be very useful as a tumor MARKER OF THE LUNG especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non SMALL CELL CARCINOMA for the evaluation of treatment effectiveness.",MARKER OF THE LUNG,SMALL CELL CARCINOMA
450,SMALL CELL CARCINOMA diagnosis MARKER OF THE LUNG,diagnosis,0.937042571331636,"In conclusion, NSE was considered to be very useful as a tumor MARKER OF THE LUNG especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non SMALL CELL CARCINOMA for the evaluation of treatment effectiveness.",MARKER OF THE LUNG,SMALL CELL CARCINOMA
451,no_relation,diagnosis,0.937042571331636,"In conclusion, NSE was considered to be very useful as a tumor MARKER OF THE LUNG especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non SMALL CELL CARCINOMA for the evaluation of treatment effectiveness.",MARKER OF THE LUNG,SMALL CELL CARCINOMA
452,SMALL CELL CARCINOMA diagnosis MARKER OF THE LUNG,diagnosis,0.937042571331636,"In conclusion, NSE was considered to be very useful as a tumor MARKER OF THE LUNG especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non SMALL CELL CARCINOMA for the evaluation of treatment effectiveness.",MARKER OF THE LUNG,SMALL CELL CARCINOMA
453,no_relation,diagnosis,0.937042571331636,"In conclusion, NSE was considered to be very useful as a tumor MARKER OF THE LUNG especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non SMALL CELL CARCINOMA for the evaluation of treatment effectiveness.",MARKER OF THE LUNG,SMALL CELL CARCINOMA
454,SMALL CELL CARCINOMA diagnosis MARKER OF THE LUNG,diagnosis,0.937042571331636,"In conclusion, NSE was considered to be very useful as a tumor MARKER OF THE LUNG especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non SMALL CELL CARCINOMA for the evaluation of treatment effectiveness.",MARKER OF THE LUNG,SMALL CELL CARCINOMA
455,BONE location OSTEOMYELITIS,location,0.824163383692134,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
456,BONE location OSTEOMYELITIS,location,0.824163383692134,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
457,OSTEOMYELITIS location BONE,location,0.824163383692134,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
458,BONE location OSTEOMYELITIS,location,0.824163383692134,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
459,BONE location OSTEOMYELITIS,location,0.824163383692134,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
460,BONE location OSTEOMYELITIS,location,0.824163383692134,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
461,OSTEOMYELITIS location BONE,location,0.824163383692134,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
462,PREGNANCY contraindicates CAPTOPRIL,contraindicates,0.9707253433941508,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
463,CAPTOPRIL contraindicates PREGNANCY,contraindicates,0.9707253433941508,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
464,no_relation,contraindicates,0.9707253433941508,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
465,PREGNANCY contraindicates CAPTOPRIL,contraindicates,0.9707253433941508,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
466,no_relation,contraindicates,0.9707253433941508,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
467,CAPTOPRIL contraindicates PREGNANCY,contraindicates,0.9707253433941508,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
468,no_relation,contraindicates,0.9707253433941508,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY
469,TRICHOFOLLICULOMA contraindicates FOLLICULAR DIFFERENTIATION,contraindicates,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
470,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,contraindicates,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
471,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,contraindicates,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
472,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,contraindicates,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
473,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,contraindicates,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
474,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,contraindicates,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
475,TRICHOFOLLICULOMA contraindicates FOLLICULAR DIFFERENTIATION,contraindicates,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
476,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,causes,0.42426406871192895,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
477,ROBUST REDUCTION IN PAIN causes THE TREATMENT OF VULVODYNIA FOUND THAT 17,causes,0.42426406871192895,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
478,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,causes,0.42426406871192895,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
479,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,causes,0.42426406871192895,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
480,no_relation,causes,0.42426406871192895,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
481,no_relation,causes,0.42426406871192895,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
482,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,causes,0.42426406871192895,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17
483,DIABETES causes DIABETIC NEUROPATHY,causes,0.977355554850442,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
484,DIABETIC NEUROPATHY causes DIABETES,causes,0.977355554850442,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
485,DIABETES causes DIABETIC NEUROPATHY,causes,0.977355554850442,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
486,DIABETES causes DIABETIC NEUROPATHY,causes,0.977355554850442,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
487,DIABETIC NEUROPATHY causes DIABETES,causes,0.977355554850442,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
488,DIABETIC NEUROPATHY causes DIABETES,causes,0.977355554850442,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
489,DIABETES causes DIABETIC NEUROPATHY,causes,0.977355554850442,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES
490,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,causes,0.971285862357264,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
491,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,causes,0.971285862357264,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
492,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,causes,0.971285862357264,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
493,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,causes,0.971285862357264,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
494,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,causes,0.971285862357264,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
495,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,causes,0.971285862357264,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
496,THE ACCELERATION OF HYPERTENSION causes ELEVATED BLOOD PRESSURE,causes,0.971285862357264,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION
497,no_relation,causes,0.5303300858899109,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
498,OSTEOPOROSIS causes CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,causes,0.5303300858899109,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
499,no_relation,causes,0.5303300858899109,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
500,no_relation,causes,0.5303300858899109,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
501,no_relation,causes,0.5303300858899109,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
502,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS causes OSTEOPOROSIS,causes,0.5303300858899109,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
503,no_relation,causes,0.5303300858899109,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
504,no_relation,causes,0.970494958830946,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
505,MONONUCLEOSIS causes EPSTEIN BARR VIRUS (EBV,causes,0.970494958830946,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
506,EPSTEIN BARR VIRUS (EBV causes MONONUCLEOSIS,causes,0.970494958830946,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
507,MONONUCLEOSIS causes EPSTEIN BARR VIRUS (EBV,causes,0.970494958830946,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
508,EPSTEIN BARR VIRUS (EBV causes MONONUCLEOSIS,causes,0.970494958830946,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
509,no_relation,causes,0.970494958830946,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
510,EPSTEIN BARR VIRUS (EBV causes MONONUCLEOSIS,causes,0.970494958830946,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS
511,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.981980506061966,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
512,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.981980506061966,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
513,no_relation,treats,0.981980506061966,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
514,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.981980506061966,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
515,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,treats,0.981980506061966,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
516,no_relation,treats,0.981980506061966,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
517,no_relation,treats,0.981980506061966,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT
518,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,causes,0.7875615306482171,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
519,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,causes,0.7875615306482171,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
520,COMPLICATIONS OF PREGNANCY causes ECTOPIC PREGNANCY,causes,0.7875615306482171,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
521,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,causes,0.7875615306482171,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
522,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,causes,0.7875615306482171,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
523,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,causes,0.7875615306482171,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
524,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,causes,0.7875615306482171,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY
525,ADMINISTRATION OF THE DRUG AFTER THE TEST causes AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,causes,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
526,no_relation,causes,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
527,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN causes ADMINISTRATION OF THE DRUG AFTER THE TEST,causes,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
528,no_relation,causes,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
529,ADMINISTRATION OF THE DRUG AFTER THE TEST causes AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,causes,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
530,no_relation,causes,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
531,no_relation,causes,0.371390676354104,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN
532,no_relation,treats,0.9354143466934848,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
533,CLOMIPRAMINE treats PAIN RELIEF,treats,0.9354143466934848,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
534,no_relation,treats,0.9354143466934848,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
535,CLOMIPRAMINE treats PAIN RELIEF,treats,0.9354143466934848,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
536,PAIN RELIEF treats CLOMIPRAMINE,treats,0.9354143466934848,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
537,CLOMIPRAMINE treats PAIN RELIEF,treats,0.9354143466934848,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
538,CLOMIPRAMINE treats PAIN RELIEF,treats,0.9354143466934848,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE
539,IVERMECTIN treats ONCHOCERCIASIS,treats,1.0,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
540,ONCHOCERCIASIS treats IVERMECTIN,treats,1.0,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
541,IVERMECTIN treats ONCHOCERCIASIS,treats,1.0,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
542,IVERMECTIN treats ONCHOCERCIASIS,treats,1.0,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
543,IVERMECTIN treats ONCHOCERCIASIS,treats,1.0,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
544,IVERMECTIN treats ONCHOCERCIASIS,treats,1.0,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
545,IVERMECTIN treats ONCHOCERCIASIS,treats,1.0,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN
546,no_relation,causes,0.617213399848368,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
547,no_relation,causes,0.617213399848368,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
548,SQUAMOUS CARCINOMA IN SITU causes SEVERE DYSPLASIA,causes,0.617213399848368,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
549,SEVERE DYSPLASIA causes SQUAMOUS CARCINOMA IN SITU,causes,0.617213399848368,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
550,no_relation,causes,0.617213399848368,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
551,no_relation,causes,0.617213399848368,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
552,no_relation,causes,0.617213399848368,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU
553,CALCIFICATION causes PILOMATRICOMA,causes,0.589767824619588,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
554,PILOMATRICOMA causes CALCIFICATION,causes,0.589767824619588,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
555,CALCIFICATION causes PILOMATRICOMA,causes,0.589767824619588,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
556,no_relation,causes,0.589767824619588,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
557,CALCIFICATION causes PILOMATRICOMA,causes,0.589767824619588,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
558,no_relation,causes,0.589767824619588,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
559,PILOMATRICOMA causes CALCIFICATION,causes,0.589767824619588,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA
560,TRICHOFOLLICULOMA diagnosis FOLLICULAR DIFFERENTIATION,diagnosis,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
561,no_relation,diagnosis,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
562,no_relation,diagnosis,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
563,no_relation,diagnosis,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
564,no_relation,diagnosis,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
565,TRICHOFOLLICULOMA diagnosis FOLLICULAR DIFFERENTIATION,diagnosis,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
566,TRICHOFOLLICULOMA diagnosis FOLLICULAR DIFFERENTIATION,diagnosis,0.4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA
567,no_relation,causes,0.9950371902099888,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
568,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,causes,0.9950371902099888,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
569,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,causes,0.9950371902099888,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
570,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,causes,0.9950371902099888,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
571,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,causes,0.9950371902099888,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
572,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,causes,0.9950371902099888,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
573,HYPERAMMONEMIA causes PRIMARY CARNITINE DEFICIENCY,causes,0.9950371902099888,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY
574,MENTAL RETARDATION causes X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,causes,0.589767824619588,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
575,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS causes MENTAL RETARDATION,causes,0.589767824619588,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
576,no_relation,causes,0.589767824619588,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
577,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS causes MENTAL RETARDATION,causes,0.589767824619588,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
578,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS causes MENTAL RETARDATION,causes,0.589767824619588,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
579,no_relation,causes,0.589767824619588,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
580,MENTAL RETARDATION causes X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,causes,0.589767824619588,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS
581,CLOMIPRAMINE treats PANIC DISORDER,treats,0.981980506061966,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
582,CLOMIPRAMINE treats PANIC DISORDER,treats,0.981980506061966,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
583,CLOMIPRAMINE treats PANIC DISORDER,treats,0.981980506061966,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
584,no_relation,treats,0.981980506061966,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
585,PANIC DISORDER treats CLOMIPRAMINE,treats,0.981980506061966,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
586,CLOMIPRAMINE treats PANIC DISORDER,treats,0.981980506061966,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
587,CLOMIPRAMINE treats PANIC DISORDER,treats,0.981980506061966,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE
588,no_relation,causes,0.9258200997725508,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
589,no_relation,causes,0.9258200997725508,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
590,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS causes SUBSET OF LUPUS ERYTHEMATOSUS,causes,0.9258200997725508,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
591,no_relation,causes,0.9258200997725508,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
592,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS causes SUBSET OF LUPUS ERYTHEMATOSUS,causes,0.9258200997725508,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
593,no_relation,causes,0.9258200997725508,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
594,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS causes SUBSET OF LUPUS ERYTHEMATOSUS,causes,0.9258200997725508,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS
595,TUBERCULIN treats TUBERCULOSIS,treats,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
596,no_relation,treats,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
597,TUBERCULIN treats TUBERCULOSIS,treats,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
598,no_relation,treats,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
599,no_relation,treats,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
600,TUBERCULIN treats TUBERCULOSIS,treats,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
601,no_relation,treats,0.6741998624632421,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to TUBERCULIN on admission, 2% to 3% of these developed TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN
602,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
603,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
604,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
605,EXOGENOUS OBESITY treats PHENTERMINE,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
606,no_relation,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
607,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
608,PHENTERMINE treats EXOGENOUS OBESITY,treats,0.9830783046228492,"3 ,   39 ,   40  Obesity  Not  indicated for the management of EXOGENOUS OBESITY   +    (either alone or in combination with weight loss agents such as PHENTERMINE although weight loss reported in some patients receiving the drug for other disorders.",EXOGENOUS OBESITY,PHENTERMINE
609,no_relation,causes,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
610,no_relation,causes,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
611,no_relation,causes,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
612,no_relation,causes,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
613,no_relation,causes,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
614,no_relation,causes,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
615,no_relation,causes,0.371390676354104,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and INTESTINAL METAPLASIA and INTESTINAL TYPE ADENOCARCINOMA has also been reported in the gallbladder.",INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA
616,DEFICIENCY OF SULFUR AMINO causes PROTEIN CALORIE MALNUTRITION,causes,0.997054485501582,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
617,PROTEIN CALORIE MALNUTRITION causes DEFICIENCY OF SULFUR AMINO,causes,0.997054485501582,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
618,PROTEIN CALORIE MALNUTRITION causes DEFICIENCY OF SULFUR AMINO,causes,0.997054485501582,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
619,DEFICIENCY OF SULFUR AMINO causes PROTEIN CALORIE MALNUTRITION,causes,0.997054485501582,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
620,PROTEIN CALORIE MALNUTRITION causes DEFICIENCY OF SULFUR AMINO,causes,0.997054485501582,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
621,DEFICIENCY OF SULFUR AMINO causes PROTEIN CALORIE MALNUTRITION,causes,0.997054485501582,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
622,PROTEIN CALORIE MALNUTRITION causes DEFICIENCY OF SULFUR AMINO,causes,0.997054485501582,DEFICIENCY OF SULFUR AMINO acids occurs in certain pathophysiological states such as PROTEIN CALORIE MALNUTRITION,PROTEIN CALORIE MALNUTRITION,DEFICIENCY OF SULFUR AMINO
623,no_relation,treats,0.338061701891407,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
624,no_relation,treats,0.338061701891407,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
625,FORMALDEHYDE CONCENTRATION treats FORMALDEHYDE TOXICITY,treats,0.338061701891407,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
626,FORMALDEHYDE CONCENTRATION treats FORMALDEHYDE TOXICITY,treats,0.338061701891407,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
627,FORMALDEHYDE CONCENTRATION treats FORMALDEHYDE TOXICITY,treats,0.338061701891407,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
628,no_relation,treats,0.338061701891407,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
629,FORMALDEHYDE CONCENTRATION treats FORMALDEHYDE TOXICITY,treats,0.338061701891407,"FORMALDEHYDE TOXICITY was partly reversible because once the FORMALDEHYDE CONCENTRATION was extremely low or virtually removed from the system, the methane production rate was partially recovered.",FORMALDEHYDE CONCENTRATION,FORMALDEHYDE TOXICITY
630,PREECLAMPSIA causes PREGNANCY COMPLICATION,causes,0.854242196177249,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
631,PREGNANCY COMPLICATION causes PREECLAMPSIA,causes,0.854242196177249,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
632,PREECLAMPSIA causes PREGNANCY COMPLICATION,causes,0.854242196177249,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
633,PREGNANCY COMPLICATION causes PREECLAMPSIA,causes,0.854242196177249,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
634,PREECLAMPSIA causes PREGNANCY COMPLICATION,causes,0.854242196177249,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
635,PREECLAMPSIA causes PREGNANCY COMPLICATION,causes,0.854242196177249,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
636,PREECLAMPSIA causes PREGNANCY COMPLICATION,causes,0.854242196177249,"PREECLAMPSIA is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",PREGNANCY COMPLICATION,PREECLAMPSIA
637,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
638,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
639,no_relation,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
640,CARIES treats FETAL FLUORIDE,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
641,no_relation,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
642,no_relation,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
643,FETAL FLUORIDE treats CARIES,treats,0.917662935482247,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
644,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.5393598899705939,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
645,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.5393598899705939,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
646,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.5393598899705939,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
647,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.5393598899705939,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
648,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.5393598899705939,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
649,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.5393598899705939,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
650,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.5393598899705939,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
651,DEFEROXAMINE treats IRON OVERLOAD,treats,0.997054485501582,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
652,DEFEROXAMINE treats IRON OVERLOAD,treats,0.997054485501582,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
653,DEFEROXAMINE treats IRON OVERLOAD,treats,0.997054485501582,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
654,DEFEROXAMINE treats IRON OVERLOAD,treats,0.997054485501582,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
655,no_relation,treats,0.997054485501582,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
656,DEFEROXAMINE treats IRON OVERLOAD,treats,0.997054485501582,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
657,DEFEROXAMINE treats IRON OVERLOAD,treats,0.997054485501582,"Despite the successes of DEFEROXAMINE (DFO) in the treatment and prevention of IRON OVERLOAD an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",IRON OVERLOAD,DEFEROXAMINE
658,TUBERCULOSIS diagnosis PPD INTRADERMAL,diagnosis,0.99654575824488,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
659,TUBERCULOSIS diagnosis PPD INTRADERMAL,diagnosis,0.99654575824488,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
660,TUBERCULOSIS diagnosis PPD INTRADERMAL,diagnosis,0.99654575824488,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
661,TUBERCULOSIS diagnosis PPD INTRADERMAL,diagnosis,0.99654575824488,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
662,TUBERCULOSIS diagnosis PPD INTRADERMAL,diagnosis,0.99654575824488,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
663,TUBERCULOSIS diagnosis PPD INTRADERMAL,diagnosis,0.99654575824488,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
664,TUBERCULOSIS diagnosis PPD INTRADERMAL,diagnosis,0.99654575824488,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD INTRADERMAL is the recommended test to screen for TUBERCULOSIS infection.",TUBERCULOSIS,PPD INTRADERMAL
665,no_relation,causes,0.985329278164293,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
666,METASTATIC LESIONS causes LIVER METASTASIS,causes,0.985329278164293,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
667,LIVER METASTASIS causes METASTATIC LESIONS,causes,0.985329278164293,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
668,LIVER METASTASIS causes METASTATIC LESIONS,causes,0.985329278164293,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
669,METASTATIC LESIONS causes LIVER METASTASIS,causes,0.985329278164293,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
670,LIVER METASTASIS causes METASTATIC LESIONS,causes,0.985329278164293,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
671,LIVER METASTASIS causes METASTATIC LESIONS,causes,0.985329278164293,Twenty one primary lesions in patients without metastasis and 26 primary and METASTATIC LESIONS in patients with LIVER METASTASIS were studied.,METASTATIC LESIONS,LIVER METASTASIS
672,BRAIN location MULTIFOCAL LEUKOENCEPHALOPATHY,location,0.943456353049726,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
673,BRAIN location MULTIFOCAL LEUKOENCEPHALOPATHY,location,0.943456353049726,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
674,BRAIN location MULTIFOCAL LEUKOENCEPHALOPATHY,location,0.943456353049726,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
675,BRAIN location MULTIFOCAL LEUKOENCEPHALOPATHY,location,0.943456353049726,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
676,BRAIN location MULTIFOCAL LEUKOENCEPHALOPATHY,location,0.943456353049726,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
677,BRAIN location MULTIFOCAL LEUKOENCEPHALOPATHY,location,0.943456353049726,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
678,BRAIN location MULTIFOCAL LEUKOENCEPHALOPATHY,location,0.943456353049726,Neurotropic JC virus reaches the BRAIN and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY a demyelinating disease of the central nervous system with a high mortality rate.,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY
679,NEUROFIBROMATOSIS location NERVOUS SYSTEM,location,0.7559289460184542,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
680,NERVOUS SYSTEM location NEUROFIBROMATOSIS,location,0.7559289460184542,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
681,no_relation,location,0.7559289460184542,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
682,NERVOUS SYSTEM location NEUROFIBROMATOSIS,location,0.7559289460184542,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
683,NERVOUS SYSTEM location NEUROFIBROMATOSIS,location,0.7559289460184542,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
684,NERVOUS SYSTEM location NEUROFIBROMATOSIS,location,0.7559289460184542,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
685,no_relation,location,0.7559289460184542,"NEUROFIBROMATOSIS Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the NERVOUS SYSTEM",NERVOUS SYSTEM,NEUROFIBROMATOSIS
686,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.970142500145332,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
687,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.970142500145332,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
688,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.970142500145332,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
689,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.970142500145332,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
690,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.970142500145332,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
691,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.970142500145332,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
692,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.970142500145332,"We describe a case of a 29 year old patient with a history of INFECTIOUS MONONUCLEOSIS followed by FEVER weight loss, and splenomegaly.",FEVER,INFECTIOUS MONONUCLEOSIS
693,PULMONARY METASTASES causes METASTATIC LESIONS,causes,0.9931270663228408,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
694,PULMONARY METASTASES causes METASTATIC LESIONS,causes,0.9931270663228408,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
695,PULMONARY METASTASES causes METASTATIC LESIONS,causes,0.9931270663228408,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
696,METASTATIC LESIONS causes PULMONARY METASTASES,causes,0.9931270663228408,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
697,METASTATIC LESIONS causes PULMONARY METASTASES,causes,0.9931270663228408,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
698,PULMONARY METASTASES causes METASTATIC LESIONS,causes,0.9931270663228408,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
699,no_relation,causes,0.9931270663228408,"Between May 1969 and September 1989, 677 METASTATIC LESIONS were resected during 107 operations in 100 patients with PULMONARY METASTASES from various primary sites at the Center for Adult Diseases, Osaka, Japan.",METASTATIC LESIONS,PULMONARY METASTASES
700,PV causes THROMBOSIS,causes,0.753778361444409,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
701,no_relation,causes,0.753778361444409,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
702,no_relation,causes,0.753778361444409,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
703,PV causes THROMBOSIS,causes,0.753778361444409,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
704,PV causes THROMBOSIS,causes,0.753778361444409,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
705,THROMBOSIS causes PV,causes,0.753778361444409,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
706,no_relation,causes,0.753778361444409,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent THROMBOSIS in PV,THROMBOSIS,PV
707,HEMOCHROMATOSIS contraindicates IRON,contraindicates,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
708,no_relation,contraindicates,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
709,HEMOCHROMATOSIS contraindicates IRON,contraindicates,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
710,IRON contraindicates HEMOCHROMATOSIS,contraindicates,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
711,HEMOCHROMATOSIS contraindicates IRON,contraindicates,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
712,HEMOCHROMATOSIS contraindicates IRON,contraindicates,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
713,IRON contraindicates HEMOCHROMATOSIS,contraindicates,0.6974858324629161,A high intake of iron is harmful for patients with HEMOCHROMATOSIS and for others at risk for IRON overload.,HEMOCHROMATOSIS,IRON
714,BUMETANIDE treats EDEMA,treats,0.875,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
715,BUMETANIDE treats EDEMA,treats,0.875,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
716,no_relation,treats,0.875,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
717,BUMETANIDE treats EDEMA,treats,0.875,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
718,BUMETANIDE treats EDEMA,treats,0.875,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
719,BUMETANIDE treats EDEMA,treats,0.875,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
720,BUMETANIDE treats EDEMA,treats,0.875,"Slight stria edema was present at 10 min, marked edema at 1 hr and no EDEMA 24 h after BUMETANIDE",EDEMA,BUMETANIDE
721,no_relation,causes,0.905821627315676,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
722,NICOTINE causes NICOTINE ADDICTION,causes,0.905821627315676,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
723,NICOTINE causes NICOTINE ADDICTION,causes,0.905821627315676,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
724,NICOTINE causes NICOTINE ADDICTION,causes,0.905821627315676,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
725,NICOTINE causes NICOTINE ADDICTION,causes,0.905821627315676,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
726,NICOTINE causes NICOTINE ADDICTION,causes,0.905821627315676,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
727,no_relation,causes,0.905821627315676,Greater knowledge of the effects of nicotine addiction and employment in programs that provided NICOTINE ADDICTION education or treatment increased the odds of counselors' providing NICOTINE counseling.,NICOTINE,NICOTINE ADDICTION
728,BOVINE TUBERCULOSIS (BTB) causes MYCOBACTERIUM BOVIS,causes,0.9491579957524988,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
729,MYCOBACTERIUM BOVIS causes BOVINE TUBERCULOSIS (BTB),causes,0.9491579957524988,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
730,MYCOBACTERIUM BOVIS causes BOVINE TUBERCULOSIS (BTB),causes,0.9491579957524988,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
731,BOVINE TUBERCULOSIS (BTB) causes MYCOBACTERIUM BOVIS,causes,0.9491579957524988,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
732,MYCOBACTERIUM BOVIS causes BOVINE TUBERCULOSIS (BTB),causes,0.9491579957524988,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
733,MYCOBACTERIUM BOVIS causes BOVINE TUBERCULOSIS (BTB),causes,0.9491579957524988,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
734,MYCOBACTERIUM BOVIS causes BOVINE TUBERCULOSIS (BTB),causes,0.9491579957524988,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and MYCOBACTERIUM BOVIS is considered to be a possible risk factor for onward transmission of BOVINE TUBERCULOSIS (BTB) in infected cattle and is known to compromise diagnostic tests.,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS (BTB)
735,no_relation,treats,0.977355554850442,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
736,MESALAMINE treats ULCERATIVE COLITIS,treats,0.977355554850442,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
737,MESALAMINE treats ULCERATIVE COLITIS,treats,0.977355554850442,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
738,MESALAMINE treats ULCERATIVE COLITIS,treats,0.977355554850442,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
739,MESALAMINE treats ULCERATIVE COLITIS,treats,0.977355554850442,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
740,ULCERATIVE COLITIS treats MESALAMINE,treats,0.977355554850442,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
741,MESALAMINE treats ULCERATIVE COLITIS,treats,0.977355554850442,Safety and efficacy of controlled release MESALAMINE for maintenance of remission in ULCERATIVE COLITIS,ULCERATIVE COLITIS,MESALAMINE
742,ACUTE TOLERANCE diagnosis DRUG NAIVE ANIMALS,diagnosis,0.7624928516630229,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
743,DRUG NAIVE ANIMALS diagnosis ACUTE TOLERANCE,diagnosis,0.7624928516630229,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
744,DRUG NAIVE ANIMALS diagnosis ACUTE TOLERANCE,diagnosis,0.7624928516630229,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
745,DRUG NAIVE ANIMALS diagnosis ACUTE TOLERANCE,diagnosis,0.7624928516630229,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
746,no_relation,diagnosis,0.7624928516630229,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
747,no_relation,diagnosis,0.7624928516630229,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
748,ACUTE TOLERANCE diagnosis DRUG NAIVE ANIMALS,diagnosis,0.7624928516630229,"In the OF experiment, the occurrence of ACUTE TOLERANCE was examined for different spontaneous behaviours in DRUG NAIVE ANIMALS.",DRUG NAIVE ANIMALS,ACUTE TOLERANCE
749,SERUM DIGOXIN CONCENTRATION causes SUICIDAL DIGOXIN POISONING,causes,0.7022468831767831,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
750,SERUM DIGOXIN CONCENTRATION causes SUICIDAL DIGOXIN POISONING,causes,0.7022468831767831,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
751,SUICIDAL DIGOXIN POISONING causes SERUM DIGOXIN CONCENTRATION,causes,0.7022468831767831,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
752,SERUM DIGOXIN CONCENTRATION causes SUICIDAL DIGOXIN POISONING,causes,0.7022468831767831,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
753,SUICIDAL DIGOXIN POISONING causes SERUM DIGOXIN CONCENTRATION,causes,0.7022468831767831,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
754,SUICIDAL DIGOXIN POISONING causes SERUM DIGOXIN CONCENTRATION,causes,0.7022468831767831,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
755,SUICIDAL DIGOXIN POISONING causes SERUM DIGOXIN CONCENTRATION,causes,0.7022468831767831,In two patients with SUICIDAL DIGOXIN POISONING the correlations between SERUM DIGOXIN CONCENTRATION and changes in the duration of QTc and the flattening of the T waves were studied.,SERUM DIGOXIN CONCENTRATION,SUICIDAL DIGOXIN POISONING
756,LIVER location LIVER FAILURE,location,0.938314863256836,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
757,LIVER location LIVER FAILURE,location,0.938314863256836,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
758,LIVER FAILURE location LIVER,location,0.938314863256836,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
759,LIVER location LIVER FAILURE,location,0.938314863256836,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
760,no_relation,location,0.938314863256836,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
761,LIVER location LIVER FAILURE,location,0.938314863256836,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
762,LIVER location LIVER FAILURE,location,0.938314863256836,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
763,SKIN location HIVES,location,0.905821627315676,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
764,SKIN location HIVES,location,0.905821627315676,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
765,no_relation,location,0.905821627315676,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
766,SKIN location HIVES,location,0.905821627315676,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
767,SKIN location HIVES,location,0.905821627315676,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
768,no_relation,location,0.905821627315676,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
769,SKIN location HIVES,location,0.905821627315676,"Involvement of the SKIN or mucosal tissue (e.g., generalized HIVES; itching or flushing; swollen lips, tongue, or uvula)  b.",SKIN,HIVES
770,STURGE WEBER SYNDROME causes SEIZURE DISORDERS,causes,0.985329278164293,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
771,STURGE WEBER SYNDROME causes SEIZURE DISORDERS,causes,0.985329278164293,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
772,STURGE WEBER SYNDROME causes SEIZURE DISORDERS,causes,0.985329278164293,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
773,STURGE WEBER SYNDROME causes SEIZURE DISORDERS,causes,0.985329278164293,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
774,STURGE WEBER SYNDROME causes SEIZURE DISORDERS,causes,0.985329278164293,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
775,STURGE WEBER SYNDROME causes SEIZURE DISORDERS,causes,0.985329278164293,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
776,STURGE WEBER SYNDROME causes SEIZURE DISORDERS,causes,0.985329278164293,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and SEIZURE DISORDERS characterize the STURGE WEBER SYNDROME,SEIZURE DISORDERS,STURGE WEBER SYNDROME
777,no_relation,location,0.8728715609439692,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
778,LYMPH VESSELS location LYMPHANGIOMA,location,0.8728715609439692,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
779,LYMPH VESSELS location LYMPHANGIOMA,location,0.8728715609439692,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
780,LYMPH VESSELS location LYMPHANGIOMA,location,0.8728715609439692,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
781,LYMPH VESSELS location LYMPHANGIOMA,location,0.8728715609439692,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
782,LYMPH VESSELS location LYMPHANGIOMA,location,0.8728715609439692,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
783,LYMPH VESSELS location LYMPHANGIOMA,location,0.8728715609439692,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
784,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.889000889001333,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
785,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.889000889001333,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
786,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.889000889001333,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
787,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.889000889001333,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
788,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.889000889001333,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
789,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.889000889001333,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
790,no_relation,causes,0.889000889001333,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
791,THYROID DISEASE diagnosis TOTAL THYROXINE,diagnosis,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
792,THYROID DISEASE diagnosis TOTAL THYROXINE,diagnosis,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
793,THYROID DISEASE diagnosis TOTAL THYROXINE,diagnosis,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
794,THYROID DISEASE diagnosis TOTAL THYROXINE,diagnosis,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
795,no_relation,diagnosis,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
796,no_relation,diagnosis,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
797,THYROID DISEASE diagnosis TOTAL THYROXINE,diagnosis,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
798,ACQUIRED IMMUNE DEFICIENCY SYNDROME causes HUMAN IMMUNODEFICIENCY VIRUS (HIV),causes,0.9761870601839532,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
799,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNE DEFICIENCY SYNDROME,causes,0.9761870601839532,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
800,no_relation,causes,0.9761870601839532,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
801,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNE DEFICIENCY SYNDROME,causes,0.9761870601839532,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
802,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNE DEFICIENCY SYNDROME,causes,0.9761870601839532,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
803,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes ACQUIRED IMMUNE DEFICIENCY SYNDROME,causes,0.9761870601839532,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
804,no_relation,causes,0.9761870601839532,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
805,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.8728715609439692,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
806,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.8728715609439692,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
807,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.8728715609439692,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
808,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.8728715609439692,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
809,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.8728715609439692,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
810,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.8728715609439692,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
811,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.8728715609439692,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
812,GLUTEN SENSITIVITY diagnosis RECTAL GLUTEN CHALLENGE,diagnosis,0.970494958830946,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
813,GLUTEN SENSITIVITY diagnosis RECTAL GLUTEN CHALLENGE,diagnosis,0.970494958830946,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
814,GLUTEN SENSITIVITY diagnosis RECTAL GLUTEN CHALLENGE,diagnosis,0.970494958830946,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
815,RECTAL GLUTEN CHALLENGE diagnosis GLUTEN SENSITIVITY,diagnosis,0.970494958830946,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
816,GLUTEN SENSITIVITY diagnosis RECTAL GLUTEN CHALLENGE,diagnosis,0.970494958830946,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
817,GLUTEN SENSITIVITY diagnosis RECTAL GLUTEN CHALLENGE,diagnosis,0.970494958830946,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
818,GLUTEN SENSITIVITY diagnosis RECTAL GLUTEN CHALLENGE,diagnosis,0.970494958830946,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
819,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
820,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
821,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
822,no_relation,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
823,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
824,no_relation,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
825,CHARCOAL treats ACETAMINOPHEN OVERDOSE,treats,0.881917103688197,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
826,no_relation,diagnosis,0.911684611677103,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
827,HAEMATURIA diagnosis CARCINOMA OF THE BLADDER,diagnosis,0.911684611677103,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
828,HAEMATURIA diagnosis CARCINOMA OF THE BLADDER,diagnosis,0.911684611677103,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
829,CARCINOMA OF THE BLADDER diagnosis HAEMATURIA,diagnosis,0.911684611677103,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
830,no_relation,diagnosis,0.911684611677103,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
831,CARCINOMA OF THE BLADDER diagnosis HAEMATURIA,diagnosis,0.911684611677103,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
832,CARCINOMA OF THE BLADDER diagnosis HAEMATURIA,diagnosis,0.911684611677103,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
833,SEIZURES causes STATUS EPILEPTICUS,causes,0.918558653543692,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
834,SEIZURES causes STATUS EPILEPTICUS,causes,0.918558653543692,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
835,STATUS EPILEPTICUS causes SEIZURES,causes,0.918558653543692,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
836,no_relation,causes,0.918558653543692,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
837,SEIZURES causes STATUS EPILEPTICUS,causes,0.918558653543692,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
838,SEIZURES causes STATUS EPILEPTICUS,causes,0.918558653543692,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
839,no_relation,causes,0.918558653543692,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
840,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.676123403782813,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
841,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.676123403782813,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
842,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.676123403782813,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
843,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.676123403782813,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
844,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.676123403782813,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
845,no_relation,treats,0.676123403782813,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
846,ARREST ARRHYTHMIA treats AGENTS (ATROPINE,treats,0.676123403782813,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
847,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.4472135954999579,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
848,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.4472135954999579,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
849,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.4472135954999579,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
850,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.4472135954999579,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
851,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.4472135954999579,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
852,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.4472135954999579,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
853,THYROTOXICOSIS causes GRAVES' DISEASE,causes,0.4472135954999579,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
854,CUSHING'S SYNDROME diagnosis AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION,diagnosis,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
855,CUSHING'S SYNDROME diagnosis AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION,diagnosis,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
856,no_relation,diagnosis,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
857,no_relation,diagnosis,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
858,CUSHING'S SYNDROME diagnosis AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION,diagnosis,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
859,no_relation,diagnosis,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
860,no_relation,diagnosis,0.639602149066831,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
861,DEDIFFERENTIATION causes GLIOBLASTOMA,causes,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
862,DEDIFFERENTIATION causes GLIOBLASTOMA,causes,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
863,no_relation,causes,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
864,GLIOBLASTOMA causes DEDIFFERENTIATION,causes,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
865,no_relation,causes,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
866,DEDIFFERENTIATION causes GLIOBLASTOMA,causes,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
867,GLIOBLASTOMA causes DEDIFFERENTIATION,causes,0.35921060405355,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
868,PHLEBITIS location VARICES,location,0.462910049886276,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
869,VARICES location PHLEBITIS,location,0.462910049886276,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
870,VARICES location PHLEBITIS,location,0.462910049886276,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
871,no_relation,location,0.462910049886276,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
872,VARICES location PHLEBITIS,location,0.462910049886276,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
873,no_relation,location,0.462910049886276,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
874,PHLEBITIS location VARICES,location,0.462910049886276,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
875,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.371390676354104,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
876,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.371390676354104,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
877,LYME DISEASE causes BORRELIA BURGDORFERI,causes,0.371390676354104,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
878,LYME DISEASE causes BORRELIA BURGDORFERI,causes,0.371390676354104,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
879,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.371390676354104,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
880,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.371390676354104,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
881,BORRELIA BURGDORFERI causes LYME DISEASE,causes,0.371390676354104,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
882,ALLERGIC REACTIONS causes ALLERGIC ASTHMA,causes,0.583459965991578,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
883,ALLERGIC ASTHMA causes ALLERGIC REACTIONS,causes,0.583459965991578,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
884,ALLERGIC REACTIONS causes ALLERGIC ASTHMA,causes,0.583459965991578,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
885,no_relation,causes,0.583459965991578,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
886,ALLERGIC ASTHMA causes ALLERGIC REACTIONS,causes,0.583459965991578,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
887,ALLERGIC REACTIONS causes ALLERGIC ASTHMA,causes,0.583459965991578,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
888,ALLERGIC REACTIONS causes ALLERGIC ASTHMA,causes,0.583459965991578,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
889,no_relation,causes,0.4574957109978139,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
890,CHRONIC NEUROGENIC BLADDERS causes PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE,causes,0.4574957109978139,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
891,no_relation,causes,0.4574957109978139,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
892,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE causes CHRONIC NEUROGENIC BLADDERS,causes,0.4574957109978139,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
893,no_relation,causes,0.4574957109978139,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
894,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE causes CHRONIC NEUROGENIC BLADDERS,causes,0.4574957109978139,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
895,no_relation,causes,0.4574957109978139,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
896,no_relation,causes,0.6859943405700349,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
897,no_relation,causes,0.6859943405700349,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
898,no_relation,causes,0.6859943405700349,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
899,no_relation,causes,0.6859943405700349,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
900,OF RADIATION INDUCED THYROID CANCER causes EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,causes,0.6859943405700349,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
901,no_relation,causes,0.6859943405700349,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
902,EVEN WHEN THE THYROID GLAND IS OUTSIDE OF causes OF RADIATION INDUCED THYROID CANCER,causes,0.6859943405700349,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
903,OSTEOID OSTEOMA causes PAIN,causes,0.830747160735697,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
904,PAIN causes OSTEOID OSTEOMA,causes,0.830747160735697,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
905,OSTEOID OSTEOMA causes PAIN,causes,0.830747160735697,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
906,OSTEOID OSTEOMA causes PAIN,causes,0.830747160735697,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
907,no_relation,causes,0.830747160735697,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
908,OSTEOID OSTEOMA causes PAIN,causes,0.830747160735697,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
909,OSTEOID OSTEOMA causes PAIN,causes,0.830747160735697,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
910,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
911,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
912,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
913,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
914,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
915,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
916,no_relation,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
917,PEMPHIGUS VULGARIS location DISEASE OF THE SKIN AND MUCOUS MEMBRANES,location,0.8006407690254359,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
918,no_relation,location,0.8006407690254359,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
919,no_relation,location,0.8006407690254359,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
920,PEMPHIGUS VULGARIS location DISEASE OF THE SKIN AND MUCOUS MEMBRANES,location,0.8006407690254359,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
921,no_relation,location,0.8006407690254359,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
922,no_relation,location,0.8006407690254359,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
923,DISEASE OF THE SKIN AND MUCOUS MEMBRANES location PEMPHIGUS VULGARIS,location,0.8006407690254359,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS
924,SCHIZOPHRENIA treats RISPERIDONE,treats,0.911684611677103,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
925,RISPERIDONE treats SCHIZOPHRENIA,treats,0.911684611677103,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
926,RISPERIDONE treats SCHIZOPHRENIA,treats,0.911684611677103,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
927,RISPERIDONE treats SCHIZOPHRENIA,treats,0.911684611677103,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
928,RISPERIDONE treats SCHIZOPHRENIA,treats,0.911684611677103,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
929,RISPERIDONE treats SCHIZOPHRENIA,treats,0.911684611677103,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
930,RISPERIDONE treats SCHIZOPHRENIA,treats,0.911684611677103,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE
931,HAEMOPHILIA A treats HUMAN FACTOR VIII (FVIII),treats,0.98058067569092,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
932,HAEMOPHILIA A treats HUMAN FACTOR VIII (FVIII),treats,0.98058067569092,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
933,HAEMOPHILIA A treats HUMAN FACTOR VIII (FVIII),treats,0.98058067569092,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
934,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,treats,0.98058067569092,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
935,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,treats,0.98058067569092,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
936,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,treats,0.98058067569092,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
937,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,treats,0.98058067569092,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII)
938,FISTULA TRACT location CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,location,0.9494253265550828,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
939,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL location FISTULA TRACT,location,0.9494253265550828,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
940,FISTULA TRACT location CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,location,0.9494253265550828,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
941,FISTULA TRACT location CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,location,0.9494253265550828,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
942,FISTULA TRACT location CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,location,0.9494253265550828,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
943,no_relation,location,0.9494253265550828,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
944,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL location FISTULA TRACT,location,0.9494253265550828,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL
945,VITILIGO location SKIN,location,0.942809041582064,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
946,VITILIGO location SKIN,location,0.942809041582064,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
947,SKIN location VITILIGO,location,0.942809041582064,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
948,SKIN location VITILIGO,location,0.942809041582064,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
949,no_relation,location,0.942809041582064,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
950,VITILIGO location SKIN,location,0.942809041582064,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
951,SKIN location VITILIGO,location,0.942809041582064,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO
952,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
953,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
954,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
955,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
956,FISH OIL treats CARDIAC ARRHYTHMIAS,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
957,no_relation,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
958,no_relation,treats,0.975900072948533,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL
959,SKIN location INFLAMMATORY DERMATOSES,location,0.975900072948533,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
960,SKIN location INFLAMMATORY DERMATOSES,location,0.975900072948533,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
961,SKIN location INFLAMMATORY DERMATOSES,location,0.975900072948533,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
962,SKIN location INFLAMMATORY DERMATOSES,location,0.975900072948533,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
963,SKIN location INFLAMMATORY DERMATOSES,location,0.975900072948533,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
964,SKIN location INFLAMMATORY DERMATOSES,location,0.975900072948533,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
965,no_relation,location,0.975900072948533,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES
966,no_relation,diagnosis,0.753778361444409,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
967,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosis HEMOPHAGOCYTOSIS,diagnosis,0.753778361444409,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
968,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosis HEMOPHAGOCYTOSIS,diagnosis,0.753778361444409,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
969,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosis HEMOPHAGOCYTOSIS,diagnosis,0.753778361444409,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
970,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosis HEMOPHAGOCYTOSIS,diagnosis,0.753778361444409,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
971,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosis HEMOPHAGOCYTOSIS,diagnosis,0.753778361444409,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
972,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosis HEMOPHAGOCYTOSIS,diagnosis,0.753778361444409,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
973,PODOPHYLLOTOXIN treats PENILE WARTS,treats,0.995893206467704,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
974,no_relation,treats,0.995893206467704,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
975,PODOPHYLLOTOXIN treats PENILE WARTS,treats,0.995893206467704,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
976,PODOPHYLLOTOXIN treats PENILE WARTS,treats,0.995893206467704,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
977,PENILE WARTS treats PODOPHYLLOTOXIN,treats,0.995893206467704,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
978,PODOPHYLLOTOXIN treats PENILE WARTS,treats,0.995893206467704,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
979,PODOPHYLLOTOXIN treats PENILE WARTS,treats,0.995893206467704,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN
980,PARACETAMOL treats MINOR PAIN,treats,0.936329177569044,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
981,PARACETAMOL treats MINOR PAIN,treats,0.936329177569044,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
982,PARACETAMOL treats MINOR PAIN,treats,0.936329177569044,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
983,PARACETAMOL treats MINOR PAIN,treats,0.936329177569044,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
984,PARACETAMOL treats MINOR PAIN,treats,0.936329177569044,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
985,PARACETAMOL treats MINOR PAIN,treats,0.936329177569044,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
986,PARACETAMOL treats MINOR PAIN,treats,0.936329177569044,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
987,HYPERTENSION diagnosis BLOOD PRESSURE ELEVATION,diagnosis,0.35921060405355,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
988,no_relation,diagnosis,0.35921060405355,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
989,HYPERTENSION diagnosis BLOOD PRESSURE ELEVATION,diagnosis,0.35921060405355,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
990,BLOOD PRESSURE ELEVATION diagnosis HYPERTENSION,diagnosis,0.35921060405355,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
991,BLOOD PRESSURE ELEVATION diagnosis HYPERTENSION,diagnosis,0.35921060405355,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
992,no_relation,diagnosis,0.35921060405355,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
993,no_relation,diagnosis,0.35921060405355,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION
994,FREE LUNG CELLS location BRONCHIAL CARCINOMA,location,0.38490017945975,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
995,FREE LUNG CELLS location BRONCHIAL CARCINOMA,location,0.38490017945975,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
996,FREE LUNG CELLS location BRONCHIAL CARCINOMA,location,0.38490017945975,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
997,FREE LUNG CELLS location BRONCHIAL CARCINOMA,location,0.38490017945975,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
998,BRONCHIAL CARCINOMA location FREE LUNG CELLS,location,0.38490017945975,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
999,FREE LUNG CELLS location BRONCHIAL CARCINOMA,location,0.38490017945975,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
1000,FREE LUNG CELLS location BRONCHIAL CARCINOMA,location,0.38490017945975,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA
1001,no_relation,causes,0.848528137423857,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1002,no_relation,causes,0.848528137423857,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1003,BCL 2 GENE causes FOLLICULAR LYMPHOMA,causes,0.848528137423857,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1004,FOLLICULAR LYMPHOMA causes BCL 2 GENE,causes,0.848528137423857,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1005,BCL 2 GENE causes FOLLICULAR LYMPHOMA,causes,0.848528137423857,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1006,no_relation,causes,0.848528137423857,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1007,BCL 2 GENE causes FOLLICULAR LYMPHOMA,causes,0.848528137423857,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1008,no_relation,treats,0.790569415042095,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
1009,ENALAPRIL treats CONGESTIVE HEART FAILURE,treats,0.790569415042095,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
1010,ENALAPRIL treats CONGESTIVE HEART FAILURE,treats,0.790569415042095,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
1011,ENALAPRIL treats CONGESTIVE HEART FAILURE,treats,0.790569415042095,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
1012,ENALAPRIL treats CONGESTIVE HEART FAILURE,treats,0.790569415042095,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
1013,ENALAPRIL treats CONGESTIVE HEART FAILURE,treats,0.790569415042095,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
1014,ENALAPRIL treats CONGESTIVE HEART FAILURE,treats,0.790569415042095,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL
1015,ARRHYTHMIAS contraindicates ANTIARRHYTHMIC DRUG EFFICACY,contraindicates,0.304997140665209,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
1016,ANTIARRHYTHMIC DRUG EFFICACY contraindicates ARRHYTHMIAS,contraindicates,0.304997140665209,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
1017,no_relation,contraindicates,0.304997140665209,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
1018,ARRHYTHMIAS contraindicates ANTIARRHYTHMIC DRUG EFFICACY,contraindicates,0.304997140665209,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
1019,ANTIARRHYTHMIC DRUG EFFICACY contraindicates ARRHYTHMIAS,contraindicates,0.304997140665209,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
1020,no_relation,contraindicates,0.304997140665209,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
1021,no_relation,contraindicates,0.304997140665209,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY
1022,no_relation,treats,0.970494958830946,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
1023,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.970494958830946,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
1024,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.970494958830946,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
1025,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.970494958830946,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
1026,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.970494958830946,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
1027,THROMBOEMBOLIC EVENTS treats FONDAPARINUX,treats,0.970494958830946,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
1028,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.970494958830946,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
1029,ANGINA PECTORIS causes PAIN,causes,0.875189948987367,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
1030,no_relation,causes,0.875189948987367,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
1031,no_relation,causes,0.875189948987367,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
1032,ANGINA PECTORIS causes PAIN,causes,0.875189948987367,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
1033,ANGINA PECTORIS causes PAIN,causes,0.875189948987367,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
1034,ANGINA PECTORIS causes PAIN,causes,0.875189948987367,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
1035,no_relation,causes,0.875189948987367,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS
1036,no_relation,causes,0.34815531191139604,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
1037,no_relation,causes,0.34815531191139604,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
1038,LEVODOPA causes PARKINSON'S DISEASE,causes,0.34815531191139604,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
1039,PARKINSON'S DISEASE causes LEVODOPA,causes,0.34815531191139604,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
1040,LEVODOPA causes PARKINSON'S DISEASE,causes,0.34815531191139604,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
1041,LEVODOPA causes PARKINSON'S DISEASE,causes,0.34815531191139604,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
1042,PARKINSON'S DISEASE causes LEVODOPA,causes,0.34815531191139604,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
1043,HYPERTENSION treats CANDESARTAN CILEXETIL,treats,0.975900072948533,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
1044,HYPERTENSION treats CANDESARTAN CILEXETIL,treats,0.975900072948533,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
1045,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.975900072948533,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
1046,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.975900072948533,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
1047,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.975900072948533,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
1048,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.975900072948533,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
1049,CANDESARTAN CILEXETIL treats HYPERTENSION,treats,0.975900072948533,"Sever P, Holzgreve H. Long term efficacy and tolerability of CANDESARTAN CILEXETIL in patients with mild to moderate HYPERTENSION",HYPERTENSION,CANDESARTAN CILEXETIL
1050,DRUG causes TOLERANCE,causes,0.875189948987367,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
1051,DRUG causes TOLERANCE,causes,0.875189948987367,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
1052,DRUG causes TOLERANCE,causes,0.875189948987367,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
1053,DRUG causes TOLERANCE,causes,0.875189948987367,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
1054,no_relation,causes,0.875189948987367,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
1055,TOLERANCE causes DRUG,causes,0.875189948987367,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
1056,no_relation,causes,0.875189948987367,The state of dependence was established by recording the development of TOLERANCE to the analgesic action of the DRUG and the effect of acute withdrawal of morphine and injection of nalorphine on one test group.2.,DRUG,TOLERANCE
1057,DIAZEPAM treats STATUS EPILEPTICUS,treats,0.936329177569044,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1058,DIAZEPAM treats STATUS EPILEPTICUS,treats,0.936329177569044,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1059,DIAZEPAM treats STATUS EPILEPTICUS,treats,0.936329177569044,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1060,DIAZEPAM treats STATUS EPILEPTICUS,treats,0.936329177569044,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1061,STATUS EPILEPTICUS treats DIAZEPAM,treats,0.936329177569044,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1062,DIAZEPAM treats STATUS EPILEPTICUS,treats,0.936329177569044,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1063,DIAZEPAM treats STATUS EPILEPTICUS,treats,0.936329177569044,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1064,PYRIDOXINE treats PYRIDOXINE DEPENDENT SEIZURES,treats,0.9901475429766742,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
1065,no_relation,treats,0.9901475429766742,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
1066,PYRIDOXINE DEPENDENT SEIZURES treats PYRIDOXINE,treats,0.9901475429766742,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
1067,PYRIDOXINE treats PYRIDOXINE DEPENDENT SEIZURES,treats,0.9901475429766742,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
1068,PYRIDOXINE treats PYRIDOXINE DEPENDENT SEIZURES,treats,0.9901475429766742,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
1069,PYRIDOXINE treats PYRIDOXINE DEPENDENT SEIZURES,treats,0.9901475429766742,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
1070,PYRIDOXINE treats PYRIDOXINE DEPENDENT SEIZURES,treats,0.9901475429766742,"In an infant with typical PYRIDOXINE DEPENDENT SEIZURES CSF GABA level, was determined before treatment with PYRIDOXINE",PYRIDOXINE DEPENDENT SEIZURES,PYRIDOXINE
1071,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.8955334711889901,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1072,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.8955334711889901,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1073,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.8955334711889901,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1074,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.8955334711889901,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1075,COMPLICATION OF PREGNANCY causes PREECLAMPSIA,causes,0.8955334711889901,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1076,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.8955334711889901,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1077,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,causes,0.8955334711889901,PREECLAMPSIA a common COMPLICATION OF PREGNANCY is associated with alteration in the concentration of leptin in maternal blood.,COMPLICATION OF PREGNANCY,PREECLAMPSIA
1078,DCIS diagnosis CALCIFICATIONS,diagnosis,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
1079,DCIS diagnosis CALCIFICATIONS,diagnosis,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
1080,DCIS diagnosis CALCIFICATIONS,diagnosis,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
1081,DCIS diagnosis CALCIFICATIONS,diagnosis,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
1082,DCIS diagnosis CALCIFICATIONS,diagnosis,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
1083,DCIS diagnosis CALCIFICATIONS,diagnosis,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
1084,CALCIFICATIONS diagnosis DCIS,diagnosis,0.7022468831767831,C. Excisional biopsy of the remaining CALCIFICATIONS reveals DCIS,CALCIFICATIONS,DCIS
1085,no_relation,diagnosis,0.320256307610174,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
1086,POSTTRAUMATIC EPILEPSY diagnosis CRANIOCEREBRAL TRAUMA,diagnosis,0.320256307610174,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
1087,CRANIOCEREBRAL TRAUMA diagnosis POSTTRAUMATIC EPILEPSY,diagnosis,0.320256307610174,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
1088,CRANIOCEREBRAL TRAUMA diagnosis POSTTRAUMATIC EPILEPSY,diagnosis,0.320256307610174,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
1089,CRANIOCEREBRAL TRAUMA diagnosis POSTTRAUMATIC EPILEPSY,diagnosis,0.320256307610174,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
1090,no_relation,diagnosis,0.320256307610174,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
1091,POSTTRAUMATIC EPILEPSY diagnosis CRANIOCEREBRAL TRAUMA,diagnosis,0.320256307610174,It also allowed to predict the development of POSTTRAUMATIC EPILEPSY in individuals with CRANIOCEREBRAL TRAUMA in the past.,POSTTRAUMATIC EPILEPSY,CRANIOCEREBRAL TRAUMA
1092,no_relation,diagnosis,0.744208407535251,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1093,no_relation,diagnosis,0.744208407535251,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1094,no_relation,diagnosis,0.744208407535251,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1095,no_relation,diagnosis,0.744208407535251,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1096,COELIAC DISEASE diagnosis GLUTEN,diagnosis,0.744208407535251,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1097,no_relation,diagnosis,0.744208407535251,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1098,COELIAC DISEASE diagnosis GLUTEN,diagnosis,0.744208407535251,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1099,VENTRICULAR TACHYCARDIA causes ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,causes,0.8164965809277259,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
1100,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA causes VENTRICULAR TACHYCARDIA,causes,0.8164965809277259,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
1101,VENTRICULAR TACHYCARDIA causes ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,causes,0.8164965809277259,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
1102,VENTRICULAR TACHYCARDIA causes ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,causes,0.8164965809277259,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
1103,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA causes VENTRICULAR TACHYCARDIA,causes,0.8164965809277259,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
1104,VENTRICULAR TACHYCARDIA causes ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,causes,0.8164965809277259,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
1105,VENTRICULAR TACHYCARDIA causes ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,causes,0.8164965809277259,Radiofrequency catheter ablation of the slow atrioventricular nodal pathway resulted in cure of atrioventricular nodal reentrant tachycardia and the prevention of spontaneous recurrence of VENTRICULAR TACHYCARDIA suggesting a role of ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA in triggering the clinical episodes of ventricular tachycardia.,ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA,VENTRICULAR TACHYCARDIA
1106,PAROXETINE treats PANIC DISORDER,treats,0.970142500145332,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
1107,PAROXETINE treats PANIC DISORDER,treats,0.970142500145332,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
1108,PAROXETINE treats PANIC DISORDER,treats,0.970142500145332,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
1109,PAROXETINE treats PANIC DISORDER,treats,0.970142500145332,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
1110,PAROXETINE treats PANIC DISORDER,treats,0.970142500145332,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
1111,no_relation,treats,0.970142500145332,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
1112,PAROXETINE treats PANIC DISORDER,treats,0.970142500145332,"Lecrubier Y, Bakker A, Dunbar G et al. A comparison of paroxetine, clomipramine and placebo in the treatment of PANIC DISORDER: Collaborative PAROXETINE Panic Study Investigators.",PANIC DISORDER,PAROXETINE
1113,AMLODIPINE treats HYPERTENSION,treats,0.984731927834662,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
1114,AMLODIPINE treats HYPERTENSION,treats,0.984731927834662,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
1115,AMLODIPINE treats HYPERTENSION,treats,0.984731927834662,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
1116,AMLODIPINE treats HYPERTENSION,treats,0.984731927834662,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
1117,AMLODIPINE treats HYPERTENSION,treats,0.984731927834662,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
1118,no_relation,treats,0.984731927834662,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
1119,AMLODIPINE treats HYPERTENSION,treats,0.984731927834662,"11  >     Benazepril/Amlodipine Fixed combination Therapy for HYPERTENSION  Oral:  In studies using benazepril/AMLODIPINE fixed combination in dosages of benazepril hydrochloride 10 40 mg daily and amlodipine 2.5 10 mg daily, BP response increased with increasing amlodipine dosage in all patient groups and increased with increasing benazepril dosage in nonblack patient groups.",HYPERTENSION,AMLODIPINE
1120,NICOTINE causes NICOTINE WITHDRAWAL,causes,0.7453559924999301,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
1121,no_relation,causes,0.7453559924999301,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
1122,no_relation,causes,0.7453559924999301,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
1123,NICOTINE causes NICOTINE WITHDRAWAL,causes,0.7453559924999301,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
1124,no_relation,causes,0.7453559924999301,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
1125,NICOTINE causes NICOTINE WITHDRAWAL,causes,0.7453559924999301,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
1126,NICOTINE causes NICOTINE WITHDRAWAL,causes,0.7453559924999301,"Animal models of NICOTINE WITHDRAWAL indicate involvement of striatal serotonin (5 HT) systems in NICOTINE reward, withdrawal and craving.",NICOTINE,NICOTINE WITHDRAWAL
1127,no_relation,causes,0.7293249574894731,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
1128,SIDS causes SUDDEN INFANT DEATHS,causes,0.7293249574894731,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
1129,no_relation,causes,0.7293249574894731,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
1130,no_relation,causes,0.7293249574894731,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
1131,SIDS causes SUDDEN INFANT DEATHS,causes,0.7293249574894731,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
1132,no_relation,causes,0.7293249574894731,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
1133,SIDS causes SUDDEN INFANT DEATHS,causes,0.7293249574894731,"Identification of more LQTS mutations in SIDS cases could provide new insights into the pathophysiology of SIDS and, consequently, reduce the number of unexplained SUDDEN INFANT DEATHS",SIDS,SUDDEN INFANT DEATHS
1134,no_relation,causes,0.768221279597376,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
1135,HEADACHES causes MIGRAINE,causes,0.768221279597376,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
1136,no_relation,causes,0.768221279597376,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
1137,no_relation,causes,0.768221279597376,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
1138,no_relation,causes,0.768221279597376,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
1139,no_relation,causes,0.768221279597376,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
1140,MIGRAINE causes HEADACHES,causes,0.768221279597376,HEADACHES associated with acute illnesses may be a precursor to later MIGRAINE,HEADACHES,MIGRAINE
1141,HEMORRHAGIC FEVER WITH RENAL SYNDROME causes HANTAAN VIRUS,causes,0.452267016866645,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
1142,HANTAAN VIRUS causes HEMORRHAGIC FEVER WITH RENAL SYNDROME,causes,0.452267016866645,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
1143,HANTAAN VIRUS causes HEMORRHAGIC FEVER WITH RENAL SYNDROME,causes,0.452267016866645,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
1144,no_relation,causes,0.452267016866645,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
1145,no_relation,causes,0.452267016866645,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
1146,no_relation,causes,0.452267016866645,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
1147,HANTAAN VIRUS causes HEMORRHAGIC FEVER WITH RENAL SYNDROME,causes,0.452267016866645,"Convalescent phase sera from patients with HEMORRHAGIC FEVER WITH RENAL SYNDROME (HFRS) having higher IF antibody titers to Hantaan virus than to nephropathia epidemica (NE) virus were capable of neutralizing HANTAAN VIRUS, while sera from patients with higher IF antibody titers to NE virus than Hantaan virus did not contain neutralizing antibody to Hantaan virus.",HANTAAN VIRUS,HEMORRHAGIC FEVER WITH RENAL SYNDROME
1148,SCABIES causes MITES,causes,0.964763821237732,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
1149,MITES causes SCABIES,causes,0.964763821237732,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
1150,MITES causes SCABIES,causes,0.964763821237732,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
1151,MITES causes SCABIES,causes,0.964763821237732,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
1152,MITES causes SCABIES,causes,0.964763821237732,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
1153,MITES causes SCABIES,causes,0.964763821237732,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
1154,MITES causes SCABIES,causes,0.964763821237732,"? Investigations of the prevalence of mites in the personal environment of 37 cases of normal SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",MITES,SCABIES
1155,GANGLIOGLIOMAS causes SEIZURE,causes,0.986393923832143,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
1156,no_relation,causes,0.986393923832143,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
1157,GANGLIOGLIOMAS causes SEIZURE,causes,0.986393923832143,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
1158,GANGLIOGLIOMAS causes SEIZURE,causes,0.986393923832143,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
1159,GANGLIOGLIOMAS causes SEIZURE,causes,0.986393923832143,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
1160,GANGLIOGLIOMAS causes SEIZURE,causes,0.986393923832143,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
1161,GANGLIOGLIOMAS causes SEIZURE,causes,0.986393923832143,"Good SEIZURE outcome is expected in patients with GANGLIOGLIOMAS despite years of medically intractable epilepsy, once the tumor is resected.",SEIZURE,GANGLIOGLIOMAS
1162,LENS location CATARACT FORMATION,location,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
1163,no_relation,location,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
1164,LENS location CATARACT FORMATION,location,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
1165,LENS location CATARACT FORMATION,location,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
1166,CATARACT FORMATION location LENS,location,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
1167,no_relation,location,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
1168,LENS location CATARACT FORMATION,location,0.560112033611204,The evidence reviewed here supports the hypothesis that metal catalyzed oxidation reactions occur in the lens and may make a significant contribution to the changes seen in the LENS with age and in CATARACT FORMATION.,LENS,CATARACT FORMATION
1169,PATHOLOGIC FRACTURES causes SOLITARY BONE METASTASIS,causes,0.5547001962252289,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
1170,no_relation,causes,0.5547001962252289,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
1171,no_relation,causes,0.5547001962252289,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
1172,no_relation,causes,0.5547001962252289,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
1173,no_relation,causes,0.5547001962252289,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
1174,no_relation,causes,0.5547001962252289,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
1175,SOLITARY BONE METASTASIS causes PATHOLOGIC FRACTURES,causes,0.5547001962252289,"A favorable prognosis was more likely in women and patients with adenocarcinoma, SOLITARY BONE METASTASIS no metastases to the appendicular bone, no PATHOLOGIC FRACTURES performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor.",PATHOLOGIC FRACTURES,SOLITARY BONE METASTASIS
1176,HYDROQUINONE treats HYPERPIGMENTATION,treats,0.99654575824488,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
1177,HYPERPIGMENTATION treats HYDROQUINONE,treats,0.99654575824488,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
1178,HYDROQUINONE treats HYPERPIGMENTATION,treats,0.99654575824488,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
1179,HYDROQUINONE treats HYPERPIGMENTATION,treats,0.99654575824488,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
1180,no_relation,treats,0.99654575824488,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
1181,HYDROQUINONE treats HYPERPIGMENTATION,treats,0.99654575824488,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
1182,HYDROQUINONE treats HYPERPIGMENTATION,treats,0.99654575824488,"Treatment  Treatment of HYPERPIGMENTATION may include HYDROQUINONE kojic acid, alpha hydroxy acids, azelaic acid, ascorbic acid, tretinoin (Retinol), topical glucocorticoids, and licorice extract.",HYPERPIGMENTATION,HYDROQUINONE
1183,no_relation,causes,0.4472135954999579,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1184,no_relation,causes,0.4472135954999579,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1185,no_relation,causes,0.4472135954999579,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1186,no_relation,causes,0.4472135954999579,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1187,SKIN causes PETECHIAE,causes,0.4472135954999579,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1188,no_relation,causes,0.4472135954999579,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1189,no_relation,causes,0.4472135954999579,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1190,HEADACHE causes CHRONIC MIGRAINE,causes,0.474712663277541,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
1191,CHRONIC MIGRAINE causes HEADACHE,causes,0.474712663277541,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
1192,HEADACHE causes CHRONIC MIGRAINE,causes,0.474712663277541,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
1193,CHRONIC MIGRAINE causes HEADACHE,causes,0.474712663277541,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
1194,no_relation,causes,0.474712663277541,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
1195,CHRONIC MIGRAINE causes HEADACHE,causes,0.474712663277541,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
1196,no_relation,causes,0.474712663277541,CHRONIC MIGRAINE is a common form of disabling headache presenting in HEADACHE subspecialty practice.,HEADACHE,CHRONIC MIGRAINE
1197,GLUTEN causes COELIAC DISEASE,causes,0.496138938356834,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1198,GLUTEN causes COELIAC DISEASE,causes,0.496138938356834,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1199,GLUTEN causes COELIAC DISEASE,causes,0.496138938356834,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1200,GLUTEN causes COELIAC DISEASE,causes,0.496138938356834,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1201,no_relation,causes,0.496138938356834,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1202,GLUTEN causes COELIAC DISEASE,causes,0.496138938356834,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1203,no_relation,causes,0.496138938356834,The results highlight the importance of gluten challenge and intestinal biopsy in the diagnosis of coeliac disease and strongly suggest that a normal biopsy after a 3 month GLUTEN challenge (as described above) excludes COELIAC DISEASE.,GLUTEN,COELIAC DISEASE
1204,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.43301270189221897,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
1205,no_relation,treats,0.43301270189221897,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
1206,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.43301270189221897,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
1207,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.43301270189221897,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
1208,no_relation,treats,0.43301270189221897,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
1209,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.43301270189221897,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
1210,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.43301270189221897,"A 49 year old man with classic manifestations of Cushing's syndrome had undetectable levels of ACTH, lack of suppression of HYPERCORTISOLISM with DEXAMETHASONE in doses of 2, 8, or 16 mg per day, bilaterally enlarged adrenal glands on MRI, and bilateral adrenal uptake of iodocholesterol.",HYPERCORTISOLISM,DEXAMETHASONE
1211,AGGRESSIVE CLINICAL COURSE causes PLASMA CELL LEUKAEMIA,causes,0.609994281330419,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
1212,PLASMA CELL LEUKAEMIA causes AGGRESSIVE CLINICAL COURSE,causes,0.609994281330419,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
1213,AGGRESSIVE CLINICAL COURSE causes PLASMA CELL LEUKAEMIA,causes,0.609994281330419,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
1214,PLASMA CELL LEUKAEMIA causes AGGRESSIVE CLINICAL COURSE,causes,0.609994281330419,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
1215,no_relation,causes,0.609994281330419,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
1216,PLASMA CELL LEUKAEMIA causes AGGRESSIVE CLINICAL COURSE,causes,0.609994281330419,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
1217,no_relation,causes,0.609994281330419,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
1218,METASTATIC MULTIPLE MYELOMA treats ZOLEDRONIC ACID,treats,0.903696114115064,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
1219,ZOLEDRONIC ACID treats METASTATIC MULTIPLE MYELOMA,treats,0.903696114115064,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
1220,ZOLEDRONIC ACID treats METASTATIC MULTIPLE MYELOMA,treats,0.903696114115064,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
1221,ZOLEDRONIC ACID treats METASTATIC MULTIPLE MYELOMA,treats,0.903696114115064,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
1222,ZOLEDRONIC ACID treats METASTATIC MULTIPLE MYELOMA,treats,0.903696114115064,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
1223,ZOLEDRONIC ACID treats METASTATIC MULTIPLE MYELOMA,treats,0.903696114115064,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
1224,ZOLEDRONIC ACID treats METASTATIC MULTIPLE MYELOMA,treats,0.903696114115064,We collected resource use data prospectively for 930 patients alongside a multinational trial of ZOLEDRONIC ACID versus pamidronate for patients with METASTATIC MULTIPLE MYELOMA or breast cancer and > or =1 bone lesion.,METASTATIC MULTIPLE MYELOMA,ZOLEDRONIC ACID
1225,TUBERCULIN NEGATIVE causes TUBERCULOSIS,causes,0.371390676354104,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
1226,no_relation,causes,0.371390676354104,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
1227,TUBERCULOSIS causes TUBERCULIN NEGATIVE,causes,0.371390676354104,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
1228,TUBERCULIN NEGATIVE causes TUBERCULOSIS,causes,0.371390676354104,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
1229,no_relation,causes,0.371390676354104,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
1230,TUBERCULIN NEGATIVE causes TUBERCULOSIS,causes,0.371390676354104,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
1231,no_relation,causes,0.371390676354104,A low TUBERCULOSIS risk differential was similarly observed between TUBERCULIN NEGATIVE and untreated tuberculin positive subjects in the historical cohort.,TUBERCULOSIS,TUBERCULIN NEGATIVE
1232,IRON causes IRON DEFICIENCY ANEMIA,causes,0.4850712500726661,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1233,no_relation,causes,0.4850712500726661,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1234,no_relation,causes,0.4850712500726661,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1235,no_relation,causes,0.4850712500726661,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1236,no_relation,causes,0.4850712500726661,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1237,no_relation,causes,0.4850712500726661,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1238,IRON causes IRON DEFICIENCY ANEMIA,causes,0.4850712500726661,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1239,LYMPHOMATOID PAPULOSIS causes PAPULES,causes,0.98058067569092,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
1240,LYMPHOMATOID PAPULOSIS causes PAPULES,causes,0.98058067569092,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
1241,LYMPHOMATOID PAPULOSIS causes PAPULES,causes,0.98058067569092,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
1242,no_relation,causes,0.98058067569092,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
1243,PAPULES causes LYMPHOMATOID PAPULOSIS,causes,0.98058067569092,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
1244,no_relation,causes,0.98058067569092,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
1245,LYMPHOMATOID PAPULOSIS causes PAPULES,causes,0.98058067569092,"In this review, we discuss the clinical and histologic features of LYMPHOMATOID PAPULOSIS a cutaneous disorder characterized by recurrent eruptions of self healing PAPULES and small nodules with histologic findings suggestive of malignant lymphoma.",PAPULES,LYMPHOMATOID PAPULOSIS
1246,no_relation,causes,0.404061017820884,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
1247,HYPERTENSION causes ELEVATED BP,causes,0.404061017820884,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
1248,no_relation,causes,0.404061017820884,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
1249,no_relation,causes,0.404061017820884,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
1250,ELEVATED BP causes HYPERTENSION,causes,0.404061017820884,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
1251,ELEVATED BP causes HYPERTENSION,causes,0.404061017820884,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
1252,no_relation,causes,0.404061017820884,Alcohol sensitivity and alcohol use were both associated with ELEVATED BP and risk of HYPERTENSION in an older Chinese population.,ELEVATED BP,HYPERTENSION
1253,METHOTREXATE treats LEUKEMIA,treats,0.9830783046228492,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
1254,METHOTREXATE treats LEUKEMIA,treats,0.9830783046228492,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
1255,METHOTREXATE treats LEUKEMIA,treats,0.9830783046228492,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
1256,METHOTREXATE treats LEUKEMIA,treats,0.9830783046228492,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
1257,METHOTREXATE treats LEUKEMIA,treats,0.9830783046228492,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
1258,METHOTREXATE treats LEUKEMIA,treats,0.9830783046228492,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
1259,METHOTREXATE treats LEUKEMIA,treats,0.9830783046228492,We report two patients with LEUKEMIA treated with high dose METHOTREXATE,LEUKEMIA,METHOTREXATE
1260,CISAPRIDE causes FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,causes,0.560112033611204,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
1261,CISAPRIDE causes FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,causes,0.560112033611204,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
1262,FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS causes CISAPRIDE,causes,0.560112033611204,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
1263,CISAPRIDE causes FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,causes,0.560112033611204,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
1264,FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS causes CISAPRIDE,causes,0.560112033611204,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
1265,FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS causes CISAPRIDE,causes,0.560112033611204,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
1266,CISAPRIDE causes FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,causes,0.560112033611204,"The influence of CISAPRIDE on FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS was studied in a double blind cross over investigation in 24 consecutive patients selected by endoscopy, 12 with microscopical evidence of gastro oesophageal reflux and 12 with additional macroscopic oesophagitis.",FOOD STIMULATED GASTRO OESOPHAGEAL REFLUX MECHANISMS,CISAPRIDE
1267,no_relation,causes,0.7715167498104591,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
1268,NEUROPATHIC PAIN causes PAIN CAUSED BY SOMATOSENSORY,causes,0.7715167498104591,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
1269,NEUROPATHIC PAIN causes PAIN CAUSED BY SOMATOSENSORY,causes,0.7715167498104591,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
1270,PAIN CAUSED BY SOMATOSENSORY causes NEUROPATHIC PAIN,causes,0.7715167498104591,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
1271,PAIN CAUSED BY SOMATOSENSORY causes NEUROPATHIC PAIN,causes,0.7715167498104591,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
1272,no_relation,causes,0.7715167498104591,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
1273,NEUROPATHIC PAIN causes PAIN CAUSED BY SOMATOSENSORY,causes,0.7715167498104591,"Essentially, the classification of chronic pain falls into 3 broad categories: (1) pain owing to tissue disease or damage (nociceptive pain), (2) PAIN CAUSED BY SOMATOSENSORY system disease or damage (NEUROPATHIC PAIN and (3) pain without a known somatic background.",PAIN CAUSED BY SOMATOSENSORY,NEUROPATHIC PAIN
1274,ATOPY causes HAY FEVER,causes,0.488677777425221,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
1275,ATOPY causes HAY FEVER,causes,0.488677777425221,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
1276,no_relation,causes,0.488677777425221,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
1277,no_relation,causes,0.488677777425221,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
1278,ATOPY causes HAY FEVER,causes,0.488677777425221,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
1279,no_relation,causes,0.488677777425221,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
1280,no_relation,causes,0.488677777425221,Malignancies were observed less frequently in the closest relatives of the patients suffering from HAY FEVER with the most proved hereditary liability of ATOPY than in the relatives of control groups.,HAY FEVER,ATOPY
1281,PAIN causes CLUSTER HEADACHE,causes,0.923380516876639,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
1282,CLUSTER HEADACHE causes PAIN,causes,0.923380516876639,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
1283,CLUSTER HEADACHE causes PAIN,causes,0.923380516876639,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
1284,CLUSTER HEADACHE causes PAIN,causes,0.923380516876639,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
1285,no_relation,causes,0.923380516876639,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
1286,CLUSTER HEADACHE causes PAIN,causes,0.923380516876639,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
1287,CLUSTER HEADACHE causes PAIN,causes,0.923380516876639,"Although the pain in both disorders is excruciating, CLUSTER HEADACHE PAIN is episodic and unilateral, typically surrounds the eye, and lasts 15 to 180 minutes; the pain of trigeminal neuralgia lasts just seconds and is usually limited to the tissues overlying the maxillary and mandibular divisions of the trigeminal nerve.",PAIN,CLUSTER HEADACHE
1288,DIABETES treats ISLET CELL NEOGENESIS,treats,0.99654575824488,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
1289,ISLET CELL NEOGENESIS treats DIABETES,treats,0.99654575824488,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
1290,ISLET CELL NEOGENESIS treats DIABETES,treats,0.99654575824488,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
1291,ISLET CELL NEOGENESIS treats DIABETES,treats,0.99654575824488,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
1292,DIABETES treats ISLET CELL NEOGENESIS,treats,0.99654575824488,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
1293,ISLET CELL NEOGENESIS treats DIABETES,treats,0.99654575824488,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
1294,ISLET CELL NEOGENESIS treats DIABETES,treats,0.99654575824488,"If islet cell tolerance could be re induced, a major clinical hurdle to curing DIABETES by ISLET CELL NEOGENESIS may be overcome.",ISLET CELL NEOGENESIS,DIABETES
1295,no_relation,diagnosis,0.995893206467704,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
1296,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.995893206467704,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
1297,HALOTHANE diagnosis MALIGNANT HYPERTHERMIA,diagnosis,0.995893206467704,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
1298,no_relation,diagnosis,0.995893206467704,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
1299,MALIGNANT HYPERTHERMIA diagnosis HALOTHANE,diagnosis,0.995893206467704,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
1300,no_relation,diagnosis,0.995893206467704,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
1301,HALOTHANE diagnosis MALIGNANT HYPERTHERMIA,diagnosis,0.995893206467704,In view of the wide spectrum of drug sensitivity characterizing subjects with MALIGNANT HYPERTHERMIA it is suggested that exposure to A23187 be added to the HALOTHANE and caffeine tests currently used to detect this disease.,MALIGNANT HYPERTHERMIA,HALOTHANE
1302,LONG ACTING RISPERIDONE treats SCHIZOPHRENIA,treats,0.9931270663228408,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
1303,LONG ACTING RISPERIDONE treats SCHIZOPHRENIA,treats,0.9931270663228408,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
1304,LONG ACTING RISPERIDONE treats SCHIZOPHRENIA,treats,0.9931270663228408,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
1305,LONG ACTING RISPERIDONE treats SCHIZOPHRENIA,treats,0.9931270663228408,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
1306,SCHIZOPHRENIA treats LONG ACTING RISPERIDONE,treats,0.9931270663228408,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
1307,LONG ACTING RISPERIDONE treats SCHIZOPHRENIA,treats,0.9931270663228408,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
1308,LONG ACTING RISPERIDONE treats SCHIZOPHRENIA,treats,0.9931270663228408,CONCLUSIONS: LONG ACTING RISPERIDONE is effective and generally well tolerated in patients with SCHIZOPHRENIA including those patients with stable symptoms.,SCHIZOPHRENIA,LONG ACTING RISPERIDONE
1309,GLUCOSE IV treats SEVERE HYPOGLYCAEMIA (SH),treats,0.913811548620257,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
1310,GLUCOSE IV treats SEVERE HYPOGLYCAEMIA (SH),treats,0.913811548620257,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
1311,GLUCOSE IV treats SEVERE HYPOGLYCAEMIA (SH),treats,0.913811548620257,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
1312,GLUCOSE IV treats SEVERE HYPOGLYCAEMIA (SH),treats,0.913811548620257,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
1313,GLUCOSE IV treats SEVERE HYPOGLYCAEMIA (SH),treats,0.913811548620257,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
1314,GLUCOSE IV treats SEVERE HYPOGLYCAEMIA (SH),treats,0.913811548620257,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
1315,GLUCOSE IV treats SEVERE HYPOGLYCAEMIA (SH),treats,0.913811548620257,The objectives of the present analyses were to assess the association between HbA1c levels and SEVERE HYPOGLYCAEMIA (SH) treatment with GLUCOSE IV.,SEVERE HYPOGLYCAEMIA (SH),GLUCOSE IV
1316,no_relation,causes,0.50709255283711,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1317,LOW DOSE HEPARIN PROPHYLA causes MBOLISM AFTER MA,causes,0.50709255283711,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1318,no_relation,causes,0.50709255283711,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1319,no_relation,causes,0.50709255283711,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1320,no_relation,causes,0.50709255283711,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1321,MBOLISM AFTER MA causes LOW DOSE HEPARIN PROPHYLA,causes,0.50709255283711,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1322,no_relation,causes,0.50709255283711,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1323,ATOPIC DIATHESIS causes ATOPIC DERMATITIS,causes,0.9931270663228408,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
1324,ATOPIC DERMATITIS causes ATOPIC DIATHESIS,causes,0.9931270663228408,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
1325,ATOPIC DIATHESIS causes ATOPIC DERMATITIS,causes,0.9931270663228408,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
1326,no_relation,causes,0.9931270663228408,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
1327,ATOPIC DERMATITIS causes ATOPIC DIATHESIS,causes,0.9931270663228408,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
1328,no_relation,causes,0.9931270663228408,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
1329,ATOPIC DIATHESIS causes ATOPIC DERMATITIS,causes,0.9931270663228408,ATOPIC DERMATITIS the dermatologic manifestation of the ATOPIC DIATHESIS has a variety of clinical presentations.,ATOPIC DERMATITIS,ATOPIC DIATHESIS
1330,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1331,LOW DOSE HEPARIN PROPHYLA treats MBOLISM AFTER MA,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1332,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1333,LOW DOSE HEPARIN PROPHYLA treats MBOLISM AFTER MA,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1334,LOW DOSE HEPARIN PROPHYLA treats MBOLISM AFTER MA,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1335,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1336,no_relation,treats,0.338061701891407,"The object of the present investigation was to identify those who, among high risk patients, would break through LOW DOSE HEPARIN PROPHYLAxis and develop thromboeMBOLISM AFTER MAjor abdominal surgery.",MBOLISM AFTER MA,LOW DOSE HEPARIN PROPHYLA
1337,LIVER DISEASE causes INDOCYANINE GREEN (ICG UPTAKE EXCRETION,causes,0.802955068546966,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
1338,INDOCYANINE GREEN (ICG UPTAKE EXCRETION causes LIVER DISEASE,causes,0.802955068546966,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
1339,LIVER DISEASE causes INDOCYANINE GREEN (ICG UPTAKE EXCRETION,causes,0.802955068546966,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
1340,no_relation,causes,0.802955068546966,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
1341,INDOCYANINE GREEN (ICG UPTAKE EXCRETION causes LIVER DISEASE,causes,0.802955068546966,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
1342,INDOCYANINE GREEN (ICG UPTAKE EXCRETION causes LIVER DISEASE,causes,0.802955068546966,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
1343,INDOCYANINE GREEN (ICG UPTAKE EXCRETION causes LIVER DISEASE,causes,0.802955068546966,The purpose of the present paper is to clarify the disturbance of the INDOCYANINE GREEN (ICG UPTAKE EXCRETION mechanism in patients with LIVER DISEASE,LIVER DISEASE,INDOCYANINE GREEN (ICG UPTAKE EXCRETION
1344,CATARACT FORMATION causes LENS TRANSPARENCY,causes,0.9901475429766742,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
1345,no_relation,causes,0.9901475429766742,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
1346,CATARACT FORMATION causes LENS TRANSPARENCY,causes,0.9901475429766742,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
1347,CATARACT FORMATION causes LENS TRANSPARENCY,causes,0.9901475429766742,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
1348,no_relation,causes,0.9901475429766742,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
1349,no_relation,causes,0.9901475429766742,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
1350,CATARACT FORMATION causes LENS TRANSPARENCY,causes,0.9901475429766742,The last stage of CATARACT FORMATION results in a total loss of LENS TRANSPARENCY and leakage of lens proteins.,LENS TRANSPARENCY,CATARACT FORMATION
1351,EPILEPSY causes NUMBER OF SEIZURES,causes,0.9045340337332908,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
1352,EPILEPSY causes NUMBER OF SEIZURES,causes,0.9045340337332908,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
1353,EPILEPSY causes NUMBER OF SEIZURES,causes,0.9045340337332908,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
1354,no_relation,causes,0.9045340337332908,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
1355,NUMBER OF SEIZURES causes EPILEPSY,causes,0.9045340337332908,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
1356,no_relation,causes,0.9045340337332908,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
1357,no_relation,causes,0.9045340337332908,Menopause tends to occur earlier in women with EPILEPSY especially in the setting of a high lifetime NUMBER OF SEIZURES and lifetime use of multiple enzyme inducing AEDs.,NUMBER OF SEIZURES,EPILEPSY
1358,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
1359,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
1360,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
1361,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
1362,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
1363,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
1364,CLINDAMYCIN treats BACTERIAL VAGINOSIS,treats,0.995893206467704,CLINDAMYCIN versus metronidazole in the treatment of BACTERIAL VAGINOSIS,BACTERIAL VAGINOSIS,CLINDAMYCIN
1365,ALUMINUM causes ALUMINUM INTOXICATION,causes,0.843274042711568,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
1366,ALUMINUM causes ALUMINUM INTOXICATION,causes,0.843274042711568,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
1367,ALUMINUM causes ALUMINUM INTOXICATION,causes,0.843274042711568,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
1368,ALUMINUM causes ALUMINUM INTOXICATION,causes,0.843274042711568,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
1369,ALUMINUM causes ALUMINUM INTOXICATION,causes,0.843274042711568,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
1370,ALUMINUM INTOXICATION causes ALUMINUM,causes,0.843274042711568,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
1371,ALUMINUM causes ALUMINUM INTOXICATION,causes,0.843274042711568,ALUMINUM INTOXICATION is common in patients with chronic renal failure because of absorption of aluminum during dialysis from ALUMINUM containing dyalysate water and ingestion of phosphate binders containing aluminum.,ALUMINUM,ALUMINUM INTOXICATION
1372,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1373,no_relation,causes,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1374,no_relation,causes,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1375,BONE METASTASES causes PATHOLOGIC FRACTURES,causes,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1376,no_relation,causes,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1377,no_relation,causes,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1378,no_relation,causes,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1379,SEIZURE causes EPILEPSY,causes,0.8888888888888891,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
1380,EPILEPSY causes SEIZURE,causes,0.8888888888888891,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
1381,EPILEPSY causes SEIZURE,causes,0.8888888888888891,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
1382,EPILEPSY causes SEIZURE,causes,0.8888888888888891,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
1383,EPILEPSY causes SEIZURE,causes,0.8888888888888891,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
1384,EPILEPSY causes SEIZURE,causes,0.8888888888888891,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
1385,EPILEPSY causes SEIZURE,causes,0.8888888888888891,Epileptic women were found to have a 26.1% risk of seizure deterioration during pregnancy and the single most important factor for predicting SEIZURE prognosis was the severity of EPILEPSY prepregnancy.,SEIZURE,EPILEPSY
1386,no_relation,causes,0.620173672946042,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
1387,ANAPLASTIC ASTROCYTOMAS causes ANAPLASIA,causes,0.620173672946042,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
1388,ANAPLASIA causes ANAPLASTIC ASTROCYTOMAS,causes,0.620173672946042,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
1389,no_relation,causes,0.620173672946042,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
1390,no_relation,causes,0.620173672946042,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
1391,ANAPLASIA causes ANAPLASTIC ASTROCYTOMAS,causes,0.620173672946042,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
1392,ANAPLASTIC ASTROCYTOMAS causes ANAPLASIA,causes,0.620173672946042,ANAPLASTIC ASTROCYTOMAS and glioblastomas showed progressive reduction of parenchymal positivity as ANAPLASIA increased.,ANAPLASIA,ANAPLASTIC ASTROCYTOMAS
1393,no_relation,diagnosis,0.304997140665209,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
1394,no_relation,diagnosis,0.304997140665209,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
1395,no_relation,diagnosis,0.304997140665209,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
1396,ENTERIC FEVER diagnosis INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS,diagnosis,0.304997140665209,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
1397,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS diagnosis ENTERIC FEVER,diagnosis,0.304997140665209,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
1398,no_relation,diagnosis,0.304997140665209,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
1399,no_relation,diagnosis,0.304997140665209,"11,12  DIFFERENTIAL DIAGNOSIS  The differential diagnosis of brucellosis includes ENTERIC FEVER malaria, INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS [EBV] infection), atypical mononucleosis (cytomegalovirus infection), Q fever, miliary tuberculosis, subacute bacterial endocarditis, HIV infection, and visceral leishmaniasis (kala azar.",ENTERIC FEVER,INFECTIOUS MONONUCLEOSIS (EPSTEIN BARR VIRUS
1400,RESPIRATORY DISTRESS causes WET LUNG,causes,0.845154254728516,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
1401,WET LUNG causes RESPIRATORY DISTRESS,causes,0.845154254728516,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
1402,WET LUNG causes RESPIRATORY DISTRESS,causes,0.845154254728516,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
1403,WET LUNG causes RESPIRATORY DISTRESS,causes,0.845154254728516,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
1404,no_relation,causes,0.845154254728516,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
1405,no_relation,causes,0.845154254728516,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
1406,WET LUNG causes RESPIRATORY DISTRESS,causes,0.845154254728516,Tracheobronchial saline lavage to dislodge meconium may precipitate RESPIRATORY DISTRESS a WET LUNG appearance and respiratory failure.,RESPIRATORY DISTRESS,WET LUNG
1407,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
1408,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
1409,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
1410,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
1411,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
1412,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
1413,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
1414,VIRUSES causes VIRAL INFECTION,causes,0.936329177569044,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
1415,VIRUSES causes VIRAL INFECTION,causes,0.936329177569044,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
1416,no_relation,causes,0.936329177569044,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
1417,no_relation,causes,0.936329177569044,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
1418,VIRUSES causes VIRAL INFECTION,causes,0.936329177569044,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
1419,no_relation,causes,0.936329177569044,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
1420,VIRUSES causes VIRAL INFECTION,causes,0.936329177569044,"In order to determine the mode of antiviral action, the fragrant sumac extract was added at different times to the cells or VIRUSES during the VIRAL INFECTION cycle.",VIRUSES,VIRAL INFECTION
1421,SKIN location DERMATOPHYTOSES,location,0.981980506061966,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
1422,SKIN location DERMATOPHYTOSES,location,0.981980506061966,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
1423,SKIN location DERMATOPHYTOSES,location,0.981980506061966,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
1424,SKIN location DERMATOPHYTOSES,location,0.981980506061966,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
1425,DERMATOPHYTOSES location SKIN,location,0.981980506061966,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
1426,DERMATOPHYTOSES location SKIN,location,0.981980506061966,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
1427,SKIN location DERMATOPHYTOSES,location,0.981980506061966,"Between 1994 and 1998, a total of 790 feather, hair and SKIN specimens from a variety of animals with suspected DERMATOPHYTOSES were studied, of which 248 (31.4%) yielded dermatophytes.",SKIN,DERMATOPHYTOSES
1428,CONDITION (BINGE) causes BINGE EATING,causes,0.680413817439772,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
1429,CONDITION (BINGE) causes BINGE EATING,causes,0.680413817439772,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
1430,CONDITION (BINGE) causes BINGE EATING,causes,0.680413817439772,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
1431,no_relation,causes,0.680413817439772,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
1432,CONDITION (BINGE) causes BINGE EATING,causes,0.680413817439772,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
1433,no_relation,causes,0.680413817439772,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
1434,CONDITION (BINGE) causes BINGE EATING,causes,0.680413817439772,"Primary end points included the Eating Disorders Inventory (EDI), the Severity Index of Bulimic CONDITION (BINGE) Clinical Global Impression (CGI) scores, and the number of BINGE EATING episodes per week.",BINGE EATING,CONDITION (BINGE)
1435,STAPHYLOCOCCI causes STAPHYLOCOCCAL INFECTIONS,causes,0.7624928516630229,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1436,STAPHYLOCOCCI causes STAPHYLOCOCCAL INFECTIONS,causes,0.7624928516630229,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1437,STAPHYLOCOCCI causes STAPHYLOCOCCAL INFECTIONS,causes,0.7624928516630229,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1438,no_relation,causes,0.7624928516630229,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1439,STAPHYLOCOCCI causes STAPHYLOCOCCAL INFECTIONS,causes,0.7624928516630229,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1440,STAPHYLOCOCCI causes STAPHYLOCOCCAL INFECTIONS,causes,0.7624928516630229,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1441,no_relation,causes,0.7624928516630229,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1442,ATROPINE treats BRADYCARDIA,treats,0.9931270663228408,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
1443,ATROPINE treats BRADYCARDIA,treats,0.9931270663228408,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
1444,ATROPINE treats BRADYCARDIA,treats,0.9931270663228408,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
1445,ATROPINE treats BRADYCARDIA,treats,0.9931270663228408,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
1446,ATROPINE treats BRADYCARDIA,treats,0.9931270663228408,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
1447,ATROPINE treats BRADYCARDIA,treats,0.9931270663228408,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
1448,ATROPINE treats BRADYCARDIA,treats,0.9931270663228408,Bilateral vagotomy also inhibited both effects whereas atropine only reduced the BRADYCARDIA but the combination of ATROPINE and tertatolol suppressed the bradycardia.,BRADYCARDIA,ATROPINE
1449,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
1450,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
1451,ASCITES treats FUROSEMIDE,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
1452,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
1453,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
1454,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
1455,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
1456,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9594032236002472,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
1457,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9594032236002472,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
1458,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9594032236002472,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
1459,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9594032236002472,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
1460,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9594032236002472,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
1461,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9594032236002472,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
1462,MYCOBACTERIUM LEPRAE causes LEPROSY,causes,0.9594032236002472,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY
1463,HEPATITIS B INFECTION treats HEPATITIS B VACCINE,treats,0.964763821237732,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
1464,HEPATITIS B VACCINE treats HEPATITIS B INFECTION,treats,0.964763821237732,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
1465,HEPATITIS B VACCINE treats HEPATITIS B INFECTION,treats,0.964763821237732,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
1466,no_relation,treats,0.964763821237732,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
1467,no_relation,treats,0.964763821237732,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
1468,HEPATITIS B VACCINE treats HEPATITIS B INFECTION,treats,0.964763821237732,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
1469,no_relation,treats,0.964763821237732,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE
1470,BRAIN location CEREBRAL ISCHEMIA,location,0.9491579957524988,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
1471,BRAIN location CEREBRAL ISCHEMIA,location,0.9491579957524988,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
1472,BRAIN location CEREBRAL ISCHEMIA,location,0.9491579957524988,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
1473,BRAIN location CEREBRAL ISCHEMIA,location,0.9491579957524988,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
1474,BRAIN location CEREBRAL ISCHEMIA,location,0.9491579957524988,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
1475,BRAIN location CEREBRAL ISCHEMIA,location,0.9491579957524988,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
1476,no_relation,location,0.9491579957524988,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA
1477,BRONCHIAL HYPERREACTIVITY treats METHACHOLINE,treats,0.693375245281537,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
1478,no_relation,treats,0.693375245281537,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
1479,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.693375245281537,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
1480,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.693375245281537,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
1481,no_relation,treats,0.693375245281537,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
1482,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.693375245281537,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
1483,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.693375245281537,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE
1484,OSTEOPOROSIS causes BONE CELLS,causes,0.529812942826018,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
1485,no_relation,causes,0.529812942826018,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
1486,no_relation,causes,0.529812942826018,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
1487,OSTEOPOROSIS causes BONE CELLS,causes,0.529812942826018,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
1488,no_relation,causes,0.529812942826018,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
1489,BONE CELLS causes OSTEOPOROSIS,causes,0.529812942826018,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
1490,BONE CELLS causes OSTEOPOROSIS,causes,0.529812942826018,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS
1491,no_relation,causes,0.492365963917331,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
1492,no_relation,causes,0.492365963917331,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
1493,HEPATOMA causes ASCITES,causes,0.492365963917331,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
1494,ASCITES causes HEPATOMA,causes,0.492365963917331,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
1495,no_relation,causes,0.492365963917331,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
1496,ASCITES causes HEPATOMA,causes,0.492365963917331,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
1497,no_relation,causes,0.492365963917331,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA
1498,no_relation,causes,0.3396831102433789,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1499,CLL causes LYMPHADENOPATHY,causes,0.3396831102433789,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1500,LYMPHADENOPATHY causes CLL,causes,0.3396831102433789,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1501,CLL causes LYMPHADENOPATHY,causes,0.3396831102433789,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1502,CLL causes LYMPHADENOPATHY,causes,0.3396831102433789,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1503,LYMPHADENOPATHY causes CLL,causes,0.3396831102433789,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1504,no_relation,causes,0.3396831102433789,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1505,no_relation,location,0.384110639798688,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
1506,DPA INDUCED CICATRICIAL PEMPHIGOID location MUCOUS AND CUTANEOUS INVOLVEMENT,location,0.384110639798688,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
1507,DPA INDUCED CICATRICIAL PEMPHIGOID location MUCOUS AND CUTANEOUS INVOLVEMENT,location,0.384110639798688,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
1508,MUCOUS AND CUTANEOUS INVOLVEMENT location DPA INDUCED CICATRICIAL PEMPHIGOID,location,0.384110639798688,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
1509,MUCOUS AND CUTANEOUS INVOLVEMENT location DPA INDUCED CICATRICIAL PEMPHIGOID,location,0.384110639798688,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
1510,no_relation,location,0.384110639798688,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
1511,no_relation,location,0.384110639798688,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID
1512,SEVERE DYSPLASIA causes CARCINOMA IN SITU,causes,0.50709255283711,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
1513,SEVERE DYSPLASIA causes CARCINOMA IN SITU,causes,0.50709255283711,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
1514,no_relation,causes,0.50709255283711,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
1515,no_relation,causes,0.50709255283711,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
1516,no_relation,causes,0.50709255283711,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
1517,CARCINOMA IN SITU causes SEVERE DYSPLASIA,causes,0.50709255283711,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
1518,CARCINOMA IN SITU causes SEVERE DYSPLASIA,causes,0.50709255283711,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU
1519,GLUCAGON treats HYPOGLYCEMIA,treats,1.0,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
1520,GLUCAGON treats HYPOGLYCEMIA,treats,1.0,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
1521,GLUCAGON treats HYPOGLYCEMIA,treats,1.0,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
1522,GLUCAGON treats HYPOGLYCEMIA,treats,1.0,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
1523,GLUCAGON treats HYPOGLYCEMIA,treats,1.0,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
1524,GLUCAGON treats HYPOGLYCEMIA,treats,1.0,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
1525,GLUCAGON treats HYPOGLYCEMIA,treats,1.0,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON
1526,no_relation,causes,0.412081691846067,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
1527,X LINKED INFANTILE SPASMS causes SEIZURES,causes,0.412081691846067,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
1528,no_relation,causes,0.412081691846067,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
1529,X LINKED INFANTILE SPASMS causes SEIZURES,causes,0.412081691846067,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
1530,X LINKED INFANTILE SPASMS causes SEIZURES,causes,0.412081691846067,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
1531,no_relation,causes,0.412081691846067,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
1532,no_relation,causes,0.412081691846067,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS
1533,BRONCHIECTASIS diagnosis SEGMENTAL BRONCHI,diagnosis,0.620173672946042,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
1534,no_relation,diagnosis,0.620173672946042,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
1535,BRONCHIECTASIS diagnosis SEGMENTAL BRONCHI,diagnosis,0.620173672946042,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
1536,no_relation,diagnosis,0.620173672946042,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
1537,BRONCHIECTASIS diagnosis SEGMENTAL BRONCHI,diagnosis,0.620173672946042,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
1538,no_relation,diagnosis,0.620173672946042,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
1539,BRONCHIECTASIS diagnosis SEGMENTAL BRONCHI,diagnosis,0.620173672946042,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS
1540,CHRONIC LYMPHOCYTIC LEUKAEMIA causes INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,causes,0.9830783046228492,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
1541,no_relation,causes,0.9830783046228492,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
1542,CHRONIC LYMPHOCYTIC LEUKAEMIA causes INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,causes,0.9830783046228492,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
1543,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS causes CHRONIC LYMPHOCYTIC LEUKAEMIA,causes,0.9830783046228492,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
1544,no_relation,causes,0.9830783046228492,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
1545,CHRONIC LYMPHOCYTIC LEUKAEMIA causes INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,causes,0.9830783046228492,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
1546,no_relation,causes,0.9830783046228492,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA
1547,no_relation,causes,0.31622776601683805,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1548,SALMONELLA ISOLATES causes AMPICILLIN,causes,0.31622776601683805,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1549,no_relation,causes,0.31622776601683805,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1550,no_relation,causes,0.31622776601683805,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1551,no_relation,causes,0.31622776601683805,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1552,AMPICILLIN causes SALMONELLA ISOLATES,causes,0.31622776601683805,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1553,no_relation,causes,0.31622776601683805,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1554,no_relation,treats,0.905821627315676,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1555,no_relation,treats,0.905821627315676,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1556,CLL treats LYMPHADENOPATHY,treats,0.905821627315676,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1557,CLL treats LYMPHADENOPATHY,treats,0.905821627315676,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1558,no_relation,treats,0.905821627315676,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1559,CLL treats LYMPHADENOPATHY,treats,0.905821627315676,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1560,no_relation,treats,0.905821627315676,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL
1561,CIRRHOSIS treats MILK THISTLE,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
1562,MILK THISTLE treats CIRRHOSIS,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
1563,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
1564,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
1565,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
1566,MILK THISTLE treats CIRRHOSIS,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
1567,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
1568,HEART location MYOCARDIAL ISCHAEMIA,location,0.9830783046228492,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
1569,HEART location MYOCARDIAL ISCHAEMIA,location,0.9830783046228492,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
1570,HEART location MYOCARDIAL ISCHAEMIA,location,0.9830783046228492,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
1571,HEART location MYOCARDIAL ISCHAEMIA,location,0.9830783046228492,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
1572,HEART location MYOCARDIAL ISCHAEMIA,location,0.9830783046228492,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
1573,no_relation,location,0.9830783046228492,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
1574,HEART location MYOCARDIAL ISCHAEMIA,location,0.9830783046228492,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA
1575,HASHIMOTO'S THYROIDITIS location THYROID,location,0.939793423488437,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
1576,THYROID location HASHIMOTO'S THYROIDITIS,location,0.939793423488437,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
1577,THYROID location HASHIMOTO'S THYROIDITIS,location,0.939793423488437,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
1578,THYROID location HASHIMOTO'S THYROIDITIS,location,0.939793423488437,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
1579,THYROID location HASHIMOTO'S THYROIDITIS,location,0.939793423488437,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
1580,THYROID location HASHIMOTO'S THYROIDITIS,location,0.939793423488437,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
1581,no_relation,location,0.939793423488437,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS
1582,THALIDOMIDE treats REFRACTORY MYELOMA,treats,0.970142500145332,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
1583,THALIDOMIDE treats REFRACTORY MYELOMA,treats,0.970142500145332,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
1584,THALIDOMIDE treats REFRACTORY MYELOMA,treats,0.970142500145332,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
1585,THALIDOMIDE treats REFRACTORY MYELOMA,treats,0.970142500145332,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
1586,THALIDOMIDE treats REFRACTORY MYELOMA,treats,0.970142500145332,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
1587,THALIDOMIDE treats REFRACTORY MYELOMA,treats,0.970142500145332,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
1588,THALIDOMIDE treats REFRACTORY MYELOMA,treats,0.970142500145332,THALIDOMIDE was used in 73 patients with REFRACTORY MYELOMA in 15 of 45 institutes participating in the Japan Myeloma Study Group.,REFRACTORY MYELOMA,THALIDOMIDE
1589,PATELLO FEMORAL JOINT location ARTHROSIS OF THE KNEE,location,0.9000703207408192,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
1590,ARTHROSIS OF THE KNEE location PATELLO FEMORAL JOINT,location,0.9000703207408192,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
1591,no_relation,location,0.9000703207408192,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
1592,PATELLO FEMORAL JOINT location ARTHROSIS OF THE KNEE,location,0.9000703207408192,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
1593,PATELLO FEMORAL JOINT location ARTHROSIS OF THE KNEE,location,0.9000703207408192,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
1594,no_relation,location,0.9000703207408192,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
1595,PATELLO FEMORAL JOINT location ARTHROSIS OF THE KNEE,location,0.9000703207408192,The progressive radiological changes in the PATELLO FEMORAL JOINT after upper tibial osteotomy performed for ARTHROSIS OF THE KNEE were studied more than 10 years after the surgical procedure.,PATELLO FEMORAL JOINT,ARTHROSIS OF THE KNEE
1596,no_relation,treats,0.439057039958762,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1597,no_relation,treats,0.439057039958762,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1598,no_relation,treats,0.439057039958762,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1599,no_relation,treats,0.439057039958762,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1600,SPLENIC RUPTURE treats INFECTIOUS MONONUCLEOSIS,treats,0.439057039958762,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1601,no_relation,treats,0.439057039958762,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1602,no_relation,treats,0.439057039958762,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1603,SPLENIC RUPTURE causes INFECTIOUS MONONUCLEOSIS,causes,0.878114079917523,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1604,no_relation,causes,0.878114079917523,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1605,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.878114079917523,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1606,no_relation,causes,0.878114079917523,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1607,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.878114079917523,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1608,INFECTIOUS MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.878114079917523,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1609,SPLENIC RUPTURE causes INFECTIOUS MONONUCLEOSIS,causes,0.878114079917523,This case report draws the attention to the possibility of a conservative surgical treatment of a SPLENIC RUPTURE in the course of INFECTIOUS MONONUCLEOSIS,SPLENIC RUPTURE,INFECTIOUS MONONUCLEOSIS
1610,CANDIDA treats CANDIDEMIA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
1611,no_relation,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
1612,CANDIDA treats CANDIDEMIA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
1613,CANDIDA treats CANDIDEMIA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
1614,CANDIDEMIA treats CANDIDA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
1615,no_relation,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
1616,CANDIDA treats CANDIDEMIA,treats,0.351123441588392,Treatment of CANDIDEMIA is more complicated because of the changing epidemiology of CANDIDA and introduction of newer antifungal agents.,CANDIDA,CANDIDEMIA
1617,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
1618,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
1619,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
1620,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
1621,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
1622,no_relation,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
1623,LIPOSOMAL AMPHOTERICIN B treats DRUG RESISTANT VISCERAL LEISHMANIASIS,treats,0.979957887012223,"This report is of the successful treatment of a patient with multiply DRUG RESISTANT VISCERAL LEISHMANIASIS with a commercially prepared formulation of LIPOSOMAL AMPHOTERICIN B (L AmB) ('AmBisome', Vestar, San Dimas, California, USA.",DRUG RESISTANT VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
1624,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1625,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1626,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1627,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1628,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1629,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1630,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1631,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1632,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1633,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1634,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1635,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1636,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1637,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1638,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1639,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1640,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1641,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1642,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1643,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1644,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1645,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1646,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1647,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1648,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1649,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1650,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1651,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1652,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1653,MULTICENTRIC RETICULOHISTIOCYTOSIS causes SYSTEMIC DISEASE,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1654,SYSTEMIC DISEASE causes MULTICENTRIC RETICULOHISTIOCYTOSIS,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1655,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1656,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1657,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1658,no_relation,causes,0.4375949745,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
1659,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1660,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1661,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1662,no_relation,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1663,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1664,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1665,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1666,no_relation,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1667,no_relation,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1668,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1669,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1670,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1671,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1672,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1673,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1674,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1675,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1676,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1677,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1678,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1679,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1680,no_relation,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1681,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1682,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1683,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1684,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1685,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1686,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1687,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1688,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1689,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1690,no_relation,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1691,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1692,no_relation,causes,0.979957887,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf????����鰹申��申���鐃初�膩��鐃緒申鐃緒申鐔顔��э申?鐃緒��鰹申羝�申����渇���申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃初�鐃�??����渇���申��申鐃緒申鐃緒申鐃緒申??鐃緒��鰹申羝�申��申?鐃緒申�鰹申羝�申���鐃初���申鐃緒申鐃緒申薜合����鐃�鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃�����鰹申��申���鐃初�膩��鐃緒申????����鰹申薜合�����渇�膩��鐃緒申鐃緒申羝�申鐃遵�������渇���申��申鐃緒申鐃緒申鐃醇柑鐃初���申鐃緒申�渇�膩��鐃醇�鐃初�鐃�鐃緒��鰹申羝�申��申鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申����活�鐃緒申鐃緒申鐃緒申羝�申����渇�膩��鐃緒申鐃緒申羝�申鐃緒申鐃�??鐃緒��鰹申羝�申鐃緒申�渇���申鐃醇�鐃処�鐃緒申鐃緒申鐃初���申��申鐃初�膩�����鐃処�鐃緒申鐃緒申鐃緒申羇誌申���鐃緒申鐃緒申��申鐃緒申鐃緒申鐃緒申�鰹申薜合���申?鐃緒��鰹申羝�申��申t spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1693,DIABETIC POLYNEUROPATHY causes DIABETES,causes,0.7559289460184542,"15   In this study and other large studies, the prevalence of diabetic polyneuropathy increased with the duration of DIABETES, and a strong correlation existed between the presence of DIABETIC POLYNEUROPATHY, retinopathy, and nephropathy",DIABETIC POLYNEUROPATHY,DIABETES
1694,DIABETIC POLYNEUROPATHY causes DIABETES,causes,0.7559289460184542,"15   In this study and other large studies, the prevalence of diabetic polyneuropathy increased with the duration of DIABETES, and a strong correlation existed between the presence of DIABETIC POLYNEUROPATHY, retinopathy, and nephropathy",DIABETIC POLYNEUROPATHY,DIABETES
1695,DIABETES causes DIABETIC POLYNEUROPATHY,causes,0.7559289460184542,"15   In this study and other large studies, the prevalence of diabetic polyneuropathy increased with the duration of DIABETES, and a strong correlation existed between the presence of DIABETIC POLYNEUROPATHY, retinopathy, and nephropathy",DIABETIC POLYNEUROPATHY,DIABETES
1696,no_relation,causes,0.7559289460184542,"15   In this study and other large studies, the prevalence of diabetic polyneuropathy increased with the duration of DIABETES, and a strong correlation existed between the presence of DIABETIC POLYNEUROPATHY, retinopathy, and nephropathy",DIABETIC POLYNEUROPATHY,DIABETES
1697,DIABETES causes DIABETIC POLYNEUROPATHY,causes,0.7559289460184542,"15   In this study and other large studies, the prevalence of diabetic polyneuropathy increased with the duration of DIABETES, and a strong correlation existed between the presence of DIABETIC POLYNEUROPATHY, retinopathy, and nephropathy",DIABETIC POLYNEUROPATHY,DIABETES
1698,DIABETES causes DIABETIC POLYNEUROPATHY,causes,0.7559289460184542,"15   In this study and other large studies, the prevalence of diabetic polyneuropathy increased with the duration of DIABETES, and a strong correlation existed between the presence of DIABETIC POLYNEUROPATHY, retinopathy, and nephropathy",DIABETIC POLYNEUROPATHY,DIABETES
1699,no_relation,causes,0.7559289460184542,"15   In this study and other large studies, the prevalence of diabetic polyneuropathy increased with the duration of DIABETES, and a strong correlation existed between the presence of DIABETIC POLYNEUROPATHY, retinopathy, and nephropathy",DIABETIC POLYNEUROPATHY,DIABETES
1700,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1701,PRECOCIOUS PUBERTY causes MCCUNE-ALBRIGHT SYNDROME,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1702,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1703,no_relation,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1704,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1705,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1706,MCCUNE-ALBRIGHT SYNDROME causes PRECOCIOUS PUBERTY,causes,1.0,"The MCCUNE-ALBRIGHT SYNDROME is characterized by cafe-au-lait spots, PRECOCIOUS PUBERTY and fibrous dysplasia",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
1707,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887012223,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1708,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887012223,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1709,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887012223,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1710,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887012223,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1711,no_relation,causes,0.979957887012223,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1712,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887012223,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1713,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887012223,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1714,no_relation,causes,0.676123403782813,"The incidence and mortality, pathogenesis, clinical manifestations, and management of SEPSIS and the SEPSIS SYNDROME are reviewed, and the use of antiendotoxin monoclonal antibodies to treat patients with sepsis is discussed",SEPSIS SYNDROME,SEPSIS
1715,no_relation,causes,0.676123403782813,"The incidence and mortality, pathogenesis, clinical manifestations, and management of SEPSIS and the SEPSIS SYNDROME are reviewed, and the use of antiendotoxin monoclonal antibodies to treat patients with sepsis is discussed",SEPSIS SYNDROME,SEPSIS
1716,SEPSIS SYNDROME causes SEPSIS,causes,0.676123403782813,"The incidence and mortality, pathogenesis, clinical manifestations, and management of SEPSIS and the SEPSIS SYNDROME are reviewed, and the use of antiendotoxin monoclonal antibodies to treat patients with sepsis is discussed",SEPSIS SYNDROME,SEPSIS
1717,no_relation,causes,0.676123403782813,"The incidence and mortality, pathogenesis, clinical manifestations, and management of SEPSIS and the SEPSIS SYNDROME are reviewed, and the use of antiendotoxin monoclonal antibodies to treat patients with sepsis is discussed",SEPSIS SYNDROME,SEPSIS
1718,SEPSIS causes SEPSIS SYNDROME,causes,0.676123403782813,"The incidence and mortality, pathogenesis, clinical manifestations, and management of SEPSIS and the SEPSIS SYNDROME are reviewed, and the use of antiendotoxin monoclonal antibodies to treat patients with sepsis is discussed",SEPSIS SYNDROME,SEPSIS
1719,SEPSIS causes SEPSIS SYNDROME,causes,0.676123403782813,"The incidence and mortality, pathogenesis, clinical manifestations, and management of SEPSIS and the SEPSIS SYNDROME are reviewed, and the use of antiendotoxin monoclonal antibodies to treat patients with sepsis is discussed",SEPSIS SYNDROME,SEPSIS
1720,SEPSIS causes SEPSIS SYNDROME,causes,0.676123403782813,"The incidence and mortality, pathogenesis, clinical manifestations, and management of SEPSIS and the SEPSIS SYNDROME are reviewed, and the use of antiendotoxin monoclonal antibodies to treat patients with sepsis is discussed",SEPSIS SYNDROME,SEPSIS
1721,no_relation,causes,0.452267016866645,This case provides further evidence of a genetic predisposition to RHEUMATIC FEVER and demonstrates the continued value of penicillin in the prophylaxis of ACUTE RHEUMATIC FEVER,ACUTE RHEUMATIC FEVER,RHEUMATIC FEVER
1722,RHEUMATIC FEVER causes ACUTE RHEUMATIC FEVER,causes,0.452267016866645,This case provides further evidence of a genetic predisposition to RHEUMATIC FEVER and demonstrates the continued value of penicillin in the prophylaxis of ACUTE RHEUMATIC FEVER,ACUTE RHEUMATIC FEVER,RHEUMATIC FEVER
1723,RHEUMATIC FEVER causes ACUTE RHEUMATIC FEVER,causes,0.452267016866645,This case provides further evidence of a genetic predisposition to RHEUMATIC FEVER and demonstrates the continued value of penicillin in the prophylaxis of ACUTE RHEUMATIC FEVER,ACUTE RHEUMATIC FEVER,RHEUMATIC FEVER
1724,no_relation,causes,0.452267016866645,This case provides further evidence of a genetic predisposition to RHEUMATIC FEVER and demonstrates the continued value of penicillin in the prophylaxis of ACUTE RHEUMATIC FEVER,ACUTE RHEUMATIC FEVER,RHEUMATIC FEVER
1725,ACUTE RHEUMATIC FEVER causes RHEUMATIC FEVER,causes,0.452267016866645,This case provides further evidence of a genetic predisposition to RHEUMATIC FEVER and demonstrates the continued value of penicillin in the prophylaxis of ACUTE RHEUMATIC FEVER,ACUTE RHEUMATIC FEVER,RHEUMATIC FEVER
1726,no_relation,causes,0.452267016866645,This case provides further evidence of a genetic predisposition to RHEUMATIC FEVER and demonstrates the continued value of penicillin in the prophylaxis of ACUTE RHEUMATIC FEVER,ACUTE RHEUMATIC FEVER,RHEUMATIC FEVER
1727,no_relation,causes,0.452267016866645,This case provides further evidence of a genetic predisposition to RHEUMATIC FEVER and demonstrates the continued value of penicillin in the prophylaxis of ACUTE RHEUMATIC FEVER,ACUTE RHEUMATIC FEVER,RHEUMATIC FEVER
1728,no_relation,causes,0.42426406871192895,"They include increased oxygen consumption, HYPERVENTILATION and RESPIRATORY ALKALOSIS; increased cardiac output, systemic peripheral resistance and blood pressure; delayed gastric emptying; impaired uterine contractility and diminished uterine perfusion; and metabolic acidaemia",RESPIRATORY ALKALOSIS,HYPERVENTILATION
1729,no_relation,causes,0.42426406871192895,"They include increased oxygen consumption, HYPERVENTILATION and RESPIRATORY ALKALOSIS; increased cardiac output, systemic peripheral resistance and blood pressure; delayed gastric emptying; impaired uterine contractility and diminished uterine perfusion; and metabolic acidaemia",RESPIRATORY ALKALOSIS,HYPERVENTILATION
1730,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.42426406871192895,"They include increased oxygen consumption, HYPERVENTILATION and RESPIRATORY ALKALOSIS; increased cardiac output, systemic peripheral resistance and blood pressure; delayed gastric emptying; impaired uterine contractility and diminished uterine perfusion; and metabolic acidaemia",RESPIRATORY ALKALOSIS,HYPERVENTILATION
1731,no_relation,causes,0.42426406871192895,"They include increased oxygen consumption, HYPERVENTILATION and RESPIRATORY ALKALOSIS; increased cardiac output, systemic peripheral resistance and blood pressure; delayed gastric emptying; impaired uterine contractility and diminished uterine perfusion; and metabolic acidaemia",RESPIRATORY ALKALOSIS,HYPERVENTILATION
1732,no_relation,causes,0.42426406871192895,"They include increased oxygen consumption, HYPERVENTILATION and RESPIRATORY ALKALOSIS; increased cardiac output, systemic peripheral resistance and blood pressure; delayed gastric emptying; impaired uterine contractility and diminished uterine perfusion; and metabolic acidaemia",RESPIRATORY ALKALOSIS,HYPERVENTILATION
1733,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.42426406871192895,"They include increased oxygen consumption, HYPERVENTILATION and RESPIRATORY ALKALOSIS; increased cardiac output, systemic peripheral resistance and blood pressure; delayed gastric emptying; impaired uterine contractility and diminished uterine perfusion; and metabolic acidaemia",RESPIRATORY ALKALOSIS,HYPERVENTILATION
1734,no_relation,causes,0.42426406871192895,"They include increased oxygen consumption, HYPERVENTILATION and RESPIRATORY ALKALOSIS; increased cardiac output, systemic peripheral resistance and blood pressure; delayed gastric emptying; impaired uterine contractility and diminished uterine perfusion; and metabolic acidaemia",RESPIRATORY ALKALOSIS,HYPERVENTILATION
1735,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.875189948987367,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with LYMPHADENOPATHY, fever, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1736,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.875189948987367,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with LYMPHADENOPATHY, fever, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1737,no_relation,causes,0.875189948987367,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with LYMPHADENOPATHY, fever, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1738,no_relation,causes,0.875189948987367,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with LYMPHADENOPATHY, fever, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1739,no_relation,causes,0.875189948987367,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with LYMPHADENOPATHY, fever, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1740,no_relation,causes,0.875189948987367,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with LYMPHADENOPATHY, fever, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1741,no_relation,causes,0.875189948987367,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with LYMPHADENOPATHY, fever, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1742,HYPERTENSIVE DISEASE causes HYPERTENSIVE CRISIS,causes,0.857492925712544,The blood antidiuretic activity was studied in patients with HYPERTENSIVE DISEASE in a period between crises and during a HYPERTENSIVE CRISIS,HYPERTENSIVE DISEASE,HYPERTENSIVE CRISIS
1743,no_relation,causes,0.857492925712544,The blood antidiuretic activity was studied in patients with HYPERTENSIVE DISEASE in a period between crises and during a HYPERTENSIVE CRISIS,HYPERTENSIVE DISEASE,HYPERTENSIVE CRISIS
1744,HYPERTENSIVE DISEASE causes HYPERTENSIVE CRISIS,causes,0.857492925712544,The blood antidiuretic activity was studied in patients with HYPERTENSIVE DISEASE in a period between crises and during a HYPERTENSIVE CRISIS,HYPERTENSIVE DISEASE,HYPERTENSIVE CRISIS
1745,HYPERTENSIVE DISEASE causes HYPERTENSIVE CRISIS,causes,0.857492925712544,The blood antidiuretic activity was studied in patients with HYPERTENSIVE DISEASE in a period between crises and during a HYPERTENSIVE CRISIS,HYPERTENSIVE DISEASE,HYPERTENSIVE CRISIS
1746,HYPERTENSIVE DISEASE causes HYPERTENSIVE CRISIS,causes,0.857492925712544,The blood antidiuretic activity was studied in patients with HYPERTENSIVE DISEASE in a period between crises and during a HYPERTENSIVE CRISIS,HYPERTENSIVE DISEASE,HYPERTENSIVE CRISIS
1747,HYPERTENSIVE DISEASE causes HYPERTENSIVE CRISIS,causes,0.857492925712544,The blood antidiuretic activity was studied in patients with HYPERTENSIVE DISEASE in a period between crises and during a HYPERTENSIVE CRISIS,HYPERTENSIVE DISEASE,HYPERTENSIVE CRISIS
1748,HYPERTENSIVE DISEASE causes HYPERTENSIVE CRISIS,causes,0.857492925712544,The blood antidiuretic activity was studied in patients with HYPERTENSIVE DISEASE in a period between crises and during a HYPERTENSIVE CRISIS,HYPERTENSIVE DISEASE,HYPERTENSIVE CRISIS
1749,DYSPLASIA causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1750,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1751,DYSPLASIA causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1752,DYSPLASIA causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1753,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1754,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1755,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1756,DYSPLASIA causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1757,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1758,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1759,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1760,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1761,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1762,DYSPLASIA causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1763,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1764,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1765,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1766,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1767,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1768,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1769,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1770,no_relation,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1771,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1772,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1773,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1774,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1775,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1776,no_relation,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1777,no_relation,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1778,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1779,no_relation,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1780,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1781,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1782,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1783,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1784,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1785,no_relation,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1786,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1787,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1788,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1789,no_relation,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1790,no_relation,causes,0.95257934441568,"Acute toxoplasmosis  may mimic INFECTIOUS MONONUCLEOSIS with lymphadenopathy, FEVER, malaise, myalgia, hepatosplenomegaly, and less commonly, pharyngitis",FEVER,INFECTIOUS MONONUCLEOSIS
1791,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1792,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1793,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1794,no_relation,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1795,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1796,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1797,no_relation,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1798,no_relation,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1799,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1800,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1801,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1802,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1803,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1804,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1805,no_relation,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1806,no_relation,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1807,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1808,INEFFECTIVE HEMATOPOIESIS causes MYELODYSPLASTIC SYNDROMES,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1809,no_relation,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1810,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1811,MYELODYSPLASTIC SYNDROMES causes INEFFECTIVE HEMATOPOIESIS,causes,0.993883734673619,MYELODYSPLASTIC SYNDROMES (MDS) are clonal myeloid disorders characterized by INEFFECTIVE HEMATOPOIESIS resulting in refractory cytopenias,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
1812,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1813,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1814,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1815,no_relation,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1816,BENIGN FOLLICULAR TUMORS location HAIR FOLLICLES,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1817,BENIGN FOLLICULAR TUMORS location HAIR FOLLICLES,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1818,no_relation,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1819,no_relation,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1820,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1821,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1822,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1823,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1824,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1825,BENIGN FOLLICULAR TUMORS location HAIR FOLLICLES,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1826,no_relation,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1827,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1828,no_relation,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1829,no_relation,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1830,HAIR FOLLICLES location BENIGN FOLLICULAR TUMORS,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1831,no_relation,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1832,BENIGN FOLLICULAR TUMORS location HAIR FOLLICLES,location,0.7624928516630229,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
1833,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1834,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1835,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1836,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1837,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1838,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1839,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1840,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1841,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1842,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1843,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1844,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1845,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1846,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1847,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1848,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1849,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1850,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1851,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1852,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1853,no_relation,causes,0.666666666666667,It may produce FEVER and sore throat in young children and INFECTIOUS MONONUCLEOSIS in teenagers and young adults,FEVER,INFECTIOUS MONONUCLEOSIS
1854,FEVER causes INFECTIOUS MONONUCLEOSIS,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
1855,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
1856,INFECTIOUS MONONUCLEOSIS causes FEVER,causes,0.8944271909999159,"Alternatively, the disease may resemble INFECTIOUS MONONUCLEOSIS with FEVER, pharyngitis, hepatosplenomegaly, and adenopathy",FEVER,INFECTIOUS MONONUCLEOSIS
1857,RADIAL GROWTH PHASE causes SUPERFICIAL SPREADING MELANOMA,causes,0.384110639798688,The biologic behavior of the intraepidermal component of SUPERFICIAL SPREADING MELANOMA (the RADIAL GROWTH PHASE) has been demonstrated to have significantly different properties than those of the cells in the vertical growth phase,RADIAL GROWTH PHASE,SUPERFICIAL SPREADING MELANOMA
1858,RADIAL GROWTH PHASE causes SUPERFICIAL SPREADING MELANOMA,causes,0.384110639798688,The biologic behavior of the intraepidermal component of SUPERFICIAL SPREADING MELANOMA (the RADIAL GROWTH PHASE) has been demonstrated to have significantly different properties than those of the cells in the vertical growth phase,RADIAL GROWTH PHASE,SUPERFICIAL SPREADING MELANOMA
1859,no_relation,causes,0.384110639798688,The biologic behavior of the intraepidermal component of SUPERFICIAL SPREADING MELANOMA (the RADIAL GROWTH PHASE) has been demonstrated to have significantly different properties than those of the cells in the vertical growth phase,RADIAL GROWTH PHASE,SUPERFICIAL SPREADING MELANOMA
1860,ESSENTIAL THROMBOCYTHEMIA causes ELEVATED PLATELET COUNT,causes,0.308606699924184,"When accompanied by an ELEVATED PLATELET COUNT, these precursor stages may clinically mimick ESSENTIAL THROMBOCYTHEMIA because they are not recognized by the conventional criteria",ELEVATED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
1861,no_relation,causes,0.308606699924184,"When accompanied by an ELEVATED PLATELET COUNT, these precursor stages may clinically mimick ESSENTIAL THROMBOCYTHEMIA because they are not recognized by the conventional criteria",ELEVATED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
1862,no_relation,causes,0.308606699924184,"When accompanied by an ELEVATED PLATELET COUNT, these precursor stages may clinically mimick ESSENTIAL THROMBOCYTHEMIA because they are not recognized by the conventional criteria",ELEVATED PLATELET COUNT,ESSENTIAL THROMBOCYTHEMIA
1863,HAEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.8682431421244592,"However, the patient deteriorated, with fevers, weight loss, PANCYTOPENIA and laboratory features consistent with the HAEMOPHAGOCYTIC SYNDROME",PANCYTOPENIA,HAEMOPHAGOCYTIC SYNDROME
1864,PANCYTOPENIA causes HAEMOPHAGOCYTIC SYNDROME,causes,0.8682431421244592,"However, the patient deteriorated, with fevers, weight loss, PANCYTOPENIA and laboratory features consistent with the HAEMOPHAGOCYTIC SYNDROME",PANCYTOPENIA,HAEMOPHAGOCYTIC SYNDROME
1865,PANCYTOPENIA causes HAEMOPHAGOCYTIC SYNDROME,causes,0.8682431421244592,"However, the patient deteriorated, with fevers, weight loss, PANCYTOPENIA and laboratory features consistent with the HAEMOPHAGOCYTIC SYNDROME",PANCYTOPENIA,HAEMOPHAGOCYTIC SYNDROME
1866,HAEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.8682431421244592,"However, the patient deteriorated, with fevers, weight loss, PANCYTOPENIA and laboratory features consistent with the HAEMOPHAGOCYTIC SYNDROME",PANCYTOPENIA,HAEMOPHAGOCYTIC SYNDROME
1867,HAEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.8682431421244592,"However, the patient deteriorated, with fevers, weight loss, PANCYTOPENIA and laboratory features consistent with the HAEMOPHAGOCYTIC SYNDROME",PANCYTOPENIA,HAEMOPHAGOCYTIC SYNDROME
1868,HAEMOPHAGOCYTIC SYNDROME causes PANCYTOPENIA,causes,0.8682431421244592,"However, the patient deteriorated, with fevers, weight loss, PANCYTOPENIA and laboratory features consistent with the HAEMOPHAGOCYTIC SYNDROME",PANCYTOPENIA,HAEMOPHAGOCYTIC SYNDROME
1869,HEPATOCELLULAR CARCINOMA causes FEVER,causes,0.964901281354015,A 52-year-old man with HEPATOCELLULAR CARCINOMA (HCC) was admitted with cough and FEVER,FEVER,HEPATOCELLULAR CARCINOMA
1870,FEVER causes HEPATOCELLULAR CARCINOMA,causes,0.964901281354015,A 52-year-old man with HEPATOCELLULAR CARCINOMA (HCC) was admitted with cough and FEVER,FEVER,HEPATOCELLULAR CARCINOMA
1871,HEPATOCELLULAR CARCINOMA causes FEVER,causes,0.964901281354015,A 52-year-old man with HEPATOCELLULAR CARCINOMA (HCC) was admitted with cough and FEVER,FEVER,HEPATOCELLULAR CARCINOMA
1872,SPLENOMEGALY causes GAMMA HEAVY CHAIN DISEASE,causes,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
1873,GAMMA HEAVY CHAIN DISEASE causes SPLENOMEGALY,causes,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
1874,no_relation,causes,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
1875,LIVER location HEPATIC METASTASIS,location,0.956182887467515,A 45-year-old woman underwent a resection for a HEPATIC METASTASIS of the LIVER caused by a carcinoma of the colon,LIVER,HEPATIC METASTASIS
1876,LIVER location HEPATIC METASTASIS,location,0.956182887467515,A 45-year-old woman underwent a resection for a HEPATIC METASTASIS of the LIVER caused by a carcinoma of the colon,LIVER,HEPATIC METASTASIS
1877,HEPATIC METASTASIS location LIVER,location,0.956182887467515,A 45-year-old woman underwent a resection for a HEPATIC METASTASIS of the LIVER caused by a carcinoma of the colon,LIVER,HEPATIC METASTASIS
1878,no_relation,diagnosis,0.452267016866645,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
1879,SPINAL CORD diagnosis NEUROMYELITIS OPTICA,diagnosis,0.452267016866645,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
1880,NEUROMYELITIS OPTICA diagnosis SPINAL CORD,diagnosis,0.452267016866645,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
1881,PANCREAS causes PANCREATITIS,causes,0.486664263392288,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
1882,no_relation,causes,0.486664263392288,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
1883,PANCREAS causes PANCREATITIS,causes,0.486664263392288,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
1884,no_relation,causes,0.462910049886276,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1885,COLITIS causes COLON,causes,0.462910049886276,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1886,COLITIS causes COLON,causes,0.462910049886276,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1887,COLON location COLITIS,location,0.617213399848368,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1888,COLON location COLITIS,location,0.617213399848368,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1889,COLON location COLITIS,location,0.617213399848368,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1890,COLITIS location COLON,location,0.617213399848368,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1891,COLON location COLITIS,location,0.617213399848368,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1892,no_relation,location,0.617213399848368,"In conclusion, chronic exposure to CSC alters relevant neuronal, neuroendocrine and immune functions that could be directly or indirectly involved in the damage of the histological integrity of the COLON comparable with that seen during the development of COLITIS",COLON,COLITIS
1893,HUNTINGTON'S DISEASE causes BASAL GANGLIA STRUCTURES,causes,0.676123403782813,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
1894,no_relation,causes,0.676123403782813,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
1895,no_relation,causes,0.676123403782813,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
1896,HUNTINGTON'S DISEASE location BASAL GANGLIA STRUCTURES,location,0.50709255283711,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
1897,no_relation,location,0.50709255283711,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
1898,HUNTINGTON'S DISEASE location BASAL GANGLIA STRUCTURES,location,0.50709255283711,Studies of eye movements in patients with HUNTINGTON'S DISEASE (HD) have suggested that frontal lobe-BASAL GANGLIA STRUCTURES are more involved in HD than the parietal lobes,BASAL GANGLIA STRUCTURES,HUNTINGTON'S DISEASE
1899,SPINAL CORD treats SPINAL CORD INJURY,treats,0.617213399848368,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
1900,SPINAL CORD INJURY treats SPINAL CORD,treats,0.617213399848368,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
1901,SPINAL CORD treats SPINAL CORD INJURY,treats,0.617213399848368,"Recent reports have also shown that exercise induces molecular mechanisms that benefit the SPINAL CORD and can improve recovery after SPINAL CORD INJURY (SCI); therefore, we repeated the assays in the spinal cord",SPINAL CORD,SPINAL CORD INJURY
1902,no_relation,causes,0.514495755427526,DISEASE NAME AND SYNONYMS: Syndromic diarrhea - Phenotypic diarrhea - Tricho-hepato-enteric syndrome - Intractable diarrhea of infancy with facial dysmorphism - Trichorrhexis nodosa and CIRRHOSIS - NEONATAL HEMOCHROMATOSIS phenotype with intractable diarrhea and hair abnormalities - Intractable infant diarrhea associated with phenotypic abnormalities and immune deficiency,CIRRHOSIS,NEONATAL HEMOCHROMATOSIS
1903,CIRRHOSIS causes NEONATAL HEMOCHROMATOSIS,causes,0.514495755427526,DISEASE NAME AND SYNONYMS: Syndromic diarrhea - Phenotypic diarrhea - Tricho-hepato-enteric syndrome - Intractable diarrhea of infancy with facial dysmorphism - Trichorrhexis nodosa and CIRRHOSIS - NEONATAL HEMOCHROMATOSIS phenotype with intractable diarrhea and hair abnormalities - Intractable infant diarrhea associated with phenotypic abnormalities and immune deficiency,CIRRHOSIS,NEONATAL HEMOCHROMATOSIS
1904,no_relation,causes,0.514495755427526,DISEASE NAME AND SYNONYMS: Syndromic diarrhea - Phenotypic diarrhea - Tricho-hepato-enteric syndrome - Intractable diarrhea of infancy with facial dysmorphism - Trichorrhexis nodosa and CIRRHOSIS - NEONATAL HEMOCHROMATOSIS phenotype with intractable diarrhea and hair abnormalities - Intractable infant diarrhea associated with phenotypic abnormalities and immune deficiency,CIRRHOSIS,NEONATAL HEMOCHROMATOSIS
1905,ASTHMA causes ATOPIC DERMATITIS,causes,0.98058067569092,"Indeed, epicutaneous sensitization of mice to a protein antigen induces both a localized allergic dermatitis and hyperresponsiveness to methacholine, which suggests that epicutaneous exposure to antigen in ATOPIC DERMATITIS may enhance the development of ASTHMA",ASTHMA,ATOPIC DERMATITIS
1906,ATOPIC DERMATITIS causes ASTHMA,causes,0.98058067569092,"Indeed, epicutaneous sensitization of mice to a protein antigen induces both a localized allergic dermatitis and hyperresponsiveness to methacholine, which suggests that epicutaneous exposure to antigen in ATOPIC DERMATITIS may enhance the development of ASTHMA",ASTHMA,ATOPIC DERMATITIS
1907,ATOPIC DERMATITIS causes ASTHMA,causes,0.98058067569092,"Indeed, epicutaneous sensitization of mice to a protein antigen induces both a localized allergic dermatitis and hyperresponsiveness to methacholine, which suggests that epicutaneous exposure to antigen in ATOPIC DERMATITIS may enhance the development of ASTHMA",ASTHMA,ATOPIC DERMATITIS
1908,STURGE-WEBER SYNDROME causes GLAUCOMA,causes,0.629940788348712,"The results of our data can serve as a guide for estimating relative risk figures for seizures, GLAUCOMA, and mental retardation in children with STURGE-WEBER SYNDROME",GLAUCOMA,STURGE-WEBER SYNDROME
1909,STURGE-WEBER SYNDROME causes GLAUCOMA,causes,0.629940788348712,"The results of our data can serve as a guide for estimating relative risk figures for seizures, GLAUCOMA, and mental retardation in children with STURGE-WEBER SYNDROME",GLAUCOMA,STURGE-WEBER SYNDROME
1910,no_relation,causes,0.629940788348712,"The results of our data can serve as a guide for estimating relative risk figures for seizures, GLAUCOMA, and mental retardation in children with STURGE-WEBER SYNDROME",GLAUCOMA,STURGE-WEBER SYNDROME
1911,LUPUS causes HAEMOLYTIC ANAEMIA,causes,0.927172649945531,"The presence of HAEMOLYTIC ANAEMIA in LUPUS patients was associated with a higher frequency of proteinuria (OR = 2.70, P = 0.000031), urinary cellular casts (OR = 2.83, P = 0.000062), seizures (OR = 2.96, P = 0.00024), pericarditis (OR = 2.21, P = 0.0019), pleuritis (OR = 1.72, P = 0.028) and lymphopenia (OR = 1.79, P = 0.015",HAEMOLYTIC ANAEMIA,LUPUS
1912,LUPUS causes HAEMOLYTIC ANAEMIA,causes,0.927172649945531,"The presence of HAEMOLYTIC ANAEMIA in LUPUS patients was associated with a higher frequency of proteinuria (OR = 2.70, P = 0.000031), urinary cellular casts (OR = 2.83, P = 0.000062), seizures (OR = 2.96, P = 0.00024), pericarditis (OR = 2.21, P = 0.0019), pleuritis (OR = 1.72, P = 0.028) and lymphopenia (OR = 1.79, P = 0.015",HAEMOLYTIC ANAEMIA,LUPUS
1913,HAEMOLYTIC ANAEMIA causes LUPUS,causes,0.927172649945531,"The presence of HAEMOLYTIC ANAEMIA in LUPUS patients was associated with a higher frequency of proteinuria (OR = 2.70, P = 0.000031), urinary cellular casts (OR = 2.83, P = 0.000062), seizures (OR = 2.96, P = 0.00024), pericarditis (OR = 2.21, P = 0.0019), pleuritis (OR = 1.72, P = 0.028) and lymphopenia (OR = 1.79, P = 0.015",HAEMOLYTIC ANAEMIA,LUPUS
1914,no_relation,causes,0.493196961916072,"The cleavage of MUC5AC and the generation of the reactive new C-terminus could contribute to the adherent and viscous mucus found at chronic lung diseases such as ASTHMA and CYSTIC FIBROSIS, characterized by mucus hypersecretion and lowered pH of the airways",ASTHMA,CYSTIC FIBROSIS
1915,no_relation,causes,0.493196961916072,"The cleavage of MUC5AC and the generation of the reactive new C-terminus could contribute to the adherent and viscous mucus found at chronic lung diseases such as ASTHMA and CYSTIC FIBROSIS, characterized by mucus hypersecretion and lowered pH of the airways",ASTHMA,CYSTIC FIBROSIS
1916,no_relation,causes,0.493196961916072,"The cleavage of MUC5AC and the generation of the reactive new C-terminus could contribute to the adherent and viscous mucus found at chronic lung diseases such as ASTHMA and CYSTIC FIBROSIS, characterized by mucus hypersecretion and lowered pH of the airways",ASTHMA,CYSTIC FIBROSIS
1917,HUNTINGTON'S DISEASE causes DEMENTIA,causes,0.8888888888888891,"A controlled prospective study compared the performance of 14 patients with dementia of Alzheimer type (DAT) and 14 patients with HUNTINGTON'S DISEASE (HD), who were matched for overall level of DEMENTIA, on a battery of semantic and episodic memory tests",DEMENTIA,HUNTINGTON'S DISEASE
1918,DEMENTIA causes HUNTINGTON'S DISEASE,causes,0.8888888888888891,"A controlled prospective study compared the performance of 14 patients with dementia of Alzheimer type (DAT) and 14 patients with HUNTINGTON'S DISEASE (HD), who were matched for overall level of DEMENTIA, on a battery of semantic and episodic memory tests",DEMENTIA,HUNTINGTON'S DISEASE
1919,DEMENTIA causes HUNTINGTON'S DISEASE,causes,0.8888888888888891,"A controlled prospective study compared the performance of 14 patients with dementia of Alzheimer type (DAT) and 14 patients with HUNTINGTON'S DISEASE (HD), who were matched for overall level of DEMENTIA, on a battery of semantic and episodic memory tests",DEMENTIA,HUNTINGTON'S DISEASE
1920,no_relation,treats,0.609994281330419,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
1921,HAIR PULLING treats TRICHOTILLOMANIA,treats,0.609994281330419,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
1922,no_relation,treats,0.609994281330419,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
1923,no_relation,treats,0.609994281330419,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
1924,TRICHOTILLOMANIA treats HAIR PULLING,treats,0.609994281330419,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
1925,HAIR PULLING treats TRICHOTILLOMANIA,treats,0.609994281330419,Investigations of the affective and sensory states contributing to the etiology and maintenance of HAIR PULLING may help to elucidate the classification of TRICHOTILLOMANIA (TTM) as an impulse control disorder or obsessive-compulsive spectrum disorder,HAIR PULLING,TRICHOTILLOMANIA
1926,DEXAMETHASONE treats CUSHING SYNDROME,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
1927,DEXAMETHASONE treats CUSHING SYNDROME,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
1928,no_relation,treats,0.7624928516630229,"We tried to detect salivary cortisol level with drug loading test(DEXAMETHASONE for CUSHING SYNDROME, and ACTH for adrenal insufficiency) with time interval",CUSHING SYNDROME,DEXAMETHASONE
1929,WARFARIN treats PULMONARY EMBOLISM,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
1930,WARFARIN treats PULMONARY EMBOLISM,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
1931,no_relation,treats,0.9950371902099888,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
1932,ADEFOVIR treats HBV,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
1933,ADEFOVIR treats HBV,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
1934,ADEFOVIR treats HBV,treats,1.0,Individuals Coinfected with HBV and HIV  Use of ADEFOVIR for the treatment of chronic HBV infection in patients with unrecognized or untreated HIV infection may result in emergence of HIV resistance,HBV,ADEFOVIR
1935,RHEUMATOID ARTHRITIS diagnosis DIFLUNISAL,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1936,no_relation,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1937,no_relation,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1938,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
1939,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
1940,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
1941,ENDOMETRIAL CARCINOMA contraindicates POSTMENOPAUSAL BLEEDING,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
1942,no_relation,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
1943,POSTMENOPAUSAL BLEEDING contraindicates ENDOMETRIAL CARCINOMA,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
1944,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
1945,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
1946,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,1.0,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
1947,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
1948,no_relation,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
1949,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
1950,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
1951,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
1952,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.997054485501582,"These areas include rubella virus as a cause of congenital rubella syndrome, FOLIC ACID as a preventive factor for NEURAL TUBE DEFECTS, cytomegalovirus infection as a cause of birth defects and developmental disabilities, and alcohol as a cause of fetal alcohol spectrum disorders",NEURAL TUBE DEFECTS,FOLIC ACID
1953,LIGNOCAINE treats PAIN,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
1954,LIGNOCAINE treats PAIN,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
1955,LIGNOCAINE treats PAIN,treats,0.995893206467704,When administered intravenously in the dorsum of the hand the pain score and the number of patients who experienced PAIN was reduced significantly by mixing the agent with LIGNOCAINE when compared with a bolus injection,PAIN,LIGNOCAINE
1956,MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
1957,MONONUCLEOSIS causes SPLENIC RUPTURE,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
1958,no_relation,causes,0.970494958830946,We do not recommend observation of SPLENIC RUPTURE in patients with MONONUCLEOSIS because of the danger of delayed hemorrhage,SPLENIC RUPTURE,MONONUCLEOSIS
1959,INVASIVE DUCTAL CARCINOMA causes SOLID PATTERN,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1960,no_relation,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1961,no_relation,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1962,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
1963,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
1964,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
1965,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
1966,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
1967,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
1968,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
1969,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
1970,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
1971,no_relation,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
1972,ENDOMETRIAL CARCINOMA causes POSTMENOPAUSAL BLEEDING,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
1973,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CARCINOMA,causes,0.7715167498104591,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
1974,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
1975,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
1976,ITRACONAZOLE treats BLASTOMYCOSIS,treats,1.0,"Children with BLASTOMYCOSIS should be treated with ITRACONAZOLE, 5 to 7 mg/kg/day",BLASTOMYCOSIS,ITRACONAZOLE
1977,TERBINAFINE treats TINEA CAPITIS,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
1978,TERBINAFINE treats TINEA CAPITIS,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
1979,TERBINAFINE treats TINEA CAPITIS,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
1980,DCIS diagnosis MICROCALCIFICATION,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
1981,DCIS diagnosis MICROCALCIFICATION,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
1982,DCIS diagnosis MICROCALCIFICATION,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
1983,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
1984,no_relation,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
1985,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
1986,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
1987,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
1988,no_relation,causes,0.416025147168922,"SMMCI has also been found as an isolated finding or together with other anomalies such as MICROCEPHALY, short stature, endocrine pathology, and choanal atresia",MICROCEPHALY,SMMCI
1989,RUBELLA VACCINE treats RUBELLA,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
1990,no_relation,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
1991,RUBELLA VACCINE treats RUBELLA,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
1992,no_relation,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
1993,RUBELLA VACCINE treats RUBELLA,treats,1.0,RUBELLA VACCINE should continue to be used to immunize susceptible adult women against RUBELLA in order to further the goal of elimination of the congenital rubella syndrome,RUBELLA,RUBELLA VACCINE
1994,no_relation,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1995,RHEUMATOID ARTHRITIS diagnosis DIFLUNISAL,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1996,no_relation,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1997,no_relation,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1998,RHEUMATOID ARTHRITIS diagnosis DIFLUNISAL,diagnosis,0.34874291623145803,"Palmer DG, Ferry DG, Gibbins BL et al. Ibuprofen and DIFLUNISAL in RHEUMATOID ARTHRITIS: a double-blind comparative trial",RHEUMATOID ARTHRITIS,DIFLUNISAL
1999,ANAPHYLAXIS treats EPINEPHRINE,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
2000,no_relation,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
2001,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
2002,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
2003,ANAPHYLAXIS treats EPINEPHRINE,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
2004,MALIGNANT PLEURAL MESOTHELIOMA causes CHEST PAIN,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
2005,MALIGNANT PLEURAL MESOTHELIOMA causes CHEST PAIN,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
2006,no_relation,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
2007,no_relation,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
2008,MALIGNANT PLEURAL MESOTHELIOMA causes CHEST PAIN,causes,0.98058067569092,"In patients with MALIGNANT PLEURAL MESOTHELIOMA, radiotherapy is useful in the palliation of symptoms of CHEST PAIN and painful masses",CHEST PAIN,MALIGNANT PLEURAL MESOTHELIOMA
2009,no_relation,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
2010,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
2011,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
2012,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
2013,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.896258159530272,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
2014,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2015,no_relation,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2016,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2017,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2018,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2019,ISOTRETINOIN treats ACNE,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2020,ISOTRETINOIN treats ACNE,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2021,no_relation,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2022,ISOTRETINOIN treats ACNE,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2023,ISOTRETINOIN treats ACNE,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2024,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
2025,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
2026,no_relation,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
2027,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
2028,ERECTILE DYSFUNCTION treats PAPAVERINE,treats,0.9838699100999068,"In our experience, E1-PG intracavernous injection has proven to be more effective than PAPAVERINE in the treatment of ERECTILE DYSFUNCTION and therefore, added to its safety and degree of acceptance, we consider it a first choice approach in the diagnosis and treatment of erectile dysfunction in males",ERECTILE DYSFUNCTION,PAPAVERINE
2029,IMIPRAMINE treats DEPRESSION,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
2030,IMIPRAMINE treats DEPRESSION,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
2031,no_relation,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
2032,IMIPRAMINE treats DEPRESSION,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
2033,DEPRESSION treats IMIPRAMINE,treats,1.0,A double-blind comparison of the efficacy and safety of paroxetine and IMIPRAMINE in the treatment of DEPRESSION with dementia,DEPRESSION,IMIPRAMINE
2034,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
2035,no_relation,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
2036,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
2037,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
2038,OSTEOPOROSIS treats CHOLECALCIFEROL,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
2039,no_relation,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
2040,ORLISTAT treats OBESITY,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
2041,ORLISTAT treats OBESITY,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
2042,ORLISTAT treats OBESITY,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
2043,ORLISTAT treats OBESITY,treats,0.9578262852211508,"James WP, Avenell A, Broom J et al. A one-year trial to assess the value of ORLISTAT in the management of OBESITY",OBESITY,ORLISTAT
2044,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
2045,no_relation,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
2046,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
2047,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
2048,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
2049,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
2050,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
2051,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
2052,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
2053,no_relation,causes,0.34815531191139604,Evidence: ? Vigilant intraoperative management of HYPERTENSION is essential during resection of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
2054,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
2055,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
2056,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
2057,MULTIPLE MYELOMA treats INTERFERON,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
2058,INTERFERON treats MULTIPLE MYELOMA,treats,1.0,The use of INTERFERON in the treatment of MULTIPLE MYELOMA,MULTIPLE MYELOMA,INTERFERON
2059,TERBINAFINE treats TINEA CAPITIS,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
2060,TERBINAFINE treats TINEA CAPITIS,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
2061,TERBINAFINE treats TINEA CAPITIS,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
2062,TINEA CAPITIS treats TERBINAFINE,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
2063,TERBINAFINE treats TINEA CAPITIS,treats,0.9950371902099888,"Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of TERBINAFINE in the treatment of TINEA CAPITIS",TINEA CAPITIS,TERBINAFINE
2064,ONDANSETRON treats EMESIS,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
2065,ONDANSETRON treats EMESIS,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
2066,no_relation,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
2067,ONDANSETRON treats EMESIS,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
2068,ONDANSETRON treats EMESIS,treats,0.964901281354015,Eight patients achieved good control of nausea and EMESIS with ondansetron alone while two patients required ONDANSETRON and diphenhydramine,EMESIS,ONDANSETRON
2069,DEXAMETHASONE contraindicates HYPERCORTISOLISM,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2070,HYPERCORTISOLISM contraindicates DEXAMETHASONE,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2071,HYPERCORTISOLISM contraindicates DEXAMETHASONE,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2072,DEXAMETHASONE contraindicates HYPERCORTISOLISM,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2073,no_relation,contraindicates,0.468521285665818,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2074,no_relation,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
2075,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
2076,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
2077,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
2078,SIMVASTATIN treats HYPERCHOLESTEROLEMIA,treats,1.0,"Tikkanen MJ, Laakso M, Ilmonen M et al. Treatment of HYPERCHOLESTEROLEMIA and combined hyperlipidemia with SIMVASTATIN and gemfibrozil in patients with NIDDM",HYPERCHOLESTEROLEMIA,SIMVASTATIN
2079,OSTEOPOROSIS diagnose_by_test_or_drug BONE,diagnosis,0.4472135955,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
2080,OSTEOPOROSIS diagnose_by_test_or_drug BONE,diagnosis,0.4472135955,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
2081,no_relation,diagnosis,0.4472135955,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
2082,no_relation,diagnosis,0.4472135955,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
2083,BONE diagnose_by_test_or_drug OSTEOPOROSIS,diagnosis,0.4472135955,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
2084,OSTEOPOROSIS diagnose_by_test_or_drug BONE,diagnosis,0.4472135955,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
2085,BONE diagnose_by_test_or_drug OSTEOPOROSIS,diagnosis,0.4472135955,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
2086,SPONDYLOARTHROPATHIES causes ANKYLOSING SPONDYLITIS,causes,0.8333333333,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
2087,no_relation,causes,0.8333333333,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
2088,no_relation,causes,0.8333333333,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
2089,SPONDYLOARTHROPATHIES causes ANKYLOSING SPONDYLITIS,causes,0.8333333333,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
2090,no_relation,causes,0.8333333333,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
2091,ANKYLOSING SPONDYLITIS causes SPONDYLOARTHROPATHIES,causes,0.8333333333,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
2092,no_relation,causes,0.8333333333,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
2093,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.9958932065,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
2094,no_relation,diagnosis,0.9958932065,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
2095,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.9958932065,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
2096,no_relation,diagnosis,0.9958932065,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
2097,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.9958932065,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
2098,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.9958932065,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
2099,DEPRESSION diagnose_by_test_or_drug DEXAMETHASONE,diagnosis,0.9958932065,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
2100,PHAEOCHROMOCYTOMA causes HYPERTENSION,causes,0.8944271909999999,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
2101,HYPERTENSION causes PHAEOCHROMOCYTOMA,causes,0.8944271909999999,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
2102,no_relation,causes,0.8944271909999999,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
2103,no_relation,causes,0.8944271909999999,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
2104,PHAEOCHROMOCYTOMA causes HYPERTENSION,causes,0.8944271909999999,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
2105,HYPERTENSION causes PHAEOCHROMOCYTOMA,causes,0.8944271909999999,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
2106,PHAEOCHROMOCYTOMA causes HYPERTENSION,causes,0.8944271909999999,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
2107,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.9701425001,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
2108,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.9701425001,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
2109,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.9701425001,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
2110,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.9701425001,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
2111,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.9701425001,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
2112,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.9701425001,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
2113,THALIDOMIDE treats CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,treats,0.9701425001,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
2114,TUBERCULIN treats 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),treats,0.6123724357,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
2115,no_relation,treats,0.6123724357,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
2116,no_relation,treats,0.6123724357,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
2117,no_relation,treats,0.6123724357,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
2118,10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) treats TUBERCULIN,treats,0.6123724357,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
2119,no_relation,treats,0.6123724357,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
2120,no_relation,treats,0.6123724357,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
2121,INFLUENZA VIRUS causes PANDEMIC INFLUENZA,causes,0.913811548620257,51  Pandemic Influenza  Treatment or prevention of PANDEMIC INFLUENZA   +    caused by susceptible strains of INFLUENZA VIRUS,PANDEMIC INFLUENZA,INFLUENZA VIRUS
2122,INFLUENZA VIRUS causes PANDEMIC INFLUENZA,causes,0.913811548620257,51  Pandemic Influenza  Treatment or prevention of PANDEMIC INFLUENZA   +    caused by susceptible strains of INFLUENZA VIRUS,PANDEMIC INFLUENZA,INFLUENZA VIRUS
2123,INFLUENZA VIRUS causes PANDEMIC INFLUENZA,causes,0.913811548620257,51  Pandemic Influenza  Treatment or prevention of PANDEMIC INFLUENZA   +    caused by susceptible strains of INFLUENZA VIRUS,PANDEMIC INFLUENZA,INFLUENZA VIRUS
2124,INFLUENZA VIRUS causes PANDEMIC INFLUENZA,causes,0.913811548620257,51  Pandemic Influenza  Treatment or prevention of PANDEMIC INFLUENZA   +    caused by susceptible strains of INFLUENZA VIRUS,PANDEMIC INFLUENZA,INFLUENZA VIRUS
2125,INFLUENZA VIRUS causes PANDEMIC INFLUENZA,causes,0.913811548620257,51  Pandemic Influenza  Treatment or prevention of PANDEMIC INFLUENZA   +    caused by susceptible strains of INFLUENZA VIRUS,PANDEMIC INFLUENZA,INFLUENZA VIRUS
2126,INFLUENZA VIRUS causes PANDEMIC INFLUENZA,causes,0.913811548620257,51  Pandemic Influenza  Treatment or prevention of PANDEMIC INFLUENZA   +    caused by susceptible strains of INFLUENZA VIRUS,PANDEMIC INFLUENZA,INFLUENZA VIRUS
2127,no_relation,causes,0.913811548620257,51  Pandemic Influenza  Treatment or prevention of PANDEMIC INFLUENZA   +    caused by susceptible strains of INFLUENZA VIRUS,PANDEMIC INFLUENZA,INFLUENZA VIRUS
2128,no_relation,causes,0.557086014531156,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
2129,LATENT TB causes TUBERCULOSIS,causes,0.557086014531156,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
2130,no_relation,causes,0.557086014531156,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
2131,no_relation,causes,0.557086014531156,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
2132,no_relation,causes,0.557086014531156,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
2133,no_relation,causes,0.557086014531156,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
2134,no_relation,causes,0.557086014531156,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
2135,NF2 causes HEARING LOSS,causes,0.9,"edit] Management of Hearing Loss in NF2  Because HEARING LOSS in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology.",HEARING LOSS,NF2
2136,NF2 causes HEARING LOSS,causes,0.9,"edit] Management of Hearing Loss in NF2  Because HEARING LOSS in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology.",HEARING LOSS,NF2
2137,no_relation,causes,0.9,"edit] Management of Hearing Loss in NF2  Because HEARING LOSS in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology.",HEARING LOSS,NF2
2138,no_relation,causes,0.9,"edit] Management of Hearing Loss in NF2  Because HEARING LOSS in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology.",HEARING LOSS,NF2
2139,no_relation,causes,0.9,"edit] Management of Hearing Loss in NF2  Because HEARING LOSS in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology.",HEARING LOSS,NF2
2140,NF2 causes HEARING LOSS,causes,0.9,"edit] Management of Hearing Loss in NF2  Because HEARING LOSS in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology.",HEARING LOSS,NF2
2141,NF2 causes HEARING LOSS,causes,0.9,"edit] Management of Hearing Loss in NF2  Because HEARING LOSS in those with NF2 almost always occurs after acquisition of verbal language skills, patients do not always integrate well into the Deaf culture and are more likely to resort to auditory assistive technology.",HEARING LOSS,NF2
2142,no_relation,causes,0.9237604307034007,DIABETES INSIPIDUS may develop if less VASOPRESSIN is released because the hypothalamus is compressed.,DIABETES INSIPIDUS,VASOPRESSIN
2143,VASOPRESSIN causes DIABETES INSIPIDUS,causes,0.9237604307034007,DIABETES INSIPIDUS may develop if less VASOPRESSIN is released because the hypothalamus is compressed.,DIABETES INSIPIDUS,VASOPRESSIN
2144,VASOPRESSIN causes DIABETES INSIPIDUS,causes,0.9237604307034007,DIABETES INSIPIDUS may develop if less VASOPRESSIN is released because the hypothalamus is compressed.,DIABETES INSIPIDUS,VASOPRESSIN
2145,no_relation,causes,0.9237604307034007,DIABETES INSIPIDUS may develop if less VASOPRESSIN is released because the hypothalamus is compressed.,DIABETES INSIPIDUS,VASOPRESSIN
2146,DIABETES INSIPIDUS causes VASOPRESSIN,causes,0.9237604307034007,DIABETES INSIPIDUS may develop if less VASOPRESSIN is released because the hypothalamus is compressed.,DIABETES INSIPIDUS,VASOPRESSIN
2147,no_relation,causes,0.9237604307034007,DIABETES INSIPIDUS may develop if less VASOPRESSIN is released because the hypothalamus is compressed.,DIABETES INSIPIDUS,VASOPRESSIN
2148,no_relation,causes,0.9237604307034007,DIABETES INSIPIDUS may develop if less VASOPRESSIN is released because the hypothalamus is compressed.,DIABETES INSIPIDUS,VASOPRESSIN
2149,no_relation,causes,0.8427009716003839,"175 ,   176 ,   177 ,   178 ,   179 ,   187 ,   188    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefixime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2150,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.8427009716003839,"175 ,   176 ,   177 ,   178 ,   179 ,   187 ,   188    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefixime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2151,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.8427009716003839,"175 ,   176 ,   177 ,   178 ,   179 ,   187 ,   188    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefixime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2152,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.8427009716003839,"175 ,   176 ,   177 ,   178 ,   179 ,   187 ,   188    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefixime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2153,no_relation,causes,0.8427009716003839,"175 ,   176 ,   177 ,   178 ,   179 ,   187 ,   188    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefixime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2154,no_relation,causes,0.8427009716003839,"175 ,   176 ,   177 ,   178 ,   179 ,   187 ,   188    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefixime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2155,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.8427009716003839,"175 ,   176 ,   177 ,   178 ,   179 ,   187 ,   188    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefixime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2156,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.9950371902099888,"Abstract  November 2010  7 Infectious Disease  XVIII Infective Endocarditis  ELIZABETH G. NABEL, MD, FACP President, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA  INFECTIVE ENDOCARDITIS is a microbial infection of a cardiac valve or the mural endocardium caused by BACTERIA or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
2157,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.9950371902099888,"Abstract  November 2010  7 Infectious Disease  XVIII Infective Endocarditis  ELIZABETH G. NABEL, MD, FACP President, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA  INFECTIVE ENDOCARDITIS is a microbial infection of a cardiac valve or the mural endocardium caused by BACTERIA or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
2158,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.9950371902099888,"Abstract  November 2010  7 Infectious Disease  XVIII Infective Endocarditis  ELIZABETH G. NABEL, MD, FACP President, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA  INFECTIVE ENDOCARDITIS is a microbial infection of a cardiac valve or the mural endocardium caused by BACTERIA or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
2159,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.9950371902099888,"Abstract  November 2010  7 Infectious Disease  XVIII Infective Endocarditis  ELIZABETH G. NABEL, MD, FACP President, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA  INFECTIVE ENDOCARDITIS is a microbial infection of a cardiac valve or the mural endocardium caused by BACTERIA or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
2160,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.9950371902099888,"Abstract  November 2010  7 Infectious Disease  XVIII Infective Endocarditis  ELIZABETH G. NABEL, MD, FACP President, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA  INFECTIVE ENDOCARDITIS is a microbial infection of a cardiac valve or the mural endocardium caused by BACTERIA or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
2161,INFECTIVE ENDOCARDITIS causes BACTERIA,causes,0.9950371902099888,"Abstract  November 2010  7 Infectious Disease  XVIII Infective Endocarditis  ELIZABETH G. NABEL, MD, FACP President, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA  INFECTIVE ENDOCARDITIS is a microbial infection of a cardiac valve or the mural endocardium caused by BACTERIA or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
2162,BACTERIA causes INFECTIVE ENDOCARDITIS,causes,0.9950371902099888,"Abstract  November 2010  7 Infectious Disease  XVIII Infective Endocarditis  ELIZABETH G. NABEL, MD, FACP President, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA  INFECTIVE ENDOCARDITIS is a microbial infection of a cardiac valve or the mural endocardium caused by BACTERIA or fungi.",INFECTIVE ENDOCARDITIS,BACTERIA
2163,COCAINE causes COCAINE ADDICTION,causes,0.668153104781061,"COCAINE ADDICTION continues to be the most difficult to manage behind heroin, and according to some scientists, addiction to COCAINE may be almost impossible to stop.",COCAINE ADDICTION,COCAINE
2164,COCAINE causes COCAINE ADDICTION,causes,0.668153104781061,"COCAINE ADDICTION continues to be the most difficult to manage behind heroin, and according to some scientists, addiction to COCAINE may be almost impossible to stop.",COCAINE ADDICTION,COCAINE
2165,COCAINE causes COCAINE ADDICTION,causes,0.668153104781061,"COCAINE ADDICTION continues to be the most difficult to manage behind heroin, and according to some scientists, addiction to COCAINE may be almost impossible to stop.",COCAINE ADDICTION,COCAINE
2166,no_relation,causes,0.668153104781061,"COCAINE ADDICTION continues to be the most difficult to manage behind heroin, and according to some scientists, addiction to COCAINE may be almost impossible to stop.",COCAINE ADDICTION,COCAINE
2167,COCAINE causes COCAINE ADDICTION,causes,0.668153104781061,"COCAINE ADDICTION continues to be the most difficult to manage behind heroin, and according to some scientists, addiction to COCAINE may be almost impossible to stop.",COCAINE ADDICTION,COCAINE
2168,COCAINE causes COCAINE ADDICTION,causes,0.668153104781061,"COCAINE ADDICTION continues to be the most difficult to manage behind heroin, and according to some scientists, addiction to COCAINE may be almost impossible to stop.",COCAINE ADDICTION,COCAINE
2169,COCAINE causes COCAINE ADDICTION,causes,0.668153104781061,"COCAINE ADDICTION continues to be the most difficult to manage behind heroin, and according to some scientists, addiction to COCAINE may be almost impossible to stop.",COCAINE ADDICTION,COCAINE
2170,BELL'S PALSY causes ACUTE FACIAL NERVE PARALYSIS,causes,1.0,edit] Infranuclear lesions [edit] Bell's palsy  BELL'S PALSY is the most common cause of ACUTE FACIAL NERVE PARALYSIS,ACUTE FACIAL NERVE PARALYSIS,BELL'S PALSY
2171,BELL'S PALSY causes ACUTE FACIAL NERVE PARALYSIS,causes,1.0,edit] Infranuclear lesions [edit] Bell's palsy  BELL'S PALSY is the most common cause of ACUTE FACIAL NERVE PARALYSIS,ACUTE FACIAL NERVE PARALYSIS,BELL'S PALSY
2172,BELL'S PALSY causes ACUTE FACIAL NERVE PARALYSIS,causes,1.0,edit] Infranuclear lesions [edit] Bell's palsy  BELL'S PALSY is the most common cause of ACUTE FACIAL NERVE PARALYSIS,ACUTE FACIAL NERVE PARALYSIS,BELL'S PALSY
2173,BELL'S PALSY causes ACUTE FACIAL NERVE PARALYSIS,causes,1.0,edit] Infranuclear lesions [edit] Bell's palsy  BELL'S PALSY is the most common cause of ACUTE FACIAL NERVE PARALYSIS,ACUTE FACIAL NERVE PARALYSIS,BELL'S PALSY
2174,BELL'S PALSY causes ACUTE FACIAL NERVE PARALYSIS,causes,1.0,edit] Infranuclear lesions [edit] Bell's palsy  BELL'S PALSY is the most common cause of ACUTE FACIAL NERVE PARALYSIS,ACUTE FACIAL NERVE PARALYSIS,BELL'S PALSY
2175,BELL'S PALSY causes ACUTE FACIAL NERVE PARALYSIS,causes,1.0,edit] Infranuclear lesions [edit] Bell's palsy  BELL'S PALSY is the most common cause of ACUTE FACIAL NERVE PARALYSIS,ACUTE FACIAL NERVE PARALYSIS,BELL'S PALSY
2176,BELL'S PALSY causes ACUTE FACIAL NERVE PARALYSIS,causes,1.0,edit] Infranuclear lesions [edit] Bell's palsy  BELL'S PALSY is the most common cause of ACUTE FACIAL NERVE PARALYSIS,ACUTE FACIAL NERVE PARALYSIS,BELL'S PALSY
2177,ASBESTOS FIBERS causes ASBESTOSIS,causes,0.981980506061966,Rationale: • Epidemiologic studies clearly suggest that ASBESTOSIS develops after significant and heavy exposure to ASBESTOS FIBERS,ASBESTOSIS,ASBESTOS FIBERS
2178,ASBESTOS FIBERS causes ASBESTOSIS,causes,0.981980506061966,Rationale: • Epidemiologic studies clearly suggest that ASBESTOSIS develops after significant and heavy exposure to ASBESTOS FIBERS,ASBESTOSIS,ASBESTOS FIBERS
2179,ASBESTOS FIBERS causes ASBESTOSIS,causes,0.981980506061966,Rationale: • Epidemiologic studies clearly suggest that ASBESTOSIS develops after significant and heavy exposure to ASBESTOS FIBERS,ASBESTOSIS,ASBESTOS FIBERS
2180,ASBESTOS FIBERS causes ASBESTOSIS,causes,0.981980506061966,Rationale: • Epidemiologic studies clearly suggest that ASBESTOSIS develops after significant and heavy exposure to ASBESTOS FIBERS,ASBESTOSIS,ASBESTOS FIBERS
2181,ASBESTOS FIBERS causes ASBESTOSIS,causes,0.981980506061966,Rationale: • Epidemiologic studies clearly suggest that ASBESTOSIS develops after significant and heavy exposure to ASBESTOS FIBERS,ASBESTOSIS,ASBESTOS FIBERS
2182,ASBESTOS FIBERS causes ASBESTOSIS,causes,0.981980506061966,Rationale: • Epidemiologic studies clearly suggest that ASBESTOSIS develops after significant and heavy exposure to ASBESTOS FIBERS,ASBESTOSIS,ASBESTOS FIBERS
2183,ASBESTOS FIBERS causes ASBESTOSIS,causes,0.981980506061966,Rationale: • Epidemiologic studies clearly suggest that ASBESTOSIS develops after significant and heavy exposure to ASBESTOS FIBERS,ASBESTOSIS,ASBESTOS FIBERS
2184,RAT TAILED MAGGOT ( E causes INTESTINAL MYIASIS,causes,1.0,"The larva, called RAT TAILED MAGGOT ( E tenax ), may cause INTESTINAL MYIASIS in humans.",INTESTINAL MYIASIS,RAT TAILED MAGGOT ( E
2185,RAT TAILED MAGGOT ( E causes INTESTINAL MYIASIS,causes,1.0,"The larva, called RAT TAILED MAGGOT ( E tenax ), may cause INTESTINAL MYIASIS in humans.",INTESTINAL MYIASIS,RAT TAILED MAGGOT ( E
2186,RAT TAILED MAGGOT ( E causes INTESTINAL MYIASIS,causes,1.0,"The larva, called RAT TAILED MAGGOT ( E tenax ), may cause INTESTINAL MYIASIS in humans.",INTESTINAL MYIASIS,RAT TAILED MAGGOT ( E
2187,RAT TAILED MAGGOT ( E causes INTESTINAL MYIASIS,causes,1.0,"The larva, called RAT TAILED MAGGOT ( E tenax ), may cause INTESTINAL MYIASIS in humans.",INTESTINAL MYIASIS,RAT TAILED MAGGOT ( E
2188,RAT TAILED MAGGOT ( E causes INTESTINAL MYIASIS,causes,1.0,"The larva, called RAT TAILED MAGGOT ( E tenax ), may cause INTESTINAL MYIASIS in humans.",INTESTINAL MYIASIS,RAT TAILED MAGGOT ( E
2189,RAT TAILED MAGGOT ( E causes INTESTINAL MYIASIS,causes,1.0,"The larva, called RAT TAILED MAGGOT ( E tenax ), may cause INTESTINAL MYIASIS in humans.",INTESTINAL MYIASIS,RAT TAILED MAGGOT ( E
2190,RAT TAILED MAGGOT ( E causes INTESTINAL MYIASIS,causes,1.0,"The larva, called RAT TAILED MAGGOT ( E tenax ), may cause INTESTINAL MYIASIS in humans.",INTESTINAL MYIASIS,RAT TAILED MAGGOT ( E
2191,BURKHOLDERIA PSEUDOMALLEI causes DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,causes,0.997054485501582,BURKHOLDERIA PSEUDOMALLEI  causes a distinct DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY limited to the Asian tropics (see  Melioidosis.,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,BURKHOLDERIA PSEUDOMALLEI
2192,BURKHOLDERIA PSEUDOMALLEI causes DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,causes,0.997054485501582,BURKHOLDERIA PSEUDOMALLEI  causes a distinct DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY limited to the Asian tropics (see  Melioidosis.,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,BURKHOLDERIA PSEUDOMALLEI
2193,BURKHOLDERIA PSEUDOMALLEI causes DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,causes,0.997054485501582,BURKHOLDERIA PSEUDOMALLEI  causes a distinct DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY limited to the Asian tropics (see  Melioidosis.,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,BURKHOLDERIA PSEUDOMALLEI
2194,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY causes BURKHOLDERIA PSEUDOMALLEI,causes,0.997054485501582,BURKHOLDERIA PSEUDOMALLEI  causes a distinct DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY limited to the Asian tropics (see  Melioidosis.,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,BURKHOLDERIA PSEUDOMALLEI
2195,BURKHOLDERIA PSEUDOMALLEI causes DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,causes,0.997054485501582,BURKHOLDERIA PSEUDOMALLEI  causes a distinct DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY limited to the Asian tropics (see  Melioidosis.,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,BURKHOLDERIA PSEUDOMALLEI
2196,BURKHOLDERIA PSEUDOMALLEI causes DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,causes,0.997054485501582,BURKHOLDERIA PSEUDOMALLEI  causes a distinct DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY limited to the Asian tropics (see  Melioidosis.,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,BURKHOLDERIA PSEUDOMALLEI
2197,BURKHOLDERIA PSEUDOMALLEI causes DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,causes,0.997054485501582,BURKHOLDERIA PSEUDOMALLEI  causes a distinct DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY limited to the Asian tropics (see  Melioidosis.,DISEASE KNOWN AS MELIOIDOSIS THAT IS MOSTLY,BURKHOLDERIA PSEUDOMALLEI
2198,PRESCRIPTION OPIOIDS causes OPIOID ABUSE,causes,0.43301270189221897,Rationale: • OPIOID ABUSE including nonmedical use of PRESCRIPTION OPIOIDS is a significant public health problem.,OPIOID ABUSE,PRESCRIPTION OPIOIDS
2199,OPIOID ABUSE causes PRESCRIPTION OPIOIDS,causes,0.43301270189221897,Rationale: • OPIOID ABUSE including nonmedical use of PRESCRIPTION OPIOIDS is a significant public health problem.,OPIOID ABUSE,PRESCRIPTION OPIOIDS
2200,PRESCRIPTION OPIOIDS causes OPIOID ABUSE,causes,0.43301270189221897,Rationale: • OPIOID ABUSE including nonmedical use of PRESCRIPTION OPIOIDS is a significant public health problem.,OPIOID ABUSE,PRESCRIPTION OPIOIDS
2201,no_relation,causes,0.43301270189221897,Rationale: • OPIOID ABUSE including nonmedical use of PRESCRIPTION OPIOIDS is a significant public health problem.,OPIOID ABUSE,PRESCRIPTION OPIOIDS
2202,no_relation,causes,0.43301270189221897,Rationale: • OPIOID ABUSE including nonmedical use of PRESCRIPTION OPIOIDS is a significant public health problem.,OPIOID ABUSE,PRESCRIPTION OPIOIDS
2203,PRESCRIPTION OPIOIDS causes OPIOID ABUSE,causes,0.43301270189221897,Rationale: • OPIOID ABUSE including nonmedical use of PRESCRIPTION OPIOIDS is a significant public health problem.,OPIOID ABUSE,PRESCRIPTION OPIOIDS
2204,no_relation,causes,0.43301270189221897,Rationale: • OPIOID ABUSE including nonmedical use of PRESCRIPTION OPIOIDS is a significant public health problem.,OPIOID ABUSE,PRESCRIPTION OPIOIDS
2205,no_relation,causes,0.3396831102433789,Rationale: • Chronic pelvic pain may emerge from latent pain generators following trauma or stress and can overlap with other IDIOPATHIC PAIN CONDITIONS such as FIBROMYALGIA,IDIOPATHIC PAIN CONDITIONS,FIBROMYALGIA
2206,no_relation,causes,0.3396831102433789,Rationale: • Chronic pelvic pain may emerge from latent pain generators following trauma or stress and can overlap with other IDIOPATHIC PAIN CONDITIONS such as FIBROMYALGIA,IDIOPATHIC PAIN CONDITIONS,FIBROMYALGIA
2207,no_relation,causes,0.3396831102433789,Rationale: • Chronic pelvic pain may emerge from latent pain generators following trauma or stress and can overlap with other IDIOPATHIC PAIN CONDITIONS such as FIBROMYALGIA,IDIOPATHIC PAIN CONDITIONS,FIBROMYALGIA
2208,no_relation,causes,0.3396831102433789,Rationale: • Chronic pelvic pain may emerge from latent pain generators following trauma or stress and can overlap with other IDIOPATHIC PAIN CONDITIONS such as FIBROMYALGIA,IDIOPATHIC PAIN CONDITIONS,FIBROMYALGIA
2209,FIBROMYALGIA causes IDIOPATHIC PAIN CONDITIONS,causes,0.3396831102433789,Rationale: • Chronic pelvic pain may emerge from latent pain generators following trauma or stress and can overlap with other IDIOPATHIC PAIN CONDITIONS such as FIBROMYALGIA,IDIOPATHIC PAIN CONDITIONS,FIBROMYALGIA
2210,FIBROMYALGIA causes IDIOPATHIC PAIN CONDITIONS,causes,0.3396831102433789,Rationale: • Chronic pelvic pain may emerge from latent pain generators following trauma or stress and can overlap with other IDIOPATHIC PAIN CONDITIONS such as FIBROMYALGIA,IDIOPATHIC PAIN CONDITIONS,FIBROMYALGIA
2211,IDIOPATHIC PAIN CONDITIONS causes FIBROMYALGIA,causes,0.3396831102433789,Rationale: • Chronic pelvic pain may emerge from latent pain generators following trauma or stress and can overlap with other IDIOPATHIC PAIN CONDITIONS such as FIBROMYALGIA,IDIOPATHIC PAIN CONDITIONS,FIBROMYALGIA
2212,HEREDITARY FANCONI SYNDROME causes POLYURIA,causes,0.997458699830735,"In HEREDITARY FANCONI SYNDROME the chief clinical features—proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, POLYURIA and polydipsia—usually appear in infancy.",POLYURIA,HEREDITARY FANCONI SYNDROME
2213,HEREDITARY FANCONI SYNDROME causes POLYURIA,causes,0.997458699830735,"In HEREDITARY FANCONI SYNDROME the chief clinical features—proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, POLYURIA and polydipsia—usually appear in infancy.",POLYURIA,HEREDITARY FANCONI SYNDROME
2214,HEREDITARY FANCONI SYNDROME causes POLYURIA,causes,0.997458699830735,"In HEREDITARY FANCONI SYNDROME the chief clinical features—proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, POLYURIA and polydipsia—usually appear in infancy.",POLYURIA,HEREDITARY FANCONI SYNDROME
2215,HEREDITARY FANCONI SYNDROME causes POLYURIA,causes,0.997458699830735,"In HEREDITARY FANCONI SYNDROME the chief clinical features—proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, POLYURIA and polydipsia—usually appear in infancy.",POLYURIA,HEREDITARY FANCONI SYNDROME
2216,no_relation,causes,0.997458699830735,"In HEREDITARY FANCONI SYNDROME the chief clinical features—proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, POLYURIA and polydipsia—usually appear in infancy.",POLYURIA,HEREDITARY FANCONI SYNDROME
2217,no_relation,causes,0.997458699830735,"In HEREDITARY FANCONI SYNDROME the chief clinical features—proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, POLYURIA and polydipsia—usually appear in infancy.",POLYURIA,HEREDITARY FANCONI SYNDROME
2218,POLYURIA causes HEREDITARY FANCONI SYNDROME,causes,0.997458699830735,"In HEREDITARY FANCONI SYNDROME the chief clinical features—proximal tubular acidosis, hypophosphatemic rickets, hypokalemia, POLYURIA and polydipsia—usually appear in infancy.",POLYURIA,HEREDITARY FANCONI SYNDROME
2219,MS RELATED SYMPTOMS causes SPASTICITY,causes,0.896258159530272,"COMMENTARY  It has been suggested that marijuana has a beneficial effect on various MS RELATED SYMPTOMS including SPASTICITY pain, and tremor.",SPASTICITY,MS RELATED SYMPTOMS
2220,SPASTICITY causes MS RELATED SYMPTOMS,causes,0.896258159530272,"COMMENTARY  It has been suggested that marijuana has a beneficial effect on various MS RELATED SYMPTOMS including SPASTICITY pain, and tremor.",SPASTICITY,MS RELATED SYMPTOMS
2221,no_relation,causes,0.896258159530272,"COMMENTARY  It has been suggested that marijuana has a beneficial effect on various MS RELATED SYMPTOMS including SPASTICITY pain, and tremor.",SPASTICITY,MS RELATED SYMPTOMS
2222,MS RELATED SYMPTOMS causes SPASTICITY,causes,0.896258159530272,"COMMENTARY  It has been suggested that marijuana has a beneficial effect on various MS RELATED SYMPTOMS including SPASTICITY pain, and tremor.",SPASTICITY,MS RELATED SYMPTOMS
2223,no_relation,causes,0.896258159530272,"COMMENTARY  It has been suggested that marijuana has a beneficial effect on various MS RELATED SYMPTOMS including SPASTICITY pain, and tremor.",SPASTICITY,MS RELATED SYMPTOMS
2224,MS RELATED SYMPTOMS causes SPASTICITY,causes,0.896258159530272,"COMMENTARY  It has been suggested that marijuana has a beneficial effect on various MS RELATED SYMPTOMS including SPASTICITY pain, and tremor.",SPASTICITY,MS RELATED SYMPTOMS
2225,no_relation,causes,0.896258159530272,"COMMENTARY  It has been suggested that marijuana has a beneficial effect on various MS RELATED SYMPTOMS including SPASTICITY pain, and tremor.",SPASTICITY,MS RELATED SYMPTOMS
2226,no_relation,causes,0.99654575824488,"◊ Pyramidal signs such as hyperreflexia, spasticity, Babinski signs ◊ SENSORY LOSS especially sensory level and impaired vibratory and proprioceptive sensation in limbs ◊ Ataxia of gait and limb movements • See table  History and Physical Examination Elements for MS",SENSORY LOSS,MS
2227,MS causes SENSORY LOSS,causes,0.99654575824488,"◊ Pyramidal signs such as hyperreflexia, spasticity, Babinski signs ◊ SENSORY LOSS especially sensory level and impaired vibratory and proprioceptive sensation in limbs ◊ Ataxia of gait and limb movements • See table  History and Physical Examination Elements for MS",SENSORY LOSS,MS
2228,MS causes SENSORY LOSS,causes,0.99654575824488,"◊ Pyramidal signs such as hyperreflexia, spasticity, Babinski signs ◊ SENSORY LOSS especially sensory level and impaired vibratory and proprioceptive sensation in limbs ◊ Ataxia of gait and limb movements • See table  History and Physical Examination Elements for MS",SENSORY LOSS,MS
2229,MS causes SENSORY LOSS,causes,0.99654575824488,"◊ Pyramidal signs such as hyperreflexia, spasticity, Babinski signs ◊ SENSORY LOSS especially sensory level and impaired vibratory and proprioceptive sensation in limbs ◊ Ataxia of gait and limb movements • See table  History and Physical Examination Elements for MS",SENSORY LOSS,MS
2230,no_relation,causes,0.99654575824488,"◊ Pyramidal signs such as hyperreflexia, spasticity, Babinski signs ◊ SENSORY LOSS especially sensory level and impaired vibratory and proprioceptive sensation in limbs ◊ Ataxia of gait and limb movements • See table  History and Physical Examination Elements for MS",SENSORY LOSS,MS
2231,MS causes SENSORY LOSS,causes,0.99654575824488,"◊ Pyramidal signs such as hyperreflexia, spasticity, Babinski signs ◊ SENSORY LOSS especially sensory level and impaired vibratory and proprioceptive sensation in limbs ◊ Ataxia of gait and limb movements • See table  History and Physical Examination Elements for MS",SENSORY LOSS,MS
2232,MS causes SENSORY LOSS,causes,0.99654575824488,"◊ Pyramidal signs such as hyperreflexia, spasticity, Babinski signs ◊ SENSORY LOSS especially sensory level and impaired vibratory and proprioceptive sensation in limbs ◊ Ataxia of gait and limb movements • See table  History and Physical Examination Elements for MS",SENSORY LOSS,MS
2233,no_relation,causes,0.985329278164293,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2234,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.985329278164293,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2235,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.985329278164293,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2236,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.985329278164293,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2237,no_relation,causes,0.985329278164293,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2238,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,causes,0.985329278164293,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2239,NEUROBLASTOMA causes SPONTANEOUS ADRENAL HEMORRHAGE,causes,0.985329278164293,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA
2240,NEUROFIBROMATOSIS TYPE I causes CAFÉ AU LAIT SPOTS,causes,0.90913729009699,"Specifically, having six or more CAFÉ AU LAIT SPOTS greater than 5 mm in diameter before puberty, or greater than 15 mm in diameter after puberty, are cardinal diagnostic features of NEUROFIBROMATOSIS TYPE I.",CAFÉ AU LAIT SPOTS,NEUROFIBROMATOSIS TYPE I
2241,NEUROFIBROMATOSIS TYPE I causes CAFÉ AU LAIT SPOTS,causes,0.90913729009699,"Specifically, having six or more CAFÉ AU LAIT SPOTS greater than 5 mm in diameter before puberty, or greater than 15 mm in diameter after puberty, are cardinal diagnostic features of NEUROFIBROMATOSIS TYPE I.",CAFÉ AU LAIT SPOTS,NEUROFIBROMATOSIS TYPE I
2242,NEUROFIBROMATOSIS TYPE I causes CAFÉ AU LAIT SPOTS,causes,0.90913729009699,"Specifically, having six or more CAFÉ AU LAIT SPOTS greater than 5 mm in diameter before puberty, or greater than 15 mm in diameter after puberty, are cardinal diagnostic features of NEUROFIBROMATOSIS TYPE I.",CAFÉ AU LAIT SPOTS,NEUROFIBROMATOSIS TYPE I
2243,NEUROFIBROMATOSIS TYPE I causes CAFÉ AU LAIT SPOTS,causes,0.90913729009699,"Specifically, having six or more CAFÉ AU LAIT SPOTS greater than 5 mm in diameter before puberty, or greater than 15 mm in diameter after puberty, are cardinal diagnostic features of NEUROFIBROMATOSIS TYPE I.",CAFÉ AU LAIT SPOTS,NEUROFIBROMATOSIS TYPE I
2244,no_relation,causes,0.90913729009699,"Specifically, having six or more CAFÉ AU LAIT SPOTS greater than 5 mm in diameter before puberty, or greater than 15 mm in diameter after puberty, are cardinal diagnostic features of NEUROFIBROMATOSIS TYPE I.",CAFÉ AU LAIT SPOTS,NEUROFIBROMATOSIS TYPE I
2245,NEUROFIBROMATOSIS TYPE I causes CAFÉ AU LAIT SPOTS,causes,0.90913729009699,"Specifically, having six or more CAFÉ AU LAIT SPOTS greater than 5 mm in diameter before puberty, or greater than 15 mm in diameter after puberty, are cardinal diagnostic features of NEUROFIBROMATOSIS TYPE I.",CAFÉ AU LAIT SPOTS,NEUROFIBROMATOSIS TYPE I
2246,NEUROFIBROMATOSIS TYPE I causes CAFÉ AU LAIT SPOTS,causes,0.90913729009699,"Specifically, having six or more CAFÉ AU LAIT SPOTS greater than 5 mm in diameter before puberty, or greater than 15 mm in diameter after puberty, are cardinal diagnostic features of NEUROFIBROMATOSIS TYPE I.",CAFÉ AU LAIT SPOTS,NEUROFIBROMATOSIS TYPE I
2247,no_relation,causes,0.9918365981341758,CHRONIC DIARRHEA is another common feature of ETHYLMALONIC ENCEPHALOPATHY,CHRONIC DIARRHEA,ETHYLMALONIC ENCEPHALOPATHY
2248,ETHYLMALONIC ENCEPHALOPATHY causes CHRONIC DIARRHEA,causes,0.9918365981341758,CHRONIC DIARRHEA is another common feature of ETHYLMALONIC ENCEPHALOPATHY,CHRONIC DIARRHEA,ETHYLMALONIC ENCEPHALOPATHY
2249,ETHYLMALONIC ENCEPHALOPATHY causes CHRONIC DIARRHEA,causes,0.9918365981341758,CHRONIC DIARRHEA is another common feature of ETHYLMALONIC ENCEPHALOPATHY,CHRONIC DIARRHEA,ETHYLMALONIC ENCEPHALOPATHY
2250,CHRONIC DIARRHEA causes ETHYLMALONIC ENCEPHALOPATHY,causes,0.9918365981341758,CHRONIC DIARRHEA is another common feature of ETHYLMALONIC ENCEPHALOPATHY,CHRONIC DIARRHEA,ETHYLMALONIC ENCEPHALOPATHY
2251,ETHYLMALONIC ENCEPHALOPATHY causes CHRONIC DIARRHEA,causes,0.9918365981341758,CHRONIC DIARRHEA is another common feature of ETHYLMALONIC ENCEPHALOPATHY,CHRONIC DIARRHEA,ETHYLMALONIC ENCEPHALOPATHY
2252,no_relation,causes,0.9918365981341758,CHRONIC DIARRHEA is another common feature of ETHYLMALONIC ENCEPHALOPATHY,CHRONIC DIARRHEA,ETHYLMALONIC ENCEPHALOPATHY
2253,no_relation,causes,0.9918365981341758,CHRONIC DIARRHEA is another common feature of ETHYLMALONIC ENCEPHALOPATHY,CHRONIC DIARRHEA,ETHYLMALONIC ENCEPHALOPATHY
2254,no_relation,causes,0.964763821237732,"BLOODY DIARRHEA fever, and abdominal pain suggest inflammatory bowel disease (ULCERATIVE COLITIS CROHN'S DISEASE or an infectious colitis (eg,  Shigella,Salmonella,Campylobacter,  amebiasis.",BLOODY DIARRHEA,(ULCERATIVE COLITIS CROHN'S DISEASE
2255,(ULCERATIVE COLITIS CROHN'S DISEASE causes BLOODY DIARRHEA,causes,0.964763821237732,"BLOODY DIARRHEA fever, and abdominal pain suggest inflammatory bowel disease (ULCERATIVE COLITIS CROHN'S DISEASE or an infectious colitis (eg,  Shigella,Salmonella,Campylobacter,  amebiasis.",BLOODY DIARRHEA,(ULCERATIVE COLITIS CROHN'S DISEASE
2256,(ULCERATIVE COLITIS CROHN'S DISEASE causes BLOODY DIARRHEA,causes,0.964763821237732,"BLOODY DIARRHEA fever, and abdominal pain suggest inflammatory bowel disease (ULCERATIVE COLITIS CROHN'S DISEASE or an infectious colitis (eg,  Shigella,Salmonella,Campylobacter,  amebiasis.",BLOODY DIARRHEA,(ULCERATIVE COLITIS CROHN'S DISEASE
2257,(ULCERATIVE COLITIS CROHN'S DISEASE causes BLOODY DIARRHEA,causes,0.964763821237732,"BLOODY DIARRHEA fever, and abdominal pain suggest inflammatory bowel disease (ULCERATIVE COLITIS CROHN'S DISEASE or an infectious colitis (eg,  Shigella,Salmonella,Campylobacter,  amebiasis.",BLOODY DIARRHEA,(ULCERATIVE COLITIS CROHN'S DISEASE
2258,no_relation,causes,0.964763821237732,"BLOODY DIARRHEA fever, and abdominal pain suggest inflammatory bowel disease (ULCERATIVE COLITIS CROHN'S DISEASE or an infectious colitis (eg,  Shigella,Salmonella,Campylobacter,  amebiasis.",BLOODY DIARRHEA,(ULCERATIVE COLITIS CROHN'S DISEASE
2259,BLOODY DIARRHEA causes (ULCERATIVE COLITIS CROHN'S DISEASE,causes,0.964763821237732,"BLOODY DIARRHEA fever, and abdominal pain suggest inflammatory bowel disease (ULCERATIVE COLITIS CROHN'S DISEASE or an infectious colitis (eg,  Shigella,Salmonella,Campylobacter,  amebiasis.",BLOODY DIARRHEA,(ULCERATIVE COLITIS CROHN'S DISEASE
2260,(ULCERATIVE COLITIS CROHN'S DISEASE causes BLOODY DIARRHEA,causes,0.964763821237732,"BLOODY DIARRHEA fever, and abdominal pain suggest inflammatory bowel disease (ULCERATIVE COLITIS CROHN'S DISEASE or an infectious colitis (eg,  Shigella,Salmonella,Campylobacter,  amebiasis.",BLOODY DIARRHEA,(ULCERATIVE COLITIS CROHN'S DISEASE
2261,DRUG causes LUPUS SYNDROME,causes,0.788263422531435,"Long term, high dose (> 300 mg/day) hydralazine has been associated with a drug induced LUPUS SYNDROME which resolves when the DRUG is stopped.",LUPUS SYNDROME,DRUG
2262,LUPUS SYNDROME causes DRUG,causes,0.788263422531435,"Long term, high dose (> 300 mg/day) hydralazine has been associated with a drug induced LUPUS SYNDROME which resolves when the DRUG is stopped.",LUPUS SYNDROME,DRUG
2263,DRUG causes LUPUS SYNDROME,causes,0.788263422531435,"Long term, high dose (> 300 mg/day) hydralazine has been associated with a drug induced LUPUS SYNDROME which resolves when the DRUG is stopped.",LUPUS SYNDROME,DRUG
2264,DRUG causes LUPUS SYNDROME,causes,0.788263422531435,"Long term, high dose (> 300 mg/day) hydralazine has been associated with a drug induced LUPUS SYNDROME which resolves when the DRUG is stopped.",LUPUS SYNDROME,DRUG
2265,DRUG causes LUPUS SYNDROME,causes,0.788263422531435,"Long term, high dose (> 300 mg/day) hydralazine has been associated with a drug induced LUPUS SYNDROME which resolves when the DRUG is stopped.",LUPUS SYNDROME,DRUG
2266,DRUG causes LUPUS SYNDROME,causes,0.788263422531435,"Long term, high dose (> 300 mg/day) hydralazine has been associated with a drug induced LUPUS SYNDROME which resolves when the DRUG is stopped.",LUPUS SYNDROME,DRUG
2267,DRUG causes LUPUS SYNDROME,causes,0.788263422531435,"Long term, high dose (> 300 mg/day) hydralazine has been associated with a drug induced LUPUS SYNDROME which resolves when the DRUG is stopped.",LUPUS SYNDROME,DRUG
2268,no_relation,causes,0.943456353049726,167  Typhoid Fever and Other Salmonella Infections   +  >     TYPHOID FEVER or Septicemia caused by S. typhi or S. paratyphi  +  IV or IM:  2 4 g once daily.,TYPHOID FEVER,IM
2269,IM causes TYPHOID FEVER,causes,0.943456353049726,167  Typhoid Fever and Other Salmonella Infections   +  >     TYPHOID FEVER or Septicemia caused by S. typhi or S. paratyphi  +  IV or IM:  2 4 g once daily.,TYPHOID FEVER,IM
2270,IM causes TYPHOID FEVER,causes,0.943456353049726,167  Typhoid Fever and Other Salmonella Infections   +  >     TYPHOID FEVER or Septicemia caused by S. typhi or S. paratyphi  +  IV or IM:  2 4 g once daily.,TYPHOID FEVER,IM
2271,no_relation,causes,0.943456353049726,167  Typhoid Fever and Other Salmonella Infections   +  >     TYPHOID FEVER or Septicemia caused by S. typhi or S. paratyphi  +  IV or IM:  2 4 g once daily.,TYPHOID FEVER,IM
2272,no_relation,causes,0.943456353049726,167  Typhoid Fever and Other Salmonella Infections   +  >     TYPHOID FEVER or Septicemia caused by S. typhi or S. paratyphi  +  IV or IM:  2 4 g once daily.,TYPHOID FEVER,IM
2273,IM causes TYPHOID FEVER,causes,0.943456353049726,167  Typhoid Fever and Other Salmonella Infections   +  >     TYPHOID FEVER or Septicemia caused by S. typhi or S. paratyphi  +  IV or IM:  2 4 g once daily.,TYPHOID FEVER,IM
2274,no_relation,causes,0.943456353049726,167  Typhoid Fever and Other Salmonella Infections   +  >     TYPHOID FEVER or Septicemia caused by S. typhi or S. paratyphi  +  IV or IM:  2 4 g once daily.,TYPHOID FEVER,IM
2275,MUMPS VIRUS causes PAROTITIS,causes,1.0,"The association of aseptic meningitis with PAROTITIS pancreatitis (abdominal pain and increased serum amylase levels), or oophoritis (abdominal pain and ovarian tenderness on pelvic examination) is a clue that MUMPS VIRUS is the causative agent.",PAROTITIS,MUMPS VIRUS
2276,MUMPS VIRUS causes PAROTITIS,causes,1.0,"The association of aseptic meningitis with PAROTITIS pancreatitis (abdominal pain and increased serum amylase levels), or oophoritis (abdominal pain and ovarian tenderness on pelvic examination) is a clue that MUMPS VIRUS is the causative agent.",PAROTITIS,MUMPS VIRUS
2277,MUMPS VIRUS causes PAROTITIS,causes,1.0,"The association of aseptic meningitis with PAROTITIS pancreatitis (abdominal pain and increased serum amylase levels), or oophoritis (abdominal pain and ovarian tenderness on pelvic examination) is a clue that MUMPS VIRUS is the causative agent.",PAROTITIS,MUMPS VIRUS
2278,MUMPS VIRUS causes PAROTITIS,causes,1.0,"The association of aseptic meningitis with PAROTITIS pancreatitis (abdominal pain and increased serum amylase levels), or oophoritis (abdominal pain and ovarian tenderness on pelvic examination) is a clue that MUMPS VIRUS is the causative agent.",PAROTITIS,MUMPS VIRUS
2279,MUMPS VIRUS causes PAROTITIS,causes,1.0,"The association of aseptic meningitis with PAROTITIS pancreatitis (abdominal pain and increased serum amylase levels), or oophoritis (abdominal pain and ovarian tenderness on pelvic examination) is a clue that MUMPS VIRUS is the causative agent.",PAROTITIS,MUMPS VIRUS
2280,MUMPS VIRUS causes PAROTITIS,causes,1.0,"The association of aseptic meningitis with PAROTITIS pancreatitis (abdominal pain and increased serum amylase levels), or oophoritis (abdominal pain and ovarian tenderness on pelvic examination) is a clue that MUMPS VIRUS is the causative agent.",PAROTITIS,MUMPS VIRUS
2281,MUMPS VIRUS causes PAROTITIS,causes,1.0,"The association of aseptic meningitis with PAROTITIS pancreatitis (abdominal pain and increased serum amylase levels), or oophoritis (abdominal pain and ovarian tenderness on pelvic examination) is a clue that MUMPS VIRUS is the causative agent.",PAROTITIS,MUMPS VIRUS
2282,AMEBIASIS causes ENTAMOEBA HISTOLYTICA,causes,0.838627869377535,AMEBIASIS  (Entamebiasis)  AMEBIASIS is infection with  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
2283,AMEBIASIS causes ENTAMOEBA HISTOLYTICA,causes,0.838627869377535,AMEBIASIS  (Entamebiasis)  AMEBIASIS is infection with  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
2284,ENTAMOEBA HISTOLYTICA causes AMEBIASIS,causes,0.838627869377535,AMEBIASIS  (Entamebiasis)  AMEBIASIS is infection with  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
2285,no_relation,causes,0.838627869377535,AMEBIASIS  (Entamebiasis)  AMEBIASIS is infection with  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
2286,AMEBIASIS causes ENTAMOEBA HISTOLYTICA,causes,0.838627869377535,AMEBIASIS  (Entamebiasis)  AMEBIASIS is infection with  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
2287,no_relation,causes,0.838627869377535,AMEBIASIS  (Entamebiasis)  AMEBIASIS is infection with  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
2288,no_relation,causes,0.838627869377535,AMEBIASIS  (Entamebiasis)  AMEBIASIS is infection with  ENTAMOEBA HISTOLYTICA.,AMEBIASIS,ENTAMOEBA HISTOLYTICA
2289,HANTAAN VIRUS causes EPIDEMIC HEMORRHAGIC FEVER,causes,1.0,"22   The prototype hantavirus is HANTAAN VIRUS which causes EPIDEMIC HEMORRHAGIC FEVER in China and Korea, but many different hantaviruses are now recognized.",EPIDEMIC HEMORRHAGIC FEVER,HANTAAN VIRUS
2290,HANTAAN VIRUS causes EPIDEMIC HEMORRHAGIC FEVER,causes,1.0,"22   The prototype hantavirus is HANTAAN VIRUS which causes EPIDEMIC HEMORRHAGIC FEVER in China and Korea, but many different hantaviruses are now recognized.",EPIDEMIC HEMORRHAGIC FEVER,HANTAAN VIRUS
2291,HANTAAN VIRUS causes EPIDEMIC HEMORRHAGIC FEVER,causes,1.0,"22   The prototype hantavirus is HANTAAN VIRUS which causes EPIDEMIC HEMORRHAGIC FEVER in China and Korea, but many different hantaviruses are now recognized.",EPIDEMIC HEMORRHAGIC FEVER,HANTAAN VIRUS
2292,HANTAAN VIRUS causes EPIDEMIC HEMORRHAGIC FEVER,causes,1.0,"22   The prototype hantavirus is HANTAAN VIRUS which causes EPIDEMIC HEMORRHAGIC FEVER in China and Korea, but many different hantaviruses are now recognized.",EPIDEMIC HEMORRHAGIC FEVER,HANTAAN VIRUS
2293,HANTAAN VIRUS causes EPIDEMIC HEMORRHAGIC FEVER,causes,1.0,"22   The prototype hantavirus is HANTAAN VIRUS which causes EPIDEMIC HEMORRHAGIC FEVER in China and Korea, but many different hantaviruses are now recognized.",EPIDEMIC HEMORRHAGIC FEVER,HANTAAN VIRUS
2294,HANTAAN VIRUS causes EPIDEMIC HEMORRHAGIC FEVER,causes,1.0,"22   The prototype hantavirus is HANTAAN VIRUS which causes EPIDEMIC HEMORRHAGIC FEVER in China and Korea, but many different hantaviruses are now recognized.",EPIDEMIC HEMORRHAGIC FEVER,HANTAAN VIRUS
2295,HANTAAN VIRUS causes EPIDEMIC HEMORRHAGIC FEVER,causes,1.0,"22   The prototype hantavirus is HANTAAN VIRUS which causes EPIDEMIC HEMORRHAGIC FEVER in China and Korea, but many different hantaviruses are now recognized.",EPIDEMIC HEMORRHAGIC FEVER,HANTAAN VIRUS
2296,no_relation,causes,0.486664263392288,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2297,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.486664263392288,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2298,no_relation,causes,0.486664263392288,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2299,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.486664263392288,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2300,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.486664263392288,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2301,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.486664263392288,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2302,no_relation,causes,0.486664263392288,Treatment with C1 inhibitor concentrate in ABDOMINAL PAIN attacks of patients with HEREDITARY ANGIOEDEMA,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2303,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.985329278164293,Evidence: • A review article ( 19 ) describes three criteria that must be met to indicate that endometriosis is the cause of chronic pelvic pain: ◊ PELVIC PAIN must be cyclic ◊ Endometriosis must be diagnosed surgically ◊ The treatment of ENDOMETRIOSIS results in prolonged pain relief  Comments: • None.,PELVIC PAIN,ENDOMETRIOSIS
2304,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.985329278164293,Evidence: • A review article ( 19 ) describes three criteria that must be met to indicate that endometriosis is the cause of chronic pelvic pain: ◊ PELVIC PAIN must be cyclic ◊ Endometriosis must be diagnosed surgically ◊ The treatment of ENDOMETRIOSIS results in prolonged pain relief  Comments: • None.,PELVIC PAIN,ENDOMETRIOSIS
2305,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.985329278164293,Evidence: • A review article ( 19 ) describes three criteria that must be met to indicate that endometriosis is the cause of chronic pelvic pain: ◊ PELVIC PAIN must be cyclic ◊ Endometriosis must be diagnosed surgically ◊ The treatment of ENDOMETRIOSIS results in prolonged pain relief  Comments: • None.,PELVIC PAIN,ENDOMETRIOSIS
2306,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.985329278164293,Evidence: • A review article ( 19 ) describes three criteria that must be met to indicate that endometriosis is the cause of chronic pelvic pain: ◊ PELVIC PAIN must be cyclic ◊ Endometriosis must be diagnosed surgically ◊ The treatment of ENDOMETRIOSIS results in prolonged pain relief  Comments: • None.,PELVIC PAIN,ENDOMETRIOSIS
2307,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.985329278164293,Evidence: • A review article ( 19 ) describes three criteria that must be met to indicate that endometriosis is the cause of chronic pelvic pain: ◊ PELVIC PAIN must be cyclic ◊ Endometriosis must be diagnosed surgically ◊ The treatment of ENDOMETRIOSIS results in prolonged pain relief  Comments: • None.,PELVIC PAIN,ENDOMETRIOSIS
2308,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.985329278164293,Evidence: • A review article ( 19 ) describes three criteria that must be met to indicate that endometriosis is the cause of chronic pelvic pain: ◊ PELVIC PAIN must be cyclic ◊ Endometriosis must be diagnosed surgically ◊ The treatment of ENDOMETRIOSIS results in prolonged pain relief  Comments: • None.,PELVIC PAIN,ENDOMETRIOSIS
2309,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.985329278164293,Evidence: • A review article ( 19 ) describes three criteria that must be met to indicate that endometriosis is the cause of chronic pelvic pain: ◊ PELVIC PAIN must be cyclic ◊ Endometriosis must be diagnosed surgically ◊ The treatment of ENDOMETRIOSIS results in prolonged pain relief  Comments: • None.,PELVIC PAIN,ENDOMETRIOSIS
2310,no_relation,causes,0.8838834764831841,"Nonendocrine tumors, such as FACIAL ANGIOFIBROMA and truncal collagenoma, are highly specific for MEN1",FACIAL ANGIOFIBROMA,MEN1
2311,FACIAL ANGIOFIBROMA causes MEN1,causes,0.8838834764831841,"Nonendocrine tumors, such as FACIAL ANGIOFIBROMA and truncal collagenoma, are highly specific for MEN1",FACIAL ANGIOFIBROMA,MEN1
2312,no_relation,causes,0.8838834764831841,"Nonendocrine tumors, such as FACIAL ANGIOFIBROMA and truncal collagenoma, are highly specific for MEN1",FACIAL ANGIOFIBROMA,MEN1
2313,MEN1 causes FACIAL ANGIOFIBROMA,causes,0.8838834764831841,"Nonendocrine tumors, such as FACIAL ANGIOFIBROMA and truncal collagenoma, are highly specific for MEN1",FACIAL ANGIOFIBROMA,MEN1
2314,MEN1 causes FACIAL ANGIOFIBROMA,causes,0.8838834764831841,"Nonendocrine tumors, such as FACIAL ANGIOFIBROMA and truncal collagenoma, are highly specific for MEN1",FACIAL ANGIOFIBROMA,MEN1
2315,no_relation,causes,0.8838834764831841,"Nonendocrine tumors, such as FACIAL ANGIOFIBROMA and truncal collagenoma, are highly specific for MEN1",FACIAL ANGIOFIBROMA,MEN1
2316,no_relation,causes,0.8838834764831841,"Nonendocrine tumors, such as FACIAL ANGIOFIBROMA and truncal collagenoma, are highly specific for MEN1",FACIAL ANGIOFIBROMA,MEN1
2317,HPV causes WARTS (CONDYLOMATA ACUMINATA,causes,0.99654575824488,Human Papillomavirus (HPV) Infections: External Genital and Perianal Warts  Interferon alfa 2b: Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA caused by HPV,WARTS (CONDYLOMATA ACUMINATA,HPV
2318,HPV causes WARTS (CONDYLOMATA ACUMINATA,causes,0.99654575824488,Human Papillomavirus (HPV) Infections: External Genital and Perianal Warts  Interferon alfa 2b: Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA caused by HPV,WARTS (CONDYLOMATA ACUMINATA,HPV
2319,WARTS (CONDYLOMATA ACUMINATA causes HPV,causes,0.99654575824488,Human Papillomavirus (HPV) Infections: External Genital and Perianal Warts  Interferon alfa 2b: Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA caused by HPV,WARTS (CONDYLOMATA ACUMINATA,HPV
2320,HPV causes WARTS (CONDYLOMATA ACUMINATA,causes,0.99654575824488,Human Papillomavirus (HPV) Infections: External Genital and Perianal Warts  Interferon alfa 2b: Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA caused by HPV,WARTS (CONDYLOMATA ACUMINATA,HPV
2321,HPV causes WARTS (CONDYLOMATA ACUMINATA,causes,0.99654575824488,Human Papillomavirus (HPV) Infections: External Genital and Perianal Warts  Interferon alfa 2b: Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA caused by HPV,WARTS (CONDYLOMATA ACUMINATA,HPV
2322,WARTS (CONDYLOMATA ACUMINATA causes HPV,causes,0.99654575824488,Human Papillomavirus (HPV) Infections: External Genital and Perianal Warts  Interferon alfa 2b: Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA caused by HPV,WARTS (CONDYLOMATA ACUMINATA,HPV
2323,HPV causes WARTS (CONDYLOMATA ACUMINATA,causes,0.99654575824488,Human Papillomavirus (HPV) Infections: External Genital and Perianal Warts  Interferon alfa 2b: Treatment of external genital and perianal exophytic WARTS (CONDYLOMATA ACUMINATA caused by HPV,WARTS (CONDYLOMATA ACUMINATA,HPV
2324,VULVODYNIA causes PAIN,causes,0.982707629823991,"60   VULVODYNIA is further characterized by whether the PAIN is generalized or localized and whether it occurs with or without provocation, or both.",PAIN,VULVODYNIA
2325,VULVODYNIA causes PAIN,causes,0.982707629823991,"60   VULVODYNIA is further characterized by whether the PAIN is generalized or localized and whether it occurs with or without provocation, or both.",PAIN,VULVODYNIA
2326,VULVODYNIA causes PAIN,causes,0.982707629823991,"60   VULVODYNIA is further characterized by whether the PAIN is generalized or localized and whether it occurs with or without provocation, or both.",PAIN,VULVODYNIA
2327,VULVODYNIA causes PAIN,causes,0.982707629823991,"60   VULVODYNIA is further characterized by whether the PAIN is generalized or localized and whether it occurs with or without provocation, or both.",PAIN,VULVODYNIA
2328,VULVODYNIA causes PAIN,causes,0.982707629823991,"60   VULVODYNIA is further characterized by whether the PAIN is generalized or localized and whether it occurs with or without provocation, or both.",PAIN,VULVODYNIA
2329,VULVODYNIA causes PAIN,causes,0.982707629823991,"60   VULVODYNIA is further characterized by whether the PAIN is generalized or localized and whether it occurs with or without provocation, or both.",PAIN,VULVODYNIA
2330,VULVODYNIA causes PAIN,causes,0.982707629823991,"60   VULVODYNIA is further characterized by whether the PAIN is generalized or localized and whether it occurs with or without provocation, or both.",PAIN,VULVODYNIA
2331,no_relation,causes,0.981980506061966,"In 1933, the discovery of a cohort of people with sinusitis, bronchiectasis, and DEXTROCARDIA led to the description of KARTAGENER SYNDROME",DEXTROCARDIA,KARTAGENER SYNDROME
2332,no_relation,causes,0.981980506061966,"In 1933, the discovery of a cohort of people with sinusitis, bronchiectasis, and DEXTROCARDIA led to the description of KARTAGENER SYNDROME",DEXTROCARDIA,KARTAGENER SYNDROME
2333,no_relation,causes,0.981980506061966,"In 1933, the discovery of a cohort of people with sinusitis, bronchiectasis, and DEXTROCARDIA led to the description of KARTAGENER SYNDROME",DEXTROCARDIA,KARTAGENER SYNDROME
2334,no_relation,causes,0.981980506061966,"In 1933, the discovery of a cohort of people with sinusitis, bronchiectasis, and DEXTROCARDIA led to the description of KARTAGENER SYNDROME",DEXTROCARDIA,KARTAGENER SYNDROME
2335,no_relation,causes,0.981980506061966,"In 1933, the discovery of a cohort of people with sinusitis, bronchiectasis, and DEXTROCARDIA led to the description of KARTAGENER SYNDROME",DEXTROCARDIA,KARTAGENER SYNDROME
2336,no_relation,causes,0.981980506061966,"In 1933, the discovery of a cohort of people with sinusitis, bronchiectasis, and DEXTROCARDIA led to the description of KARTAGENER SYNDROME",DEXTROCARDIA,KARTAGENER SYNDROME
2337,KARTAGENER SYNDROME causes DEXTROCARDIA,causes,0.981980506061966,"In 1933, the discovery of a cohort of people with sinusitis, bronchiectasis, and DEXTROCARDIA led to the description of KARTAGENER SYNDROME",DEXTROCARDIA,KARTAGENER SYNDROME
2338,no_relation,causes,0.7826237921249258,"Infants born with this disease may have facial angiofibromas, astrocytomas of the CENTRAL NERVOUS SYSTEM hamartomas of the retina, and other lesions, producing HYDROCEPHALUS mental retardation, autism, and seizures.",CENTRAL NERVOUS SYSTEM,HYDROCEPHALUS
2339,no_relation,causes,0.7826237921249258,"Infants born with this disease may have facial angiofibromas, astrocytomas of the CENTRAL NERVOUS SYSTEM hamartomas of the retina, and other lesions, producing HYDROCEPHALUS mental retardation, autism, and seizures.",CENTRAL NERVOUS SYSTEM,HYDROCEPHALUS
2340,no_relation,causes,0.7826237921249258,"Infants born with this disease may have facial angiofibromas, astrocytomas of the CENTRAL NERVOUS SYSTEM hamartomas of the retina, and other lesions, producing HYDROCEPHALUS mental retardation, autism, and seizures.",CENTRAL NERVOUS SYSTEM,HYDROCEPHALUS
2341,CENTRAL NERVOUS SYSTEM causes HYDROCEPHALUS,causes,0.7826237921249258,"Infants born with this disease may have facial angiofibromas, astrocytomas of the CENTRAL NERVOUS SYSTEM hamartomas of the retina, and other lesions, producing HYDROCEPHALUS mental retardation, autism, and seizures.",CENTRAL NERVOUS SYSTEM,HYDROCEPHALUS
2342,CENTRAL NERVOUS SYSTEM causes HYDROCEPHALUS,causes,0.7826237921249258,"Infants born with this disease may have facial angiofibromas, astrocytomas of the CENTRAL NERVOUS SYSTEM hamartomas of the retina, and other lesions, producing HYDROCEPHALUS mental retardation, autism, and seizures.",CENTRAL NERVOUS SYSTEM,HYDROCEPHALUS
2343,no_relation,causes,0.7826237921249258,"Infants born with this disease may have facial angiofibromas, astrocytomas of the CENTRAL NERVOUS SYSTEM hamartomas of the retina, and other lesions, producing HYDROCEPHALUS mental retardation, autism, and seizures.",CENTRAL NERVOUS SYSTEM,HYDROCEPHALUS
2344,no_relation,causes,0.7826237921249258,"Infants born with this disease may have facial angiofibromas, astrocytomas of the CENTRAL NERVOUS SYSTEM hamartomas of the retina, and other lesions, producing HYDROCEPHALUS mental retardation, autism, and seizures.",CENTRAL NERVOUS SYSTEM,HYDROCEPHALUS
2345,DRUGS causes IMPAIRED GLUCOSE TOLERANCE,causes,0.995893206467704,"DRUGS Chemical Agents, and Toxins  INTRODUCTION  Many pharmaceutical agents are known to cause IMPAIRED GLUCOSE TOLERANCE and, occasionally, diabetes [ see  Table 2.",IMPAIRED GLUCOSE TOLERANCE,DRUGS
2346,DRUGS causes IMPAIRED GLUCOSE TOLERANCE,causes,0.995893206467704,"DRUGS Chemical Agents, and Toxins  INTRODUCTION  Many pharmaceutical agents are known to cause IMPAIRED GLUCOSE TOLERANCE and, occasionally, diabetes [ see  Table 2.",IMPAIRED GLUCOSE TOLERANCE,DRUGS
2347,no_relation,causes,0.995893206467704,"DRUGS Chemical Agents, and Toxins  INTRODUCTION  Many pharmaceutical agents are known to cause IMPAIRED GLUCOSE TOLERANCE and, occasionally, diabetes [ see  Table 2.",IMPAIRED GLUCOSE TOLERANCE,DRUGS
2348,DRUGS causes IMPAIRED GLUCOSE TOLERANCE,causes,0.995893206467704,"DRUGS Chemical Agents, and Toxins  INTRODUCTION  Many pharmaceutical agents are known to cause IMPAIRED GLUCOSE TOLERANCE and, occasionally, diabetes [ see  Table 2.",IMPAIRED GLUCOSE TOLERANCE,DRUGS
2349,DRUGS causes IMPAIRED GLUCOSE TOLERANCE,causes,0.995893206467704,"DRUGS Chemical Agents, and Toxins  INTRODUCTION  Many pharmaceutical agents are known to cause IMPAIRED GLUCOSE TOLERANCE and, occasionally, diabetes [ see  Table 2.",IMPAIRED GLUCOSE TOLERANCE,DRUGS
2350,DRUGS causes IMPAIRED GLUCOSE TOLERANCE,causes,0.995893206467704,"DRUGS Chemical Agents, and Toxins  INTRODUCTION  Many pharmaceutical agents are known to cause IMPAIRED GLUCOSE TOLERANCE and, occasionally, diabetes [ see  Table 2.",IMPAIRED GLUCOSE TOLERANCE,DRUGS
2351,no_relation,causes,0.995893206467704,"DRUGS Chemical Agents, and Toxins  INTRODUCTION  Many pharmaceutical agents are known to cause IMPAIRED GLUCOSE TOLERANCE and, occasionally, diabetes [ see  Table 2.",IMPAIRED GLUCOSE TOLERANCE,DRUGS
2352,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.5714285714285711,"116  Warnings/Precautions  Warnings  Risk of Transmissible Agents in Plasma derived Preparations  Because HBIG is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
2353,VIRAL HEPATITIS causes HUMAN VIRUSES,causes,0.5714285714285711,"116  Warnings/Precautions  Warnings  Risk of Transmissible Agents in Plasma derived Preparations  Because HBIG is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
2354,VIRAL HEPATITIS causes HUMAN VIRUSES,causes,0.5714285714285711,"116  Warnings/Precautions  Warnings  Risk of Transmissible Agents in Plasma derived Preparations  Because HBIG is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
2355,no_relation,causes,0.5714285714285711,"116  Warnings/Precautions  Warnings  Risk of Transmissible Agents in Plasma derived Preparations  Because HBIG is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
2356,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.5714285714285711,"116  Warnings/Precautions  Warnings  Risk of Transmissible Agents in Plasma derived Preparations  Because HBIG is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
2357,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.5714285714285711,"116  Warnings/Precautions  Warnings  Risk of Transmissible Agents in Plasma derived Preparations  Because HBIG is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
2358,HUMAN VIRUSES causes VIRAL HEPATITIS,causes,0.5714285714285711,"116  Warnings/Precautions  Warnings  Risk of Transmissible Agents in Plasma derived Preparations  Because HBIG is prepared from pooled human plasma, it is a potential vehicle for transmission of HUMAN VIRUSES including the causative agents of VIRAL HEPATITIS and HIV infection, and theoretically may carry a risk of transmitting the causative agent of Creutzfeldt Jakob disease (CJD) or variant CJD (vCJD.",VIRAL HEPATITIS,HUMAN VIRUSES
2359,ITP causes PERSISTENT SEVERE THROMBOCYTOPENIA,causes,0.481125224324688,• Note that splenectomy is recommended for patients with persistent platelet counts  9  cells/L for 4 to 6 weeks and for patients who have had ITP for 3 months with PERSISTENT SEVERE THROMBOCYTOPENIA (platelet count  9  cells/L) despite treatment.,PERSISTENT SEVERE THROMBOCYTOPENIA,ITP
2360,PERSISTENT SEVERE THROMBOCYTOPENIA causes ITP,causes,0.481125224324688,• Note that splenectomy is recommended for patients with persistent platelet counts  9  cells/L for 4 to 6 weeks and for patients who have had ITP for 3 months with PERSISTENT SEVERE THROMBOCYTOPENIA (platelet count  9  cells/L) despite treatment.,PERSISTENT SEVERE THROMBOCYTOPENIA,ITP
2361,no_relation,causes,0.481125224324688,• Note that splenectomy is recommended for patients with persistent platelet counts  9  cells/L for 4 to 6 weeks and for patients who have had ITP for 3 months with PERSISTENT SEVERE THROMBOCYTOPENIA (platelet count  9  cells/L) despite treatment.,PERSISTENT SEVERE THROMBOCYTOPENIA,ITP
2362,no_relation,causes,0.481125224324688,• Note that splenectomy is recommended for patients with persistent platelet counts  9  cells/L for 4 to 6 weeks and for patients who have had ITP for 3 months with PERSISTENT SEVERE THROMBOCYTOPENIA (platelet count  9  cells/L) despite treatment.,PERSISTENT SEVERE THROMBOCYTOPENIA,ITP
2363,no_relation,causes,0.481125224324688,• Note that splenectomy is recommended for patients with persistent platelet counts  9  cells/L for 4 to 6 weeks and for patients who have had ITP for 3 months with PERSISTENT SEVERE THROMBOCYTOPENIA (platelet count  9  cells/L) despite treatment.,PERSISTENT SEVERE THROMBOCYTOPENIA,ITP
2364,ITP causes PERSISTENT SEVERE THROMBOCYTOPENIA,causes,0.481125224324688,• Note that splenectomy is recommended for patients with persistent platelet counts  9  cells/L for 4 to 6 weeks and for patients who have had ITP for 3 months with PERSISTENT SEVERE THROMBOCYTOPENIA (platelet count  9  cells/L) despite treatment.,PERSISTENT SEVERE THROMBOCYTOPENIA,ITP
2365,no_relation,causes,0.481125224324688,• Note that splenectomy is recommended for patients with persistent platelet counts  9  cells/L for 4 to 6 weeks and for patients who have had ITP for 3 months with PERSISTENT SEVERE THROMBOCYTOPENIA (platelet count  9  cells/L) despite treatment.,PERSISTENT SEVERE THROMBOCYTOPENIA,ITP
2366,POSTPARTUM THYROTOXICOSIS causes GRAVES DISEASE,causes,0.7559289460184542,"For example, a woman with POSTPARTUM THYROTOXICOSIS could have painless (postpartum) thyroiditis, GRAVES DISEASE or even factitious thyrotoxicosis—each of which would be treated quite differently.",GRAVES DISEASE,POSTPARTUM THYROTOXICOSIS
2367,GRAVES DISEASE causes POSTPARTUM THYROTOXICOSIS,causes,0.7559289460184542,"For example, a woman with POSTPARTUM THYROTOXICOSIS could have painless (postpartum) thyroiditis, GRAVES DISEASE or even factitious thyrotoxicosis—each of which would be treated quite differently.",GRAVES DISEASE,POSTPARTUM THYROTOXICOSIS
2368,no_relation,causes,0.7559289460184542,"For example, a woman with POSTPARTUM THYROTOXICOSIS could have painless (postpartum) thyroiditis, GRAVES DISEASE or even factitious thyrotoxicosis—each of which would be treated quite differently.",GRAVES DISEASE,POSTPARTUM THYROTOXICOSIS
2369,POSTPARTUM THYROTOXICOSIS causes GRAVES DISEASE,causes,0.7559289460184542,"For example, a woman with POSTPARTUM THYROTOXICOSIS could have painless (postpartum) thyroiditis, GRAVES DISEASE or even factitious thyrotoxicosis—each of which would be treated quite differently.",GRAVES DISEASE,POSTPARTUM THYROTOXICOSIS
2370,no_relation,causes,0.7559289460184542,"For example, a woman with POSTPARTUM THYROTOXICOSIS could have painless (postpartum) thyroiditis, GRAVES DISEASE or even factitious thyrotoxicosis—each of which would be treated quite differently.",GRAVES DISEASE,POSTPARTUM THYROTOXICOSIS
2371,no_relation,causes,0.7559289460184542,"For example, a woman with POSTPARTUM THYROTOXICOSIS could have painless (postpartum) thyroiditis, GRAVES DISEASE or even factitious thyrotoxicosis—each of which would be treated quite differently.",GRAVES DISEASE,POSTPARTUM THYROTOXICOSIS
2372,no_relation,causes,0.7559289460184542,"For example, a woman with POSTPARTUM THYROTOXICOSIS could have painless (postpartum) thyroiditis, GRAVES DISEASE or even factitious thyrotoxicosis—each of which would be treated quite differently.",GRAVES DISEASE,POSTPARTUM THYROTOXICOSIS
2373,CHONDROITIN SULFATE TREATED causes PAIN,causes,0.4833682445228321,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
2374,no_relation,causes,0.4833682445228321,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
2375,no_relation,causes,0.4833682445228321,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
2376,no_relation,causes,0.4833682445228321,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
2377,no_relation,causes,0.4833682445228321,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
2378,CHONDROITIN SULFATE TREATED causes PAIN,causes,0.4833682445228321,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
2379,CHONDROITIN SULFATE TREATED causes PAIN,causes,0.4833682445228321,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
2380,ASCENDING PARALYSIS causes ACUTE HEPATIC PORPHYRIA,causes,0.441726104299386,• Reviews indicate that ACUTE HEPATIC PORPHYRIA with neuropsychiatric disturbances and signs of autonomic dysfunction and ASCENDING PARALYSIS with bilateral facial weakness may mimic rabies.,ASCENDING PARALYSIS,ACUTE HEPATIC PORPHYRIA
2381,no_relation,causes,0.441726104299386,• Reviews indicate that ACUTE HEPATIC PORPHYRIA with neuropsychiatric disturbances and signs of autonomic dysfunction and ASCENDING PARALYSIS with bilateral facial weakness may mimic rabies.,ASCENDING PARALYSIS,ACUTE HEPATIC PORPHYRIA
2382,ACUTE HEPATIC PORPHYRIA causes ASCENDING PARALYSIS,causes,0.441726104299386,• Reviews indicate that ACUTE HEPATIC PORPHYRIA with neuropsychiatric disturbances and signs of autonomic dysfunction and ASCENDING PARALYSIS with bilateral facial weakness may mimic rabies.,ASCENDING PARALYSIS,ACUTE HEPATIC PORPHYRIA
2383,no_relation,causes,0.441726104299386,• Reviews indicate that ACUTE HEPATIC PORPHYRIA with neuropsychiatric disturbances and signs of autonomic dysfunction and ASCENDING PARALYSIS with bilateral facial weakness may mimic rabies.,ASCENDING PARALYSIS,ACUTE HEPATIC PORPHYRIA
2384,ACUTE HEPATIC PORPHYRIA causes ASCENDING PARALYSIS,causes,0.441726104299386,• Reviews indicate that ACUTE HEPATIC PORPHYRIA with neuropsychiatric disturbances and signs of autonomic dysfunction and ASCENDING PARALYSIS with bilateral facial weakness may mimic rabies.,ASCENDING PARALYSIS,ACUTE HEPATIC PORPHYRIA
2385,no_relation,causes,0.441726104299386,• Reviews indicate that ACUTE HEPATIC PORPHYRIA with neuropsychiatric disturbances and signs of autonomic dysfunction and ASCENDING PARALYSIS with bilateral facial weakness may mimic rabies.,ASCENDING PARALYSIS,ACUTE HEPATIC PORPHYRIA
2386,no_relation,causes,0.441726104299386,• Reviews indicate that ACUTE HEPATIC PORPHYRIA with neuropsychiatric disturbances and signs of autonomic dysfunction and ASCENDING PARALYSIS with bilateral facial weakness may mimic rabies.,ASCENDING PARALYSIS,ACUTE HEPATIC PORPHYRIA
2387,BORRELIA RECURRENTIS causes FEVER,causes,0.986393923832143,"i ,   l  Relapsing Fever  Treatment of relapsing FEVER caused by  BORRELIA RECURRENTIS.",FEVER,BORRELIA RECURRENTIS
2388,BORRELIA RECURRENTIS causes FEVER,causes,0.986393923832143,"i ,   l  Relapsing Fever  Treatment of relapsing FEVER caused by  BORRELIA RECURRENTIS.",FEVER,BORRELIA RECURRENTIS
2389,BORRELIA RECURRENTIS causes FEVER,causes,0.986393923832143,"i ,   l  Relapsing Fever  Treatment of relapsing FEVER caused by  BORRELIA RECURRENTIS.",FEVER,BORRELIA RECURRENTIS
2390,BORRELIA RECURRENTIS causes FEVER,causes,0.986393923832143,"i ,   l  Relapsing Fever  Treatment of relapsing FEVER caused by  BORRELIA RECURRENTIS.",FEVER,BORRELIA RECURRENTIS
2391,BORRELIA RECURRENTIS causes FEVER,causes,0.986393923832143,"i ,   l  Relapsing Fever  Treatment of relapsing FEVER caused by  BORRELIA RECURRENTIS.",FEVER,BORRELIA RECURRENTIS
2392,BORRELIA RECURRENTIS causes FEVER,causes,0.986393923832143,"i ,   l  Relapsing Fever  Treatment of relapsing FEVER caused by  BORRELIA RECURRENTIS.",FEVER,BORRELIA RECURRENTIS
2393,BORRELIA RECURRENTIS causes FEVER,causes,0.986393923832143,"i ,   l  Relapsing Fever  Treatment of relapsing FEVER caused by  BORRELIA RECURRENTIS.",FEVER,BORRELIA RECURRENTIS
2394,HTLV 1 causes HAM/TSP,causes,0.9778024140774092,"However, HAM/TSP is a relatively rare complication of HTLV 1 with an incidence roughly comparable to that of adult T cell leukemia, another rare condition associated with HTLV 1.",HAM/TSP,HTLV 1
2395,HTLV 1 causes HAM/TSP,causes,0.9778024140774092,"However, HAM/TSP is a relatively rare complication of HTLV 1 with an incidence roughly comparable to that of adult T cell leukemia, another rare condition associated with HTLV 1.",HAM/TSP,HTLV 1
2396,no_relation,causes,0.9778024140774092,"However, HAM/TSP is a relatively rare complication of HTLV 1 with an incidence roughly comparable to that of adult T cell leukemia, another rare condition associated with HTLV 1.",HAM/TSP,HTLV 1
2397,HTLV 1 causes HAM/TSP,causes,0.9778024140774092,"However, HAM/TSP is a relatively rare complication of HTLV 1 with an incidence roughly comparable to that of adult T cell leukemia, another rare condition associated with HTLV 1.",HAM/TSP,HTLV 1
2398,HTLV 1 causes HAM/TSP,causes,0.9778024140774092,"However, HAM/TSP is a relatively rare complication of HTLV 1 with an incidence roughly comparable to that of adult T cell leukemia, another rare condition associated with HTLV 1.",HAM/TSP,HTLV 1
2399,HAM/TSP causes HTLV 1,causes,0.9778024140774092,"However, HAM/TSP is a relatively rare complication of HTLV 1 with an incidence roughly comparable to that of adult T cell leukemia, another rare condition associated with HTLV 1.",HAM/TSP,HTLV 1
2400,HTLV 1 causes HAM/TSP,causes,0.9778024140774092,"However, HAM/TSP is a relatively rare complication of HTLV 1 with an incidence roughly comparable to that of adult T cell leukemia, another rare condition associated with HTLV 1.",HAM/TSP,HTLV 1
2401,no_relation,causes,0.34188172937891403,"1 ,   60 ,   171  NEOMYCIN ALLERGY  Havrix ®  and Twinrix ®  contains trace amounts of NEOMYCIN SULFATE.",NEOMYCIN ALLERGY,NEOMYCIN SULFATE
2402,no_relation,causes,0.34188172937891403,"1 ,   60 ,   171  NEOMYCIN ALLERGY  Havrix ®  and Twinrix ®  contains trace amounts of NEOMYCIN SULFATE.",NEOMYCIN ALLERGY,NEOMYCIN SULFATE
2403,no_relation,causes,0.34188172937891403,"1 ,   60 ,   171  NEOMYCIN ALLERGY  Havrix ®  and Twinrix ®  contains trace amounts of NEOMYCIN SULFATE.",NEOMYCIN ALLERGY,NEOMYCIN SULFATE
2404,no_relation,causes,0.34188172937891403,"1 ,   60 ,   171  NEOMYCIN ALLERGY  Havrix ®  and Twinrix ®  contains trace amounts of NEOMYCIN SULFATE.",NEOMYCIN ALLERGY,NEOMYCIN SULFATE
2405,NEOMYCIN ALLERGY causes NEOMYCIN SULFATE,causes,0.34188172937891403,"1 ,   60 ,   171  NEOMYCIN ALLERGY  Havrix ®  and Twinrix ®  contains trace amounts of NEOMYCIN SULFATE.",NEOMYCIN ALLERGY,NEOMYCIN SULFATE
2406,NEOMYCIN SULFATE causes NEOMYCIN ALLERGY,causes,0.34188172937891403,"1 ,   60 ,   171  NEOMYCIN ALLERGY  Havrix ®  and Twinrix ®  contains trace amounts of NEOMYCIN SULFATE.",NEOMYCIN ALLERGY,NEOMYCIN SULFATE
2407,no_relation,causes,0.34188172937891403,"1 ,   60 ,   171  NEOMYCIN ALLERGY  Havrix ®  and Twinrix ®  contains trace amounts of NEOMYCIN SULFATE.",NEOMYCIN ALLERGY,NEOMYCIN SULFATE
2408,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.995893206467704,BACILLUS ANTHRACIS  causes ANTHRAX and has been used in biological warfare.,ANTHRAX,BACILLUS ANTHRACIS
2409,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.995893206467704,BACILLUS ANTHRACIS  causes ANTHRAX and has been used in biological warfare.,ANTHRAX,BACILLUS ANTHRACIS
2410,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.995893206467704,BACILLUS ANTHRACIS  causes ANTHRAX and has been used in biological warfare.,ANTHRAX,BACILLUS ANTHRACIS
2411,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.995893206467704,BACILLUS ANTHRACIS  causes ANTHRAX and has been used in biological warfare.,ANTHRAX,BACILLUS ANTHRACIS
2412,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.995893206467704,BACILLUS ANTHRACIS  causes ANTHRAX and has been used in biological warfare.,ANTHRAX,BACILLUS ANTHRACIS
2413,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.995893206467704,BACILLUS ANTHRACIS  causes ANTHRAX and has been used in biological warfare.,ANTHRAX,BACILLUS ANTHRACIS
2414,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.995893206467704,BACILLUS ANTHRACIS  causes ANTHRAX and has been used in biological warfare.,ANTHRAX,BACILLUS ANTHRACIS
2415,no_relation,causes,0.9878291611472622,PAIN with mastication (jaw claudication) may indicate POLYMYALGIA RHEUMATICA or giant cell (temporal) arteritis.,PAIN,POLYMYALGIA RHEUMATICA
2416,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.9878291611472622,PAIN with mastication (jaw claudication) may indicate POLYMYALGIA RHEUMATICA or giant cell (temporal) arteritis.,PAIN,POLYMYALGIA RHEUMATICA
2417,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.9878291611472622,PAIN with mastication (jaw claudication) may indicate POLYMYALGIA RHEUMATICA or giant cell (temporal) arteritis.,PAIN,POLYMYALGIA RHEUMATICA
2418,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.9878291611472622,PAIN with mastication (jaw claudication) may indicate POLYMYALGIA RHEUMATICA or giant cell (temporal) arteritis.,PAIN,POLYMYALGIA RHEUMATICA
2419,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.9878291611472622,PAIN with mastication (jaw claudication) may indicate POLYMYALGIA RHEUMATICA or giant cell (temporal) arteritis.,PAIN,POLYMYALGIA RHEUMATICA
2420,PAIN causes POLYMYALGIA RHEUMATICA,causes,0.9878291611472622,PAIN with mastication (jaw claudication) may indicate POLYMYALGIA RHEUMATICA or giant cell (temporal) arteritis.,PAIN,POLYMYALGIA RHEUMATICA
2421,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.9878291611472622,PAIN with mastication (jaw claudication) may indicate POLYMYALGIA RHEUMATICA or giant cell (temporal) arteritis.,PAIN,POLYMYALGIA RHEUMATICA
2422,no_relation,causes,0.468521285665818,Enterotoxigenic and enteropathogenic strains are major causes of diarrhea in infants and traveler's DIARRHEA in adults (see  TRAVELER'S DIARRHEA.,DIARRHEA,TRAVELER'S DIARRHEA
2423,TRAVELER'S DIARRHEA causes DIARRHEA,causes,0.468521285665818,Enterotoxigenic and enteropathogenic strains are major causes of diarrhea in infants and traveler's DIARRHEA in adults (see  TRAVELER'S DIARRHEA.,DIARRHEA,TRAVELER'S DIARRHEA
2424,TRAVELER'S DIARRHEA causes DIARRHEA,causes,0.468521285665818,Enterotoxigenic and enteropathogenic strains are major causes of diarrhea in infants and traveler's DIARRHEA in adults (see  TRAVELER'S DIARRHEA.,DIARRHEA,TRAVELER'S DIARRHEA
2425,TRAVELER'S DIARRHEA causes DIARRHEA,causes,0.468521285665818,Enterotoxigenic and enteropathogenic strains are major causes of diarrhea in infants and traveler's DIARRHEA in adults (see  TRAVELER'S DIARRHEA.,DIARRHEA,TRAVELER'S DIARRHEA
2426,TRAVELER'S DIARRHEA causes DIARRHEA,causes,0.468521285665818,Enterotoxigenic and enteropathogenic strains are major causes of diarrhea in infants and traveler's DIARRHEA in adults (see  TRAVELER'S DIARRHEA.,DIARRHEA,TRAVELER'S DIARRHEA
2427,no_relation,causes,0.468521285665818,Enterotoxigenic and enteropathogenic strains are major causes of diarrhea in infants and traveler's DIARRHEA in adults (see  TRAVELER'S DIARRHEA.,DIARRHEA,TRAVELER'S DIARRHEA
2428,no_relation,causes,0.468521285665818,Enterotoxigenic and enteropathogenic strains are major causes of diarrhea in infants and traveler's DIARRHEA in adults (see  TRAVELER'S DIARRHEA.,DIARRHEA,TRAVELER'S DIARRHEA
2429,no_relation,causes,0.442325868464691,"Enormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr usually  Diagnosis  CDI must be differentiated from other causes of polyuria, particularly PSYCHOGENIC POLYDIPSIA (see  Table 151 4 ) and NDI",PSYCHOGENIC POLYDIPSIA,NDI
2430,NDI causes PSYCHOGENIC POLYDIPSIA,causes,0.442325868464691,"Enormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr usually  Diagnosis  CDI must be differentiated from other causes of polyuria, particularly PSYCHOGENIC POLYDIPSIA (see  Table 151 4 ) and NDI",PSYCHOGENIC POLYDIPSIA,NDI
2431,no_relation,causes,0.442325868464691,"Enormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr usually  Diagnosis  CDI must be differentiated from other causes of polyuria, particularly PSYCHOGENIC POLYDIPSIA (see  Table 151 4 ) and NDI",PSYCHOGENIC POLYDIPSIA,NDI
2432,no_relation,causes,0.442325868464691,"Enormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr usually  Diagnosis  CDI must be differentiated from other causes of polyuria, particularly PSYCHOGENIC POLYDIPSIA (see  Table 151 4 ) and NDI",PSYCHOGENIC POLYDIPSIA,NDI
2433,no_relation,causes,0.442325868464691,"Enormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr usually  Diagnosis  CDI must be differentiated from other causes of polyuria, particularly PSYCHOGENIC POLYDIPSIA (see  Table 151 4 ) and NDI",PSYCHOGENIC POLYDIPSIA,NDI
2434,no_relation,causes,0.442325868464691,"Enormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr usually  Diagnosis  CDI must be differentiated from other causes of polyuria, particularly PSYCHOGENIC POLYDIPSIA (see  Table 151 4 ) and NDI",PSYCHOGENIC POLYDIPSIA,NDI
2435,no_relation,causes,0.442325868464691,"Enormous quantities of fluid may be ingested, and large volumes (3 to 30 L/day) of very dilute urine (sp gr usually  Diagnosis  CDI must be differentiated from other causes of polyuria, particularly PSYCHOGENIC POLYDIPSIA (see  Table 151 4 ) and NDI",PSYCHOGENIC POLYDIPSIA,NDI
2436,TACHYCARDIA causes CARDIAC TACHYARRHYTHMIA,causes,0.538815906080325,a  CARDIAC TACHYARRHYTHMIA  Investigate any TACHYCARDIA before administration since dicyclomine may increase heart rate.,TACHYCARDIA,CARDIAC TACHYARRHYTHMIA
2437,no_relation,causes,0.538815906080325,a  CARDIAC TACHYARRHYTHMIA  Investigate any TACHYCARDIA before administration since dicyclomine may increase heart rate.,TACHYCARDIA,CARDIAC TACHYARRHYTHMIA
2438,no_relation,causes,0.538815906080325,a  CARDIAC TACHYARRHYTHMIA  Investigate any TACHYCARDIA before administration since dicyclomine may increase heart rate.,TACHYCARDIA,CARDIAC TACHYARRHYTHMIA
2439,no_relation,causes,0.538815906080325,a  CARDIAC TACHYARRHYTHMIA  Investigate any TACHYCARDIA before administration since dicyclomine may increase heart rate.,TACHYCARDIA,CARDIAC TACHYARRHYTHMIA
2440,CARDIAC TACHYARRHYTHMIA causes TACHYCARDIA,causes,0.538815906080325,a  CARDIAC TACHYARRHYTHMIA  Investigate any TACHYCARDIA before administration since dicyclomine may increase heart rate.,TACHYCARDIA,CARDIAC TACHYARRHYTHMIA
2441,TACHYCARDIA causes CARDIAC TACHYARRHYTHMIA,causes,0.538815906080325,a  CARDIAC TACHYARRHYTHMIA  Investigate any TACHYCARDIA before administration since dicyclomine may increase heart rate.,TACHYCARDIA,CARDIAC TACHYARRHYTHMIA
2442,TACHYCARDIA causes CARDIAC TACHYARRHYTHMIA,causes,0.538815906080325,a  CARDIAC TACHYARRHYTHMIA  Investigate any TACHYCARDIA before administration since dicyclomine may increase heart rate.,TACHYCARDIA,CARDIAC TACHYARRHYTHMIA
2443,no_relation,causes,0.308606699924184,"daughter, DES    The daughter of a mother who received DIETHYLSTILBESTROL (DES) during PREGNANCY",PREGNANCY,DIETHYLSTILBESTROL
2444,no_relation,causes,0.308606699924184,"daughter, DES    The daughter of a mother who received DIETHYLSTILBESTROL (DES) during PREGNANCY",PREGNANCY,DIETHYLSTILBESTROL
2445,no_relation,causes,0.308606699924184,"daughter, DES    The daughter of a mother who received DIETHYLSTILBESTROL (DES) during PREGNANCY",PREGNANCY,DIETHYLSTILBESTROL
2446,no_relation,causes,0.308606699924184,"daughter, DES    The daughter of a mother who received DIETHYLSTILBESTROL (DES) during PREGNANCY",PREGNANCY,DIETHYLSTILBESTROL
2447,no_relation,causes,0.308606699924184,"daughter, DES    The daughter of a mother who received DIETHYLSTILBESTROL (DES) during PREGNANCY",PREGNANCY,DIETHYLSTILBESTROL
2448,PREGNANCY causes DIETHYLSTILBESTROL,causes,0.308606699924184,"daughter, DES    The daughter of a mother who received DIETHYLSTILBESTROL (DES) during PREGNANCY",PREGNANCY,DIETHYLSTILBESTROL
2449,PREGNANCY causes DIETHYLSTILBESTROL,causes,0.308606699924184,"daughter, DES    The daughter of a mother who received DIETHYLSTILBESTROL (DES) during PREGNANCY",PREGNANCY,DIETHYLSTILBESTROL
2450,no_relation,causes,0.830747160735697,Symptoms of abscess due to AEROBIC BACTERIA develop more acutely and resemble BACTERIAL PNEUMONIA,BACTERIAL PNEUMONIA,AEROBIC BACTERIA
2451,no_relation,causes,0.830747160735697,Symptoms of abscess due to AEROBIC BACTERIA develop more acutely and resemble BACTERIAL PNEUMONIA,BACTERIAL PNEUMONIA,AEROBIC BACTERIA
2452,no_relation,causes,0.830747160735697,Symptoms of abscess due to AEROBIC BACTERIA develop more acutely and resemble BACTERIAL PNEUMONIA,BACTERIAL PNEUMONIA,AEROBIC BACTERIA
2453,AEROBIC BACTERIA causes BACTERIAL PNEUMONIA,causes,0.830747160735697,Symptoms of abscess due to AEROBIC BACTERIA develop more acutely and resemble BACTERIAL PNEUMONIA,BACTERIAL PNEUMONIA,AEROBIC BACTERIA
2454,BACTERIAL PNEUMONIA causes AEROBIC BACTERIA,causes,0.830747160735697,Symptoms of abscess due to AEROBIC BACTERIA develop more acutely and resemble BACTERIAL PNEUMONIA,BACTERIAL PNEUMONIA,AEROBIC BACTERIA
2455,no_relation,causes,0.830747160735697,Symptoms of abscess due to AEROBIC BACTERIA develop more acutely and resemble BACTERIAL PNEUMONIA,BACTERIAL PNEUMONIA,AEROBIC BACTERIA
2456,no_relation,causes,0.830747160735697,Symptoms of abscess due to AEROBIC BACTERIA develop more acutely and resemble BACTERIAL PNEUMONIA,BACTERIAL PNEUMONIA,AEROBIC BACTERIA
2457,no_relation,causes,0.4780914437337581,Evidence:  The estimated pretest probability is ~0.5% for PHEOCHROMOCYTOMA In patients with HYPERTENSION ( 1.,HYPERTENSION,PHEOCHROMOCYTOMA
2458,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.4780914437337581,Evidence:  The estimated pretest probability is ~0.5% for PHEOCHROMOCYTOMA In patients with HYPERTENSION ( 1.,HYPERTENSION,PHEOCHROMOCYTOMA
2459,no_relation,causes,0.4780914437337581,Evidence:  The estimated pretest probability is ~0.5% for PHEOCHROMOCYTOMA In patients with HYPERTENSION ( 1.,HYPERTENSION,PHEOCHROMOCYTOMA
2460,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.4780914437337581,Evidence:  The estimated pretest probability is ~0.5% for PHEOCHROMOCYTOMA In patients with HYPERTENSION ( 1.,HYPERTENSION,PHEOCHROMOCYTOMA
2461,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.4780914437337581,Evidence:  The estimated pretest probability is ~0.5% for PHEOCHROMOCYTOMA In patients with HYPERTENSION ( 1.,HYPERTENSION,PHEOCHROMOCYTOMA
2462,no_relation,causes,0.4780914437337581,Evidence:  The estimated pretest probability is ~0.5% for PHEOCHROMOCYTOMA In patients with HYPERTENSION ( 1.,HYPERTENSION,PHEOCHROMOCYTOMA
2463,no_relation,causes,0.4780914437337581,Evidence:  The estimated pretest probability is ~0.5% for PHEOCHROMOCYTOMA In patients with HYPERTENSION ( 1.,HYPERTENSION,PHEOCHROMOCYTOMA
2464,no_relation,causes,0.7330166661378309,"Many of these patients are later found to have Alzheimer disease in addition to Parkinson disease Creutzfeldt Jakob disease  Rapid progression, early age of onset, prominent MYOCLONUS characteristic EEG pattern of triphasic sharp waves (1 2 Hz)  Cerebrospinal fluid test (commercially available) identifying protein 14 3 3 has a moderately high specificity for CREUTZFELDT JAKOB DISEASE",MYOCLONUS,CREUTZFELDT JAKOB DISEASE
2465,MYOCLONUS causes CREUTZFELDT JAKOB DISEASE,causes,0.7330166661378309,"Many of these patients are later found to have Alzheimer disease in addition to Parkinson disease Creutzfeldt Jakob disease  Rapid progression, early age of onset, prominent MYOCLONUS characteristic EEG pattern of triphasic sharp waves (1 2 Hz)  Cerebrospinal fluid test (commercially available) identifying protein 14 3 3 has a moderately high specificity for CREUTZFELDT JAKOB DISEASE",MYOCLONUS,CREUTZFELDT JAKOB DISEASE
2466,CREUTZFELDT JAKOB DISEASE causes MYOCLONUS,causes,0.7330166661378309,"Many of these patients are later found to have Alzheimer disease in addition to Parkinson disease Creutzfeldt Jakob disease  Rapid progression, early age of onset, prominent MYOCLONUS characteristic EEG pattern of triphasic sharp waves (1 2 Hz)  Cerebrospinal fluid test (commercially available) identifying protein 14 3 3 has a moderately high specificity for CREUTZFELDT JAKOB DISEASE",MYOCLONUS,CREUTZFELDT JAKOB DISEASE
2467,no_relation,causes,0.7330166661378309,"Many of these patients are later found to have Alzheimer disease in addition to Parkinson disease Creutzfeldt Jakob disease  Rapid progression, early age of onset, prominent MYOCLONUS characteristic EEG pattern of triphasic sharp waves (1 2 Hz)  Cerebrospinal fluid test (commercially available) identifying protein 14 3 3 has a moderately high specificity for CREUTZFELDT JAKOB DISEASE",MYOCLONUS,CREUTZFELDT JAKOB DISEASE
2468,MYOCLONUS causes CREUTZFELDT JAKOB DISEASE,causes,0.7330166661378309,"Many of these patients are later found to have Alzheimer disease in addition to Parkinson disease Creutzfeldt Jakob disease  Rapid progression, early age of onset, prominent MYOCLONUS characteristic EEG pattern of triphasic sharp waves (1 2 Hz)  Cerebrospinal fluid test (commercially available) identifying protein 14 3 3 has a moderately high specificity for CREUTZFELDT JAKOB DISEASE",MYOCLONUS,CREUTZFELDT JAKOB DISEASE
2469,no_relation,causes,0.7330166661378309,"Many of these patients are later found to have Alzheimer disease in addition to Parkinson disease Creutzfeldt Jakob disease  Rapid progression, early age of onset, prominent MYOCLONUS characteristic EEG pattern of triphasic sharp waves (1 2 Hz)  Cerebrospinal fluid test (commercially available) identifying protein 14 3 3 has a moderately high specificity for CREUTZFELDT JAKOB DISEASE",MYOCLONUS,CREUTZFELDT JAKOB DISEASE
2470,MYOCLONUS causes CREUTZFELDT JAKOB DISEASE,causes,0.7330166661378309,"Many of these patients are later found to have Alzheimer disease in addition to Parkinson disease Creutzfeldt Jakob disease  Rapid progression, early age of onset, prominent MYOCLONUS characteristic EEG pattern of triphasic sharp waves (1 2 Hz)  Cerebrospinal fluid test (commercially available) identifying protein 14 3 3 has a moderately high specificity for CREUTZFELDT JAKOB DISEASE",MYOCLONUS,CREUTZFELDT JAKOB DISEASE
2471,VZV M causes NFECTION,causes,1.0," VZV May cause serious iNFECTION particularly pneumonia, in adult women.",NFECTION,VZV M
2472,VZV M causes NFECTION,causes,1.0," VZV May cause serious iNFECTION particularly pneumonia, in adult women.",NFECTION,VZV M
2473,VZV M causes NFECTION,causes,1.0," VZV May cause serious iNFECTION particularly pneumonia, in adult women.",NFECTION,VZV M
2474,VZV M causes NFECTION,causes,1.0," VZV May cause serious iNFECTION particularly pneumonia, in adult women.",NFECTION,VZV M
2475,VZV M causes NFECTION,causes,1.0," VZV May cause serious iNFECTION particularly pneumonia, in adult women.",NFECTION,VZV M
2476,VZV M causes NFECTION,causes,1.0," VZV May cause serious iNFECTION particularly pneumonia, in adult women.",NFECTION,VZV M
2477,VZV M causes NFECTION,causes,1.0," VZV May cause serious iNFECTION particularly pneumonia, in adult women.",NFECTION,VZV M
2478,no_relation,causes,0.375,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
2479,AUTOIMMUNE HEMOLYTIC ANEMIA causes HEMOLYSIS,causes,0.375,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
2480,AUTOIMMUNE HEMOLYTIC ANEMIA causes HEMOLYSIS,causes,0.375,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
2481,AUTOIMMUNE HEMOLYTIC ANEMIA causes HEMOLYSIS,causes,0.375,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
2482,AUTOIMMUNE HEMOLYTIC ANEMIA causes HEMOLYSIS,causes,0.375,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
2483,AUTOIMMUNE HEMOLYTIC ANEMIA causes HEMOLYSIS,causes,0.375,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
2484,HEMOLYSIS causes AUTOIMMUNE HEMOLYTIC ANEMIA,causes,0.375,"Richmond GW, Ray I, Korenblitt A. Initial stabilization preceding enhanced HEMOLYSIS in AUTOIMMUNE HEMOLYTIC ANEMIA treated with intravenous gammaglobulin.",HEMOLYSIS,AUTOIMMUNE HEMOLYTIC ANEMIA
2485,no_relation,causes,0.404061017820884,"117   Compliance date for preparations with annual sales   117  Hemorrhoids  Anorectal preparations (e.g., creams, gels, ointments, suppositories) containing PHENYLEPHRINE HYDROCHLORIDE are used  topically  or  rectally  to provide temporary symptomatic relief of external or internal HEMORRHOIDS.",HEMORRHOIDS,PHENYLEPHRINE HYDROCHLORIDE
2486,no_relation,causes,0.404061017820884,"117   Compliance date for preparations with annual sales   117  Hemorrhoids  Anorectal preparations (e.g., creams, gels, ointments, suppositories) containing PHENYLEPHRINE HYDROCHLORIDE are used  topically  or  rectally  to provide temporary symptomatic relief of external or internal HEMORRHOIDS.",HEMORRHOIDS,PHENYLEPHRINE HYDROCHLORIDE
2487,no_relation,causes,0.404061017820884,"117   Compliance date for preparations with annual sales   117  Hemorrhoids  Anorectal preparations (e.g., creams, gels, ointments, suppositories) containing PHENYLEPHRINE HYDROCHLORIDE are used  topically  or  rectally  to provide temporary symptomatic relief of external or internal HEMORRHOIDS.",HEMORRHOIDS,PHENYLEPHRINE HYDROCHLORIDE
2488,no_relation,causes,0.404061017820884,"117   Compliance date for preparations with annual sales   117  Hemorrhoids  Anorectal preparations (e.g., creams, gels, ointments, suppositories) containing PHENYLEPHRINE HYDROCHLORIDE are used  topically  or  rectally  to provide temporary symptomatic relief of external or internal HEMORRHOIDS.",HEMORRHOIDS,PHENYLEPHRINE HYDROCHLORIDE
2489,no_relation,causes,0.404061017820884,"117   Compliance date for preparations with annual sales   117  Hemorrhoids  Anorectal preparations (e.g., creams, gels, ointments, suppositories) containing PHENYLEPHRINE HYDROCHLORIDE are used  topically  or  rectally  to provide temporary symptomatic relief of external or internal HEMORRHOIDS.",HEMORRHOIDS,PHENYLEPHRINE HYDROCHLORIDE
2490,no_relation,causes,0.404061017820884,"117   Compliance date for preparations with annual sales   117  Hemorrhoids  Anorectal preparations (e.g., creams, gels, ointments, suppositories) containing PHENYLEPHRINE HYDROCHLORIDE are used  topically  or  rectally  to provide temporary symptomatic relief of external or internal HEMORRHOIDS.",HEMORRHOIDS,PHENYLEPHRINE HYDROCHLORIDE
2491,no_relation,causes,0.404061017820884,"117   Compliance date for preparations with annual sales   117  Hemorrhoids  Anorectal preparations (e.g., creams, gels, ointments, suppositories) containing PHENYLEPHRINE HYDROCHLORIDE are used  topically  or  rectally  to provide temporary symptomatic relief of external or internal HEMORRHOIDS.",HEMORRHOIDS,PHENYLEPHRINE HYDROCHLORIDE
2492,NOCARDIA causes NOCARDIOSIS,causes,0.948683298050514,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
2493,NOCARDIA causes NOCARDIOSIS,causes,0.948683298050514,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
2494,NOCARDIOSIS causes NOCARDIA,causes,0.948683298050514,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
2495,NOCARDIA causes NOCARDIOSIS,causes,0.948683298050514,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
2496,NOCARDIA causes NOCARDIOSIS,causes,0.948683298050514,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
2497,NOCARDIA causes NOCARDIOSIS,causes,0.948683298050514,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
2498,NOCARDIOSIS causes NOCARDIA,causes,0.948683298050514,106  Nocardiosis  Alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA,NOCARDIOSIS,NOCARDIA
2499,no_relation,causes,0.976546150525391,"ANDERSEN SYNDROME is characterized by periodic paralysis, which may be accompanied by fixed weakness; long QT syndrome with cardiac ventricular arrhythmias; and dysmorphic craniofacial features, such as MICROGNATHIA low set ears, short stature, and syndactyly.",MICROGNATHIA,ANDERSEN SYNDROME
2500,no_relation,causes,0.976546150525391,"ANDERSEN SYNDROME is characterized by periodic paralysis, which may be accompanied by fixed weakness; long QT syndrome with cardiac ventricular arrhythmias; and dysmorphic craniofacial features, such as MICROGNATHIA low set ears, short stature, and syndactyly.",MICROGNATHIA,ANDERSEN SYNDROME
2501,ANDERSEN SYNDROME causes MICROGNATHIA,causes,0.976546150525391,"ANDERSEN SYNDROME is characterized by periodic paralysis, which may be accompanied by fixed weakness; long QT syndrome with cardiac ventricular arrhythmias; and dysmorphic craniofacial features, such as MICROGNATHIA low set ears, short stature, and syndactyly.",MICROGNATHIA,ANDERSEN SYNDROME
2502,ANDERSEN SYNDROME causes MICROGNATHIA,causes,0.976546150525391,"ANDERSEN SYNDROME is characterized by periodic paralysis, which may be accompanied by fixed weakness; long QT syndrome with cardiac ventricular arrhythmias; and dysmorphic craniofacial features, such as MICROGNATHIA low set ears, short stature, and syndactyly.",MICROGNATHIA,ANDERSEN SYNDROME
2503,ANDERSEN SYNDROME causes MICROGNATHIA,causes,0.976546150525391,"ANDERSEN SYNDROME is characterized by periodic paralysis, which may be accompanied by fixed weakness; long QT syndrome with cardiac ventricular arrhythmias; and dysmorphic craniofacial features, such as MICROGNATHIA low set ears, short stature, and syndactyly.",MICROGNATHIA,ANDERSEN SYNDROME
2504,ANDERSEN SYNDROME causes MICROGNATHIA,causes,0.976546150525391,"ANDERSEN SYNDROME is characterized by periodic paralysis, which may be accompanied by fixed weakness; long QT syndrome with cardiac ventricular arrhythmias; and dysmorphic craniofacial features, such as MICROGNATHIA low set ears, short stature, and syndactyly.",MICROGNATHIA,ANDERSEN SYNDROME
2505,no_relation,causes,0.976546150525391,"ANDERSEN SYNDROME is characterized by periodic paralysis, which may be accompanied by fixed weakness; long QT syndrome with cardiac ventricular arrhythmias; and dysmorphic craniofacial features, such as MICROGNATHIA low set ears, short stature, and syndactyly.",MICROGNATHIA,ANDERSEN SYNDROME
2506,MALIGNANT TERTIAN MALARIA causes PLASMODIUM VIVAX,causes,0.762000762001143,Febrile stage varies from 4 to 6 hr. Benign tertian malaria is caused by  PLASMODIUM VIVAX  MALIGNANT TERTIAN MALARIA by  Plasmodium falciparum.,MALIGNANT TERTIAN MALARIA,PLASMODIUM VIVAX
2507,MALIGNANT TERTIAN MALARIA causes PLASMODIUM VIVAX,causes,0.762000762001143,Febrile stage varies from 4 to 6 hr. Benign tertian malaria is caused by  PLASMODIUM VIVAX  MALIGNANT TERTIAN MALARIA by  Plasmodium falciparum.,MALIGNANT TERTIAN MALARIA,PLASMODIUM VIVAX
2508,no_relation,causes,0.762000762001143,Febrile stage varies from 4 to 6 hr. Benign tertian malaria is caused by  PLASMODIUM VIVAX  MALIGNANT TERTIAN MALARIA by  Plasmodium falciparum.,MALIGNANT TERTIAN MALARIA,PLASMODIUM VIVAX
2509,no_relation,causes,0.762000762001143,Febrile stage varies from 4 to 6 hr. Benign tertian malaria is caused by  PLASMODIUM VIVAX  MALIGNANT TERTIAN MALARIA by  Plasmodium falciparum.,MALIGNANT TERTIAN MALARIA,PLASMODIUM VIVAX
2510,no_relation,causes,0.762000762001143,Febrile stage varies from 4 to 6 hr. Benign tertian malaria is caused by  PLASMODIUM VIVAX  MALIGNANT TERTIAN MALARIA by  Plasmodium falciparum.,MALIGNANT TERTIAN MALARIA,PLASMODIUM VIVAX
2511,PLASMODIUM VIVAX causes MALIGNANT TERTIAN MALARIA,causes,0.762000762001143,Febrile stage varies from 4 to 6 hr. Benign tertian malaria is caused by  PLASMODIUM VIVAX  MALIGNANT TERTIAN MALARIA by  Plasmodium falciparum.,MALIGNANT TERTIAN MALARIA,PLASMODIUM VIVAX
2512,no_relation,causes,0.762000762001143,Febrile stage varies from 4 to 6 hr. Benign tertian malaria is caused by  PLASMODIUM VIVAX  MALIGNANT TERTIAN MALARIA by  Plasmodium falciparum.,MALIGNANT TERTIAN MALARIA,PLASMODIUM VIVAX
2513,PHOTOSENSITIVITY causes PORPHYRIA CUTANEA TARDA,causes,0.970494958830946,"PORPHYRIA CUTANEA TARDA is characterized by PHOTOSENSITIVITY vesicle formation (especially on the dorsa of the hands) [ see Figure 13 ], and hypertrichosis.",PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
2514,no_relation,causes,0.970494958830946,"PORPHYRIA CUTANEA TARDA is characterized by PHOTOSENSITIVITY vesicle formation (especially on the dorsa of the hands) [ see Figure 13 ], and hypertrichosis.",PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
2515,PORPHYRIA CUTANEA TARDA causes PHOTOSENSITIVITY,causes,0.970494958830946,"PORPHYRIA CUTANEA TARDA is characterized by PHOTOSENSITIVITY vesicle formation (especially on the dorsa of the hands) [ see Figure 13 ], and hypertrichosis.",PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
2516,PORPHYRIA CUTANEA TARDA causes PHOTOSENSITIVITY,causes,0.970494958830946,"PORPHYRIA CUTANEA TARDA is characterized by PHOTOSENSITIVITY vesicle formation (especially on the dorsa of the hands) [ see Figure 13 ], and hypertrichosis.",PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
2517,PORPHYRIA CUTANEA TARDA causes PHOTOSENSITIVITY,causes,0.970494958830946,"PORPHYRIA CUTANEA TARDA is characterized by PHOTOSENSITIVITY vesicle formation (especially on the dorsa of the hands) [ see Figure 13 ], and hypertrichosis.",PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
2518,no_relation,causes,0.970494958830946,"PORPHYRIA CUTANEA TARDA is characterized by PHOTOSENSITIVITY vesicle formation (especially on the dorsa of the hands) [ see Figure 13 ], and hypertrichosis.",PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
2519,no_relation,causes,0.970494958830946,"PORPHYRIA CUTANEA TARDA is characterized by PHOTOSENSITIVITY vesicle formation (especially on the dorsa of the hands) [ see Figure 13 ], and hypertrichosis.",PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA
2520,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.964901281354015,A patient with HEREDITARY ANGIOEDEMA has severe ABDOMINAL PAIN,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2521,no_relation,causes,0.964901281354015,A patient with HEREDITARY ANGIOEDEMA has severe ABDOMINAL PAIN,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2522,no_relation,causes,0.964901281354015,A patient with HEREDITARY ANGIOEDEMA has severe ABDOMINAL PAIN,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2523,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.964901281354015,A patient with HEREDITARY ANGIOEDEMA has severe ABDOMINAL PAIN,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2524,no_relation,causes,0.964901281354015,A patient with HEREDITARY ANGIOEDEMA has severe ABDOMINAL PAIN,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2525,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.964901281354015,A patient with HEREDITARY ANGIOEDEMA has severe ABDOMINAL PAIN,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2526,HEREDITARY ANGIOEDEMA causes ABDOMINAL PAIN,causes,0.964901281354015,A patient with HEREDITARY ANGIOEDEMA has severe ABDOMINAL PAIN,ABDOMINAL PAIN,HEREDITARY ANGIOEDEMA
2527,BENIGN PROSTATIC HYPERPLASIA causes FINASTERIDE,causes,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
2528,no_relation,causes,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
2529,no_relation,causes,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
2530,FINASTERIDE causes BENIGN PROSTATIC HYPERPLASIA,causes,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
2531,BENIGN PROSTATIC HYPERPLASIA causes FINASTERIDE,causes,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
2532,BENIGN PROSTATIC HYPERPLASIA causes FINASTERIDE,causes,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
2533,no_relation,causes,0.6741998624632421,"1]  Gormley GJ, Stoner E, Bruskewitz RC, Imperato McGinley J, Walsh PC, McConnell JD, et al. The effect of FINASTERIDE in men with BENIGN PROSTATIC HYPERPLASIA",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
2534,no_relation,causes,0.7293249574894731,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2535,no_relation,causes,0.7293249574894731,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2536,HYPERSENSITIVITY REACTIONS causes STEVENS JOHNSON SYNDROME,causes,0.7293249574894731,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2537,no_relation,causes,0.7293249574894731,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2538,no_relation,causes,0.7293249574894731,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2539,no_relation,causes,0.7293249574894731,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2540,STEVENS JOHNSON SYNDROME causes HYPERSENSITIVITY REACTIONS,causes,0.7293249574894731,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2541,DEMENTIA WITH LEWY BODIES causes VISUAL HALLUCINATIONS,causes,0.995893206467704,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, recurrent VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2542,DEMENTIA WITH LEWY BODIES causes VISUAL HALLUCINATIONS,causes,0.995893206467704,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, recurrent VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2543,DEMENTIA WITH LEWY BODIES causes VISUAL HALLUCINATIONS,causes,0.995893206467704,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, recurrent VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2544,DEMENTIA WITH LEWY BODIES causes VISUAL HALLUCINATIONS,causes,0.995893206467704,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, recurrent VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2545,DEMENTIA WITH LEWY BODIES causes VISUAL HALLUCINATIONS,causes,0.995893206467704,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, recurrent VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2546,DEMENTIA WITH LEWY BODIES causes VISUAL HALLUCINATIONS,causes,0.995893206467704,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, recurrent VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2547,no_relation,causes,0.995893206467704,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, recurrent VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2548,PROPRANOLOL causes SUPRAVENTRICULAR TACHYCARDIA,causes,0.442325868464691,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
2549,no_relation,causes,0.442325868464691,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
2550,no_relation,causes,0.442325868464691,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
2551,PROPRANOLOL causes SUPRAVENTRICULAR TACHYCARDIA,causes,0.442325868464691,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
2552,no_relation,causes,0.442325868464691,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
2553,no_relation,causes,0.442325868464691,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
2554,SUPRAVENTRICULAR TACHYCARDIA causes PROPRANOLOL,causes,0.442325868464691,"• Hypoglycemia and respiratory depression were reported in a newborn whose mother received 160 mg of PROPRANOLOL during pregnancy, labor, and delivery for a SUPRAVENTRICULAR TACHYCARDIA",SUPRAVENTRICULAR TACHYCARDIA,PROPRANOLOL
2555,no_relation,causes,0.6488856845230501,"LACTATIONAL AMENORRHEA METHOD  LH    luteinizing hormone  MPA    MEDROXYPROGESTERONE ACETATE  OR    odds ratio  PE    pulmonary embolism  PID    pelvic inflammatory disease  POC    progestin only contraceptive pill  RR    risk ratio  STD    sexually transmitted disease  STI    sexually transmitted infection  TOP    termination of pregnancy, medical abortion  TSS    toxic shock syndrome  UTI    urinary tract infection  VTE    venous thromboembolism.",LACTATIONAL AMENORRHEA METHOD,MEDROXYPROGESTERONE ACETATE
2556,no_relation,causes,0.6488856845230501,"LACTATIONAL AMENORRHEA METHOD  LH    luteinizing hormone  MPA    MEDROXYPROGESTERONE ACETATE  OR    odds ratio  PE    pulmonary embolism  PID    pelvic inflammatory disease  POC    progestin only contraceptive pill  RR    risk ratio  STD    sexually transmitted disease  STI    sexually transmitted infection  TOP    termination of pregnancy, medical abortion  TSS    toxic shock syndrome  UTI    urinary tract infection  VTE    venous thromboembolism.",LACTATIONAL AMENORRHEA METHOD,MEDROXYPROGESTERONE ACETATE
2557,no_relation,causes,0.6488856845230501,"LACTATIONAL AMENORRHEA METHOD  LH    luteinizing hormone  MPA    MEDROXYPROGESTERONE ACETATE  OR    odds ratio  PE    pulmonary embolism  PID    pelvic inflammatory disease  POC    progestin only contraceptive pill  RR    risk ratio  STD    sexually transmitted disease  STI    sexually transmitted infection  TOP    termination of pregnancy, medical abortion  TSS    toxic shock syndrome  UTI    urinary tract infection  VTE    venous thromboembolism.",LACTATIONAL AMENORRHEA METHOD,MEDROXYPROGESTERONE ACETATE
2558,LACTATIONAL AMENORRHEA METHOD causes MEDROXYPROGESTERONE ACETATE,causes,0.6488856845230501,"LACTATIONAL AMENORRHEA METHOD  LH    luteinizing hormone  MPA    MEDROXYPROGESTERONE ACETATE  OR    odds ratio  PE    pulmonary embolism  PID    pelvic inflammatory disease  POC    progestin only contraceptive pill  RR    risk ratio  STD    sexually transmitted disease  STI    sexually transmitted infection  TOP    termination of pregnancy, medical abortion  TSS    toxic shock syndrome  UTI    urinary tract infection  VTE    venous thromboembolism.",LACTATIONAL AMENORRHEA METHOD,MEDROXYPROGESTERONE ACETATE
2559,LACTATIONAL AMENORRHEA METHOD causes MEDROXYPROGESTERONE ACETATE,causes,0.6488856845230501,"LACTATIONAL AMENORRHEA METHOD  LH    luteinizing hormone  MPA    MEDROXYPROGESTERONE ACETATE  OR    odds ratio  PE    pulmonary embolism  PID    pelvic inflammatory disease  POC    progestin only contraceptive pill  RR    risk ratio  STD    sexually transmitted disease  STI    sexually transmitted infection  TOP    termination of pregnancy, medical abortion  TSS    toxic shock syndrome  UTI    urinary tract infection  VTE    venous thromboembolism.",LACTATIONAL AMENORRHEA METHOD,MEDROXYPROGESTERONE ACETATE
2560,no_relation,causes,0.6488856845230501,"LACTATIONAL AMENORRHEA METHOD  LH    luteinizing hormone  MPA    MEDROXYPROGESTERONE ACETATE  OR    odds ratio  PE    pulmonary embolism  PID    pelvic inflammatory disease  POC    progestin only contraceptive pill  RR    risk ratio  STD    sexually transmitted disease  STI    sexually transmitted infection  TOP    termination of pregnancy, medical abortion  TSS    toxic shock syndrome  UTI    urinary tract infection  VTE    venous thromboembolism.",LACTATIONAL AMENORRHEA METHOD,MEDROXYPROGESTERONE ACETATE
2561,no_relation,causes,0.6488856845230501,"LACTATIONAL AMENORRHEA METHOD  LH    luteinizing hormone  MPA    MEDROXYPROGESTERONE ACETATE  OR    odds ratio  PE    pulmonary embolism  PID    pelvic inflammatory disease  POC    progestin only contraceptive pill  RR    risk ratio  STD    sexually transmitted disease  STI    sexually transmitted infection  TOP    termination of pregnancy, medical abortion  TSS    toxic shock syndrome  UTI    urinary tract infection  VTE    venous thromboembolism.",LACTATIONAL AMENORRHEA METHOD,MEDROXYPROGESTERONE ACETATE
2562,no_relation,causes,0.857492925712544,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2563,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS causes TOXIC SHOCK SYNDROME,causes,0.857492925712544,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2564,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS causes TOXIC SHOCK SYNDROME,causes,0.857492925712544,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2565,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS causes TOXIC SHOCK SYNDROME,causes,0.857492925712544,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2566,no_relation,causes,0.857492925712544,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2567,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS causes TOXIC SHOCK SYNDROME,causes,0.857492925712544,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2568,no_relation,causes,0.857492925712544,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2569,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.975900072948533,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2570,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.975900072948533,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2571,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.975900072948533,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2572,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.975900072948533,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2573,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.975900072948533,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2574,no_relation,causes,0.975900072948533,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2575,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.975900072948533,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2576,TTP causes THROMBOCYTOPENIA,causes,0.9045340337332908,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
2577,no_relation,causes,0.9045340337332908,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
2578,TTP causes THROMBOCYTOPENIA,causes,0.9045340337332908,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
2579,TTP causes THROMBOCYTOPENIA,causes,0.9045340337332908,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
2580,no_relation,causes,0.9045340337332908,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
2581,TTP causes THROMBOCYTOPENIA,causes,0.9045340337332908,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
2582,TTP causes THROMBOCYTOPENIA,causes,0.9045340337332908,"Common features of TTP and HUS include microangiopathic hemolytic anemia, THROMBOCYTOPENIA and the presence of platelet fibrin thrombi in the small vessels.",THROMBOCYTOPENIA,TTP
2583,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.881917103688197,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
2584,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.881917103688197,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
2585,no_relation,causes,0.881917103688197,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
2586,no_relation,causes,0.881917103688197,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
2587,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.881917103688197,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
2588,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.881917103688197,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
2589,MEGALOBLASTOSIS causes PANCYTOPENIA,causes,0.881917103688197,"Other conditions that cause PANCYTOPENIA include hypoplastic myelodysplastic syndrome, acute leukemia, MEGALOBLASTOSIS and large granular lymphocytic leukemia.",PANCYTOPENIA,MEGALOBLASTOSIS
2590,OVARIAN HYPERSTIMULATION SYNDROME causes ASCITES,causes,0.9931270663228408,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing potentially life threatening ASCITES and hypovolemia.",ASCITES,OVARIAN HYPERSTIMULATION SYNDROME
2591,OVARIAN HYPERSTIMULATION SYNDROME causes ASCITES,causes,0.9931270663228408,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing potentially life threatening ASCITES and hypovolemia.",ASCITES,OVARIAN HYPERSTIMULATION SYNDROME
2592,OVARIAN HYPERSTIMULATION SYNDROME causes ASCITES,causes,0.9931270663228408,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing potentially life threatening ASCITES and hypovolemia.",ASCITES,OVARIAN HYPERSTIMULATION SYNDROME
2593,OVARIAN HYPERSTIMULATION SYNDROME causes ASCITES,causes,0.9931270663228408,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing potentially life threatening ASCITES and hypovolemia.",ASCITES,OVARIAN HYPERSTIMULATION SYNDROME
2594,no_relation,causes,0.9931270663228408,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing potentially life threatening ASCITES and hypovolemia.",ASCITES,OVARIAN HYPERSTIMULATION SYNDROME
2595,OVARIAN HYPERSTIMULATION SYNDROME causes ASCITES,causes,0.9931270663228408,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing potentially life threatening ASCITES and hypovolemia.",ASCITES,OVARIAN HYPERSTIMULATION SYNDROME
2596,OVARIAN HYPERSTIMULATION SYNDROME causes ASCITES,causes,0.9931270663228408,"OVARIAN HYPERSTIMULATION SYNDROME occurs in 10 to 20% of patients; ovaries can become massively enlarged, and intravascular fluid volume shifts into the peritoneal space, causing potentially life threatening ASCITES and hypovolemia.",ASCITES,OVARIAN HYPERSTIMULATION SYNDROME
2597,RSD causes SPONTANOUS PAIN,causes,0.887356509416114,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2598,RSD causes SPONTANOUS PAIN,causes,0.887356509416114,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2599,no_relation,causes,0.887356509416114,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2600,RSD causes SPONTANOUS PAIN,causes,0.887356509416114,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2601,RSD causes SPONTANOUS PAIN,causes,0.887356509416114,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2602,RSD causes SPONTANOUS PAIN,causes,0.887356509416114,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2603,RSD causes SPONTANOUS PAIN,causes,0.887356509416114,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2604,DEMENTIA WITH LEWY BODIES causes RECURRENT VISUAL HALLUCINATIONS,causes,0.993883734673619,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, RECURRENT VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",RECURRENT VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2605,no_relation,causes,0.993883734673619,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, RECURRENT VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",RECURRENT VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2606,DEMENTIA WITH LEWY BODIES causes RECURRENT VISUAL HALLUCINATIONS,causes,0.993883734673619,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, RECURRENT VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",RECURRENT VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2607,no_relation,causes,0.993883734673619,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, RECURRENT VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",RECURRENT VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2608,DEMENTIA WITH LEWY BODIES causes RECURRENT VISUAL HALLUCINATIONS,causes,0.993883734673619,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, RECURRENT VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",RECURRENT VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2609,DEMENTIA WITH LEWY BODIES causes RECURRENT VISUAL HALLUCINATIONS,causes,0.993883734673619,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, RECURRENT VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",RECURRENT VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2610,DEMENTIA WITH LEWY BODIES causes RECURRENT VISUAL HALLUCINATIONS,causes,0.993883734673619,"◊ DEMENTIA WITH LEWY BODIES is a progressive cognitive decline with fluctuating symptoms, RECURRENT VISUAL HALLUCINATIONS and spontaneous, extrapyramidal signs ( 45.",RECURRENT VISUAL HALLUCINATIONS,DEMENTIA WITH LEWY BODIES
2611,no_relation,causes,0.437594974493684,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
2612,no_relation,causes,0.437594974493684,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
2613,ESTROGEN DEPENDENT BREAST CANCER causes THROMBOEMBOLIC DISEASE,causes,0.437594974493684,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
2614,no_relation,causes,0.437594974493684,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
2615,ESTROGEN DEPENDENT BREAST CANCER causes THROMBOEMBOLIC DISEASE,causes,0.437594974493684,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
2616,ESTROGEN DEPENDENT BREAST CANCER causes THROMBOEMBOLIC DISEASE,causes,0.437594974493684,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
2617,no_relation,causes,0.437594974493684,"HRT is contraindicated in women who smoke or in women with a history of an ESTROGEN DEPENDENT BREAST CANCER endometrial cancer, THROMBOEMBOLIC DISEASE acute liver disease, and vaginal bleeding of unknown cause.",THROMBOEMBOLIC DISEASE,ESTROGEN DEPENDENT BREAST CANCER
2618,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.8741572761215379,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
2619,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.8741572761215379,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
2620,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.8741572761215379,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
2621,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.8741572761215379,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
2622,GRANULOMA INGUINALE causes CALYMMATOBACTERIUM GRANULOMATIS,causes,0.8741572761215379,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
2623,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.8741572761215379,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
2624,CALYMMATOBACTERIUM GRANULOMATIS causes GRANULOMA INGUINALE,causes,0.8741572761215379,102  Granuloma Inguinale (Donovanosis)  Treatment of GRANULOMA INGUINALE (donovanosis) caused by  CALYMMATOBACTERIUM GRANULOMATIS,GRANULOMA INGUINALE,CALYMMATOBACTERIUM GRANULOMATIS
2625,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.963086824686154,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2626,no_relation,causes,0.963086824686154,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2627,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.963086824686154,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2628,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.963086824686154,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2629,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.963086824686154,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2630,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.963086824686154,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2631,NEGATIVE IRON BALANCE causes IRON DEFICIENCY ANEMIA,causes,0.963086824686154,"If NEGATIVE IRON BALANCE persists, then IRON DEFICIENCY ANEMIA is the result.",IRON DEFICIENCY ANEMIA,NEGATIVE IRON BALANCE
2632,no_relation,causes,0.811107105653813,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
2633,no_relation,causes,0.811107105653813,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
2634,no_relation,causes,0.811107105653813,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
2635,no_relation,causes,0.811107105653813,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
2636,no_relation,causes,0.811107105653813,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
2637,no_relation,causes,0.811107105653813,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
2638,ATAXIA causes FFI,causes,0.811107105653813,"40,41   In GSS, which is transmitted as an autosomal dominant trait, the affected persons develop ATAXIA followed by dementia; patients with FFI are unable to sleep.",ATAXIA,FFI
2639,no_relation,causes,0.961074462327142,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2640,RSD causes SPONTANOUS PAIN,causes,0.961074462327142,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2641,RSD causes SPONTANOUS PAIN,causes,0.961074462327142,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2642,no_relation,causes,0.961074462327142,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2643,RSD causes SPONTANOUS PAIN,causes,0.961074462327142,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2644,no_relation,causes,0.961074462327142,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2645,no_relation,causes,0.961074462327142,"Pain in RSD starts typically more distally in a limb Gout  Acute, SPONTANOUS PAIN most commonly in first metatarsophalangeal joint but can affect other joints (ankle >knee >wrist.",SPONTANOUS PAIN,RSD
2646,no_relation,causes,0.7525766947068779,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
2647,no_relation,causes,0.7525766947068779,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
2648,no_relation,causes,0.7525766947068779,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
2649,MYOTONIA CONGENITA causes MUSCLE HYPERTROPHY,causes,0.7525766947068779,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
2650,no_relation,causes,0.7525766947068779,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
2651,no_relation,causes,0.7525766947068779,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
2652,no_relation,causes,0.7525766947068779,Patients with MYOTONIA CONGENITA present with myotonia and often with MUSCLE HYPERTROPHY,MUSCLE HYPERTROPHY,MYOTONIA CONGENITA
2653,L MICDADEI causes PITTSBURGH PNEUMONIA,causes,0.9438798074485388,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
2654,no_relation,causes,0.9438798074485388,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
2655,no_relation,causes,0.9438798074485388,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
2656,PITTSBURGH PNEUMONIA causes L MICDADEI,causes,0.9438798074485388,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
2657,L MICDADEI causes PITTSBURGH PNEUMONIA,causes,0.9438798074485388,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
2658,no_relation,causes,0.9438798074485388,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
2659,no_relation,causes,0.9438798074485388,"Previously known as TATLOCK and HEBA,  L MICDADEI  was rediscovered as the PITTSBURGH PNEUMONIA agent that caused acute suppurative pneumonia in eight immunosuppressed patients from two centers in 1979.",PITTSBURGH PNEUMONIA,L MICDADEI
2660,ULTRAVIOLET RAYS causes PHOTOAGING,causes,1.0,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
2661,ULTRAVIOLET RAYS causes PHOTOAGING,causes,1.0,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
2662,ULTRAVIOLET RAYS causes PHOTOAGING,causes,1.0,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
2663,ULTRAVIOLET RAYS causes PHOTOAGING,causes,1.0,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
2664,ULTRAVIOLET RAYS causes PHOTOAGING,causes,1.0,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
2665,ULTRAVIOLET RAYS causes PHOTOAGING,causes,1.0,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
2666,ULTRAVIOLET RAYS causes PHOTOAGING,causes,1.0,PHOTOAGING    Skin damage as a result of exposure to ULTRAVIOLET RAYS,PHOTOAGING,ULTRAVIOLET RAYS
2667,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.8867963503478641,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2668,no_relation,causes,0.8867963503478641,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2669,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.8867963503478641,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2670,no_relation,causes,0.8867963503478641,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2671,no_relation,causes,0.8867963503478641,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2672,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.8867963503478641,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2673,TOXOPLASMOSIS causes TOXOPLASMA GONDII,causes,0.8867963503478641,TOXOPLASMOSIS  TOXOPLASMOSIS is infection with  TOXOPLASMA GONDII.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2674,VZV INFECTION causes HERPES ZOSTER,causes,0.997458699830735,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
2675,VZV INFECTION causes HERPES ZOSTER,causes,0.997458699830735,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
2676,no_relation,causes,0.997458699830735,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
2677,HERPES ZOSTER causes VZV INFECTION,causes,0.997458699830735,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
2678,VZV INFECTION causes HERPES ZOSTER,causes,0.997458699830735,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
2679,VZV INFECTION causes HERPES ZOSTER,causes,0.997458699830735,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
2680,VZV INFECTION causes HERPES ZOSTER,causes,0.997458699830735,Herpes Zoster  HERPES ZOSTER results from the reactivation of VZV INFECTION,VZV INFECTION,HERPES ZOSTER
2681,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM causes CEREBRAL MALARIA,causes,0.997054485501582,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
2682,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM causes CEREBRAL MALARIA,causes,0.997054485501582,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
2683,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM causes CEREBRAL MALARIA,causes,0.997054485501582,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
2684,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM causes CEREBRAL MALARIA,causes,0.997054485501582,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
2685,CEREBRAL MALARIA causes MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM,causes,0.997054485501582,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
2686,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM causes CEREBRAL MALARIA,causes,0.997054485501582,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
2687,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM causes CEREBRAL MALARIA,causes,0.997054485501582,Smear negative CEREBRAL MALARIA due to MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM acquired in the Amazon.,CEREBRAL MALARIA,MEFLOQUINE RESISTANT PLASMODIUM FALCIPARUM
2688,no_relation,causes,0.50395263067897,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
2689,no_relation,causes,0.50395263067897,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
2690,no_relation,causes,0.50395263067897,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
2691,no_relation,causes,0.50395263067897,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
2692,no_relation,causes,0.50395263067897,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
2693,no_relation,causes,0.50395263067897,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
2694,no_relation,causes,0.50395263067897,"Podzamczer D, Salazar A, Jimenez J et al. INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and TOXOPLASMOSIS in patients infected with HIV.",TOXOPLASMOSIS,INTERMITTENT TRIMETHOPRIM SULFAMETHOXAZOLE
2695,no_relation,causes,0.727606875108999,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
2696,PAGET'S DISEASE OF BONE causes BONE PAIN,causes,0.727606875108999,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
2697,no_relation,causes,0.727606875108999,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
2698,no_relation,causes,0.727606875108999,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
2699,no_relation,causes,0.727606875108999,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
2700,PAGET'S DISEASE OF BONE causes BONE PAIN,causes,0.727606875108999,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
2701,PAGET'S DISEASE OF BONE causes BONE PAIN,causes,0.727606875108999,"Evidence: • Two clinical randomized, double blind trials have shown that alendronate (40 mg, orally, daily, for 6 months) results in reduction in bone turnover markers, radiographs, and BONE PAIN when given to patients with PAGET'S DISEASE OF BONE.",BONE PAIN,PAGET'S DISEASE OF BONE
2702,no_relation,causes,0.843274042711568,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
2703,DENGUE VIRUSES causes DENGUE HEMORRHAGIC FEVER,causes,0.843274042711568,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
2704,no_relation,causes,0.843274042711568,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
2705,DENGUE VIRUSES causes DENGUE HEMORRHAGIC FEVER,causes,0.843274042711568,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
2706,DENGUE VIRUSES causes DENGUE HEMORRHAGIC FEVER,causes,0.843274042711568,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
2707,no_relation,causes,0.843274042711568,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
2708,DENGUE VIRUSES causes DENGUE HEMORRHAGIC FEVER,causes,0.843274042711568,Although all four DENGUE VIRUSES are able to produce DENGUE HEMORRHAGIC FEVER dengue 2 and dengue 3 viruses are more frequently associated with severe disease ( 9 ;  21.,DENGUE HEMORRHAGIC FEVER,DENGUE VIRUSES
2709,POSTTRAUMATIC RSD causes PAIN,causes,0.544331053951817,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
2710,POSTTRAUMATIC RSD causes PAIN,causes,0.544331053951817,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
2711,POSTTRAUMATIC RSD causes PAIN,causes,0.544331053951817,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
2712,POSTTRAUMATIC RSD causes PAIN,causes,0.544331053951817,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
2713,POSTTRAUMATIC RSD causes PAIN,causes,0.544331053951817,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
2714,POSTTRAUMATIC RSD causes PAIN,causes,0.544331053951817,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
2715,POSTTRAUMATIC RSD causes PAIN,causes,0.544331053951817,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
2716,ASPIRIN causes BLEEDING DIATHESES,causes,0.997458699830735,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
2717,ASPIRIN causes BLEEDING DIATHESES,causes,0.997458699830735,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
2718,ASPIRIN causes BLEEDING DIATHESES,causes,0.997458699830735,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
2719,ASPIRIN causes BLEEDING DIATHESES,causes,0.997458699830735,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
2720,ASPIRIN causes BLEEDING DIATHESES,causes,0.997458699830735,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
2721,ASPIRIN causes BLEEDING DIATHESES,causes,0.997458699830735,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
2722,ASPIRIN causes BLEEDING DIATHESES,causes,0.997458699830735,"History  Use of prescription, over the counter, and illicit drugs  Anticoagulants, ASPIRIN or nonsteroidal anti inflammatory drugs, antiplatelet agents, and many prescription drugs may cause BLEEDING DIATHESES",BLEEDING DIATHESES,ASPIRIN
2723,OPHTHALMIA NEONATORUM causes GONORRHOEAE,causes,0.9950371902099888,"167 ,   292  Treatment of OPHTHALMIA NEONATORUM   +    caused by  NGONORRHOEAE",OPHTHALMIA NEONATORUM,GONORRHOEAE
2724,GONORRHOEAE causes OPHTHALMIA NEONATORUM,causes,0.9950371902099888,"167 ,   292  Treatment of OPHTHALMIA NEONATORUM   +    caused by  NGONORRHOEAE",OPHTHALMIA NEONATORUM,GONORRHOEAE
2725,GONORRHOEAE causes OPHTHALMIA NEONATORUM,causes,0.9950371902099888,"167 ,   292  Treatment of OPHTHALMIA NEONATORUM   +    caused by  NGONORRHOEAE",OPHTHALMIA NEONATORUM,GONORRHOEAE
2726,GONORRHOEAE causes OPHTHALMIA NEONATORUM,causes,0.9950371902099888,"167 ,   292  Treatment of OPHTHALMIA NEONATORUM   +    caused by  NGONORRHOEAE",OPHTHALMIA NEONATORUM,GONORRHOEAE
2727,no_relation,causes,0.9950371902099888,"167 ,   292  Treatment of OPHTHALMIA NEONATORUM   +    caused by  NGONORRHOEAE",OPHTHALMIA NEONATORUM,GONORRHOEAE
2728,GONORRHOEAE causes OPHTHALMIA NEONATORUM,causes,0.9950371902099888,"167 ,   292  Treatment of OPHTHALMIA NEONATORUM   +    caused by  NGONORRHOEAE",OPHTHALMIA NEONATORUM,GONORRHOEAE
2729,GONORRHOEAE causes OPHTHALMIA NEONATORUM,causes,0.9950371902099888,"167 ,   292  Treatment of OPHTHALMIA NEONATORUM   +    caused by  NGONORRHOEAE",OPHTHALMIA NEONATORUM,GONORRHOEAE
2730,no_relation,causes,0.549442255794756,"A double blind cross over study of maximal expiratory flows and arterial blood gas tensions in normals, ASTHMATICS and bronchitis after SALBUTAMOL and ipratropin.",ASTHMATICS,SALBUTAMOL
2731,no_relation,causes,0.549442255794756,"A double blind cross over study of maximal expiratory flows and arterial blood gas tensions in normals, ASTHMATICS and bronchitis after SALBUTAMOL and ipratropin.",ASTHMATICS,SALBUTAMOL
2732,no_relation,causes,0.549442255794756,"A double blind cross over study of maximal expiratory flows and arterial blood gas tensions in normals, ASTHMATICS and bronchitis after SALBUTAMOL and ipratropin.",ASTHMATICS,SALBUTAMOL
2733,no_relation,causes,0.549442255794756,"A double blind cross over study of maximal expiratory flows and arterial blood gas tensions in normals, ASTHMATICS and bronchitis after SALBUTAMOL and ipratropin.",ASTHMATICS,SALBUTAMOL
2734,no_relation,causes,0.549442255794756,"A double blind cross over study of maximal expiratory flows and arterial blood gas tensions in normals, ASTHMATICS and bronchitis after SALBUTAMOL and ipratropin.",ASTHMATICS,SALBUTAMOL
2735,SALBUTAMOL causes ASTHMATICS,causes,0.549442255794756,"A double blind cross over study of maximal expiratory flows and arterial blood gas tensions in normals, ASTHMATICS and bronchitis after SALBUTAMOL and ipratropin.",ASTHMATICS,SALBUTAMOL
2736,ASTHMATICS causes SALBUTAMOL,causes,0.549442255794756,"A double blind cross over study of maximal expiratory flows and arterial blood gas tensions in normals, ASTHMATICS and bronchitis after SALBUTAMOL and ipratropin.",ASTHMATICS,SALBUTAMOL
2737,TREPONEMA PERTENUE causes YAWS,causes,0.948683298050514,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
2738,TREPONEMA PERTENUE causes YAWS,causes,0.948683298050514,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
2739,TREPONEMA PERTENUE causes YAWS,causes,0.948683298050514,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
2740,TREPONEMA PERTENUE causes YAWS,causes,0.948683298050514,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
2741,YAWS causes TREPONEMA PERTENUE,causes,0.948683298050514,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
2742,TREPONEMA PERTENUE causes YAWS,causes,0.948683298050514,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
2743,TREPONEMA PERTENUE causes YAWS,causes,0.948683298050514,Alternative to penicillin G for treatment of YAWS caused by  TREPONEMA PERTENUE.,YAWS,TREPONEMA PERTENUE
2744,CONFUSIONAL MIGRAINE causes HEADACHE,causes,0.9282791216329142,"CONFUSIONAL MIGRAINE presents with a HEADACHE which can be minimal, associated with a confusional state that can last from 10 minutes to 2 days.",HEADACHE,CONFUSIONAL MIGRAINE
2745,CONFUSIONAL MIGRAINE causes HEADACHE,causes,0.9282791216329142,"CONFUSIONAL MIGRAINE presents with a HEADACHE which can be minimal, associated with a confusional state that can last from 10 minutes to 2 days.",HEADACHE,CONFUSIONAL MIGRAINE
2746,HEADACHE causes CONFUSIONAL MIGRAINE,causes,0.9282791216329142,"CONFUSIONAL MIGRAINE presents with a HEADACHE which can be minimal, associated with a confusional state that can last from 10 minutes to 2 days.",HEADACHE,CONFUSIONAL MIGRAINE
2747,CONFUSIONAL MIGRAINE causes HEADACHE,causes,0.9282791216329142,"CONFUSIONAL MIGRAINE presents with a HEADACHE which can be minimal, associated with a confusional state that can last from 10 minutes to 2 days.",HEADACHE,CONFUSIONAL MIGRAINE
2748,CONFUSIONAL MIGRAINE causes HEADACHE,causes,0.9282791216329142,"CONFUSIONAL MIGRAINE presents with a HEADACHE which can be minimal, associated with a confusional state that can last from 10 minutes to 2 days.",HEADACHE,CONFUSIONAL MIGRAINE
2749,no_relation,causes,0.9282791216329142,"CONFUSIONAL MIGRAINE presents with a HEADACHE which can be minimal, associated with a confusional state that can last from 10 minutes to 2 days.",HEADACHE,CONFUSIONAL MIGRAINE
2750,no_relation,causes,0.9282791216329142,"CONFUSIONAL MIGRAINE presents with a HEADACHE which can be minimal, associated with a confusional state that can last from 10 minutes to 2 days.",HEADACHE,CONFUSIONAL MIGRAINE
2751,RSD causes REGIONAL PAIN,causes,0.903696114115064,"DIAGNOSIS  Introduction  Consider the diagnosis of RSD in all patients with a history of trauma; characteristic, persistent, REGIONAL PAIN out of proportion to the injury; vasomotor or sudomotor instability in the affected region at presentation or by history; and no alternative diagnosis to explain their symptoms.",REGIONAL PAIN,RSD
2752,RSD causes REGIONAL PAIN,causes,0.903696114115064,"DIAGNOSIS  Introduction  Consider the diagnosis of RSD in all patients with a history of trauma; characteristic, persistent, REGIONAL PAIN out of proportion to the injury; vasomotor or sudomotor instability in the affected region at presentation or by history; and no alternative diagnosis to explain their symptoms.",REGIONAL PAIN,RSD
2753,RSD causes REGIONAL PAIN,causes,0.903696114115064,"DIAGNOSIS  Introduction  Consider the diagnosis of RSD in all patients with a history of trauma; characteristic, persistent, REGIONAL PAIN out of proportion to the injury; vasomotor or sudomotor instability in the affected region at presentation or by history; and no alternative diagnosis to explain their symptoms.",REGIONAL PAIN,RSD
2754,RSD causes REGIONAL PAIN,causes,0.903696114115064,"DIAGNOSIS  Introduction  Consider the diagnosis of RSD in all patients with a history of trauma; characteristic, persistent, REGIONAL PAIN out of proportion to the injury; vasomotor or sudomotor instability in the affected region at presentation or by history; and no alternative diagnosis to explain their symptoms.",REGIONAL PAIN,RSD
2755,RSD causes REGIONAL PAIN,causes,0.903696114115064,"DIAGNOSIS  Introduction  Consider the diagnosis of RSD in all patients with a history of trauma; characteristic, persistent, REGIONAL PAIN out of proportion to the injury; vasomotor or sudomotor instability in the affected region at presentation or by history; and no alternative diagnosis to explain their symptoms.",REGIONAL PAIN,RSD
2756,RSD causes REGIONAL PAIN,causes,0.903696114115064,"DIAGNOSIS  Introduction  Consider the diagnosis of RSD in all patients with a history of trauma; characteristic, persistent, REGIONAL PAIN out of proportion to the injury; vasomotor or sudomotor instability in the affected region at presentation or by history; and no alternative diagnosis to explain their symptoms.",REGIONAL PAIN,RSD
2757,no_relation,causes,0.903696114115064,"DIAGNOSIS  Introduction  Consider the diagnosis of RSD in all patients with a history of trauma; characteristic, persistent, REGIONAL PAIN out of proportion to the injury; vasomotor or sudomotor instability in the affected region at presentation or by history; and no alternative diagnosis to explain their symptoms.",REGIONAL PAIN,RSD
2758,COLD AGGLUTININ DISEASE causes INTRAVASCULAR HEMOLYSIS,causes,0.3779644730092271,"Paroxysmal cold hemoglobinuria is very rare, characterized by INTRAVASCULAR HEMOLYSIS often following infection  Immune hemolytic anemias are often characterized by numerous spherocytes on the blood smear; erythrocyte agglutination is seen on smear with COLD AGGLUTININ DISEASE",INTRAVASCULAR HEMOLYSIS,COLD AGGLUTININ DISEASE
2759,no_relation,causes,0.3779644730092271,"Paroxysmal cold hemoglobinuria is very rare, characterized by INTRAVASCULAR HEMOLYSIS often following infection  Immune hemolytic anemias are often characterized by numerous spherocytes on the blood smear; erythrocyte agglutination is seen on smear with COLD AGGLUTININ DISEASE",INTRAVASCULAR HEMOLYSIS,COLD AGGLUTININ DISEASE
2760,COLD AGGLUTININ DISEASE causes INTRAVASCULAR HEMOLYSIS,causes,0.3779644730092271,"Paroxysmal cold hemoglobinuria is very rare, characterized by INTRAVASCULAR HEMOLYSIS often following infection  Immune hemolytic anemias are often characterized by numerous spherocytes on the blood smear; erythrocyte agglutination is seen on smear with COLD AGGLUTININ DISEASE",INTRAVASCULAR HEMOLYSIS,COLD AGGLUTININ DISEASE
2761,no_relation,causes,0.3779644730092271,"Paroxysmal cold hemoglobinuria is very rare, characterized by INTRAVASCULAR HEMOLYSIS often following infection  Immune hemolytic anemias are often characterized by numerous spherocytes on the blood smear; erythrocyte agglutination is seen on smear with COLD AGGLUTININ DISEASE",INTRAVASCULAR HEMOLYSIS,COLD AGGLUTININ DISEASE
2762,no_relation,causes,0.3779644730092271,"Paroxysmal cold hemoglobinuria is very rare, characterized by INTRAVASCULAR HEMOLYSIS often following infection  Immune hemolytic anemias are often characterized by numerous spherocytes on the blood smear; erythrocyte agglutination is seen on smear with COLD AGGLUTININ DISEASE",INTRAVASCULAR HEMOLYSIS,COLD AGGLUTININ DISEASE
2763,no_relation,causes,0.3779644730092271,"Paroxysmal cold hemoglobinuria is very rare, characterized by INTRAVASCULAR HEMOLYSIS often following infection  Immune hemolytic anemias are often characterized by numerous spherocytes on the blood smear; erythrocyte agglutination is seen on smear with COLD AGGLUTININ DISEASE",INTRAVASCULAR HEMOLYSIS,COLD AGGLUTININ DISEASE
2764,no_relation,causes,0.3779644730092271,"Paroxysmal cold hemoglobinuria is very rare, characterized by INTRAVASCULAR HEMOLYSIS often following infection  Immune hemolytic anemias are often characterized by numerous spherocytes on the blood smear; erythrocyte agglutination is seen on smear with COLD AGGLUTININ DISEASE",INTRAVASCULAR HEMOLYSIS,COLD AGGLUTININ DISEASE
2765,no_relation,causes,0.4850712500726661,BOTULINUM ANTITOXIN also may be indicated for BOTULISM that occurs in the context of biologic warfare or bioterrorism.,BOTULISM,BOTULINUM ANTITOXIN
2766,no_relation,causes,0.4850712500726661,BOTULINUM ANTITOXIN also may be indicated for BOTULISM that occurs in the context of biologic warfare or bioterrorism.,BOTULISM,BOTULINUM ANTITOXIN
2767,BOTULINUM ANTITOXIN causes BOTULISM,causes,0.4850712500726661,BOTULINUM ANTITOXIN also may be indicated for BOTULISM that occurs in the context of biologic warfare or bioterrorism.,BOTULISM,BOTULINUM ANTITOXIN
2768,BOTULISM causes BOTULINUM ANTITOXIN,causes,0.4850712500726661,BOTULINUM ANTITOXIN also may be indicated for BOTULISM that occurs in the context of biologic warfare or bioterrorism.,BOTULISM,BOTULINUM ANTITOXIN
2769,no_relation,causes,0.4850712500726661,BOTULINUM ANTITOXIN also may be indicated for BOTULISM that occurs in the context of biologic warfare or bioterrorism.,BOTULISM,BOTULINUM ANTITOXIN
2770,no_relation,causes,0.4850712500726661,BOTULINUM ANTITOXIN also may be indicated for BOTULISM that occurs in the context of biologic warfare or bioterrorism.,BOTULISM,BOTULINUM ANTITOXIN
2771,no_relation,causes,0.4850712500726661,BOTULINUM ANTITOXIN also may be indicated for BOTULISM that occurs in the context of biologic warfare or bioterrorism.,BOTULISM,BOTULINUM ANTITOXIN
2772,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.99654575824488,173  Toxoplasmosis  Prevention of TOXOPLASMOSIS caused by  TOXOPLASMA GONDII  in conjunction with other anti infectives.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2773,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.99654575824488,173  Toxoplasmosis  Prevention of TOXOPLASMOSIS caused by  TOXOPLASMA GONDII  in conjunction with other anti infectives.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2774,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.99654575824488,173  Toxoplasmosis  Prevention of TOXOPLASMOSIS caused by  TOXOPLASMA GONDII  in conjunction with other anti infectives.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2775,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.99654575824488,173  Toxoplasmosis  Prevention of TOXOPLASMOSIS caused by  TOXOPLASMA GONDII  in conjunction with other anti infectives.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2776,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.99654575824488,173  Toxoplasmosis  Prevention of TOXOPLASMOSIS caused by  TOXOPLASMA GONDII  in conjunction with other anti infectives.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2777,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.99654575824488,173  Toxoplasmosis  Prevention of TOXOPLASMOSIS caused by  TOXOPLASMA GONDII  in conjunction with other anti infectives.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2778,TOXOPLASMA GONDII causes TOXOPLASMOSIS,causes,0.99654575824488,173  Toxoplasmosis  Prevention of TOXOPLASMOSIS caused by  TOXOPLASMA GONDII  in conjunction with other anti infectives.,TOXOPLASMOSIS,TOXOPLASMA GONDII
2779,ADENOMYOSIS causes SEVERE CYCLIC MENSTRUAL PAIN,causes,0.9918365981341758,Two patterns of disease were observed: a large heterogeneous pelvic mass and an endometrial mass that mimicked endometrial carcinoma (tvml 106tvml ) Adenomyosis  ADENOMYOSIS is the occurrence of ectopic endometrial tissue in the uterus and commonly causes SEVERE CYCLIC MENSTRUAL PAIN and menorrhagia.,SEVERE CYCLIC MENSTRUAL PAIN,ADENOMYOSIS
2780,ADENOMYOSIS causes SEVERE CYCLIC MENSTRUAL PAIN,causes,0.9918365981341758,Two patterns of disease were observed: a large heterogeneous pelvic mass and an endometrial mass that mimicked endometrial carcinoma (tvml 106tvml ) Adenomyosis  ADENOMYOSIS is the occurrence of ectopic endometrial tissue in the uterus and commonly causes SEVERE CYCLIC MENSTRUAL PAIN and menorrhagia.,SEVERE CYCLIC MENSTRUAL PAIN,ADENOMYOSIS
2781,ADENOMYOSIS causes SEVERE CYCLIC MENSTRUAL PAIN,causes,0.9918365981341758,Two patterns of disease were observed: a large heterogeneous pelvic mass and an endometrial mass that mimicked endometrial carcinoma (tvml 106tvml ) Adenomyosis  ADENOMYOSIS is the occurrence of ectopic endometrial tissue in the uterus and commonly causes SEVERE CYCLIC MENSTRUAL PAIN and menorrhagia.,SEVERE CYCLIC MENSTRUAL PAIN,ADENOMYOSIS
2782,ADENOMYOSIS causes SEVERE CYCLIC MENSTRUAL PAIN,causes,0.9918365981341758,Two patterns of disease were observed: a large heterogeneous pelvic mass and an endometrial mass that mimicked endometrial carcinoma (tvml 106tvml ) Adenomyosis  ADENOMYOSIS is the occurrence of ectopic endometrial tissue in the uterus and commonly causes SEVERE CYCLIC MENSTRUAL PAIN and menorrhagia.,SEVERE CYCLIC MENSTRUAL PAIN,ADENOMYOSIS
2783,ADENOMYOSIS causes SEVERE CYCLIC MENSTRUAL PAIN,causes,0.9918365981341758,Two patterns of disease were observed: a large heterogeneous pelvic mass and an endometrial mass that mimicked endometrial carcinoma (tvml 106tvml ) Adenomyosis  ADENOMYOSIS is the occurrence of ectopic endometrial tissue in the uterus and commonly causes SEVERE CYCLIC MENSTRUAL PAIN and menorrhagia.,SEVERE CYCLIC MENSTRUAL PAIN,ADENOMYOSIS
2784,ADENOMYOSIS causes SEVERE CYCLIC MENSTRUAL PAIN,causes,0.9918365981341758,Two patterns of disease were observed: a large heterogeneous pelvic mass and an endometrial mass that mimicked endometrial carcinoma (tvml 106tvml ) Adenomyosis  ADENOMYOSIS is the occurrence of ectopic endometrial tissue in the uterus and commonly causes SEVERE CYCLIC MENSTRUAL PAIN and menorrhagia.,SEVERE CYCLIC MENSTRUAL PAIN,ADENOMYOSIS
2785,SEVERE CYCLIC MENSTRUAL PAIN causes ADENOMYOSIS,causes,0.9918365981341758,Two patterns of disease were observed: a large heterogeneous pelvic mass and an endometrial mass that mimicked endometrial carcinoma (tvml 106tvml ) Adenomyosis  ADENOMYOSIS is the occurrence of ectopic endometrial tissue in the uterus and commonly causes SEVERE CYCLIC MENSTRUAL PAIN and menorrhagia.,SEVERE CYCLIC MENSTRUAL PAIN,ADENOMYOSIS
2786,ANESTHETICS causes MALIGNANT HYPERTHERMIA,causes,0.9950371902099888,Malignant hyperthermia (see  MALIGNANT HYPERTHERMIA ) can result from exposure to some ANESTHETICS and antipsychotics; this genetic disorder has a high mortality rate.,MALIGNANT HYPERTHERMIA,ANESTHETICS
2787,ANESTHETICS causes MALIGNANT HYPERTHERMIA,causes,0.9950371902099888,Malignant hyperthermia (see  MALIGNANT HYPERTHERMIA ) can result from exposure to some ANESTHETICS and antipsychotics; this genetic disorder has a high mortality rate.,MALIGNANT HYPERTHERMIA,ANESTHETICS
2788,ANESTHETICS causes MALIGNANT HYPERTHERMIA,causes,0.9950371902099888,Malignant hyperthermia (see  MALIGNANT HYPERTHERMIA ) can result from exposure to some ANESTHETICS and antipsychotics; this genetic disorder has a high mortality rate.,MALIGNANT HYPERTHERMIA,ANESTHETICS
2789,MALIGNANT HYPERTHERMIA causes ANESTHETICS,causes,0.9950371902099888,Malignant hyperthermia (see  MALIGNANT HYPERTHERMIA ) can result from exposure to some ANESTHETICS and antipsychotics; this genetic disorder has a high mortality rate.,MALIGNANT HYPERTHERMIA,ANESTHETICS
2790,ANESTHETICS causes MALIGNANT HYPERTHERMIA,causes,0.9950371902099888,Malignant hyperthermia (see  MALIGNANT HYPERTHERMIA ) can result from exposure to some ANESTHETICS and antipsychotics; this genetic disorder has a high mortality rate.,MALIGNANT HYPERTHERMIA,ANESTHETICS
2791,ANESTHETICS causes MALIGNANT HYPERTHERMIA,causes,0.9950371902099888,Malignant hyperthermia (see  MALIGNANT HYPERTHERMIA ) can result from exposure to some ANESTHETICS and antipsychotics; this genetic disorder has a high mortality rate.,MALIGNANT HYPERTHERMIA,ANESTHETICS
2792,ANESTHETICS causes MALIGNANT HYPERTHERMIA,causes,0.9950371902099888,Malignant hyperthermia (see  MALIGNANT HYPERTHERMIA ) can result from exposure to some ANESTHETICS and antipsychotics; this genetic disorder has a high mortality rate.,MALIGNANT HYPERTHERMIA,ANESTHETICS
2793,no_relation,causes,0.8944271909999159,"Patients with STAPHYLOCOCCAL PNEUMONIA are acutely ill; purulent sputum production is the rule, and polymorpho nuclear leukocytes and STAPHYLOCOCCI can be identified on Gram stain of the sputum.",STAPHYLOCOCCAL PNEUMONIA,STAPHYLOCOCCI
2794,no_relation,causes,0.8944271909999159,"Patients with STAPHYLOCOCCAL PNEUMONIA are acutely ill; purulent sputum production is the rule, and polymorpho nuclear leukocytes and STAPHYLOCOCCI can be identified on Gram stain of the sputum.",STAPHYLOCOCCAL PNEUMONIA,STAPHYLOCOCCI
2795,STAPHYLOCOCCI causes STAPHYLOCOCCAL PNEUMONIA,causes,0.8944271909999159,"Patients with STAPHYLOCOCCAL PNEUMONIA are acutely ill; purulent sputum production is the rule, and polymorpho nuclear leukocytes and STAPHYLOCOCCI can be identified on Gram stain of the sputum.",STAPHYLOCOCCAL PNEUMONIA,STAPHYLOCOCCI
2796,STAPHYLOCOCCI causes STAPHYLOCOCCAL PNEUMONIA,causes,0.8944271909999159,"Patients with STAPHYLOCOCCAL PNEUMONIA are acutely ill; purulent sputum production is the rule, and polymorpho nuclear leukocytes and STAPHYLOCOCCI can be identified on Gram stain of the sputum.",STAPHYLOCOCCAL PNEUMONIA,STAPHYLOCOCCI
2797,no_relation,causes,0.8944271909999159,"Patients with STAPHYLOCOCCAL PNEUMONIA are acutely ill; purulent sputum production is the rule, and polymorpho nuclear leukocytes and STAPHYLOCOCCI can be identified on Gram stain of the sputum.",STAPHYLOCOCCAL PNEUMONIA,STAPHYLOCOCCI
2798,STAPHYLOCOCCAL PNEUMONIA causes STAPHYLOCOCCI,causes,0.8944271909999159,"Patients with STAPHYLOCOCCAL PNEUMONIA are acutely ill; purulent sputum production is the rule, and polymorpho nuclear leukocytes and STAPHYLOCOCCI can be identified on Gram stain of the sputum.",STAPHYLOCOCCAL PNEUMONIA,STAPHYLOCOCCI
2799,no_relation,causes,0.8944271909999159,"Patients with STAPHYLOCOCCAL PNEUMONIA are acutely ill; purulent sputum production is the rule, and polymorpho nuclear leukocytes and STAPHYLOCOCCI can be identified on Gram stain of the sputum.",STAPHYLOCOCCAL PNEUMONIA,STAPHYLOCOCCI
2800,DRUGS causes BENZODIAZEPINE TOLERANCE,causes,0.5,1  Drug and Alcohol Dependence  Possible increased frequency of BENZODIAZEPINE TOLERANCE and dependence in patients dependent on other DRUGS or alcohol; use with caution.,BENZODIAZEPINE TOLERANCE,DRUGS
2801,no_relation,causes,0.5,1  Drug and Alcohol Dependence  Possible increased frequency of BENZODIAZEPINE TOLERANCE and dependence in patients dependent on other DRUGS or alcohol; use with caution.,BENZODIAZEPINE TOLERANCE,DRUGS
2802,no_relation,causes,0.5,1  Drug and Alcohol Dependence  Possible increased frequency of BENZODIAZEPINE TOLERANCE and dependence in patients dependent on other DRUGS or alcohol; use with caution.,BENZODIAZEPINE TOLERANCE,DRUGS
2803,no_relation,causes,0.5,1  Drug and Alcohol Dependence  Possible increased frequency of BENZODIAZEPINE TOLERANCE and dependence in patients dependent on other DRUGS or alcohol; use with caution.,BENZODIAZEPINE TOLERANCE,DRUGS
2804,DRUGS causes BENZODIAZEPINE TOLERANCE,causes,0.5,1  Drug and Alcohol Dependence  Possible increased frequency of BENZODIAZEPINE TOLERANCE and dependence in patients dependent on other DRUGS or alcohol; use with caution.,BENZODIAZEPINE TOLERANCE,DRUGS
2805,DRUGS causes BENZODIAZEPINE TOLERANCE,causes,0.5,1  Drug and Alcohol Dependence  Possible increased frequency of BENZODIAZEPINE TOLERANCE and dependence in patients dependent on other DRUGS or alcohol; use with caution.,BENZODIAZEPINE TOLERANCE,DRUGS
2806,DRUGS causes BENZODIAZEPINE TOLERANCE,causes,0.5,1  Drug and Alcohol Dependence  Possible increased frequency of BENZODIAZEPINE TOLERANCE and dependence in patients dependent on other DRUGS or alcohol; use with caution.,BENZODIAZEPINE TOLERANCE,DRUGS
2807,LEPROSY causes MYCOBACTERIUM LEPRAE DNA AND MRNA,causes,0.583459965991578,2009 06 01  Quantitative real time PCR analysis of MYCOBACTERIUM LEPRAE DNA AND MRNA in human biopsy material from LEPROSY and reactional cases.,LEPROSY,MYCOBACTERIUM LEPRAE DNA AND MRNA
2808,MYCOBACTERIUM LEPRAE DNA AND MRNA causes LEPROSY,causes,0.583459965991578,2009 06 01  Quantitative real time PCR analysis of MYCOBACTERIUM LEPRAE DNA AND MRNA in human biopsy material from LEPROSY and reactional cases.,LEPROSY,MYCOBACTERIUM LEPRAE DNA AND MRNA
2809,LEPROSY causes MYCOBACTERIUM LEPRAE DNA AND MRNA,causes,0.583459965991578,2009 06 01  Quantitative real time PCR analysis of MYCOBACTERIUM LEPRAE DNA AND MRNA in human biopsy material from LEPROSY and reactional cases.,LEPROSY,MYCOBACTERIUM LEPRAE DNA AND MRNA
2810,MYCOBACTERIUM LEPRAE DNA AND MRNA causes LEPROSY,causes,0.583459965991578,2009 06 01  Quantitative real time PCR analysis of MYCOBACTERIUM LEPRAE DNA AND MRNA in human biopsy material from LEPROSY and reactional cases.,LEPROSY,MYCOBACTERIUM LEPRAE DNA AND MRNA
2811,MYCOBACTERIUM LEPRAE DNA AND MRNA causes LEPROSY,causes,0.583459965991578,2009 06 01  Quantitative real time PCR analysis of MYCOBACTERIUM LEPRAE DNA AND MRNA in human biopsy material from LEPROSY and reactional cases.,LEPROSY,MYCOBACTERIUM LEPRAE DNA AND MRNA
2812,no_relation,causes,0.583459965991578,2009 06 01  Quantitative real time PCR analysis of MYCOBACTERIUM LEPRAE DNA AND MRNA in human biopsy material from LEPROSY and reactional cases.,LEPROSY,MYCOBACTERIUM LEPRAE DNA AND MRNA
2813,MYCOBACTERIUM LEPRAE DNA AND MRNA causes LEPROSY,causes,0.583459965991578,2009 06 01  Quantitative real time PCR analysis of MYCOBACTERIUM LEPRAE DNA AND MRNA in human biopsy material from LEPROSY and reactional cases.,LEPROSY,MYCOBACTERIUM LEPRAE DNA AND MRNA
2814,DYSMENORRHEA causes PAIN,causes,0.8682431421244592,"The PAIN caused her to miss school frequently, but was not considered to be severe by her family physician who diagnosed DYSMENORRHEA",PAIN,DYSMENORRHEA
2815,DYSMENORRHEA causes PAIN,causes,0.8682431421244592,"The PAIN caused her to miss school frequently, but was not considered to be severe by her family physician who diagnosed DYSMENORRHEA",PAIN,DYSMENORRHEA
2816,DYSMENORRHEA causes PAIN,causes,0.8682431421244592,"The PAIN caused her to miss school frequently, but was not considered to be severe by her family physician who diagnosed DYSMENORRHEA",PAIN,DYSMENORRHEA
2817,DYSMENORRHEA causes PAIN,causes,0.8682431421244592,"The PAIN caused her to miss school frequently, but was not considered to be severe by her family physician who diagnosed DYSMENORRHEA",PAIN,DYSMENORRHEA
2818,DYSMENORRHEA causes PAIN,causes,0.8682431421244592,"The PAIN caused her to miss school frequently, but was not considered to be severe by her family physician who diagnosed DYSMENORRHEA",PAIN,DYSMENORRHEA
2819,DYSMENORRHEA causes PAIN,causes,0.8682431421244592,"The PAIN caused her to miss school frequently, but was not considered to be severe by her family physician who diagnosed DYSMENORRHEA",PAIN,DYSMENORRHEA
2820,DYSMENORRHEA causes PAIN,causes,0.8682431421244592,"The PAIN caused her to miss school frequently, but was not considered to be severe by her family physician who diagnosed DYSMENORRHEA",PAIN,DYSMENORRHEA
2821,no_relation,causes,0.7548294124240691,"ACUTE PANCREATITIS  ACUTE PANCREATITIS is inflammation of the PANCREAS (and, sometimes, adjacent tissues) caused by the release of activated pancreatic enzymes.",PANCREAS,ACUTE PANCREATITIS
2822,no_relation,causes,0.7548294124240691,"ACUTE PANCREATITIS  ACUTE PANCREATITIS is inflammation of the PANCREAS (and, sometimes, adjacent tissues) caused by the release of activated pancreatic enzymes.",PANCREAS,ACUTE PANCREATITIS
2823,no_relation,causes,0.7548294124240691,"ACUTE PANCREATITIS  ACUTE PANCREATITIS is inflammation of the PANCREAS (and, sometimes, adjacent tissues) caused by the release of activated pancreatic enzymes.",PANCREAS,ACUTE PANCREATITIS
2824,no_relation,causes,0.7548294124240691,"ACUTE PANCREATITIS  ACUTE PANCREATITIS is inflammation of the PANCREAS (and, sometimes, adjacent tissues) caused by the release of activated pancreatic enzymes.",PANCREAS,ACUTE PANCREATITIS
2825,PANCREAS causes ACUTE PANCREATITIS,causes,0.7548294124240691,"ACUTE PANCREATITIS  ACUTE PANCREATITIS is inflammation of the PANCREAS (and, sometimes, adjacent tissues) caused by the release of activated pancreatic enzymes.",PANCREAS,ACUTE PANCREATITIS
2826,no_relation,causes,0.7548294124240691,"ACUTE PANCREATITIS  ACUTE PANCREATITIS is inflammation of the PANCREAS (and, sometimes, adjacent tissues) caused by the release of activated pancreatic enzymes.",PANCREAS,ACUTE PANCREATITIS
2827,PANCREAS causes ACUTE PANCREATITIS,causes,0.7548294124240691,"ACUTE PANCREATITIS  ACUTE PANCREATITIS is inflammation of the PANCREAS (and, sometimes, adjacent tissues) caused by the release of activated pancreatic enzymes.",PANCREAS,ACUTE PANCREATITIS
2828,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,"Curable forms of hypertension (secondary HYPERTENSION), which are relatively rare, may be caused by coarctation of the aorta, PHEOCHROMOCYTOMA renal artery stenosis, primary aldosteronism, and Cushing's syndrome.",HYPERTENSION,PHEOCHROMOCYTOMA
2829,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,"Curable forms of hypertension (secondary HYPERTENSION), which are relatively rare, may be caused by coarctation of the aorta, PHEOCHROMOCYTOMA renal artery stenosis, primary aldosteronism, and Cushing's syndrome.",HYPERTENSION,PHEOCHROMOCYTOMA
2830,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,1.0,"Curable forms of hypertension (secondary HYPERTENSION), which are relatively rare, may be caused by coarctation of the aorta, PHEOCHROMOCYTOMA renal artery stenosis, primary aldosteronism, and Cushing's syndrome.",HYPERTENSION,PHEOCHROMOCYTOMA
2831,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,"Curable forms of hypertension (secondary HYPERTENSION), which are relatively rare, may be caused by coarctation of the aorta, PHEOCHROMOCYTOMA renal artery stenosis, primary aldosteronism, and Cushing's syndrome.",HYPERTENSION,PHEOCHROMOCYTOMA
2832,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,1.0,"Curable forms of hypertension (secondary HYPERTENSION), which are relatively rare, may be caused by coarctation of the aorta, PHEOCHROMOCYTOMA renal artery stenosis, primary aldosteronism, and Cushing's syndrome.",HYPERTENSION,PHEOCHROMOCYTOMA
2833,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,"Curable forms of hypertension (secondary HYPERTENSION), which are relatively rare, may be caused by coarctation of the aorta, PHEOCHROMOCYTOMA renal artery stenosis, primary aldosteronism, and Cushing's syndrome.",HYPERTENSION,PHEOCHROMOCYTOMA
2834,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,1.0,"Curable forms of hypertension (secondary HYPERTENSION), which are relatively rare, may be caused by coarctation of the aorta, PHEOCHROMOCYTOMA renal artery stenosis, primary aldosteronism, and Cushing's syndrome.",HYPERTENSION,PHEOCHROMOCYTOMA
2835,no_relation,causes,0.700140042014005,"polydactyly, retinitis pigmentosa, mental retardation MULTIPLE LENTIGINES SYNDROME  Deafness, SHORT STATURE cardiac defects, multiple lentigines, genital or urologic defects Rud syndrome  Congenital ichthyosis, mental retardation, epilepsy Cerebellar ataxia and hypogonadotropic hypogonadism  Cerebellar ataxia, pes cavus deformity of the chest, spina bifida A large number of hypothalamic syndromes associated with hypogonadotropic hypogonadism have been described.",SHORT STATURE,MULTIPLE LENTIGINES SYNDROME
2836,SHORT STATURE causes MULTIPLE LENTIGINES SYNDROME,causes,0.700140042014005,"polydactyly, retinitis pigmentosa, mental retardation MULTIPLE LENTIGINES SYNDROME  Deafness, SHORT STATURE cardiac defects, multiple lentigines, genital or urologic defects Rud syndrome  Congenital ichthyosis, mental retardation, epilepsy Cerebellar ataxia and hypogonadotropic hypogonadism  Cerebellar ataxia, pes cavus deformity of the chest, spina bifida A large number of hypothalamic syndromes associated with hypogonadotropic hypogonadism have been described.",SHORT STATURE,MULTIPLE LENTIGINES SYNDROME
2837,no_relation,causes,0.700140042014005,"polydactyly, retinitis pigmentosa, mental retardation MULTIPLE LENTIGINES SYNDROME  Deafness, SHORT STATURE cardiac defects, multiple lentigines, genital or urologic defects Rud syndrome  Congenital ichthyosis, mental retardation, epilepsy Cerebellar ataxia and hypogonadotropic hypogonadism  Cerebellar ataxia, pes cavus deformity of the chest, spina bifida A large number of hypothalamic syndromes associated with hypogonadotropic hypogonadism have been described.",SHORT STATURE,MULTIPLE LENTIGINES SYNDROME
2838,no_relation,causes,0.700140042014005,"polydactyly, retinitis pigmentosa, mental retardation MULTIPLE LENTIGINES SYNDROME  Deafness, SHORT STATURE cardiac defects, multiple lentigines, genital or urologic defects Rud syndrome  Congenital ichthyosis, mental retardation, epilepsy Cerebellar ataxia and hypogonadotropic hypogonadism  Cerebellar ataxia, pes cavus deformity of the chest, spina bifida A large number of hypothalamic syndromes associated with hypogonadotropic hypogonadism have been described.",SHORT STATURE,MULTIPLE LENTIGINES SYNDROME
2839,no_relation,causes,0.700140042014005,"polydactyly, retinitis pigmentosa, mental retardation MULTIPLE LENTIGINES SYNDROME  Deafness, SHORT STATURE cardiac defects, multiple lentigines, genital or urologic defects Rud syndrome  Congenital ichthyosis, mental retardation, epilepsy Cerebellar ataxia and hypogonadotropic hypogonadism  Cerebellar ataxia, pes cavus deformity of the chest, spina bifida A large number of hypothalamic syndromes associated with hypogonadotropic hypogonadism have been described.",SHORT STATURE,MULTIPLE LENTIGINES SYNDROME
2840,MULTIPLE LENTIGINES SYNDROME causes SHORT STATURE,causes,0.700140042014005,"polydactyly, retinitis pigmentosa, mental retardation MULTIPLE LENTIGINES SYNDROME  Deafness, SHORT STATURE cardiac defects, multiple lentigines, genital or urologic defects Rud syndrome  Congenital ichthyosis, mental retardation, epilepsy Cerebellar ataxia and hypogonadotropic hypogonadism  Cerebellar ataxia, pes cavus deformity of the chest, spina bifida A large number of hypothalamic syndromes associated with hypogonadotropic hypogonadism have been described.",SHORT STATURE,MULTIPLE LENTIGINES SYNDROME
2841,no_relation,causes,0.700140042014005,"polydactyly, retinitis pigmentosa, mental retardation MULTIPLE LENTIGINES SYNDROME  Deafness, SHORT STATURE cardiac defects, multiple lentigines, genital or urologic defects Rud syndrome  Congenital ichthyosis, mental retardation, epilepsy Cerebellar ataxia and hypogonadotropic hypogonadism  Cerebellar ataxia, pes cavus deformity of the chest, spina bifida A large number of hypothalamic syndromes associated with hypogonadotropic hypogonadism have been described.",SHORT STATURE,MULTIPLE LENTIGINES SYNDROME
2842,PRIMARY FIBROMYALGIA causes PAIN,causes,0.857492925712544,Functional imaging of PAIN in patients with PRIMARY FIBROMYALGIA,PAIN,PRIMARY FIBROMYALGIA
2843,PRIMARY FIBROMYALGIA causes PAIN,causes,0.857492925712544,Functional imaging of PAIN in patients with PRIMARY FIBROMYALGIA,PAIN,PRIMARY FIBROMYALGIA
2844,PRIMARY FIBROMYALGIA causes PAIN,causes,0.857492925712544,Functional imaging of PAIN in patients with PRIMARY FIBROMYALGIA,PAIN,PRIMARY FIBROMYALGIA
2845,PRIMARY FIBROMYALGIA causes PAIN,causes,0.857492925712544,Functional imaging of PAIN in patients with PRIMARY FIBROMYALGIA,PAIN,PRIMARY FIBROMYALGIA
2846,PRIMARY FIBROMYALGIA causes PAIN,causes,0.857492925712544,Functional imaging of PAIN in patients with PRIMARY FIBROMYALGIA,PAIN,PRIMARY FIBROMYALGIA
2847,no_relation,causes,0.857492925712544,Functional imaging of PAIN in patients with PRIMARY FIBROMYALGIA,PAIN,PRIMARY FIBROMYALGIA
2848,PRIMARY FIBROMYALGIA causes PAIN,causes,0.857492925712544,Functional imaging of PAIN in patients with PRIMARY FIBROMYALGIA,PAIN,PRIMARY FIBROMYALGIA
2849,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.6741998624632421,"230    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefotaxime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2850,no_relation,causes,0.6741998624632421,"230    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefotaxime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2851,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.6741998624632421,"230    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefotaxime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2852,no_relation,causes,0.6741998624632421,"230    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefotaxime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2853,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.6741998624632421,"230    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefotaxime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2854,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.6741998624632421,"230    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefotaxime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2855,ANTIBIOTIC ASSOCIATED DIARRHEA causes MILD DIARRHEA,causes,0.6741998624632421,"230    C. difficile  associated diarrhea and colitis (CDAD; also known as ANTIBIOTIC ASSOCIATED DIARRHEA and colitis or pseudomembranous colitis) has been reported with nearly all anti infectives, including cefotaxime, and may range in severity from MILD DIARRHEA to fatal colitis.",MILD DIARRHEA,ANTIBIOTIC ASSOCIATED DIARRHEA
2856,no_relation,causes,0.936585811581694,"d   One patient died after developing encephalopathy 36 hours after receiving intraventricular liposomal cytarabine;  d ,   i   the other patient developed FOCAL SEIZURES that progressed to STATUS EPILEPTICUS and died approximately 8 weeks after the last intraventricular dose of liposomal cytarabine.",FOCAL SEIZURES,STATUS EPILEPTICUS
2857,no_relation,causes,0.936585811581694,"d   One patient died after developing encephalopathy 36 hours after receiving intraventricular liposomal cytarabine;  d ,   i   the other patient developed FOCAL SEIZURES that progressed to STATUS EPILEPTICUS and died approximately 8 weeks after the last intraventricular dose of liposomal cytarabine.",FOCAL SEIZURES,STATUS EPILEPTICUS
2858,FOCAL SEIZURES causes STATUS EPILEPTICUS,causes,0.936585811581694,"d   One patient died after developing encephalopathy 36 hours after receiving intraventricular liposomal cytarabine;  d ,   i   the other patient developed FOCAL SEIZURES that progressed to STATUS EPILEPTICUS and died approximately 8 weeks after the last intraventricular dose of liposomal cytarabine.",FOCAL SEIZURES,STATUS EPILEPTICUS
2859,STATUS EPILEPTICUS causes FOCAL SEIZURES,causes,0.936585811581694,"d   One patient died after developing encephalopathy 36 hours after receiving intraventricular liposomal cytarabine;  d ,   i   the other patient developed FOCAL SEIZURES that progressed to STATUS EPILEPTICUS and died approximately 8 weeks after the last intraventricular dose of liposomal cytarabine.",FOCAL SEIZURES,STATUS EPILEPTICUS
2860,FOCAL SEIZURES causes STATUS EPILEPTICUS,causes,0.936585811581694,"d   One patient died after developing encephalopathy 36 hours after receiving intraventricular liposomal cytarabine;  d ,   i   the other patient developed FOCAL SEIZURES that progressed to STATUS EPILEPTICUS and died approximately 8 weeks after the last intraventricular dose of liposomal cytarabine.",FOCAL SEIZURES,STATUS EPILEPTICUS
2861,no_relation,causes,0.936585811581694,"d   One patient died after developing encephalopathy 36 hours after receiving intraventricular liposomal cytarabine;  d ,   i   the other patient developed FOCAL SEIZURES that progressed to STATUS EPILEPTICUS and died approximately 8 weeks after the last intraventricular dose of liposomal cytarabine.",FOCAL SEIZURES,STATUS EPILEPTICUS
2862,no_relation,causes,0.936585811581694,"d   One patient died after developing encephalopathy 36 hours after receiving intraventricular liposomal cytarabine;  d ,   i   the other patient developed FOCAL SEIZURES that progressed to STATUS EPILEPTICUS and died approximately 8 weeks after the last intraventricular dose of liposomal cytarabine.",FOCAL SEIZURES,STATUS EPILEPTICUS
2863,no_relation,causes,0.31980107453341605,"b  May maintain normal sinus rhythm for long periods in recent onset of atrial fibrillation or flutter without CHF, atrial enlargement, or left ventricular hypertrophy, but long standing ATRIAL FIBRILLATION is likely to recur even with QUINIDINE MAINTENANCE THERAPY.",ATRIAL FIBRILLATION,QUINIDINE MAINTENANCE THERAPY
2864,no_relation,causes,0.31980107453341605,"b  May maintain normal sinus rhythm for long periods in recent onset of atrial fibrillation or flutter without CHF, atrial enlargement, or left ventricular hypertrophy, but long standing ATRIAL FIBRILLATION is likely to recur even with QUINIDINE MAINTENANCE THERAPY.",ATRIAL FIBRILLATION,QUINIDINE MAINTENANCE THERAPY
2865,ATRIAL FIBRILLATION causes QUINIDINE MAINTENANCE THERAPY,causes,0.31980107453341605,"b  May maintain normal sinus rhythm for long periods in recent onset of atrial fibrillation or flutter without CHF, atrial enlargement, or left ventricular hypertrophy, but long standing ATRIAL FIBRILLATION is likely to recur even with QUINIDINE MAINTENANCE THERAPY.",ATRIAL FIBRILLATION,QUINIDINE MAINTENANCE THERAPY
2866,no_relation,causes,0.31980107453341605,"b  May maintain normal sinus rhythm for long periods in recent onset of atrial fibrillation or flutter without CHF, atrial enlargement, or left ventricular hypertrophy, but long standing ATRIAL FIBRILLATION is likely to recur even with QUINIDINE MAINTENANCE THERAPY.",ATRIAL FIBRILLATION,QUINIDINE MAINTENANCE THERAPY
2867,ATRIAL FIBRILLATION causes QUINIDINE MAINTENANCE THERAPY,causes,0.31980107453341605,"b  May maintain normal sinus rhythm for long periods in recent onset of atrial fibrillation or flutter without CHF, atrial enlargement, or left ventricular hypertrophy, but long standing ATRIAL FIBRILLATION is likely to recur even with QUINIDINE MAINTENANCE THERAPY.",ATRIAL FIBRILLATION,QUINIDINE MAINTENANCE THERAPY
2868,no_relation,causes,0.31980107453341605,"b  May maintain normal sinus rhythm for long periods in recent onset of atrial fibrillation or flutter without CHF, atrial enlargement, or left ventricular hypertrophy, but long standing ATRIAL FIBRILLATION is likely to recur even with QUINIDINE MAINTENANCE THERAPY.",ATRIAL FIBRILLATION,QUINIDINE MAINTENANCE THERAPY
2869,no_relation,causes,0.31980107453341605,"b  May maintain normal sinus rhythm for long periods in recent onset of atrial fibrillation or flutter without CHF, atrial enlargement, or left ventricular hypertrophy, but long standing ATRIAL FIBRILLATION is likely to recur even with QUINIDINE MAINTENANCE THERAPY.",ATRIAL FIBRILLATION,QUINIDINE MAINTENANCE THERAPY
2870,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.959264193758544,"100 ,   101 ,   102  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to capreomycin.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
2871,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.959264193758544,"100 ,   101 ,   102  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to capreomycin.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
2872,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.959264193758544,"100 ,   101 ,   102  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to capreomycin.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
2873,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.959264193758544,"100 ,   101 ,   102  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to capreomycin.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
2874,no_relation,causes,0.959264193758544,"100 ,   101 ,   102  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to capreomycin.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
2875,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.959264193758544,"100 ,   101 ,   102  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to capreomycin.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
2876,MYCOBACTERIUM TUBERCULOSIS causes DRUG RESISTANT TB,causes,0.959264193758544,"100 ,   101 ,   102  Second line agent used in treatment of DRUG RESISTANT TB caused by  MYCOBACTERIUM TUBERCULOSIS  known or presumed to be susceptible to capreomycin.",DRUG RESISTANT TB,MYCOBACTERIUM TUBERCULOSIS
2877,no_relation,causes,0.848874687627165,"43   In the case of decompensated DIC in which bleeding is the major clinical manifestation, HEPARIN may significantly exacerbate the bleeding and is therefore generally not indicated.",DIC,HEPARIN
2878,no_relation,causes,0.848874687627165,"43   In the case of decompensated DIC in which bleeding is the major clinical manifestation, HEPARIN may significantly exacerbate the bleeding and is therefore generally not indicated.",DIC,HEPARIN
2879,no_relation,causes,0.848874687627165,"43   In the case of decompensated DIC in which bleeding is the major clinical manifestation, HEPARIN may significantly exacerbate the bleeding and is therefore generally not indicated.",DIC,HEPARIN
2880,no_relation,causes,0.848874687627165,"43   In the case of decompensated DIC in which bleeding is the major clinical manifestation, HEPARIN may significantly exacerbate the bleeding and is therefore generally not indicated.",DIC,HEPARIN
2881,no_relation,causes,0.848874687627165,"43   In the case of decompensated DIC in which bleeding is the major clinical manifestation, HEPARIN may significantly exacerbate the bleeding and is therefore generally not indicated.",DIC,HEPARIN
2882,DIC causes HEPARIN,causes,0.848874687627165,"43   In the case of decompensated DIC in which bleeding is the major clinical manifestation, HEPARIN may significantly exacerbate the bleeding and is therefore generally not indicated.",DIC,HEPARIN
2883,HEPARIN causes DIC,causes,0.848874687627165,"43   In the case of decompensated DIC in which bleeding is the major clinical manifestation, HEPARIN may significantly exacerbate the bleeding and is therefore generally not indicated.",DIC,HEPARIN
2884,no_relation,causes,0.4574957109978139,"In  type II (intermediate) spinal muscular atrophy,  symptoms usually manifest between age 3 and 15 mo;  TYPE III SPINAL MUSCULAR ATROPHY (WOHLFART KUGELBERG WELANDER DISEASE)  usually manifests between age 15 mo and 19 yr. Findings are similar to those of type I, but progression is slower and life expectancy is longer; some patients have a normal life span.",TYPE III SPINAL MUSCULAR ATROPHY,WOHLFART KUGELBERG WELANDER DISEASE
2885,no_relation,causes,0.4574957109978139,"In  type II (intermediate) spinal muscular atrophy,  symptoms usually manifest between age 3 and 15 mo;  TYPE III SPINAL MUSCULAR ATROPHY (WOHLFART KUGELBERG WELANDER DISEASE)  usually manifests between age 15 mo and 19 yr. Findings are similar to those of type I, but progression is slower and life expectancy is longer; some patients have a normal life span.",TYPE III SPINAL MUSCULAR ATROPHY,WOHLFART KUGELBERG WELANDER DISEASE
2886,no_relation,causes,0.4574957109978139,"In  type II (intermediate) spinal muscular atrophy,  symptoms usually manifest between age 3 and 15 mo;  TYPE III SPINAL MUSCULAR ATROPHY (WOHLFART KUGELBERG WELANDER DISEASE)  usually manifests between age 15 mo and 19 yr. Findings are similar to those of type I, but progression is slower and life expectancy is longer; some patients have a normal life span.",TYPE III SPINAL MUSCULAR ATROPHY,WOHLFART KUGELBERG WELANDER DISEASE
2887,no_relation,causes,0.4574957109978139,"In  type II (intermediate) spinal muscular atrophy,  symptoms usually manifest between age 3 and 15 mo;  TYPE III SPINAL MUSCULAR ATROPHY (WOHLFART KUGELBERG WELANDER DISEASE)  usually manifests between age 15 mo and 19 yr. Findings are similar to those of type I, but progression is slower and life expectancy is longer; some patients have a normal life span.",TYPE III SPINAL MUSCULAR ATROPHY,WOHLFART KUGELBERG WELANDER DISEASE
2888,no_relation,causes,0.4574957109978139,"In  type II (intermediate) spinal muscular atrophy,  symptoms usually manifest between age 3 and 15 mo;  TYPE III SPINAL MUSCULAR ATROPHY (WOHLFART KUGELBERG WELANDER DISEASE)  usually manifests between age 15 mo and 19 yr. Findings are similar to those of type I, but progression is slower and life expectancy is longer; some patients have a normal life span.",TYPE III SPINAL MUSCULAR ATROPHY,WOHLFART KUGELBERG WELANDER DISEASE
2889,WOHLFART KUGELBERG WELANDER DISEASE causes TYPE III SPINAL MUSCULAR ATROPHY,causes,0.4574957109978139,"In  type II (intermediate) spinal muscular atrophy,  symptoms usually manifest between age 3 and 15 mo;  TYPE III SPINAL MUSCULAR ATROPHY (WOHLFART KUGELBERG WELANDER DISEASE)  usually manifests between age 15 mo and 19 yr. Findings are similar to those of type I, but progression is slower and life expectancy is longer; some patients have a normal life span.",TYPE III SPINAL MUSCULAR ATROPHY,WOHLFART KUGELBERG WELANDER DISEASE
2890,no_relation,causes,0.4574957109978139,"In  type II (intermediate) spinal muscular atrophy,  symptoms usually manifest between age 3 and 15 mo;  TYPE III SPINAL MUSCULAR ATROPHY (WOHLFART KUGELBERG WELANDER DISEASE)  usually manifests between age 15 mo and 19 yr. Findings are similar to those of type I, but progression is slower and life expectancy is longer; some patients have a normal life span.",TYPE III SPINAL MUSCULAR ATROPHY,WOHLFART KUGELBERG WELANDER DISEASE
2891,PREGNANCY causes THALIDOMIDE,causes,0.768221279597376,Warnings/Precautions  Warnings  Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving THALIDOMIDE in any amount.,PREGNANCY,THALIDOMIDE
2892,no_relation,causes,0.768221279597376,Warnings/Precautions  Warnings  Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving THALIDOMIDE in any amount.,PREGNANCY,THALIDOMIDE
2893,no_relation,causes,0.768221279597376,Warnings/Precautions  Warnings  Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving THALIDOMIDE in any amount.,PREGNANCY,THALIDOMIDE
2894,no_relation,causes,0.768221279597376,Warnings/Precautions  Warnings  Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving THALIDOMIDE in any amount.,PREGNANCY,THALIDOMIDE
2895,no_relation,causes,0.768221279597376,Warnings/Precautions  Warnings  Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving THALIDOMIDE in any amount.,PREGNANCY,THALIDOMIDE
2896,no_relation,causes,0.768221279597376,Warnings/Precautions  Warnings  Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving THALIDOMIDE in any amount.,PREGNANCY,THALIDOMIDE
2897,no_relation,causes,0.768221279597376,Warnings/Precautions  Warnings  Fetal/Neonatal Morbidity and Mortality  Extremely high risk of severe birth defects (possibly life threatening) if PREGNANCY occurs while receiving THALIDOMIDE in any amount.,PREGNANCY,THALIDOMIDE
2898,CLOSTRIDIUM BOTULINUM  TOXIN causes BOTULISM,causes,0.995893206467704,BOTULISM  BOTULISM is neuromuscular poisoning from  CLOSTRIDIUM BOTULINUM  TOXIN,BOTULISM,CLOSTRIDIUM BOTULINUM  TOXIN
2899,CLOSTRIDIUM BOTULINUM  TOXIN causes BOTULISM,causes,0.995893206467704,BOTULISM  BOTULISM is neuromuscular poisoning from  CLOSTRIDIUM BOTULINUM  TOXIN,BOTULISM,CLOSTRIDIUM BOTULINUM  TOXIN
2900,CLOSTRIDIUM BOTULINUM  TOXIN causes BOTULISM,causes,0.995893206467704,BOTULISM  BOTULISM is neuromuscular poisoning from  CLOSTRIDIUM BOTULINUM  TOXIN,BOTULISM,CLOSTRIDIUM BOTULINUM  TOXIN
2901,CLOSTRIDIUM BOTULINUM  TOXIN causes BOTULISM,causes,0.995893206467704,BOTULISM  BOTULISM is neuromuscular poisoning from  CLOSTRIDIUM BOTULINUM  TOXIN,BOTULISM,CLOSTRIDIUM BOTULINUM  TOXIN
2902,CLOSTRIDIUM BOTULINUM  TOXIN causes BOTULISM,causes,0.995893206467704,BOTULISM  BOTULISM is neuromuscular poisoning from  CLOSTRIDIUM BOTULINUM  TOXIN,BOTULISM,CLOSTRIDIUM BOTULINUM  TOXIN
2903,CLOSTRIDIUM BOTULINUM  TOXIN causes BOTULISM,causes,0.995893206467704,BOTULISM  BOTULISM is neuromuscular poisoning from  CLOSTRIDIUM BOTULINUM  TOXIN,BOTULISM,CLOSTRIDIUM BOTULINUM  TOXIN
2904,CLOSTRIDIUM BOTULINUM  TOXIN causes BOTULISM,causes,0.995893206467704,BOTULISM  BOTULISM is neuromuscular poisoning from  CLOSTRIDIUM BOTULINUM  TOXIN,BOTULISM,CLOSTRIDIUM BOTULINUM  TOXIN
2905,OXYBUTYNIN causes GLAUCOMA,causes,0.9918365981341758,"OXYBUTYNIN is short acting and often produces significant anticholinergic side effects of constipation, dry mouth, and exacerbation of GLAUCOMA",GLAUCOMA,OXYBUTYNIN
2906,no_relation,causes,0.9918365981341758,"OXYBUTYNIN is short acting and often produces significant anticholinergic side effects of constipation, dry mouth, and exacerbation of GLAUCOMA",GLAUCOMA,OXYBUTYNIN
2907,OXYBUTYNIN causes GLAUCOMA,causes,0.9918365981341758,"OXYBUTYNIN is short acting and often produces significant anticholinergic side effects of constipation, dry mouth, and exacerbation of GLAUCOMA",GLAUCOMA,OXYBUTYNIN
2908,OXYBUTYNIN causes GLAUCOMA,causes,0.9918365981341758,"OXYBUTYNIN is short acting and often produces significant anticholinergic side effects of constipation, dry mouth, and exacerbation of GLAUCOMA",GLAUCOMA,OXYBUTYNIN
2909,no_relation,causes,0.9918365981341758,"OXYBUTYNIN is short acting and often produces significant anticholinergic side effects of constipation, dry mouth, and exacerbation of GLAUCOMA",GLAUCOMA,OXYBUTYNIN
2910,no_relation,causes,0.9918365981341758,"OXYBUTYNIN is short acting and often produces significant anticholinergic side effects of constipation, dry mouth, and exacerbation of GLAUCOMA",GLAUCOMA,OXYBUTYNIN
2911,OXYBUTYNIN causes GLAUCOMA,causes,0.9918365981341758,"OXYBUTYNIN is short acting and often produces significant anticholinergic side effects of constipation, dry mouth, and exacerbation of GLAUCOMA",GLAUCOMA,OXYBUTYNIN
2912,PRIMARY VZV INFECTION causes HERPES ZOSTER,causes,0.9733285267845748,49 •  PRIMARY VZV INFECTION results in varicella (chickenpox); reactivation of infection results in HERPES ZOSTER,PRIMARY VZV INFECTION,HERPES ZOSTER
2913,PRIMARY VZV INFECTION causes HERPES ZOSTER,causes,0.9733285267845748,49 •  PRIMARY VZV INFECTION results in varicella (chickenpox); reactivation of infection results in HERPES ZOSTER,PRIMARY VZV INFECTION,HERPES ZOSTER
2914,no_relation,causes,0.9733285267845748,49 •  PRIMARY VZV INFECTION results in varicella (chickenpox); reactivation of infection results in HERPES ZOSTER,PRIMARY VZV INFECTION,HERPES ZOSTER
2915,no_relation,causes,0.9733285267845748,49 •  PRIMARY VZV INFECTION results in varicella (chickenpox); reactivation of infection results in HERPES ZOSTER,PRIMARY VZV INFECTION,HERPES ZOSTER
2916,PRIMARY VZV INFECTION causes HERPES ZOSTER,causes,0.9733285267845748,49 •  PRIMARY VZV INFECTION results in varicella (chickenpox); reactivation of infection results in HERPES ZOSTER,PRIMARY VZV INFECTION,HERPES ZOSTER
2917,no_relation,causes,0.9733285267845748,49 •  PRIMARY VZV INFECTION results in varicella (chickenpox); reactivation of infection results in HERPES ZOSTER,PRIMARY VZV INFECTION,HERPES ZOSTER
2918,PRIMARY VZV INFECTION causes HERPES ZOSTER,causes,0.9733285267845748,49 •  PRIMARY VZV INFECTION results in varicella (chickenpox); reactivation of infection results in HERPES ZOSTER,PRIMARY VZV INFECTION,HERPES ZOSTER
2919,SEIZURES causes STATUS EPILEPTICUS,causes,0.937042571331636,"HOSPITALIZATION  Introduction  Hospitalize patients when SEIZURES may be due to acute brain pathology, if consciousness does not return to normal, or for impending STATUS EPILEPTICUS",SEIZURES,STATUS EPILEPTICUS
2920,no_relation,causes,0.937042571331636,"HOSPITALIZATION  Introduction  Hospitalize patients when SEIZURES may be due to acute brain pathology, if consciousness does not return to normal, or for impending STATUS EPILEPTICUS",SEIZURES,STATUS EPILEPTICUS
2921,no_relation,causes,0.937042571331636,"HOSPITALIZATION  Introduction  Hospitalize patients when SEIZURES may be due to acute brain pathology, if consciousness does not return to normal, or for impending STATUS EPILEPTICUS",SEIZURES,STATUS EPILEPTICUS
2922,no_relation,causes,0.937042571331636,"HOSPITALIZATION  Introduction  Hospitalize patients when SEIZURES may be due to acute brain pathology, if consciousness does not return to normal, or for impending STATUS EPILEPTICUS",SEIZURES,STATUS EPILEPTICUS
2923,SEIZURES causes STATUS EPILEPTICUS,causes,0.937042571331636,"HOSPITALIZATION  Introduction  Hospitalize patients when SEIZURES may be due to acute brain pathology, if consciousness does not return to normal, or for impending STATUS EPILEPTICUS",SEIZURES,STATUS EPILEPTICUS
2924,no_relation,causes,0.937042571331636,"HOSPITALIZATION  Introduction  Hospitalize patients when SEIZURES may be due to acute brain pathology, if consciousness does not return to normal, or for impending STATUS EPILEPTICUS",SEIZURES,STATUS EPILEPTICUS
2925,STATUS EPILEPTICUS causes SEIZURES,causes,0.937042571331636,"HOSPITALIZATION  Introduction  Hospitalize patients when SEIZURES may be due to acute brain pathology, if consciousness does not return to normal, or for impending STATUS EPILEPTICUS",SEIZURES,STATUS EPILEPTICUS
2926,MEFLOQUINE causes PSYCHOSIS,causes,0.997054485501582,"MEFLOQUINE causes side effects, including nausea, dizziness, vertigo, light headedness (described as an inability to concentrate), bad dreams, seizures, and PSYCHOSIS",PSYCHOSIS,MEFLOQUINE
2927,MEFLOQUINE causes PSYCHOSIS,causes,0.997054485501582,"MEFLOQUINE causes side effects, including nausea, dizziness, vertigo, light headedness (described as an inability to concentrate), bad dreams, seizures, and PSYCHOSIS",PSYCHOSIS,MEFLOQUINE
2928,MEFLOQUINE causes PSYCHOSIS,causes,0.997054485501582,"MEFLOQUINE causes side effects, including nausea, dizziness, vertigo, light headedness (described as an inability to concentrate), bad dreams, seizures, and PSYCHOSIS",PSYCHOSIS,MEFLOQUINE
2929,MEFLOQUINE causes PSYCHOSIS,causes,0.997054485501582,"MEFLOQUINE causes side effects, including nausea, dizziness, vertigo, light headedness (described as an inability to concentrate), bad dreams, seizures, and PSYCHOSIS",PSYCHOSIS,MEFLOQUINE
2930,MEFLOQUINE causes PSYCHOSIS,causes,0.997054485501582,"MEFLOQUINE causes side effects, including nausea, dizziness, vertigo, light headedness (described as an inability to concentrate), bad dreams, seizures, and PSYCHOSIS",PSYCHOSIS,MEFLOQUINE
2931,MEFLOQUINE causes PSYCHOSIS,causes,0.997054485501582,"MEFLOQUINE causes side effects, including nausea, dizziness, vertigo, light headedness (described as an inability to concentrate), bad dreams, seizures, and PSYCHOSIS",PSYCHOSIS,MEFLOQUINE
2932,MEFLOQUINE causes PSYCHOSIS,causes,0.997054485501582,"MEFLOQUINE causes side effects, including nausea, dizziness, vertigo, light headedness (described as an inability to concentrate), bad dreams, seizures, and PSYCHOSIS",PSYCHOSIS,MEFLOQUINE
2933,CLOSTRIDIUM causes CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),causes,0.9103664774626048,120  Clostridium Infections  Alternative to penicillin G for treatment of CLOSTRIDIAL MYONECROSIS (GAS GANGRENE) caused by  Clostridium perfringens  or other  CLOSTRIDIUM,CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),CLOSTRIDIUM
2934,CLOSTRIDIUM causes CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),causes,0.9103664774626048,120  Clostridium Infections  Alternative to penicillin G for treatment of CLOSTRIDIAL MYONECROSIS (GAS GANGRENE) caused by  Clostridium perfringens  or other  CLOSTRIDIUM,CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),CLOSTRIDIUM
2935,CLOSTRIDIUM causes CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),causes,0.9103664774626048,120  Clostridium Infections  Alternative to penicillin G for treatment of CLOSTRIDIAL MYONECROSIS (GAS GANGRENE) caused by  Clostridium perfringens  or other  CLOSTRIDIUM,CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),CLOSTRIDIUM
2936,CLOSTRIDIUM causes CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),causes,0.9103664774626048,120  Clostridium Infections  Alternative to penicillin G for treatment of CLOSTRIDIAL MYONECROSIS (GAS GANGRENE) caused by  Clostridium perfringens  or other  CLOSTRIDIUM,CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),CLOSTRIDIUM
2937,CLOSTRIDIUM causes CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),causes,0.9103664774626048,120  Clostridium Infections  Alternative to penicillin G for treatment of CLOSTRIDIAL MYONECROSIS (GAS GANGRENE) caused by  Clostridium perfringens  or other  CLOSTRIDIUM,CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),CLOSTRIDIUM
2938,no_relation,causes,0.9103664774626048,120  Clostridium Infections  Alternative to penicillin G for treatment of CLOSTRIDIAL MYONECROSIS (GAS GANGRENE) caused by  Clostridium perfringens  or other  CLOSTRIDIUM,CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),CLOSTRIDIUM
2939,CLOSTRIDIUM causes CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),causes,0.9103664774626048,120  Clostridium Infections  Alternative to penicillin G for treatment of CLOSTRIDIAL MYONECROSIS (GAS GANGRENE) caused by  Clostridium perfringens  or other  CLOSTRIDIUM,CLOSTRIDIAL MYONECROSIS (GAS GANGRENE),CLOSTRIDIUM
2940,no_relation,causes,0.9931270663228408,"INFLAMMATORY BREAST CANCER has a clinical presentation of BREAST SWELLING erythema, warmth, and a peau d'orange appearance (characterized by a dimpled appearance caused by tumor infiltration of intradermal lymphatics); it may or may not be associated with a mass. These lesions are associated with a high risk of recurrence of local disease and with distant metastases.",BREAST SWELLING,INFLAMMATORY BREAST CANCER
2941,no_relation,causes,0.9931270663228408,"INFLAMMATORY BREAST CANCER has a clinical presentation of BREAST SWELLING erythema, warmth, and a peau d'orange appearance (characterized by a dimpled appearance caused by tumor infiltration of intradermal lymphatics); it may or may not be associated with a mass. These lesions are associated with a high risk of recurrence of local disease and with distant metastases.",BREAST SWELLING,INFLAMMATORY BREAST CANCER
2942,INFLAMMATORY BREAST CANCER causes BREAST SWELLING,causes,0.9931270663228408,"INFLAMMATORY BREAST CANCER has a clinical presentation of BREAST SWELLING erythema, warmth, and a peau d'orange appearance (characterized by a dimpled appearance caused by tumor infiltration of intradermal lymphatics); it may or may not be associated with a mass. These lesions are associated with a high risk of recurrence of local disease and with distant metastases.",BREAST SWELLING,INFLAMMATORY BREAST CANCER
2943,no_relation,causes,0.9931270663228408,"INFLAMMATORY BREAST CANCER has a clinical presentation of BREAST SWELLING erythema, warmth, and a peau d'orange appearance (characterized by a dimpled appearance caused by tumor infiltration of intradermal lymphatics); it may or may not be associated with a mass. These lesions are associated with a high risk of recurrence of local disease and with distant metastases.",BREAST SWELLING,INFLAMMATORY BREAST CANCER
2944,INFLAMMATORY BREAST CANCER causes BREAST SWELLING,causes,0.9931270663228408,"INFLAMMATORY BREAST CANCER has a clinical presentation of BREAST SWELLING erythema, warmth, and a peau d'orange appearance (characterized by a dimpled appearance caused by tumor infiltration of intradermal lymphatics); it may or may not be associated with a mass. These lesions are associated with a high risk of recurrence of local disease and with distant metastases.",BREAST SWELLING,INFLAMMATORY BREAST CANCER
2945,INFLAMMATORY BREAST CANCER causes BREAST SWELLING,causes,0.9931270663228408,"INFLAMMATORY BREAST CANCER has a clinical presentation of BREAST SWELLING erythema, warmth, and a peau d'orange appearance (characterized by a dimpled appearance caused by tumor infiltration of intradermal lymphatics); it may or may not be associated with a mass. These lesions are associated with a high risk of recurrence of local disease and with distant metastases.",BREAST SWELLING,INFLAMMATORY BREAST CANCER
2946,INFLAMMATORY BREAST CANCER causes BREAST SWELLING,causes,0.9931270663228408,"INFLAMMATORY BREAST CANCER has a clinical presentation of BREAST SWELLING erythema, warmth, and a peau d'orange appearance (characterized by a dimpled appearance caused by tumor infiltration of intradermal lymphatics); it may or may not be associated with a mass. These lesions are associated with a high risk of recurrence of local disease and with distant metastases.",BREAST SWELLING,INFLAMMATORY BREAST CANCER
2947,no_relation,causes,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
2948,no_relation,causes,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
2949,HYPOVOLEMIA OR HEMORRHAGIC SHOCK causes HYPOVOLEMIA,causes,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
2950,HYPOVOLEMIA OR HEMORRHAGIC SHOCK causes HYPOVOLEMIA,causes,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
2951,no_relation,causes,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
2952,no_relation,causes,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
2953,no_relation,causes,0.609994281330419,"Fluid resuscitation:  IV fluids are initiated as for any patient with HYPOVOLEMIA OR HEMORRHAGIC SHOCK (see  Intravenous Fluid Resuscitation ): healthy adults are given normal saline IV in 500  to 1000 mL aliquots until signs of HYPOVOLEMIA remit—up to a maximum of 2 L (for children 20 mL/kg, which may be repeated once.",HYPOVOLEMIA OR HEMORRHAGIC SHOCK,HYPOVOLEMIA
2954,SALMONELLA TYPHI causes TYPHOID FEVER (ENTERIC FEVER),causes,0.970142500145332,9  Typhoid Fever and Other Salmonella Infections  Alternative for treatment of TYPHOID FEVER (ENTERIC FEVER) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER (ENTERIC FEVER),SALMONELLA TYPHI
2955,SALMONELLA TYPHI causes TYPHOID FEVER (ENTERIC FEVER),causes,0.970142500145332,9  Typhoid Fever and Other Salmonella Infections  Alternative for treatment of TYPHOID FEVER (ENTERIC FEVER) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER (ENTERIC FEVER),SALMONELLA TYPHI
2956,SALMONELLA TYPHI causes TYPHOID FEVER (ENTERIC FEVER),causes,0.970142500145332,9  Typhoid Fever and Other Salmonella Infections  Alternative for treatment of TYPHOID FEVER (ENTERIC FEVER) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER (ENTERIC FEVER),SALMONELLA TYPHI
2957,SALMONELLA TYPHI causes TYPHOID FEVER (ENTERIC FEVER),causes,0.970142500145332,9  Typhoid Fever and Other Salmonella Infections  Alternative for treatment of TYPHOID FEVER (ENTERIC FEVER) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER (ENTERIC FEVER),SALMONELLA TYPHI
2958,SALMONELLA TYPHI causes TYPHOID FEVER (ENTERIC FEVER),causes,0.970142500145332,9  Typhoid Fever and Other Salmonella Infections  Alternative for treatment of TYPHOID FEVER (ENTERIC FEVER) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER (ENTERIC FEVER),SALMONELLA TYPHI
2959,SALMONELLA TYPHI causes TYPHOID FEVER (ENTERIC FEVER),causes,0.970142500145332,9  Typhoid Fever and Other Salmonella Infections  Alternative for treatment of TYPHOID FEVER (ENTERIC FEVER) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER (ENTERIC FEVER),SALMONELLA TYPHI
2960,SALMONELLA TYPHI causes TYPHOID FEVER (ENTERIC FEVER),causes,0.970142500145332,9  Typhoid Fever and Other Salmonella Infections  Alternative for treatment of TYPHOID FEVER (ENTERIC FEVER) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER (ENTERIC FEVER),SALMONELLA TYPHI
2961,MONOCLONAL GAMMOPATHY causes MACROGLOBULINEMIA,causes,0.8192880303729141,MACROGLOBULINEMIA develops in about 12% of patients with MONOCLONAL GAMMOPATHY,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
2962,MONOCLONAL GAMMOPATHY causes MACROGLOBULINEMIA,causes,0.8192880303729141,MACROGLOBULINEMIA develops in about 12% of patients with MONOCLONAL GAMMOPATHY,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
2963,MONOCLONAL GAMMOPATHY causes MACROGLOBULINEMIA,causes,0.8192880303729141,MACROGLOBULINEMIA develops in about 12% of patients with MONOCLONAL GAMMOPATHY,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
2964,MONOCLONAL GAMMOPATHY causes MACROGLOBULINEMIA,causes,0.8192880303729141,MACROGLOBULINEMIA develops in about 12% of patients with MONOCLONAL GAMMOPATHY,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
2965,MONOCLONAL GAMMOPATHY causes MACROGLOBULINEMIA,causes,0.8192880303729141,MACROGLOBULINEMIA develops in about 12% of patients with MONOCLONAL GAMMOPATHY,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
2966,MONOCLONAL GAMMOPATHY causes MACROGLOBULINEMIA,causes,0.8192880303729141,MACROGLOBULINEMIA develops in about 12% of patients with MONOCLONAL GAMMOPATHY,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
2967,MONOCLONAL GAMMOPATHY causes MACROGLOBULINEMIA,causes,0.8192880303729141,MACROGLOBULINEMIA develops in about 12% of patients with MONOCLONAL GAMMOPATHY,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA
2968,ENTEROTOXIGENIC E COLI causes TRAVELER'S DIARRHEA,causes,0.963086824686154,"edit] Antimotility agents  Loperamide can reduce diarrhea in patients with shigella,[6] but not in patients with TRAVELER'S DIARRHEA due to ENTEROTOXIGENIC E COLI[7]  A systematic review of randomized controlled trials found that loperamide may harm children less than 3 years old.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC E COLI
2969,ENTEROTOXIGENIC E COLI causes TRAVELER'S DIARRHEA,causes,0.963086824686154,"edit] Antimotility agents  Loperamide can reduce diarrhea in patients with shigella,[6] but not in patients with TRAVELER'S DIARRHEA due to ENTEROTOXIGENIC E COLI[7]  A systematic review of randomized controlled trials found that loperamide may harm children less than 3 years old.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC E COLI
2970,ENTEROTOXIGENIC E COLI causes TRAVELER'S DIARRHEA,causes,0.963086824686154,"edit] Antimotility agents  Loperamide can reduce diarrhea in patients with shigella,[6] but not in patients with TRAVELER'S DIARRHEA due to ENTEROTOXIGENIC E COLI[7]  A systematic review of randomized controlled trials found that loperamide may harm children less than 3 years old.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC E COLI
2971,TRAVELER'S DIARRHEA causes ENTEROTOXIGENIC E COLI,causes,0.963086824686154,"edit] Antimotility agents  Loperamide can reduce diarrhea in patients with shigella,[6] but not in patients with TRAVELER'S DIARRHEA due to ENTEROTOXIGENIC E COLI[7]  A systematic review of randomized controlled trials found that loperamide may harm children less than 3 years old.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC E COLI
2972,ENTEROTOXIGENIC E COLI causes TRAVELER'S DIARRHEA,causes,0.963086824686154,"edit] Antimotility agents  Loperamide can reduce diarrhea in patients with shigella,[6] but not in patients with TRAVELER'S DIARRHEA due to ENTEROTOXIGENIC E COLI[7]  A systematic review of randomized controlled trials found that loperamide may harm children less than 3 years old.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC E COLI
2973,ENTEROTOXIGENIC E COLI causes TRAVELER'S DIARRHEA,causes,0.963086824686154,"edit] Antimotility agents  Loperamide can reduce diarrhea in patients with shigella,[6] but not in patients with TRAVELER'S DIARRHEA due to ENTEROTOXIGENIC E COLI[7]  A systematic review of randomized controlled trials found that loperamide may harm children less than 3 years old.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC E COLI
2974,no_relation,causes,0.963086824686154,"edit] Antimotility agents  Loperamide can reduce diarrhea in patients with shigella,[6] but not in patients with TRAVELER'S DIARRHEA due to ENTEROTOXIGENIC E COLI[7]  A systematic review of randomized controlled trials found that loperamide may harm children less than 3 years old.",TRAVELER'S DIARRHEA,ENTEROTOXIGENIC E COLI
2975,ASCITES causes HEPATOCELLULAR CARCINOMA,causes,0.8660254037844392,"Commonly, portal hypertension (often with esophageal varices and upper GI bleeding, ASCITES portal systemic encephalopathy), hepatorenal syndrome, or even HEPATOCELLULAR CARCINOMA is present.",ASCITES,HEPATOCELLULAR CARCINOMA
2976,ASCITES causes HEPATOCELLULAR CARCINOMA,causes,0.8660254037844392,"Commonly, portal hypertension (often with esophageal varices and upper GI bleeding, ASCITES portal systemic encephalopathy), hepatorenal syndrome, or even HEPATOCELLULAR CARCINOMA is present.",ASCITES,HEPATOCELLULAR CARCINOMA
2977,HEPATOCELLULAR CARCINOMA causes ASCITES,causes,0.8660254037844392,"Commonly, portal hypertension (often with esophageal varices and upper GI bleeding, ASCITES portal systemic encephalopathy), hepatorenal syndrome, or even HEPATOCELLULAR CARCINOMA is present.",ASCITES,HEPATOCELLULAR CARCINOMA
2978,no_relation,causes,0.8660254037844392,"Commonly, portal hypertension (often with esophageal varices and upper GI bleeding, ASCITES portal systemic encephalopathy), hepatorenal syndrome, or even HEPATOCELLULAR CARCINOMA is present.",ASCITES,HEPATOCELLULAR CARCINOMA
2979,no_relation,causes,0.8660254037844392,"Commonly, portal hypertension (often with esophageal varices and upper GI bleeding, ASCITES portal systemic encephalopathy), hepatorenal syndrome, or even HEPATOCELLULAR CARCINOMA is present.",ASCITES,HEPATOCELLULAR CARCINOMA
2980,no_relation,causes,0.8660254037844392,"Commonly, portal hypertension (often with esophageal varices and upper GI bleeding, ASCITES portal systemic encephalopathy), hepatorenal syndrome, or even HEPATOCELLULAR CARCINOMA is present.",ASCITES,HEPATOCELLULAR CARCINOMA
2981,no_relation,causes,0.8660254037844392,"Commonly, portal hypertension (often with esophageal varices and upper GI bleeding, ASCITES portal systemic encephalopathy), hepatorenal syndrome, or even HEPATOCELLULAR CARCINOMA is present.",ASCITES,HEPATOCELLULAR CARCINOMA
2982,YERSINIA PESTIS causes PLAGUE PNEUMONIA DISEASE,causes,1.0,"Cleri DJ, Vernaleo JR, Lombardi LJ, et al: PLAGUE PNEUMONIA DISEASE caused by  YERSINIA PESTIS",PLAGUE PNEUMONIA DISEASE,YERSINIA PESTIS
2983,YERSINIA PESTIS causes PLAGUE PNEUMONIA DISEASE,causes,1.0,"Cleri DJ, Vernaleo JR, Lombardi LJ, et al: PLAGUE PNEUMONIA DISEASE caused by  YERSINIA PESTIS",PLAGUE PNEUMONIA DISEASE,YERSINIA PESTIS
2984,YERSINIA PESTIS causes PLAGUE PNEUMONIA DISEASE,causes,1.0,"Cleri DJ, Vernaleo JR, Lombardi LJ, et al: PLAGUE PNEUMONIA DISEASE caused by  YERSINIA PESTIS",PLAGUE PNEUMONIA DISEASE,YERSINIA PESTIS
2985,YERSINIA PESTIS causes PLAGUE PNEUMONIA DISEASE,causes,1.0,"Cleri DJ, Vernaleo JR, Lombardi LJ, et al: PLAGUE PNEUMONIA DISEASE caused by  YERSINIA PESTIS",PLAGUE PNEUMONIA DISEASE,YERSINIA PESTIS
2986,YERSINIA PESTIS causes PLAGUE PNEUMONIA DISEASE,causes,1.0,"Cleri DJ, Vernaleo JR, Lombardi LJ, et al: PLAGUE PNEUMONIA DISEASE caused by  YERSINIA PESTIS",PLAGUE PNEUMONIA DISEASE,YERSINIA PESTIS
2987,YERSINIA PESTIS causes PLAGUE PNEUMONIA DISEASE,causes,1.0,"Cleri DJ, Vernaleo JR, Lombardi LJ, et al: PLAGUE PNEUMONIA DISEASE caused by  YERSINIA PESTIS",PLAGUE PNEUMONIA DISEASE,YERSINIA PESTIS
2988,YERSINIA PESTIS causes PLAGUE PNEUMONIA DISEASE,causes,1.0,"Cleri DJ, Vernaleo JR, Lombardi LJ, et al: PLAGUE PNEUMONIA DISEASE caused by  YERSINIA PESTIS",PLAGUE PNEUMONIA DISEASE,YERSINIA PESTIS
2989,HUMAN PAPILLOMAVIRUS (HPV INFECTION) causes WARTS,causes,0.99654575824488,WARTS are caused by HUMAN PAPILLOMAVIRUS (HPV INFECTION); at least 70 HPV types are linked to skin lesions.,WARTS,HUMAN PAPILLOMAVIRUS (HPV INFECTION)
2990,HUMAN PAPILLOMAVIRUS (HPV INFECTION) causes WARTS,causes,0.99654575824488,WARTS are caused by HUMAN PAPILLOMAVIRUS (HPV INFECTION); at least 70 HPV types are linked to skin lesions.,WARTS,HUMAN PAPILLOMAVIRUS (HPV INFECTION)
2991,HUMAN PAPILLOMAVIRUS (HPV INFECTION) causes WARTS,causes,0.99654575824488,WARTS are caused by HUMAN PAPILLOMAVIRUS (HPV INFECTION); at least 70 HPV types are linked to skin lesions.,WARTS,HUMAN PAPILLOMAVIRUS (HPV INFECTION)
2992,HUMAN PAPILLOMAVIRUS (HPV INFECTION) causes WARTS,causes,0.99654575824488,WARTS are caused by HUMAN PAPILLOMAVIRUS (HPV INFECTION); at least 70 HPV types are linked to skin lesions.,WARTS,HUMAN PAPILLOMAVIRUS (HPV INFECTION)
2993,HUMAN PAPILLOMAVIRUS (HPV INFECTION) causes WARTS,causes,0.99654575824488,WARTS are caused by HUMAN PAPILLOMAVIRUS (HPV INFECTION); at least 70 HPV types are linked to skin lesions.,WARTS,HUMAN PAPILLOMAVIRUS (HPV INFECTION)
2994,HUMAN PAPILLOMAVIRUS (HPV INFECTION) causes WARTS,causes,0.99654575824488,WARTS are caused by HUMAN PAPILLOMAVIRUS (HPV INFECTION); at least 70 HPV types are linked to skin lesions.,WARTS,HUMAN PAPILLOMAVIRUS (HPV INFECTION)
2995,HUMAN PAPILLOMAVIRUS (HPV INFECTION) causes WARTS,causes,0.99654575824488,WARTS are caused by HUMAN PAPILLOMAVIRUS (HPV INFECTION); at least 70 HPV types are linked to skin lesions.,WARTS,HUMAN PAPILLOMAVIRUS (HPV INFECTION)
2996,no_relation,causes,0.577350269189626,"MACROSCOPIC HEMATURIA usually resolves spontaneously within days, and MICROSCOPIC HEMATURIA often occurs between mucosal infections.",MACROSCOPIC HEMATURIA,MICROSCOPIC HEMATURIA
2997,no_relation,causes,0.577350269189626,"MACROSCOPIC HEMATURIA usually resolves spontaneously within days, and MICROSCOPIC HEMATURIA often occurs between mucosal infections.",MACROSCOPIC HEMATURIA,MICROSCOPIC HEMATURIA
2998,no_relation,causes,0.577350269189626,"MACROSCOPIC HEMATURIA usually resolves spontaneously within days, and MICROSCOPIC HEMATURIA often occurs between mucosal infections.",MACROSCOPIC HEMATURIA,MICROSCOPIC HEMATURIA
2999,MACROSCOPIC HEMATURIA causes MICROSCOPIC HEMATURIA,causes,0.577350269189626,"MACROSCOPIC HEMATURIA usually resolves spontaneously within days, and MICROSCOPIC HEMATURIA often occurs between mucosal infections.",MACROSCOPIC HEMATURIA,MICROSCOPIC HEMATURIA
3000,no_relation,causes,0.577350269189626,"MACROSCOPIC HEMATURIA usually resolves spontaneously within days, and MICROSCOPIC HEMATURIA often occurs between mucosal infections.",MACROSCOPIC HEMATURIA,MICROSCOPIC HEMATURIA
3001,no_relation,causes,0.577350269189626,"MACROSCOPIC HEMATURIA usually resolves spontaneously within days, and MICROSCOPIC HEMATURIA often occurs between mucosal infections.",MACROSCOPIC HEMATURIA,MICROSCOPIC HEMATURIA
3002,no_relation,causes,0.577350269189626,"MACROSCOPIC HEMATURIA usually resolves spontaneously within days, and MICROSCOPIC HEMATURIA often occurs between mucosal infections.",MACROSCOPIC HEMATURIA,MICROSCOPIC HEMATURIA
3003,B MALLEI causes GLANDERS,causes,0.943456353049726,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3004,B MALLEI causes GLANDERS,causes,0.943456353049726,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3005,B MALLEI causes GLANDERS,causes,0.943456353049726,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3006,B MALLEI causes GLANDERS,causes,0.943456353049726,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3007,B MALLEI causes GLANDERS,causes,0.943456353049726,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3008,B MALLEI causes GLANDERS,causes,0.943456353049726,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3009,B MALLEI causes GLANDERS,causes,0.943456353049726,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3010,CNS causes ENCEPHALITIS,causes,0.997054485501582,"• Although HSV affecting the CNS primarily causes an ENCEPHALITIS or encephalomyelitis, cases of HSV presenting as primarily meningitis have been reported ( 20.",CNS,ENCEPHALITIS
3011,CNS causes ENCEPHALITIS,causes,0.997054485501582,"• Although HSV affecting the CNS primarily causes an ENCEPHALITIS or encephalomyelitis, cases of HSV presenting as primarily meningitis have been reported ( 20.",CNS,ENCEPHALITIS
3012,no_relation,causes,0.997054485501582,"• Although HSV affecting the CNS primarily causes an ENCEPHALITIS or encephalomyelitis, cases of HSV presenting as primarily meningitis have been reported ( 20.",CNS,ENCEPHALITIS
3013,CNS causes ENCEPHALITIS,causes,0.997054485501582,"• Although HSV affecting the CNS primarily causes an ENCEPHALITIS or encephalomyelitis, cases of HSV presenting as primarily meningitis have been reported ( 20.",CNS,ENCEPHALITIS
3014,CNS causes ENCEPHALITIS,causes,0.997054485501582,"• Although HSV affecting the CNS primarily causes an ENCEPHALITIS or encephalomyelitis, cases of HSV presenting as primarily meningitis have been reported ( 20.",CNS,ENCEPHALITIS
3015,no_relation,causes,0.997054485501582,"• Although HSV affecting the CNS primarily causes an ENCEPHALITIS or encephalomyelitis, cases of HSV presenting as primarily meningitis have been reported ( 20.",CNS,ENCEPHALITIS
3016,no_relation,causes,0.997054485501582,"• Although HSV affecting the CNS primarily causes an ENCEPHALITIS or encephalomyelitis, cases of HSV presenting as primarily meningitis have been reported ( 20.",CNS,ENCEPHALITIS
3017,STURGE WEBER SYNDROME causes CONTRALATERAL SEIZURES,causes,0.9237604307034007,Other features of the STURGE WEBER SYNDROME include ipsilateral congenital glaucoma anda CONTRALATERAL SEIZURES caused by leptomeningeal angiomatosis.,CONTRALATERAL SEIZURES,STURGE WEBER SYNDROME
3018,STURGE WEBER SYNDROME causes CONTRALATERAL SEIZURES,causes,0.9237604307034007,Other features of the STURGE WEBER SYNDROME include ipsilateral congenital glaucoma anda CONTRALATERAL SEIZURES caused by leptomeningeal angiomatosis.,CONTRALATERAL SEIZURES,STURGE WEBER SYNDROME
3019,STURGE WEBER SYNDROME causes CONTRALATERAL SEIZURES,causes,0.9237604307034007,Other features of the STURGE WEBER SYNDROME include ipsilateral congenital glaucoma anda CONTRALATERAL SEIZURES caused by leptomeningeal angiomatosis.,CONTRALATERAL SEIZURES,STURGE WEBER SYNDROME
3020,no_relation,causes,0.9237604307034007,Other features of the STURGE WEBER SYNDROME include ipsilateral congenital glaucoma anda CONTRALATERAL SEIZURES caused by leptomeningeal angiomatosis.,CONTRALATERAL SEIZURES,STURGE WEBER SYNDROME
3021,STURGE WEBER SYNDROME causes CONTRALATERAL SEIZURES,causes,0.9237604307034007,Other features of the STURGE WEBER SYNDROME include ipsilateral congenital glaucoma anda CONTRALATERAL SEIZURES caused by leptomeningeal angiomatosis.,CONTRALATERAL SEIZURES,STURGE WEBER SYNDROME
3022,no_relation,causes,0.9237604307034007,Other features of the STURGE WEBER SYNDROME include ipsilateral congenital glaucoma anda CONTRALATERAL SEIZURES caused by leptomeningeal angiomatosis.,CONTRALATERAL SEIZURES,STURGE WEBER SYNDROME
3023,STURGE WEBER SYNDROME causes CONTRALATERAL SEIZURES,causes,0.9237604307034007,Other features of the STURGE WEBER SYNDROME include ipsilateral congenital glaucoma anda CONTRALATERAL SEIZURES caused by leptomeningeal angiomatosis.,CONTRALATERAL SEIZURES,STURGE WEBER SYNDROME
3024,no_relation,causes,0.824163383692134,Other Factors  Trauma to the clinically uninvolved SKIN of patients with PSORIASIS can cause a lesion to appear at the exact site of injury; this phenomenon is known as the Kobner response.,SKIN,PSORIASIS
3025,no_relation,causes,0.824163383692134,Other Factors  Trauma to the clinically uninvolved SKIN of patients with PSORIASIS can cause a lesion to appear at the exact site of injury; this phenomenon is known as the Kobner response.,SKIN,PSORIASIS
3026,no_relation,causes,0.824163383692134,Other Factors  Trauma to the clinically uninvolved SKIN of patients with PSORIASIS can cause a lesion to appear at the exact site of injury; this phenomenon is known as the Kobner response.,SKIN,PSORIASIS
3027,PSORIASIS causes SKIN,causes,0.824163383692134,Other Factors  Trauma to the clinically uninvolved SKIN of patients with PSORIASIS can cause a lesion to appear at the exact site of injury; this phenomenon is known as the Kobner response.,SKIN,PSORIASIS
3028,no_relation,causes,0.824163383692134,Other Factors  Trauma to the clinically uninvolved SKIN of patients with PSORIASIS can cause a lesion to appear at the exact site of injury; this phenomenon is known as the Kobner response.,SKIN,PSORIASIS
3029,no_relation,causes,0.824163383692134,Other Factors  Trauma to the clinically uninvolved SKIN of patients with PSORIASIS can cause a lesion to appear at the exact site of injury; this phenomenon is known as the Kobner response.,SKIN,PSORIASIS
3030,SKIN causes PSORIASIS,causes,0.824163383692134,Other Factors  Trauma to the clinically uninvolved SKIN of patients with PSORIASIS can cause a lesion to appear at the exact site of injury; this phenomenon is known as the Kobner response.,SKIN,PSORIASIS
3031,HEADACHE causes TENSION TYPE HEADACHE,causes,0.474712663277541,"Finally, the headache started suddenly in an otherwise healthy individual, and a new daily persistent HEADACHE commonly can become TENSION TYPE HEADACHE",HEADACHE,TENSION TYPE HEADACHE
3032,TENSION TYPE HEADACHE causes HEADACHE,causes,0.474712663277541,"Finally, the headache started suddenly in an otherwise healthy individual, and a new daily persistent HEADACHE commonly can become TENSION TYPE HEADACHE",HEADACHE,TENSION TYPE HEADACHE
3033,no_relation,causes,0.474712663277541,"Finally, the headache started suddenly in an otherwise healthy individual, and a new daily persistent HEADACHE commonly can become TENSION TYPE HEADACHE",HEADACHE,TENSION TYPE HEADACHE
3034,HEADACHE causes TENSION TYPE HEADACHE,causes,0.474712663277541,"Finally, the headache started suddenly in an otherwise healthy individual, and a new daily persistent HEADACHE commonly can become TENSION TYPE HEADACHE",HEADACHE,TENSION TYPE HEADACHE
3035,HEADACHE causes TENSION TYPE HEADACHE,causes,0.474712663277541,"Finally, the headache started suddenly in an otherwise healthy individual, and a new daily persistent HEADACHE commonly can become TENSION TYPE HEADACHE",HEADACHE,TENSION TYPE HEADACHE
3036,HEADACHE causes TENSION TYPE HEADACHE,causes,0.474712663277541,"Finally, the headache started suddenly in an otherwise healthy individual, and a new daily persistent HEADACHE commonly can become TENSION TYPE HEADACHE",HEADACHE,TENSION TYPE HEADACHE
3037,HEADACHE causes TENSION TYPE HEADACHE,causes,0.474712663277541,"Finally, the headache started suddenly in an otherwise healthy individual, and a new daily persistent HEADACHE commonly can become TENSION TYPE HEADACHE",HEADACHE,TENSION TYPE HEADACHE
3038,no_relation,causes,0.328797974610715,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
3039,no_relation,causes,0.328797974610715,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
3040,TYPE 1 DIABETES causes INSULIN GLARGINE,causes,0.328797974610715,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
3041,no_relation,causes,0.328797974610715,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
3042,no_relation,causes,0.328797974610715,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
3043,no_relation,causes,0.328797974610715,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
3044,no_relation,causes,0.328797974610715,"Heise T, Nosek L, Ronn BB et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and INSULIN GLARGINE in people with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN GLARGINE
3045,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.99654575824488,"Hastings RC, Trautman JR, Enna CD et alTHALIDOMIDE in the treatment of erythema nodosum leprosum with a note on selected laboratory abnormalities in ERYTHEMA NODOSUM LEPROSUM.",ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
3046,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.99654575824488,"Hastings RC, Trautman JR, Enna CD et alTHALIDOMIDE in the treatment of erythema nodosum leprosum with a note on selected laboratory abnormalities in ERYTHEMA NODOSUM LEPROSUM.",ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
3047,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.99654575824488,"Hastings RC, Trautman JR, Enna CD et alTHALIDOMIDE in the treatment of erythema nodosum leprosum with a note on selected laboratory abnormalities in ERYTHEMA NODOSUM LEPROSUM.",ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
3048,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.99654575824488,"Hastings RC, Trautman JR, Enna CD et alTHALIDOMIDE in the treatment of erythema nodosum leprosum with a note on selected laboratory abnormalities in ERYTHEMA NODOSUM LEPROSUM.",ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
3049,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.99654575824488,"Hastings RC, Trautman JR, Enna CD et alTHALIDOMIDE in the treatment of erythema nodosum leprosum with a note on selected laboratory abnormalities in ERYTHEMA NODOSUM LEPROSUM.",ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
3050,no_relation,treats,0.99654575824488,"Hastings RC, Trautman JR, Enna CD et alTHALIDOMIDE in the treatment of erythema nodosum leprosum with a note on selected laboratory abnormalities in ERYTHEMA NODOSUM LEPROSUM.",ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
3051,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.99654575824488,"Hastings RC, Trautman JR, Enna CD et alTHALIDOMIDE in the treatment of erythema nodosum leprosum with a note on selected laboratory abnormalities in ERYTHEMA NODOSUM LEPROSUM.",ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
3052,WARFARIN treats STROKE,treats,0.964901281354015,A meta analysis of 3 RCTs has shown that WARFARIN given after MI to achieve an international normalized ratio of 2.0 to 3.0 reduced risk for STROKE,STROKE,WARFARIN
3053,WARFARIN treats STROKE,treats,0.964901281354015,A meta analysis of 3 RCTs has shown that WARFARIN given after MI to achieve an international normalized ratio of 2.0 to 3.0 reduced risk for STROKE,STROKE,WARFARIN
3054,WARFARIN treats STROKE,treats,0.964901281354015,A meta analysis of 3 RCTs has shown that WARFARIN given after MI to achieve an international normalized ratio of 2.0 to 3.0 reduced risk for STROKE,STROKE,WARFARIN
3055,no_relation,treats,0.964901281354015,A meta analysis of 3 RCTs has shown that WARFARIN given after MI to achieve an international normalized ratio of 2.0 to 3.0 reduced risk for STROKE,STROKE,WARFARIN
3056,WARFARIN treats STROKE,treats,0.964901281354015,A meta analysis of 3 RCTs has shown that WARFARIN given after MI to achieve an international normalized ratio of 2.0 to 3.0 reduced risk for STROKE,STROKE,WARFARIN
3057,WARFARIN treats STROKE,treats,0.964901281354015,A meta analysis of 3 RCTs has shown that WARFARIN given after MI to achieve an international normalized ratio of 2.0 to 3.0 reduced risk for STROKE,STROKE,WARFARIN
3058,WARFARIN treats STROKE,treats,0.964901281354015,A meta analysis of 3 RCTs has shown that WARFARIN given after MI to achieve an international normalized ratio of 2.0 to 3.0 reduced risk for STROKE,STROKE,WARFARIN
3059,no_relation,treats,0.9494253265550828,It is used prophylactically to prevent [PNEUMOCYSTIS PNEUMONIA] and toxoplasmosis in patients unable to tolerate trimethoprim with [SULFAMETHOXAZOLE].,PNEUMOCYSTIS PNEUMONIA,SULFAMETHOXAZOLE
3060,PNEUMOCYSTIS PNEUMONIA treats SULFAMETHOXAZOLE,treats,0.9494253265550828,It is used prophylactically to prevent [PNEUMOCYSTIS PNEUMONIA] and toxoplasmosis in patients unable to tolerate trimethoprim with [SULFAMETHOXAZOLE].,PNEUMOCYSTIS PNEUMONIA,SULFAMETHOXAZOLE
3061,SULFAMETHOXAZOLE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9494253265550828,It is used prophylactically to prevent [PNEUMOCYSTIS PNEUMONIA] and toxoplasmosis in patients unable to tolerate trimethoprim with [SULFAMETHOXAZOLE].,PNEUMOCYSTIS PNEUMONIA,SULFAMETHOXAZOLE
3062,no_relation,treats,0.9494253265550828,It is used prophylactically to prevent [PNEUMOCYSTIS PNEUMONIA] and toxoplasmosis in patients unable to tolerate trimethoprim with [SULFAMETHOXAZOLE].,PNEUMOCYSTIS PNEUMONIA,SULFAMETHOXAZOLE
3063,PNEUMOCYSTIS PNEUMONIA treats SULFAMETHOXAZOLE,treats,0.9494253265550828,It is used prophylactically to prevent [PNEUMOCYSTIS PNEUMONIA] and toxoplasmosis in patients unable to tolerate trimethoprim with [SULFAMETHOXAZOLE].,PNEUMOCYSTIS PNEUMONIA,SULFAMETHOXAZOLE
3064,SULFAMETHOXAZOLE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9494253265550828,It is used prophylactically to prevent [PNEUMOCYSTIS PNEUMONIA] and toxoplasmosis in patients unable to tolerate trimethoprim with [SULFAMETHOXAZOLE].,PNEUMOCYSTIS PNEUMONIA,SULFAMETHOXAZOLE
3065,SULFAMETHOXAZOLE treats PNEUMOCYSTIS PNEUMONIA,treats,0.9494253265550828,It is used prophylactically to prevent [PNEUMOCYSTIS PNEUMONIA] and toxoplasmosis in patients unable to tolerate trimethoprim with [SULFAMETHOXAZOLE].,PNEUMOCYSTIS PNEUMONIA,SULFAMETHOXAZOLE
3066,LIPOSOMAL AMPHOTERICIN B treats VISCERAL LEISHMANIASIS,treats,0.9901475429766742,"Davidson RN, di Martino L, Gradoni L et al. Short course treatment of VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B (AmBisome.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
3067,VISCERAL LEISHMANIASIS treats LIPOSOMAL AMPHOTERICIN B,treats,0.9901475429766742,"Davidson RN, di Martino L, Gradoni L et al. Short course treatment of VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B (AmBisome.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
3068,LIPOSOMAL AMPHOTERICIN B treats VISCERAL LEISHMANIASIS,treats,0.9901475429766742,"Davidson RN, di Martino L, Gradoni L et al. Short course treatment of VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B (AmBisome.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
3069,LIPOSOMAL AMPHOTERICIN B treats VISCERAL LEISHMANIASIS,treats,0.9901475429766742,"Davidson RN, di Martino L, Gradoni L et al. Short course treatment of VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B (AmBisome.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
3070,LIPOSOMAL AMPHOTERICIN B treats VISCERAL LEISHMANIASIS,treats,0.9901475429766742,"Davidson RN, di Martino L, Gradoni L et al. Short course treatment of VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B (AmBisome.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
3071,LIPOSOMAL AMPHOTERICIN B treats VISCERAL LEISHMANIASIS,treats,0.9901475429766742,"Davidson RN, di Martino L, Gradoni L et al. Short course treatment of VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B (AmBisome.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
3072,LIPOSOMAL AMPHOTERICIN B treats VISCERAL LEISHMANIASIS,treats,0.9901475429766742,"Davidson RN, di Martino L, Gradoni L et al. Short course treatment of VISCERAL LEISHMANIASIS with LIPOSOMAL AMPHOTERICIN B (AmBisome.",VISCERAL LEISHMANIASIS,LIPOSOMAL AMPHOTERICIN B
3073,WARFARIN treats PULMONARY EMBOLISM,treats,0.98058067569092,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
3074,WARFARIN treats PULMONARY EMBOLISM,treats,0.98058067569092,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
3075,WARFARIN treats PULMONARY EMBOLISM,treats,0.98058067569092,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
3076,WARFARIN treats PULMONARY EMBOLISM,treats,0.98058067569092,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
3077,WARFARIN treats PULMONARY EMBOLISM,treats,0.98058067569092,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
3078,WARFARIN treats PULMONARY EMBOLISM,treats,0.98058067569092,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
3079,WARFARIN treats PULMONARY EMBOLISM,treats,0.98058067569092,Clinical trials are currently investigating the potential value of LMWHs in the treatment of PULMONARY EMBOLISM and as an alternative to WARFARIN in secondary prevention of DVT,PULMONARY EMBOLISM,WARFARIN
3080,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
3081,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
3082,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
3083,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
3084,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
3085,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
3086,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
3087,AMPHOTERICIN B treats NEUTROPENIA,treats,0.911684611677104,"1]  Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with AMPHOTERICIN B for the treatment of candidemia in patients without NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
3088,no_relation,treats,0.911684611677104,"1]  Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with AMPHOTERICIN B for the treatment of candidemia in patients without NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
3089,AMPHOTERICIN B treats NEUTROPENIA,treats,0.911684611677104,"1]  Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with AMPHOTERICIN B for the treatment of candidemia in patients without NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
3090,no_relation,treats,0.911684611677104,"1]  Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with AMPHOTERICIN B for the treatment of candidemia in patients without NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
3091,AMPHOTERICIN B treats NEUTROPENIA,treats,0.911684611677104,"1]  Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with AMPHOTERICIN B for the treatment of candidemia in patients without NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
3092,no_relation,treats,0.911684611677104,"1]  Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with AMPHOTERICIN B for the treatment of candidemia in patients without NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
3093,AMPHOTERICIN B treats NEUTROPENIA,treats,0.911684611677104,"1]  Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with AMPHOTERICIN B for the treatment of candidemia in patients without NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
3094,UROKINASE THERAPY treats CLINICAL PULMONARY EMBOLISM,treats,0.9950371902099888,"Sasahara AA, Cannilla JE, Belko JS et al. UROKINASE THERAPY in CLINICAL PULMONARY EMBOLISM: a new thrombolytic agent.",CLINICAL PULMONARY EMBOLISM,UROKINASE THERAPY
3095,UROKINASE THERAPY treats CLINICAL PULMONARY EMBOLISM,treats,0.9950371902099888,"Sasahara AA, Cannilla JE, Belko JS et al. UROKINASE THERAPY in CLINICAL PULMONARY EMBOLISM: a new thrombolytic agent.",CLINICAL PULMONARY EMBOLISM,UROKINASE THERAPY
3096,UROKINASE THERAPY treats CLINICAL PULMONARY EMBOLISM,treats,0.9950371902099888,"Sasahara AA, Cannilla JE, Belko JS et al. UROKINASE THERAPY in CLINICAL PULMONARY EMBOLISM: a new thrombolytic agent.",CLINICAL PULMONARY EMBOLISM,UROKINASE THERAPY
3097,UROKINASE THERAPY treats CLINICAL PULMONARY EMBOLISM,treats,0.9950371902099888,"Sasahara AA, Cannilla JE, Belko JS et al. UROKINASE THERAPY in CLINICAL PULMONARY EMBOLISM: a new thrombolytic agent.",CLINICAL PULMONARY EMBOLISM,UROKINASE THERAPY
3098,UROKINASE THERAPY treats CLINICAL PULMONARY EMBOLISM,treats,0.9950371902099888,"Sasahara AA, Cannilla JE, Belko JS et al. UROKINASE THERAPY in CLINICAL PULMONARY EMBOLISM: a new thrombolytic agent.",CLINICAL PULMONARY EMBOLISM,UROKINASE THERAPY
3099,UROKINASE THERAPY treats CLINICAL PULMONARY EMBOLISM,treats,0.9950371902099888,"Sasahara AA, Cannilla JE, Belko JS et al. UROKINASE THERAPY in CLINICAL PULMONARY EMBOLISM: a new thrombolytic agent.",CLINICAL PULMONARY EMBOLISM,UROKINASE THERAPY
3100,UROKINASE THERAPY treats CLINICAL PULMONARY EMBOLISM,treats,0.9950371902099888,"Sasahara AA, Cannilla JE, Belko JS et al. UROKINASE THERAPY in CLINICAL PULMONARY EMBOLISM: a new thrombolytic agent.",CLINICAL PULMONARY EMBOLISM,UROKINASE THERAPY
3101,BENIGN PROSTATIC HYPERPLASIA treats FINASTERIDE,treats,0.99654575824488,"Kaplan SA, McConnell JD, Roehrborn CG, et al: Combination therapy with doxazosin and FINASTERIDE for BENIGN PROSTATIC HYPERPLASIA in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater.",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
3102,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"Kaplan SA, McConnell JD, Roehrborn CG, et al: Combination therapy with doxazosin and FINASTERIDE for BENIGN PROSTATIC HYPERPLASIA in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater.",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
3103,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"Kaplan SA, McConnell JD, Roehrborn CG, et al: Combination therapy with doxazosin and FINASTERIDE for BENIGN PROSTATIC HYPERPLASIA in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater.",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
3104,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"Kaplan SA, McConnell JD, Roehrborn CG, et al: Combination therapy with doxazosin and FINASTERIDE for BENIGN PROSTATIC HYPERPLASIA in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater.",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
3105,BENIGN PROSTATIC HYPERPLASIA treats FINASTERIDE,treats,0.99654575824488,"Kaplan SA, McConnell JD, Roehrborn CG, et al: Combination therapy with doxazosin and FINASTERIDE for BENIGN PROSTATIC HYPERPLASIA in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater.",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
3106,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"Kaplan SA, McConnell JD, Roehrborn CG, et al: Combination therapy with doxazosin and FINASTERIDE for BENIGN PROSTATIC HYPERPLASIA in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater.",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
3107,FINASTERIDE treats BENIGN PROSTATIC HYPERPLASIA,treats,0.99654575824488,"Kaplan SA, McConnell JD, Roehrborn CG, et al: Combination therapy with doxazosin and FINASTERIDE for BENIGN PROSTATIC HYPERPLASIA in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 Ml or greater.",BENIGN PROSTATIC HYPERPLASIA,FINASTERIDE
3108,PENICILLIN G BENZATHINE treats RHEUMATIC FEVER,treats,0.984731927834662,"Yaws, Pinta, and Bejel  >     IM  Penicillin G benzathine: A single dose of 300,000 units in children    Prevention of RHEUMATIC FEVER Recurrence  >     IM  PENICILLIN G BENZATHINE: 1.2 million units once every 3 4 weeks.",RHEUMATIC FEVER,PENICILLIN G BENZATHINE
3109,no_relation,treats,0.984731927834662,"Yaws, Pinta, and Bejel  >     IM  Penicillin G benzathine: A single dose of 300,000 units in children    Prevention of RHEUMATIC FEVER Recurrence  >     IM  PENICILLIN G BENZATHINE: 1.2 million units once every 3 4 weeks.",RHEUMATIC FEVER,PENICILLIN G BENZATHINE
3110,PENICILLIN G BENZATHINE treats RHEUMATIC FEVER,treats,0.984731927834662,"Yaws, Pinta, and Bejel  >     IM  Penicillin G benzathine: A single dose of 300,000 units in children    Prevention of RHEUMATIC FEVER Recurrence  >     IM  PENICILLIN G BENZATHINE: 1.2 million units once every 3 4 weeks.",RHEUMATIC FEVER,PENICILLIN G BENZATHINE
3111,PENICILLIN G BENZATHINE treats RHEUMATIC FEVER,treats,0.984731927834662,"Yaws, Pinta, and Bejel  >     IM  Penicillin G benzathine: A single dose of 300,000 units in children    Prevention of RHEUMATIC FEVER Recurrence  >     IM  PENICILLIN G BENZATHINE: 1.2 million units once every 3 4 weeks.",RHEUMATIC FEVER,PENICILLIN G BENZATHINE
3112,PENICILLIN G BENZATHINE treats RHEUMATIC FEVER,treats,0.984731927834662,"Yaws, Pinta, and Bejel  >     IM  Penicillin G benzathine: A single dose of 300,000 units in children    Prevention of RHEUMATIC FEVER Recurrence  >     IM  PENICILLIN G BENZATHINE: 1.2 million units once every 3 4 weeks.",RHEUMATIC FEVER,PENICILLIN G BENZATHINE
3113,PENICILLIN G BENZATHINE treats RHEUMATIC FEVER,treats,0.984731927834662,"Yaws, Pinta, and Bejel  >     IM  Penicillin G benzathine: A single dose of 300,000 units in children    Prevention of RHEUMATIC FEVER Recurrence  >     IM  PENICILLIN G BENZATHINE: 1.2 million units once every 3 4 weeks.",RHEUMATIC FEVER,PENICILLIN G BENZATHINE
3114,PENICILLIN G BENZATHINE treats RHEUMATIC FEVER,treats,0.984731927834662,"Yaws, Pinta, and Bejel  >     IM  Penicillin G benzathine: A single dose of 300,000 units in children    Prevention of RHEUMATIC FEVER Recurrence  >     IM  PENICILLIN G BENZATHINE: 1.2 million units once every 3 4 weeks.",RHEUMATIC FEVER,PENICILLIN G BENZATHINE
3115,TRIMETHOPRIM SULFAMETHOXAZOLE treats URINARY TRACT INFECTIONS,treats,0.970142500145332,"Allais JM, Preheim LC, Cuevas TA et al. Randomized, double blind comparison of ciprofloxacin and TRIMETHOPRIM SULFAMETHOXAZOLE for complicated URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
3116,TRIMETHOPRIM SULFAMETHOXAZOLE treats URINARY TRACT INFECTIONS,treats,0.970142500145332,"Allais JM, Preheim LC, Cuevas TA et al. Randomized, double blind comparison of ciprofloxacin and TRIMETHOPRIM SULFAMETHOXAZOLE for complicated URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
3117,TRIMETHOPRIM SULFAMETHOXAZOLE treats URINARY TRACT INFECTIONS,treats,0.970142500145332,"Allais JM, Preheim LC, Cuevas TA et al. Randomized, double blind comparison of ciprofloxacin and TRIMETHOPRIM SULFAMETHOXAZOLE for complicated URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
3118,TRIMETHOPRIM SULFAMETHOXAZOLE treats URINARY TRACT INFECTIONS,treats,0.970142500145332,"Allais JM, Preheim LC, Cuevas TA et al. Randomized, double blind comparison of ciprofloxacin and TRIMETHOPRIM SULFAMETHOXAZOLE for complicated URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
3119,TRIMETHOPRIM SULFAMETHOXAZOLE treats URINARY TRACT INFECTIONS,treats,0.970142500145332,"Allais JM, Preheim LC, Cuevas TA et al. Randomized, double blind comparison of ciprofloxacin and TRIMETHOPRIM SULFAMETHOXAZOLE for complicated URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
3120,TRIMETHOPRIM SULFAMETHOXAZOLE treats URINARY TRACT INFECTIONS,treats,0.970142500145332,"Allais JM, Preheim LC, Cuevas TA et al. Randomized, double blind comparison of ciprofloxacin and TRIMETHOPRIM SULFAMETHOXAZOLE for complicated URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
3121,TRIMETHOPRIM SULFAMETHOXAZOLE treats URINARY TRACT INFECTIONS,treats,0.970142500145332,"Allais JM, Preheim LC, Cuevas TA et al. Randomized, double blind comparison of ciprofloxacin and TRIMETHOPRIM SULFAMETHOXAZOLE for complicated URINARY TRACT INFECTIONS",URINARY TRACT INFECTIONS,TRIMETHOPRIM SULFAMETHOXAZOLE
3122,[PREDNISOLONE 60 MG DAILY] treats [PERICARDITIS],treats,0.993127066322842,The dose for [PERICARDITIS] is [PREDNISOLONE 60 MG DAILY] tapered off over four to eight weeks.,[PERICARDITIS],[PREDNISOLONE 60 MG DAILY]
3123,no_relation,treats,0.993127066322842,The dose for [PERICARDITIS] is [PREDNISOLONE 60 MG DAILY] tapered off over four to eight weeks.,[PERICARDITIS],[PREDNISOLONE 60 MG DAILY]
3124,[PREDNISOLONE 60 MG DAILY] treats [PERICARDITIS],treats,0.993127066322842,The dose for [PERICARDITIS] is [PREDNISOLONE 60 MG DAILY] tapered off over four to eight weeks.,[PERICARDITIS],[PREDNISOLONE 60 MG DAILY]
3125,[PREDNISOLONE 60 MG DAILY] treats [PERICARDITIS],treats,0.993127066322842,The dose for [PERICARDITIS] is [PREDNISOLONE 60 MG DAILY] tapered off over four to eight weeks.,[PERICARDITIS],[PREDNISOLONE 60 MG DAILY]
3126,[PREDNISOLONE 60 MG DAILY] treats [PERICARDITIS],treats,0.993127066322842,The dose for [PERICARDITIS] is [PREDNISOLONE 60 MG DAILY] tapered off over four to eight weeks.,[PERICARDITIS],[PREDNISOLONE 60 MG DAILY]
3127,[PREDNISOLONE 60 MG DAILY] treats [PERICARDITIS],treats,0.993127066322842,The dose for [PERICARDITIS] is [PREDNISOLONE 60 MG DAILY] tapered off over four to eight weeks.,[PERICARDITIS],[PREDNISOLONE 60 MG DAILY]
3128,[PREDNISOLONE 60 MG DAILY] treats [PERICARDITIS],treats,0.993127066322842,The dose for [PERICARDITIS] is [PREDNISOLONE 60 MG DAILY] tapered off over four to eight weeks.,[PERICARDITIS],[PREDNISOLONE 60 MG DAILY]
3129,SINGLE DOSE OFLOXACIN treats UNCOMPLICATED GONORRHOEA,treats,1.0,"Chan AS, Tang KC, Fung KK et al. SINGLE DOSE OFLOXACIN in treatment of UNCOMPLICATED GONORRHOEA",UNCOMPLICATED GONORRHOEA,SINGLE DOSE OFLOXACIN
3130,SINGLE DOSE OFLOXACIN treats UNCOMPLICATED GONORRHOEA,treats,1.0,"Chan AS, Tang KC, Fung KK et al. SINGLE DOSE OFLOXACIN in treatment of UNCOMPLICATED GONORRHOEA",UNCOMPLICATED GONORRHOEA,SINGLE DOSE OFLOXACIN
3131,SINGLE DOSE OFLOXACIN treats UNCOMPLICATED GONORRHOEA,treats,1.0,"Chan AS, Tang KC, Fung KK et al. SINGLE DOSE OFLOXACIN in treatment of UNCOMPLICATED GONORRHOEA",UNCOMPLICATED GONORRHOEA,SINGLE DOSE OFLOXACIN
3132,SINGLE DOSE OFLOXACIN treats UNCOMPLICATED GONORRHOEA,treats,1.0,"Chan AS, Tang KC, Fung KK et al. SINGLE DOSE OFLOXACIN in treatment of UNCOMPLICATED GONORRHOEA",UNCOMPLICATED GONORRHOEA,SINGLE DOSE OFLOXACIN
3133,SINGLE DOSE OFLOXACIN treats UNCOMPLICATED GONORRHOEA,treats,1.0,"Chan AS, Tang KC, Fung KK et al. SINGLE DOSE OFLOXACIN in treatment of UNCOMPLICATED GONORRHOEA",UNCOMPLICATED GONORRHOEA,SINGLE DOSE OFLOXACIN
3134,SINGLE DOSE OFLOXACIN treats UNCOMPLICATED GONORRHOEA,treats,1.0,"Chan AS, Tang KC, Fung KK et al. SINGLE DOSE OFLOXACIN in treatment of UNCOMPLICATED GONORRHOEA",UNCOMPLICATED GONORRHOEA,SINGLE DOSE OFLOXACIN
3135,SINGLE DOSE OFLOXACIN treats UNCOMPLICATED GONORRHOEA,treats,1.0,"Chan AS, Tang KC, Fung KK et al. SINGLE DOSE OFLOXACIN in treatment of UNCOMPLICATED GONORRHOEA",UNCOMPLICATED GONORRHOEA,SINGLE DOSE OFLOXACIN
3136,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
3137,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
3138,MILK THISTLE treats CIRRHOSIS,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
3139,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
3140,CIRRHOSIS treats MILK THISTLE,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
3141,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
3142,no_relation,treats,0.790569415042095,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE
3143,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.975900072948533,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
3144,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.975900072948533,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
3145,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.975900072948533,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
3146,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.975900072948533,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
3147,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.975900072948533,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
3148,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.975900072948533,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
3149,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,treats,0.975900072948533,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX
3150,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [PORTAL VEIN THROMBUS],treats,0.9950371902099888,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with [PORTAL VEIN THROMBUS]",[PORTAL VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
3151,no_relation,treats,0.9950371902099888,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with [PORTAL VEIN THROMBUS]",[PORTAL VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
3152,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [PORTAL VEIN THROMBUS],treats,0.9950371902099888,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with [PORTAL VEIN THROMBUS]",[PORTAL VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
3153,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [PORTAL VEIN THROMBUS],treats,0.9950371902099888,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with [PORTAL VEIN THROMBUS]",[PORTAL VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
3154,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [PORTAL VEIN THROMBUS],treats,0.9950371902099888,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with [PORTAL VEIN THROMBUS]",[PORTAL VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
3155,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [PORTAL VEIN THROMBUS],treats,0.9950371902099888,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with [PORTAL VEIN THROMBUS]",[PORTAL VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
3156,[INTRA ARTERIAL IODINE 131 LIPIODOL] treats [PORTAL VEIN THROMBUS],treats,0.9950371902099888,"[INTRA ARTERIAL IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with [PORTAL VEIN THROMBUS]",[PORTAL VEIN THROMBUS],[INTRA ARTERIAL IODINE 131 LIPIODOL]
3157,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
3158,no_relation,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
3159,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
3160,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
3161,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
3162,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
3163,PAPAVERINE treats ERECTILE DYSFUNCTION,treats,0.629940788348712,To evaluate the use of papaverine induced erection as a diagnostic test in men with ERECTILE DYSFUNCTION 24 patients had PAPAVERINE injected into the corpus cavernosum.,ERECTILE DYSFUNCTION,PAPAVERINE
3164,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.938314863256837,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
3165,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.938314863256837,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
3166,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.938314863256837,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
3167,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.938314863256837,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
3168,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.938314863256837,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
3169,no_relation,treats,0.938314863256837,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
3170,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.938314863256837,Studies in patients scheduled for percutaneous coronary intervention and those with unstable angina or non-Q-wave myocardial infarction have shown that a combination of intravenous GP IIb-IIIa inhibitors with ASPIRIN and heparin is associated with a reduction in death or MYOCARDIAL INFARCTION compared with therapy with aspirin and heparin alone,MYOCARDIAL INFARCTION,ASPIRIN
3171,no_relation,treats,0.753778361444409,Anecdotal reports have said that rubbing Vitamin E oil on the [VENIPUNCTURE] site may reduce [SCARRING],[SCARRING],[VENIPUNCTURE]
3172,[VENIPUNCTURE] treats [SCARRING],treats,0.753778361444409,Anecdotal reports have said that rubbing Vitamin E oil on the [VENIPUNCTURE] site may reduce [SCARRING],[SCARRING],[VENIPUNCTURE]
3173,[VENIPUNCTURE] treats [SCARRING],treats,0.753778361444409,Anecdotal reports have said that rubbing Vitamin E oil on the [VENIPUNCTURE] site may reduce [SCARRING],[SCARRING],[VENIPUNCTURE]
3174,no_relation,treats,0.753778361444409,Anecdotal reports have said that rubbing Vitamin E oil on the [VENIPUNCTURE] site may reduce [SCARRING],[SCARRING],[VENIPUNCTURE]
3175,[VENIPUNCTURE] treats [SCARRING],treats,0.753778361444409,Anecdotal reports have said that rubbing Vitamin E oil on the [VENIPUNCTURE] site may reduce [SCARRING],[SCARRING],[VENIPUNCTURE]
3176,[VENIPUNCTURE] treats [SCARRING],treats,0.753778361444409,Anecdotal reports have said that rubbing Vitamin E oil on the [VENIPUNCTURE] site may reduce [SCARRING],[SCARRING],[VENIPUNCTURE]
3177,no_relation,treats,0.753778361444409,Anecdotal reports have said that rubbing Vitamin E oil on the [VENIPUNCTURE] site may reduce [SCARRING],[SCARRING],[VENIPUNCTURE]
3178,ALLICIN treats HELICOBACTER PYLORI,treats,0.9830783046228492,"It is also acts against the stomach ulcer germ [HELICOBACTER PYLORI], however not as efficiently as [ALLICIN].",HELICOBACTER PYLORI,ALLICIN
3179,ALLICIN treats HELICOBACTER PYLORI,treats,0.9830783046228492,"It is also acts against the stomach ulcer germ [HELICOBACTER PYLORI], however not as efficiently as [ALLICIN].",HELICOBACTER PYLORI,ALLICIN
3180,ALLICIN treats HELICOBACTER PYLORI,treats,0.9830783046228492,"It is also acts against the stomach ulcer germ [HELICOBACTER PYLORI], however not as efficiently as [ALLICIN].",HELICOBACTER PYLORI,ALLICIN
3181,ALLICIN treats HELICOBACTER PYLORI,treats,0.9830783046228492,"It is also acts against the stomach ulcer germ [HELICOBACTER PYLORI], however not as efficiently as [ALLICIN].",HELICOBACTER PYLORI,ALLICIN
3182,HELICOBACTER PYLORI treats ALLICIN,treats,0.9830783046228492,"It is also acts against the stomach ulcer germ [HELICOBACTER PYLORI], however not as efficiently as [ALLICIN].",HELICOBACTER PYLORI,ALLICIN
3183,ALLICIN treats HELICOBACTER PYLORI,treats,0.9830783046228492,"It is also acts against the stomach ulcer germ [HELICOBACTER PYLORI], however not as efficiently as [ALLICIN].",HELICOBACTER PYLORI,ALLICIN
3184,ALLICIN treats HELICOBACTER PYLORI,treats,0.9830783046228492,"It is also acts against the stomach ulcer germ [HELICOBACTER PYLORI], however not as efficiently as [ALLICIN].",HELICOBACTER PYLORI,ALLICIN
3185,ANTI-DEPRESSANT treats NUTCRACKER ESOPHAGUS,treats,0.979957887,"Finally, trazodone, an [ANTI-DEPRESSANT] that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,ANTI-DEPRESSANT
3186,ANTI-DEPRESSANT treats NUTCRACKER ESOPHAGUS,treats,0.979957887,"Finally, trazodone, an [ANTI-DEPRESSANT] that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,ANTI-DEPRESSANT
3187,ANTI-DEPRESSANT treats NUTCRACKER ESOPHAGUS,treats,0.979957887,"Finally, trazodone, an [ANTI-DEPRESSANT] that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,ANTI-DEPRESSANT
3188,no_relation,treats,0.979957887,"Finally, trazodone, an [ANTI-DEPRESSANT] that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,ANTI-DEPRESSANT
3189,no_relation,treats,0.979957887,"Finally, trazodone, an [ANTI-DEPRESSANT] that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,ANTI-DEPRESSANT
3190,ANTI-DEPRESSANT treats NUTCRACKER ESOPHAGUS,treats,0.979957887,"Finally, trazodone, an [ANTI-DEPRESSANT] that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,ANTI-DEPRESSANT
3191,ANTI-DEPRESSANT treats NUTCRACKER ESOPHAGUS,treats,0.979957887,"Finally, trazodone, an [ANTI-DEPRESSANT] that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,ANTI-DEPRESSANT
3192,INJECTION SITE treats PAIN,treats,0.4200840252084029,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
3193,INJECTION SITE treats PAIN,treats,0.4200840252084029,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
3194,no_relation,treats,0.4200840252084029,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
3195,INJECTION SITE treats PAIN,treats,0.4200840252084029,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
3196,no_relation,treats,0.4200840252084029,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
3197,no_relation,treats,0.4200840252084029,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
3198,INJECTION SITE treats PAIN,treats,0.4200840252084029,"Oral availability and safety should rapidly make it the preferred agent Influenza virus vaccine  Induces protective antibodies against influenza  0.5 mL im yearly  Prevents influenza, in turn preventing worsened anemia due to infection and complications of superinfections  Fever and sore arm in  Give to all patients with hemolytic anemias Pneumococcal polysaccharide vaccine  Develops antibodies to pneumococcal antigens  0.5 mL im every 5 6 years  Can prevent the most common form of overwhelming postsplenectomy sepsis; prevents worsened anemia and severe infection in all hemolytic anemia patients  Erythema and PAIN at INJECTION SITE in 50%; systemic fever in.",INJECTION SITE,PAIN
3199,no_relation,treats,0.9970544855015808,ALBENDAZOLE THERAPY for NEUROCYSTICERCOSIS: a prospective double blind trial comparing 7 versus 14 days of treatment.,NEUROCYSTICERCOSIS,ALBENDAZOLE THERAPY
3200,ALBENDAZOLE THERAPY treats NEUROCYSTICERCOSIS,treats,0.9970544855015808,ALBENDAZOLE THERAPY for NEUROCYSTICERCOSIS: a prospective double blind trial comparing 7 versus 14 days of treatment.,NEUROCYSTICERCOSIS,ALBENDAZOLE THERAPY
3201,ALBENDAZOLE THERAPY treats NEUROCYSTICERCOSIS,treats,0.9970544855015808,ALBENDAZOLE THERAPY for NEUROCYSTICERCOSIS: a prospective double blind trial comparing 7 versus 14 days of treatment.,NEUROCYSTICERCOSIS,ALBENDAZOLE THERAPY
3202,ALBENDAZOLE THERAPY treats NEUROCYSTICERCOSIS,treats,0.9970544855015808,ALBENDAZOLE THERAPY for NEUROCYSTICERCOSIS: a prospective double blind trial comparing 7 versus 14 days of treatment.,NEUROCYSTICERCOSIS,ALBENDAZOLE THERAPY
3203,ALBENDAZOLE THERAPY treats NEUROCYSTICERCOSIS,treats,0.9970544855015808,ALBENDAZOLE THERAPY for NEUROCYSTICERCOSIS: a prospective double blind trial comparing 7 versus 14 days of treatment.,NEUROCYSTICERCOSIS,ALBENDAZOLE THERAPY
3204,ALBENDAZOLE THERAPY treats NEUROCYSTICERCOSIS,treats,0.9970544855015808,ALBENDAZOLE THERAPY for NEUROCYSTICERCOSIS: a prospective double blind trial comparing 7 versus 14 days of treatment.,NEUROCYSTICERCOSIS,ALBENDAZOLE THERAPY
3205,ALBENDAZOLE THERAPY treats NEUROCYSTICERCOSIS,treats,0.9970544855015808,ALBENDAZOLE THERAPY for NEUROCYSTICERCOSIS: a prospective double blind trial comparing 7 versus 14 days of treatment.,NEUROCYSTICERCOSIS,ALBENDAZOLE THERAPY
3206,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS treats TOXOPLASMIC ENCEPHALITIS,treats,0.994134846772434,"Carr A, Tindall B, Brew BJ et al. LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS
3207,no_relation,treats,0.994134846772434,"Carr A, Tindall B, Brew BJ et al. LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS
3208,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS treats TOXOPLASMIC ENCEPHALITIS,treats,0.994134846772434,"Carr A, Tindall B, Brew BJ et al. LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS
3209,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS treats TOXOPLASMIC ENCEPHALITIS,treats,0.994134846772434,"Carr A, Tindall B, Brew BJ et al. LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS
3210,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS treats TOXOPLASMIC ENCEPHALITIS,treats,0.994134846772434,"Carr A, Tindall B, Brew BJ et al. LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS
3211,no_relation,treats,0.994134846772434,"Carr A, Tindall B, Brew BJ et al. LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS
3212,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS treats TOXOPLASMIC ENCEPHALITIS,treats,0.994134846772434,"Carr A, Tindall B, Brew BJ et al. LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS for TOXOPLASMIC ENCEPHALITIS in patients with AIDS.",TOXOPLASMIC ENCEPHALITIS,LOW DOSE TRIMETHOPRIM SULFAMETHOXAZOLE PROPHYLAXIS
3213,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.975900072948533,"Freeman CPL, Trimble MR, Deakin JFW et al. FLUVOXAMINE VERSUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
3214,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.975900072948533,"Freeman CPL, Trimble MR, Deakin JFW et al. FLUVOXAMINE VERSUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
3215,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.975900072948533,"Freeman CPL, Trimble MR, Deakin JFW et al. FLUVOXAMINE VERSUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
3216,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.975900072948533,"Freeman CPL, Trimble MR, Deakin JFW et al. FLUVOXAMINE VERSUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
3217,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.975900072948533,"Freeman CPL, Trimble MR, Deakin JFW et al. FLUVOXAMINE VERSUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
3218,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.975900072948533,"Freeman CPL, Trimble MR, Deakin JFW et al. FLUVOXAMINE VERSUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
3219,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,0.975900072948533,"Freeman CPL, Trimble MR, Deakin JFW et al. FLUVOXAMINE VERSUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
3220,PROCARBAZINE treats MANTLE CELL LYMPHOMA,treats,0.9113223769,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, [PROCARBAZINE] and cyclophosphamide.",MANTLE CELL LYMPHOMA,PROCARBAZINE
3221,no_relation,treats,0.9113223769,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, [PROCARBAZINE] and cyclophosphamide.",MANTLE CELL LYMPHOMA,PROCARBAZINE
3222,PROCARBAZINE treats MANTLE CELL LYMPHOMA,treats,0.9113223769,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, [PROCARBAZINE] and cyclophosphamide.",MANTLE CELL LYMPHOMA,PROCARBAZINE
3223,no_relation,treats,0.9113223769,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, [PROCARBAZINE] and cyclophosphamide.",MANTLE CELL LYMPHOMA,PROCARBAZINE
3224,PROCARBAZINE treats MANTLE CELL LYMPHOMA,treats,0.9113223769,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, [PROCARBAZINE] and cyclophosphamide.",MANTLE CELL LYMPHOMA,PROCARBAZINE
3225,PROCARBAZINE treats MANTLE CELL LYMPHOMA,treats,0.9113223769,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, [PROCARBAZINE] and cyclophosphamide.",MANTLE CELL LYMPHOMA,PROCARBAZINE
3226,PROCARBAZINE treats MANTLE CELL LYMPHOMA,treats,0.9113223769,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, etoposide, [PROCARBAZINE] and cyclophosphamide.",MANTLE CELL LYMPHOMA,PROCARBAZINE
3227,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
3228,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
3229,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
3230,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
3231,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
3232,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
3233,RIFAPENTINE treats PULMONARY TUBERCULOSIS,treats,1.0,"Tam CM, Chan SL, Lam CW et alRIFAPENTINE and isoniazid in the continuation phase of treating PULMONARY TUBERCULOSIS",PULMONARY TUBERCULOSIS,RIFAPENTINE
3234,no_relation,treats,0.6933752452815359,"Although the recurrence risk is not increased, [GENETIC COUNSELING] is often recommended for families who have had a pregnancy or child with [TURNER SYNDROME].",GENETIC COUNSELING,TURNER SYNDROME
3235,GENETIC COUNSELING treats TURNER SYNDROME,treats,0.6933752452815359,"Although the recurrence risk is not increased, [GENETIC COUNSELING] is often recommended for families who have had a pregnancy or child with [TURNER SYNDROME].",GENETIC COUNSELING,TURNER SYNDROME
3236,GENETIC COUNSELING treats TURNER SYNDROME,treats,0.6933752452815359,"Although the recurrence risk is not increased, [GENETIC COUNSELING] is often recommended for families who have had a pregnancy or child with [TURNER SYNDROME].",GENETIC COUNSELING,TURNER SYNDROME
3237,GENETIC COUNSELING treats TURNER SYNDROME,treats,0.6933752452815359,"Although the recurrence risk is not increased, [GENETIC COUNSELING] is often recommended for families who have had a pregnancy or child with [TURNER SYNDROME].",GENETIC COUNSELING,TURNER SYNDROME
3238,no_relation,treats,0.6933752452815359,"Although the recurrence risk is not increased, [GENETIC COUNSELING] is often recommended for families who have had a pregnancy or child with [TURNER SYNDROME].",GENETIC COUNSELING,TURNER SYNDROME
3239,GENETIC COUNSELING treats TURNER SYNDROME,treats,0.6933752452815359,"Although the recurrence risk is not increased, [GENETIC COUNSELING] is often recommended for families who have had a pregnancy or child with [TURNER SYNDROME].",GENETIC COUNSELING,TURNER SYNDROME
3240,no_relation,treats,0.6933752452815359,"Although the recurrence risk is not increased, [GENETIC COUNSELING] is often recommended for families who have had a pregnancy or child with [TURNER SYNDROME].",GENETIC COUNSELING,TURNER SYNDROME
3241,[PENTOBARBITAL INDUCED COMA] treats [MANNITOL],treats,0.903696114115064,[PENTOBARBITAL INDUCED COMA] has been advocated in patients with acute liver failure refractory to [MANNITOL],[PENTOBARBITAL INDUCED COMA],[MANNITOL]
3242,no_relation,treats,0.903696114115064,[PENTOBARBITAL INDUCED COMA] has been advocated in patients with acute liver failure refractory to [MANNITOL],[PENTOBARBITAL INDUCED COMA],[MANNITOL]
3243,[MANNITOL] treats [PENTOBARBITAL INDUCED COMA],treats,0.903696114115064,[PENTOBARBITAL INDUCED COMA] has been advocated in patients with acute liver failure refractory to [MANNITOL],[PENTOBARBITAL INDUCED COMA],[MANNITOL]
3244,[PENTOBARBITAL INDUCED COMA] treats [MANNITOL],treats,0.903696114115064,[PENTOBARBITAL INDUCED COMA] has been advocated in patients with acute liver failure refractory to [MANNITOL],[PENTOBARBITAL INDUCED COMA],[MANNITOL]
3245,no_relation,treats,0.903696114115064,[PENTOBARBITAL INDUCED COMA] has been advocated in patients with acute liver failure refractory to [MANNITOL],[PENTOBARBITAL INDUCED COMA],[MANNITOL]
3246,[MANNITOL] treats [PENTOBARBITAL INDUCED COMA],treats,0.903696114115064,[PENTOBARBITAL INDUCED COMA] has been advocated in patients with acute liver failure refractory to [MANNITOL],[PENTOBARBITAL INDUCED COMA],[MANNITOL]
3247,[MANNITOL] treats [PENTOBARBITAL INDUCED COMA],treats,0.903696114115064,[PENTOBARBITAL INDUCED COMA] has been advocated in patients with acute liver failure refractory to [MANNITOL],[PENTOBARBITAL INDUCED COMA],[MANNITOL]
3248,[CLONIDINE] treats [LOWER BLOOD PRESSURE],treats,0.525785614053287,[CLONIDINE] suppresses sympathetic outflow resulting in [LOWER BLOOD PRESSURE] but sudden discontinuation can cause rebound hypertension due to a rebound in sympathetic outflow.,[LOWER BLOOD PRESSURE],[CLONIDINE]
3249,[CLONIDINE] treats [LOWER BLOOD PRESSURE],treats,0.525785614053287,[CLONIDINE] suppresses sympathetic outflow resulting in [LOWER BLOOD PRESSURE] but sudden discontinuation can cause rebound hypertension due to a rebound in sympathetic outflow.,[LOWER BLOOD PRESSURE],[CLONIDINE]
3250,[CLONIDINE] treats [LOWER BLOOD PRESSURE],treats,0.525785614053287,[CLONIDINE] suppresses sympathetic outflow resulting in [LOWER BLOOD PRESSURE] but sudden discontinuation can cause rebound hypertension due to a rebound in sympathetic outflow.,[LOWER BLOOD PRESSURE],[CLONIDINE]
3251,[CLONIDINE] treats [LOWER BLOOD PRESSURE],treats,0.525785614053287,[CLONIDINE] suppresses sympathetic outflow resulting in [LOWER BLOOD PRESSURE] but sudden discontinuation can cause rebound hypertension due to a rebound in sympathetic outflow.,[LOWER BLOOD PRESSURE],[CLONIDINE]
3252,[CLONIDINE] treats [LOWER BLOOD PRESSURE],treats,0.525785614053287,[CLONIDINE] suppresses sympathetic outflow resulting in [LOWER BLOOD PRESSURE] but sudden discontinuation can cause rebound hypertension due to a rebound in sympathetic outflow.,[LOWER BLOOD PRESSURE],[CLONIDINE]
3253,[CLONIDINE] treats [LOWER BLOOD PRESSURE],treats,0.525785614053287,[CLONIDINE] suppresses sympathetic outflow resulting in [LOWER BLOOD PRESSURE] but sudden discontinuation can cause rebound hypertension due to a rebound in sympathetic outflow.,[LOWER BLOOD PRESSURE],[CLONIDINE]
3254,[CLONIDINE] treats [LOWER BLOOD PRESSURE],treats,0.525785614053287,[CLONIDINE] suppresses sympathetic outflow resulting in [LOWER BLOOD PRESSURE] but sudden discontinuation can cause rebound hypertension due to a rebound in sympathetic outflow.,[LOWER BLOOD PRESSURE],[CLONIDINE]
3255,no_relation,treats,0.400891862868637,"Because of its possible anticholinergic action, [MECLIZINE] should be used carefully with patients who suffer from asthma, [GLAUCOMA], or an enlarged prostate gland.",GLAUCOMA,MECLIZINE
3256,MECLIZINE treats GLAUCOMA,treats,0.400891862868637,"Because of its possible anticholinergic action, [MECLIZINE] should be used carefully with patients who suffer from asthma, [GLAUCOMA], or an enlarged prostate gland.",GLAUCOMA,MECLIZINE
3257,MECLIZINE treats GLAUCOMA,treats,0.400891862868637,"Because of its possible anticholinergic action, [MECLIZINE] should be used carefully with patients who suffer from asthma, [GLAUCOMA], or an enlarged prostate gland.",GLAUCOMA,MECLIZINE
3258,MECLIZINE treats GLAUCOMA,treats,0.400891862868637,"Because of its possible anticholinergic action, [MECLIZINE] should be used carefully with patients who suffer from asthma, [GLAUCOMA], or an enlarged prostate gland.",GLAUCOMA,MECLIZINE
3259,no_relation,treats,0.400891862868637,"Because of its possible anticholinergic action, [MECLIZINE] should be used carefully with patients who suffer from asthma, [GLAUCOMA], or an enlarged prostate gland.",GLAUCOMA,MECLIZINE
3260,MECLIZINE treats GLAUCOMA,treats,0.400891862868637,"Because of its possible anticholinergic action, [MECLIZINE] should be used carefully with patients who suffer from asthma, [GLAUCOMA], or an enlarged prostate gland.",GLAUCOMA,MECLIZINE
3261,MECLIZINE treats GLAUCOMA,treats,0.400891862868637,"Because of its possible anticholinergic action, [MECLIZINE] should be used carefully with patients who suffer from asthma, [GLAUCOMA], or an enlarged prostate gland.",GLAUCOMA,MECLIZINE
3262,PIRACETAM treats MYOCLONUS,treats,0.9918365981,Clonazepam and high-dose [PIRACETAM] can alleviate [MYOCLONUS].,MYOCLONUS,PIRACETAM
3263,PIRACETAM treats MYOCLONUS,treats,0.9918365981,Clonazepam and high-dose [PIRACETAM] can alleviate [MYOCLONUS].,MYOCLONUS,PIRACETAM
3264,PIRACETAM treats MYOCLONUS,treats,0.9918365981,Clonazepam and high-dose [PIRACETAM] can alleviate [MYOCLONUS].,MYOCLONUS,PIRACETAM
3265,PIRACETAM treats MYOCLONUS,treats,0.9918365981,Clonazepam and high-dose [PIRACETAM] can alleviate [MYOCLONUS].,MYOCLONUS,PIRACETAM
3266,PIRACETAM treats MYOCLONUS,treats,0.9918365981,Clonazepam and high-dose [PIRACETAM] can alleviate [MYOCLONUS].,MYOCLONUS,PIRACETAM
3267,PIRACETAM treats MYOCLONUS,treats,0.9918365981,Clonazepam and high-dose [PIRACETAM] can alleviate [MYOCLONUS].,MYOCLONUS,PIRACETAM
3268,PIRACETAM treats MYOCLONUS,treats,0.9918365981,Clonazepam and high-dose [PIRACETAM] can alleviate [MYOCLONUS].,MYOCLONUS,PIRACETAM
3269,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
3270,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
3271,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
3272,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
3273,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
3274,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
3275,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,treats,1.0,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D
3276,HEPARIN treats DIC,treats,0.942809041582063,Rewarming by hemodialysis for hypothermia: failure of HEPARIN to prevent DIC,DIC,HEPARIN
3277,no_relation,treats,0.942809041582063,Rewarming by hemodialysis for hypothermia: failure of HEPARIN to prevent DIC,DIC,HEPARIN
3278,HEPARIN treats DIC,treats,0.942809041582063,Rewarming by hemodialysis for hypothermia: failure of HEPARIN to prevent DIC,DIC,HEPARIN
3279,no_relation,treats,0.942809041582063,Rewarming by hemodialysis for hypothermia: failure of HEPARIN to prevent DIC,DIC,HEPARIN
3280,HEPARIN treats DIC,treats,0.942809041582063,Rewarming by hemodialysis for hypothermia: failure of HEPARIN to prevent DIC,DIC,HEPARIN
3281,HEPARIN treats DIC,treats,0.942809041582063,Rewarming by hemodialysis for hypothermia: failure of HEPARIN to prevent DIC,DIC,HEPARIN
3282,HEPARIN treats DIC,treats,0.942809041582063,Rewarming by hemodialysis for hypothermia: failure of HEPARIN to prevent DIC,DIC,HEPARIN
3283,PROPAFENONE treats PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,treats,0.753778361444409,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3284,PROPAFENONE treats PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,treats,0.753778361444409,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3285,PROPAFENONE treats PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,treats,0.753778361444409,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3286,no_relation,treats,0.753778361444409,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3287,PROPAFENONE treats PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,treats,0.753778361444409,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3288,PROPAFENONE treats PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,treats,0.753778361444409,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3289,PROPAFENONE treats PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,treats,0.753778361444409,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3290,[INTRAVENOUS FLUMAZENIL] treats [VENTILATORY DEPRESSION],treats,0.824957911384306,"[INTRAVENOUS FLUMAZENIL] has been shown to antagonize sedation, impairment of recall, psychomotor impairment and [VENTILATORY DEPRESSION] produced by benzodiazepines in healthy human volunteers.",[VENTILATORY DEPRESSION],[INTRAVENOUS FLUMAZENIL]
3291,no_relation,treats,0.824957911384306,"[INTRAVENOUS FLUMAZENIL] has been shown to antagonize sedation, impairment of recall, psychomotor impairment and [VENTILATORY DEPRESSION] produced by benzodiazepines in healthy human volunteers.",[VENTILATORY DEPRESSION],[INTRAVENOUS FLUMAZENIL]
3292,[INTRAVENOUS FLUMAZENIL] treats [VENTILATORY DEPRESSION],treats,0.824957911384306,"[INTRAVENOUS FLUMAZENIL] has been shown to antagonize sedation, impairment of recall, psychomotor impairment and [VENTILATORY DEPRESSION] produced by benzodiazepines in healthy human volunteers.",[VENTILATORY DEPRESSION],[INTRAVENOUS FLUMAZENIL]
3293,no_relation,treats,0.824957911384306,"[INTRAVENOUS FLUMAZENIL] has been shown to antagonize sedation, impairment of recall, psychomotor impairment and [VENTILATORY DEPRESSION] produced by benzodiazepines in healthy human volunteers.",[VENTILATORY DEPRESSION],[INTRAVENOUS FLUMAZENIL]
3294,no_relation,treats,0.824957911384306,"[INTRAVENOUS FLUMAZENIL] has been shown to antagonize sedation, impairment of recall, psychomotor impairment and [VENTILATORY DEPRESSION] produced by benzodiazepines in healthy human volunteers.",[VENTILATORY DEPRESSION],[INTRAVENOUS FLUMAZENIL]
3295,[INTRAVENOUS FLUMAZENIL] treats [VENTILATORY DEPRESSION],treats,0.824957911384306,"[INTRAVENOUS FLUMAZENIL] has been shown to antagonize sedation, impairment of recall, psychomotor impairment and [VENTILATORY DEPRESSION] produced by benzodiazepines in healthy human volunteers.",[VENTILATORY DEPRESSION],[INTRAVENOUS FLUMAZENIL]
3296,[INTRAVENOUS FLUMAZENIL] treats [VENTILATORY DEPRESSION],treats,0.824957911384306,"[INTRAVENOUS FLUMAZENIL] has been shown to antagonize sedation, impairment of recall, psychomotor impairment and [VENTILATORY DEPRESSION] produced by benzodiazepines in healthy human volunteers.",[VENTILATORY DEPRESSION],[INTRAVENOUS FLUMAZENIL]
3297,[DEET] treats [TICK BORNE MENINGOENCEPHALITIS],treats,1.0,"In particular, [DEET] protects against tick bites, preventing several rickettsioses, [TICK BORNE MENINGOENCEPHALITIS] and other tick borne diseases such as Lyme disease.",[TICK BORNE MENINGOENCEPHALITIS],[DEET]
3298,[DEET] treats [TICK BORNE MENINGOENCEPHALITIS],treats,1.0,"In particular, [DEET] protects against tick bites, preventing several rickettsioses, [TICK BORNE MENINGOENCEPHALITIS] and other tick borne diseases such as Lyme disease.",[TICK BORNE MENINGOENCEPHALITIS],[DEET]
3299,[DEET] treats [TICK BORNE MENINGOENCEPHALITIS],treats,1.0,"In particular, [DEET] protects against tick bites, preventing several rickettsioses, [TICK BORNE MENINGOENCEPHALITIS] and other tick borne diseases such as Lyme disease.",[TICK BORNE MENINGOENCEPHALITIS],[DEET]
3300,[DEET] treats [TICK BORNE MENINGOENCEPHALITIS],treats,1.0,"In particular, [DEET] protects against tick bites, preventing several rickettsioses, [TICK BORNE MENINGOENCEPHALITIS] and other tick borne diseases such as Lyme disease.",[TICK BORNE MENINGOENCEPHALITIS],[DEET]
3301,[DEET] treats [TICK BORNE MENINGOENCEPHALITIS],treats,1.0,"In particular, [DEET] protects against tick bites, preventing several rickettsioses, [TICK BORNE MENINGOENCEPHALITIS] and other tick borne diseases such as Lyme disease.",[TICK BORNE MENINGOENCEPHALITIS],[DEET]
3302,[DEET] treats [TICK BORNE MENINGOENCEPHALITIS],treats,1.0,"In particular, [DEET] protects against tick bites, preventing several rickettsioses, [TICK BORNE MENINGOENCEPHALITIS] and other tick borne diseases such as Lyme disease.",[TICK BORNE MENINGOENCEPHALITIS],[DEET]
3303,no_relation,treats,1.0,"In particular, [DEET] protects against tick bites, preventing several rickettsioses, [TICK BORNE MENINGOENCEPHALITIS] and other tick borne diseases such as Lyme disease.",[TICK BORNE MENINGOENCEPHALITIS],[DEET]
3304,VITAMIN D treats INHERITED RICKETS,treats,0.589767824619589,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
3305,VITAMIN D treats INHERITED RICKETS,treats,0.589767824619589,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
3306,VITAMIN D treats INHERITED RICKETS,treats,0.589767824619589,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
3307,VITAMIN D treats INHERITED RICKETS,treats,0.589767824619589,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
3308,VITAMIN D treats INHERITED RICKETS,treats,0.589767824619589,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
3309,no_relation,treats,0.589767824619589,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
3310,no_relation,treats,0.589767824619589,"Diseases associated to Vitamin D deficiency (rickets in children, and osteomalacia or osteoporosis in adults) and autosomal recessive forms of INHERITED RICKETS illustrate the key role of VITAMIN D in calcium homeostasis and bone metabolism.",INHERITED RICKETS,VITAMIN D
3311,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
3312,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
3313,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
3314,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
3315,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
3316,FUROSEMIDE treats ASCITES,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
3317,no_relation,treats,1.0,"Herlong HF, Hunter FM, Koff RS et al. A comparison of bumetanide and FUROSEMIDE in the treatment of ASCITES: cooperative study.",ASCITES,FUROSEMIDE
3318,AZIDOTHYMIDINE treats AIDS,treats,1.0,"Richman DD, Fischl MA, Nusinoff Lehrman S et alAZIDOTHYMIDINE in the treatment of AIDS",AIDS,AZIDOTHYMIDINE
3319,AZIDOTHYMIDINE treats AIDS,treats,1.0,"Richman DD, Fischl MA, Nusinoff Lehrman S et alAZIDOTHYMIDINE in the treatment of AIDS",AIDS,AZIDOTHYMIDINE
3320,AZIDOTHYMIDINE treats AIDS,treats,1.0,"Richman DD, Fischl MA, Nusinoff Lehrman S et alAZIDOTHYMIDINE in the treatment of AIDS",AIDS,AZIDOTHYMIDINE
3321,AZIDOTHYMIDINE treats AIDS,treats,1.0,"Richman DD, Fischl MA, Nusinoff Lehrman S et alAZIDOTHYMIDINE in the treatment of AIDS",AIDS,AZIDOTHYMIDINE
3322,AZIDOTHYMIDINE treats AIDS,treats,1.0,"Richman DD, Fischl MA, Nusinoff Lehrman S et alAZIDOTHYMIDINE in the treatment of AIDS",AIDS,AZIDOTHYMIDINE
3323,AZIDOTHYMIDINE treats AIDS,treats,1.0,"Richman DD, Fischl MA, Nusinoff Lehrman S et alAZIDOTHYMIDINE in the treatment of AIDS",AIDS,AZIDOTHYMIDINE
3324,AZIDOTHYMIDINE treats AIDS,treats,1.0,"Richman DD, Fischl MA, Nusinoff Lehrman S et alAZIDOTHYMIDINE in the treatment of AIDS",AIDS,AZIDOTHYMIDINE
3325,no_relation,treats,0.878114079917523,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
3326,no_relation,treats,0.878114079917523,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
3327,no_relation,treats,0.878114079917523,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
3328,no_relation,treats,0.878114079917523,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
3329,INFLUENZA A VIRUS INFECTIONS treats A AND B VIRUS INFECTIONS,treats,0.878114079917523,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
3330,no_relation,treats,0.878114079917523,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
3331,no_relation,treats,0.878114079917523,"104 ,   152  Prevention of Avian INFLUENZA A VIRUS INFECTIONS   +  >     Oral  Dosage usually recommended for prophylaxis of seasonal influenza A AND B VIRUS INFECTIONS has been recommended.",INFLUENZA A VIRUS INFECTIONS,A AND B VIRUS INFECTIONS
3332,ERGONOVINE treats VARIANT ANGINA PECTORIS,treats,0.9434563530497272,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3333,no_relation,treats,0.9434563530497272,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3334,no_relation,treats,0.9434563530497272,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3335,VARIANT ANGINA PECTORIS treats ERGONOVINE,treats,0.9434563530497272,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3336,ERGONOVINE treats VARIANT ANGINA PECTORIS,treats,0.9434563530497272,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3337,ERGONOVINE treats VARIANT ANGINA PECTORIS,treats,0.9434563530497272,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3338,no_relation,treats,0.9434563530497272,Transient prolongation of the corrected Q T interval preceded spontaneous or ergonovine maleate provoked coronary spasm in 11 patients with VARIANT ANGINA PECTORIS whereas no significant change in the Q T interval followed ERGONOVINE administration in 27 control patients with atypical chest pain who did not have coronary spasm.,VARIANT ANGINA PECTORIS,ERGONOVINE
3339,(DORNASE ALFA treats CYSTIC FIBROSIS,treats,0.987878339907213,"Genentech, Inc. Patient information booklet: your guide to Pulmozyme ®  (DORNASE ALFA therapy for CYSTIC FIBROSIS (CF.",CYSTIC FIBROSIS,(DORNASE ALFA
3340,(DORNASE ALFA treats CYSTIC FIBROSIS,treats,0.987878339907213,"Genentech, Inc. Patient information booklet: your guide to Pulmozyme ®  (DORNASE ALFA therapy for CYSTIC FIBROSIS (CF.",CYSTIC FIBROSIS,(DORNASE ALFA
3341,(DORNASE ALFA treats CYSTIC FIBROSIS,treats,0.987878339907213,"Genentech, Inc. Patient information booklet: your guide to Pulmozyme ®  (DORNASE ALFA therapy for CYSTIC FIBROSIS (CF.",CYSTIC FIBROSIS,(DORNASE ALFA
3342,(DORNASE ALFA treats CYSTIC FIBROSIS,treats,0.987878339907213,"Genentech, Inc. Patient information booklet: your guide to Pulmozyme ®  (DORNASE ALFA therapy for CYSTIC FIBROSIS (CF.",CYSTIC FIBROSIS,(DORNASE ALFA
3343,(DORNASE ALFA treats CYSTIC FIBROSIS,treats,0.987878339907213,"Genentech, Inc. Patient information booklet: your guide to Pulmozyme ®  (DORNASE ALFA therapy for CYSTIC FIBROSIS (CF.",CYSTIC FIBROSIS,(DORNASE ALFA
3344,(DORNASE ALFA treats CYSTIC FIBROSIS,treats,0.987878339907213,"Genentech, Inc. Patient information booklet: your guide to Pulmozyme ®  (DORNASE ALFA therapy for CYSTIC FIBROSIS (CF.",CYSTIC FIBROSIS,(DORNASE ALFA
3345,(DORNASE ALFA treats CYSTIC FIBROSIS,treats,0.987878339907213,"Genentech, Inc. Patient information booklet: your guide to Pulmozyme ®  (DORNASE ALFA therapy for CYSTIC FIBROSIS (CF.",CYSTIC FIBROSIS,(DORNASE ALFA
3346,DONEPEZIL treats SLEEP APNEA,treats,1.0,[DONEPEZIL] has been found to improve [SLEEP APNEA] in Alzheimer's patients.,SLEEP APNEA,DONEPEZIL
3347,DONEPEZIL treats SLEEP APNEA,treats,1.0,[DONEPEZIL] has been found to improve [SLEEP APNEA] in Alzheimer's patients.,SLEEP APNEA,DONEPEZIL
3348,DONEPEZIL treats SLEEP APNEA,treats,1.0,[DONEPEZIL] has been found to improve [SLEEP APNEA] in Alzheimer's patients.,SLEEP APNEA,DONEPEZIL
3349,DONEPEZIL treats SLEEP APNEA,treats,1.0,[DONEPEZIL] has been found to improve [SLEEP APNEA] in Alzheimer's patients.,SLEEP APNEA,DONEPEZIL
3350,DONEPEZIL treats SLEEP APNEA,treats,1.0,[DONEPEZIL] has been found to improve [SLEEP APNEA] in Alzheimer's patients.,SLEEP APNEA,DONEPEZIL
3351,DONEPEZIL treats SLEEP APNEA,treats,1.0,[DONEPEZIL] has been found to improve [SLEEP APNEA] in Alzheimer's patients.,SLEEP APNEA,DONEPEZIL
3352,DONEPEZIL treats SLEEP APNEA,treats,1.0,[DONEPEZIL] has been found to improve [SLEEP APNEA] in Alzheimer's patients.,SLEEP APNEA,DONEPEZIL
3353,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
3354,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
3355,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
3356,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
3357,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
3358,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
3359,EPINEPHRINE treats ANAPHYLAXIS,treats,1.0,Allergic reactions are treated with antihistamines; ANAPHYLAXIS is treated with EPINEPHRINE with IV fluids and vasopressors if necessary (see  Anaphylaxis,ANAPHYLAXIS,EPINEPHRINE
3360,CLOMIPRAMINE HYDROCHLORIDE treats ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,treats,0.9282791216329142,"DeVeaugh Geiss J, Moroz G, Biederman J et al. CLOMIPRAMINE HYDROCHLORIDE in childhood and ADOLESCENT OBSESSIVE COMPULSIVE DISORDER: a multicenter trial.",ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE HYDROCHLORIDE
3361,CLOMIPRAMINE HYDROCHLORIDE treats ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,treats,0.9282791216329142,"DeVeaugh Geiss J, Moroz G, Biederman J et al. CLOMIPRAMINE HYDROCHLORIDE in childhood and ADOLESCENT OBSESSIVE COMPULSIVE DISORDER: a multicenter trial.",ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE HYDROCHLORIDE
3362,CLOMIPRAMINE HYDROCHLORIDE treats ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,treats,0.9282791216329142,"DeVeaugh Geiss J, Moroz G, Biederman J et al. CLOMIPRAMINE HYDROCHLORIDE in childhood and ADOLESCENT OBSESSIVE COMPULSIVE DISORDER: a multicenter trial.",ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE HYDROCHLORIDE
3363,no_relation,treats,0.9282791216329142,"DeVeaugh Geiss J, Moroz G, Biederman J et al. CLOMIPRAMINE HYDROCHLORIDE in childhood and ADOLESCENT OBSESSIVE COMPULSIVE DISORDER: a multicenter trial.",ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE HYDROCHLORIDE
3364,no_relation,treats,0.9282791216329142,"DeVeaugh Geiss J, Moroz G, Biederman J et al. CLOMIPRAMINE HYDROCHLORIDE in childhood and ADOLESCENT OBSESSIVE COMPULSIVE DISORDER: a multicenter trial.",ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE HYDROCHLORIDE
3365,CLOMIPRAMINE HYDROCHLORIDE treats ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,treats,0.9282791216329142,"DeVeaugh Geiss J, Moroz G, Biederman J et al. CLOMIPRAMINE HYDROCHLORIDE in childhood and ADOLESCENT OBSESSIVE COMPULSIVE DISORDER: a multicenter trial.",ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE HYDROCHLORIDE
3366,CLOMIPRAMINE HYDROCHLORIDE treats ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,treats,0.9282791216329142,"DeVeaugh Geiss J, Moroz G, Biederman J et al. CLOMIPRAMINE HYDROCHLORIDE in childhood and ADOLESCENT OBSESSIVE COMPULSIVE DISORDER: a multicenter trial.",ADOLESCENT OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE HYDROCHLORIDE
3367,[CONCOMITANT METHOTREXATE:] treats [RHEUMATOID ARTHRITIS],treats,0.975900072948533,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE:] a randomised phase III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE:]
3368,[CONCOMITANT METHOTREXATE:] treats [RHEUMATOID ARTHRITIS],treats,0.975900072948533,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE:] a randomised phase III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE:]
3369,[CONCOMITANT METHOTREXATE:] treats [RHEUMATOID ARTHRITIS],treats,0.975900072948533,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE:] a randomised phase III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE:]
3370,[CONCOMITANT METHOTREXATE:] treats [RHEUMATOID ARTHRITIS],treats,0.975900072948533,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE:] a randomised phase III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE:]
3371,[CONCOMITANT METHOTREXATE:] treats [RHEUMATOID ARTHRITIS],treats,0.975900072948533,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE:] a randomised phase III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE:]
3372,[CONCOMITANT METHOTREXATE:] treats [RHEUMATOID ARTHRITIS],treats,0.975900072948533,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE:] a randomised phase III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE:]
3373,[CONCOMITANT METHOTREXATE:] treats [RHEUMATOID ARTHRITIS],treats,0.975900072948533,title = Infliximab versus placebo in [RHEUMATOID ARTHRITIS] patients receiving [CONCOMITANT METHOTREXATE:] a randomised phase III trial.,[RHEUMATOID ARTHRITIS],[CONCOMITANT METHOTREXATE:]
3374,no_relation,treats,0.997458699830735,• HEPATITIS A VACCINE or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV INFECTION.,HAV INFECTION,HEPATITIS A VACCINE
3375,HEPATITIS A VACCINE treats HAV INFECTION,treats,0.997458699830735,• HEPATITIS A VACCINE or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV INFECTION.,HAV INFECTION,HEPATITIS A VACCINE
3376,HEPATITIS A VACCINE treats HAV INFECTION,treats,0.997458699830735,• HEPATITIS A VACCINE or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV INFECTION.,HAV INFECTION,HEPATITIS A VACCINE
3377,no_relation,treats,0.997458699830735,• HEPATITIS A VACCINE or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV INFECTION.,HAV INFECTION,HEPATITIS A VACCINE
3378,no_relation,treats,0.997458699830735,• HEPATITIS A VACCINE or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV INFECTION.,HAV INFECTION,HEPATITIS A VACCINE
3379,no_relation,treats,0.997458699830735,• HEPATITIS A VACCINE or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV INFECTION.,HAV INFECTION,HEPATITIS A VACCINE
3380,HAV INFECTION treats HEPATITIS A VACCINE,treats,0.997458699830735,• HEPATITIS A VACCINE or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV INFECTION.,HAV INFECTION,HEPATITIS A VACCINE
3381,AMANTADINE treats PARKINSON'S DISEASE,treats,0.929981109950554,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
3382,AMANTADINE treats PARKINSON'S DISEASE,treats,0.929981109950554,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
3383,AMANTADINE treats PARKINSON'S DISEASE,treats,0.929981109950554,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
3384,no_relation,treats,0.929981109950554,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
3385,AMANTADINE treats PARKINSON'S DISEASE,treats,0.929981109950554,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
3386,no_relation,treats,0.929981109950554,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
3387,AMANTADINE treats PARKINSON'S DISEASE,treats,0.929981109950554,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE
3388,no_relation,treats,0.3849001795000001,"With [CARBON DIOXIDE], it reacts to give [BENZOIC ACID] after an acidic workup.",CARBON DIOXIDE,BENZOIC ACID
3389,CARBON DIOXIDE treats BENZOIC ACID,treats,0.3849001795000001,"With [CARBON DIOXIDE], it reacts to give [BENZOIC ACID] after an acidic workup.",CARBON DIOXIDE,BENZOIC ACID
3390,no_relation,treats,0.3849001795000001,"With [CARBON DIOXIDE], it reacts to give [BENZOIC ACID] after an acidic workup.",CARBON DIOXIDE,BENZOIC ACID
3391,BENZOIC ACID treats CARBON DIOXIDE,treats,0.3849001795000001,"With [CARBON DIOXIDE], it reacts to give [BENZOIC ACID] after an acidic workup.",CARBON DIOXIDE,BENZOIC ACID
3392,no_relation,treats,0.3849001795000001,"With [CARBON DIOXIDE], it reacts to give [BENZOIC ACID] after an acidic workup.",CARBON DIOXIDE,BENZOIC ACID
3393,CARBON DIOXIDE treats BENZOIC ACID,treats,0.3849001795000001,"With [CARBON DIOXIDE], it reacts to give [BENZOIC ACID] after an acidic workup.",CARBON DIOXIDE,BENZOIC ACID
3394,no_relation,treats,0.3849001795000001,"With [CARBON DIOXIDE], it reacts to give [BENZOIC ACID] after an acidic workup.",CARBON DIOXIDE,BENZOIC ACID
3395,BENZATHINE PENICILLIN G treats RHEUMATIC FEVER,treats,0.929981109950554,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
3396,BENZATHINE PENICILLIN G treats RHEUMATIC FEVER,treats,0.929981109950554,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
3397,BENZATHINE PENICILLIN G treats RHEUMATIC FEVER,treats,0.929981109950554,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
3398,BENZATHINE PENICILLIN G treats RHEUMATIC FEVER,treats,0.929981109950554,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
3399,BENZATHINE PENICILLIN G treats RHEUMATIC FEVER,treats,0.929981109950554,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
3400,BENZATHINE PENICILLIN G treats RHEUMATIC FEVER,treats,0.929981109950554,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
3401,BENZATHINE PENICILLIN G treats RHEUMATIC FEVER,treats,0.929981109950554,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
3402,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3403,BLEPHAROSPASM treats TYPE A BOTULINUM TOXIN,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3404,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3405,no_relation,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3406,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3407,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3408,TYPE A BOTULINUM TOXIN treats BLEPHAROSPASM,treats,0.9950371902099888,Treatment with TYPE A BOTULINUM TOXIN appears to be a safe and effective means of temporarily relieving BLEPHAROSPASM,BLEPHAROSPASM,TYPE A BOTULINUM TOXIN
3409,no_relation,treats,0.474341649025257,Recent clinical studies in patients with [PRE EXISTING CARDIAC DISEASE] indicate that [TRAZODONE] may be arrhythmogenic in some patients in that population.,[PRE EXISTING CARDIAC DISEASE],[TRAZODONE]
3410,no_relation,treats,0.474341649025257,Recent clinical studies in patients with [PRE EXISTING CARDIAC DISEASE] indicate that [TRAZODONE] may be arrhythmogenic in some patients in that population.,[PRE EXISTING CARDIAC DISEASE],[TRAZODONE]
3411,[TRAZODONE] treats [PRE EXISTING CARDIAC DISEASE],treats,0.474341649025257,Recent clinical studies in patients with [PRE EXISTING CARDIAC DISEASE] indicate that [TRAZODONE] may be arrhythmogenic in some patients in that population.,[PRE EXISTING CARDIAC DISEASE],[TRAZODONE]
3412,no_relation,treats,0.474341649025257,Recent clinical studies in patients with [PRE EXISTING CARDIAC DISEASE] indicate that [TRAZODONE] may be arrhythmogenic in some patients in that population.,[PRE EXISTING CARDIAC DISEASE],[TRAZODONE]
3413,no_relation,treats,0.474341649025257,Recent clinical studies in patients with [PRE EXISTING CARDIAC DISEASE] indicate that [TRAZODONE] may be arrhythmogenic in some patients in that population.,[PRE EXISTING CARDIAC DISEASE],[TRAZODONE]
3414,no_relation,treats,0.474341649025257,Recent clinical studies in patients with [PRE EXISTING CARDIAC DISEASE] indicate that [TRAZODONE] may be arrhythmogenic in some patients in that population.,[PRE EXISTING CARDIAC DISEASE],[TRAZODONE]
3415,no_relation,treats,0.474341649025257,Recent clinical studies in patients with [PRE EXISTING CARDIAC DISEASE] indicate that [TRAZODONE] may be arrhythmogenic in some patients in that population.,[PRE EXISTING CARDIAC DISEASE],[TRAZODONE]
3416,BOTOX treats DYSTONIA,treats,0.6859943406,"[BOTOX], however, merely targets the symptoms of the disorder and is not a cure for [DYSTONIA].",DYSTONIA,BOTOX
3417,DYSTONIA treats BOTOX,treats,0.6859943406,"[BOTOX], however, merely targets the symptoms of the disorder and is not a cure for [DYSTONIA].",DYSTONIA,BOTOX
3418,no_relation,treats,0.6859943406,"[BOTOX], however, merely targets the symptoms of the disorder and is not a cure for [DYSTONIA].",DYSTONIA,BOTOX
3419,no_relation,treats,0.6859943406,"[BOTOX], however, merely targets the symptoms of the disorder and is not a cure for [DYSTONIA].",DYSTONIA,BOTOX
3420,BOTOX treats DYSTONIA,treats,0.6859943406,"[BOTOX], however, merely targets the symptoms of the disorder and is not a cure for [DYSTONIA].",DYSTONIA,BOTOX
3421,BOTOX treats DYSTONIA,treats,0.6859943406,"[BOTOX], however, merely targets the symptoms of the disorder and is not a cure for [DYSTONIA].",DYSTONIA,BOTOX
3422,no_relation,treats,0.6859943406,"[BOTOX], however, merely targets the symptoms of the disorder and is not a cure for [DYSTONIA].",DYSTONIA,BOTOX
3423,DICLOFENAC treats RHEUMATOID ARTHRITIS,treats,0.990147543,It is marketed by Pharmacia and its indication is for prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring [DICLOFENAC] for [RHEUMATOID ARTHRITIS] or osteoarthritis.,RHEUMATOID ARTHRITIS,DICLOFENAC
3424,DICLOFENAC treats RHEUMATOID ARTHRITIS,treats,0.990147543,It is marketed by Pharmacia and its indication is for prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring [DICLOFENAC] for [RHEUMATOID ARTHRITIS] or osteoarthritis.,RHEUMATOID ARTHRITIS,DICLOFENAC
3425,no_relation,treats,0.990147543,It is marketed by Pharmacia and its indication is for prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring [DICLOFENAC] for [RHEUMATOID ARTHRITIS] or osteoarthritis.,RHEUMATOID ARTHRITIS,DICLOFENAC
3426,DICLOFENAC treats RHEUMATOID ARTHRITIS,treats,0.990147543,It is marketed by Pharmacia and its indication is for prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring [DICLOFENAC] for [RHEUMATOID ARTHRITIS] or osteoarthritis.,RHEUMATOID ARTHRITIS,DICLOFENAC
3427,no_relation,treats,0.990147543,It is marketed by Pharmacia and its indication is for prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring [DICLOFENAC] for [RHEUMATOID ARTHRITIS] or osteoarthritis.,RHEUMATOID ARTHRITIS,DICLOFENAC
3428,DICLOFENAC treats RHEUMATOID ARTHRITIS,treats,0.990147543,It is marketed by Pharmacia and its indication is for prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring [DICLOFENAC] for [RHEUMATOID ARTHRITIS] or osteoarthritis.,RHEUMATOID ARTHRITIS,DICLOFENAC
3429,DICLOFENAC treats RHEUMATOID ARTHRITIS,treats,0.990147543,It is marketed by Pharmacia and its indication is for prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring [DICLOFENAC] for [RHEUMATOID ARTHRITIS] or osteoarthritis.,RHEUMATOID ARTHRITIS,DICLOFENAC
3430,[RIBOFLAVIN] treats [HEADACHE],treats,0.994134846772434,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of migraine days and hours by 44%, although with no reduction in intensity of the [HEADACHE]",[HEADACHE],[RIBOFLAVIN]
3431,[RIBOFLAVIN] treats [HEADACHE],treats,0.994134846772434,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of migraine days and hours by 44%, although with no reduction in intensity of the [HEADACHE]",[HEADACHE],[RIBOFLAVIN]
3432,no_relation,treats,0.994134846772434,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of migraine days and hours by 44%, although with no reduction in intensity of the [HEADACHE]",[HEADACHE],[RIBOFLAVIN]
3433,no_relation,treats,0.994134846772434,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of migraine days and hours by 44%, although with no reduction in intensity of the [HEADACHE]",[HEADACHE],[RIBOFLAVIN]
3434,no_relation,treats,0.994134846772434,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of migraine days and hours by 44%, although with no reduction in intensity of the [HEADACHE]",[HEADACHE],[RIBOFLAVIN]
3435,[RIBOFLAVIN] treats [HEADACHE],treats,0.994134846772434,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of migraine days and hours by 44%, although with no reduction in intensity of the [HEADACHE]",[HEADACHE],[RIBOFLAVIN]
3436,[RIBOFLAVIN] treats [HEADACHE],treats,0.994134846772434,"[RIBOFLAVIN] has been rigorously studied and has demonstrated a reduction of migraine days and hours by 44%, although with no reduction in intensity of the [HEADACHE]",[HEADACHE],[RIBOFLAVIN]
3437,HYDROXYCHLOROQUINE treats DIABETES,treats,0.979957887012223,"In patients on [HYDROXYCHLOROQUINE] for rheumatoid arthritis, incidence of [DIABETES] was reduced by 77% though causal mechanisms are unclear.",DIABETES,HYDROXYCHLOROQUINE
3438,no_relation,treats,0.979957887012223,"In patients on [HYDROXYCHLOROQUINE] for rheumatoid arthritis, incidence of [DIABETES] was reduced by 77% though causal mechanisms are unclear.",DIABETES,HYDROXYCHLOROQUINE
3439,no_relation,treats,0.979957887012223,"In patients on [HYDROXYCHLOROQUINE] for rheumatoid arthritis, incidence of [DIABETES] was reduced by 77% though causal mechanisms are unclear.",DIABETES,HYDROXYCHLOROQUINE
3440,no_relation,treats,0.979957887012223,"In patients on [HYDROXYCHLOROQUINE] for rheumatoid arthritis, incidence of [DIABETES] was reduced by 77% though causal mechanisms are unclear.",DIABETES,HYDROXYCHLOROQUINE
3441,no_relation,treats,0.979957887012223,"In patients on [HYDROXYCHLOROQUINE] for rheumatoid arthritis, incidence of [DIABETES] was reduced by 77% though causal mechanisms are unclear.",DIABETES,HYDROXYCHLOROQUINE
3442,HYDROXYCHLOROQUINE treats DIABETES,treats,0.979957887012223,"In patients on [HYDROXYCHLOROQUINE] for rheumatoid arthritis, incidence of [DIABETES] was reduced by 77% though causal mechanisms are unclear.",DIABETES,HYDROXYCHLOROQUINE
3443,HYDROXYCHLOROQUINE treats DIABETES,treats,0.979957887012223,"In patients on [HYDROXYCHLOROQUINE] for rheumatoid arthritis, incidence of [DIABETES] was reduced by 77% though causal mechanisms are unclear.",DIABETES,HYDROXYCHLOROQUINE
3444,VALACICLOVIR treats HERPES ZOSTER,treats,1.0,VALACICLOVIR compared with acyclovir for improved therapy for HERPES ZOSTER in immunocompetent adults.,HERPES ZOSTER,VALACICLOVIR
3445,VALACICLOVIR treats HERPES ZOSTER,treats,1.0,VALACICLOVIR compared with acyclovir for improved therapy for HERPES ZOSTER in immunocompetent adults.,HERPES ZOSTER,VALACICLOVIR
3446,VALACICLOVIR treats HERPES ZOSTER,treats,1.0,VALACICLOVIR compared with acyclovir for improved therapy for HERPES ZOSTER in immunocompetent adults.,HERPES ZOSTER,VALACICLOVIR
3447,VALACICLOVIR treats HERPES ZOSTER,treats,1.0,VALACICLOVIR compared with acyclovir for improved therapy for HERPES ZOSTER in immunocompetent adults.,HERPES ZOSTER,VALACICLOVIR
3448,VALACICLOVIR treats HERPES ZOSTER,treats,1.0,VALACICLOVIR compared with acyclovir for improved therapy for HERPES ZOSTER in immunocompetent adults.,HERPES ZOSTER,VALACICLOVIR
3449,VALACICLOVIR treats HERPES ZOSTER,treats,1.0,VALACICLOVIR compared with acyclovir for improved therapy for HERPES ZOSTER in immunocompetent adults.,HERPES ZOSTER,VALACICLOVIR
3450,HERPES ZOSTER treats VALACICLOVIR,treats,1.0,VALACICLOVIR compared with acyclovir for improved therapy for HERPES ZOSTER in immunocompetent adults.,HERPES ZOSTER,VALACICLOVIR
3451,no_relation,treats,0.9830783046228492,"Low dose aspirin reduced combined 3 month risk for stroke, MI and death after carotid endarterectomy  Keywords: Myocardial infarction ASPIRIN Cerebrovascular disorders Endarterectomy, carotid  ACP Journal Club.",MI,ASPIRIN
3452,ASPIRIN treats MI,treats,0.9830783046228492,"Low dose aspirin reduced combined 3 month risk for stroke, MI and death after carotid endarterectomy  Keywords: Myocardial infarction ASPIRIN Cerebrovascular disorders Endarterectomy, carotid  ACP Journal Club.",MI,ASPIRIN
3453,no_relation,treats,0.9830783046228492,"Low dose aspirin reduced combined 3 month risk for stroke, MI and death after carotid endarterectomy  Keywords: Myocardial infarction ASPIRIN Cerebrovascular disorders Endarterectomy, carotid  ACP Journal Club.",MI,ASPIRIN
3454,ASPIRIN treats MI,treats,0.9830783046228492,"Low dose aspirin reduced combined 3 month risk for stroke, MI and death after carotid endarterectomy  Keywords: Myocardial infarction ASPIRIN Cerebrovascular disorders Endarterectomy, carotid  ACP Journal Club.",MI,ASPIRIN
3455,ASPIRIN treats MI,treats,0.9830783046228492,"Low dose aspirin reduced combined 3 month risk for stroke, MI and death after carotid endarterectomy  Keywords: Myocardial infarction ASPIRIN Cerebrovascular disorders Endarterectomy, carotid  ACP Journal Club.",MI,ASPIRIN
3456,no_relation,treats,0.9830783046228492,"Low dose aspirin reduced combined 3 month risk for stroke, MI and death after carotid endarterectomy  Keywords: Myocardial infarction ASPIRIN Cerebrovascular disorders Endarterectomy, carotid  ACP Journal Club.",MI,ASPIRIN
3457,ASPIRIN treats MI,treats,0.9830783046228492,"Low dose aspirin reduced combined 3 month risk for stroke, MI and death after carotid endarterectomy  Keywords: Myocardial infarction ASPIRIN Cerebrovascular disorders Endarterectomy, carotid  ACP Journal Club.",MI,ASPIRIN
3458,no_relation,treats,1.0,"[ATROPINE] may be used to prevent a [REFLEX BRADYCARDIA] from vagal stimulation during laryngoscopy, especially in young children and infants.",REFLEX BRADYCARDIA,ATROPINE
3459,ATROPINE treats REFLEX BRADYCARDIA,treats,1.0,"[ATROPINE] may be used to prevent a [REFLEX BRADYCARDIA] from vagal stimulation during laryngoscopy, especially in young children and infants.",REFLEX BRADYCARDIA,ATROPINE
3460,ATROPINE treats REFLEX BRADYCARDIA,treats,1.0,"[ATROPINE] may be used to prevent a [REFLEX BRADYCARDIA] from vagal stimulation during laryngoscopy, especially in young children and infants.",REFLEX BRADYCARDIA,ATROPINE
3461,ATROPINE treats REFLEX BRADYCARDIA,treats,1.0,"[ATROPINE] may be used to prevent a [REFLEX BRADYCARDIA] from vagal stimulation during laryngoscopy, especially in young children and infants.",REFLEX BRADYCARDIA,ATROPINE
3462,ATROPINE treats REFLEX BRADYCARDIA,treats,1.0,"[ATROPINE] may be used to prevent a [REFLEX BRADYCARDIA] from vagal stimulation during laryngoscopy, especially in young children and infants.",REFLEX BRADYCARDIA,ATROPINE
3463,REFLEX BRADYCARDIA treats ATROPINE,treats,1.0,"[ATROPINE] may be used to prevent a [REFLEX BRADYCARDIA] from vagal stimulation during laryngoscopy, especially in young children and infants.",REFLEX BRADYCARDIA,ATROPINE
3464,ATROPINE treats REFLEX BRADYCARDIA,treats,1.0,"[ATROPINE] may be used to prevent a [REFLEX BRADYCARDIA] from vagal stimulation during laryngoscopy, especially in young children and infants.",REFLEX BRADYCARDIA,ATROPINE
3465,LOSARTAN treats ISOLATED SYSTOLIC HYPERTENSION,treats,0.8427009716003839,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
3466,no_relation,treats,0.8427009716003839,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
3467,LOSARTAN treats ISOLATED SYSTOLIC HYPERTENSION,treats,0.8427009716003839,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
3468,LOSARTAN treats ISOLATED SYSTOLIC HYPERTENSION,treats,0.8427009716003839,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
3469,LOSARTAN treats ISOLATED SYSTOLIC HYPERTENSION,treats,0.8427009716003839,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
3470,LOSARTAN treats ISOLATED SYSTOLIC HYPERTENSION,treats,0.8427009716003839,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
3471,LOSARTAN treats ISOLATED SYSTOLIC HYPERTENSION,treats,0.8427009716003839,Losartan was more effective than atenolol for ISOLATED SYSTOLIC HYPERTENSION and left ventricular hypertrophy  Keywords: Antihypertensive agents Atenolol Hydrochlorothiazide Hypertension LOSARTAN  ACP Journal Club.,ISOLATED SYSTOLIC HYPERTENSION,LOSARTAN
3472,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomised trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3473,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomised trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3474,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomised trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3475,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomised trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3476,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomised trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3477,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomised trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3478,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomised trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3479,TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV treats POLIOMYELITIS,treats,0.9950371902099888,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
3480,TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV treats POLIOMYELITIS,treats,0.9950371902099888,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
3481,POLIOMYELITIS treats TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,treats,0.9950371902099888,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
3482,TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV treats POLIOMYELITIS,treats,0.9950371902099888,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
3483,TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV treats POLIOMYELITIS,treats,0.9950371902099888,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
3484,no_relation,treats,0.9950371902099888,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
3485,POLIOMYELITIS treats TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,treats,0.9950371902099888,"It is indicated for all children    POLIOMYELITIS:  A primary series of TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV consisting of a mixture of formalin inactivated poliovirus types 1, 2, and 3, should be given during childhood and produces immunity in &gt; 99% of recipients.",TRIVALENT INACTIVATED POLIOVIRUS VACCINE (IPV,POLIOMYELITIS
3486,CEFTAZIDIME treats FEBRILE NEUTROPENIA,treats,0.9878291611472622,"Ariffin H, Arasu A, Mahfuzah M et al. Single daily ceftriaxone plus amikacin versus thrice daily CEFTAZIDIME plus amikacin as empirical treatment of FEBRILE NEUTROPENIA in children with cancer.",FEBRILE NEUTROPENIA,CEFTAZIDIME
3487,CEFTAZIDIME treats FEBRILE NEUTROPENIA,treats,0.9878291611472622,"Ariffin H, Arasu A, Mahfuzah M et al. Single daily ceftriaxone plus amikacin versus thrice daily CEFTAZIDIME plus amikacin as empirical treatment of FEBRILE NEUTROPENIA in children with cancer.",FEBRILE NEUTROPENIA,CEFTAZIDIME
3488,CEFTAZIDIME treats FEBRILE NEUTROPENIA,treats,0.9878291611472622,"Ariffin H, Arasu A, Mahfuzah M et al. Single daily ceftriaxone plus amikacin versus thrice daily CEFTAZIDIME plus amikacin as empirical treatment of FEBRILE NEUTROPENIA in children with cancer.",FEBRILE NEUTROPENIA,CEFTAZIDIME
3489,no_relation,treats,0.9878291611472622,"Ariffin H, Arasu A, Mahfuzah M et al. Single daily ceftriaxone plus amikacin versus thrice daily CEFTAZIDIME plus amikacin as empirical treatment of FEBRILE NEUTROPENIA in children with cancer.",FEBRILE NEUTROPENIA,CEFTAZIDIME
3490,CEFTAZIDIME treats FEBRILE NEUTROPENIA,treats,0.9878291611472622,"Ariffin H, Arasu A, Mahfuzah M et al. Single daily ceftriaxone plus amikacin versus thrice daily CEFTAZIDIME plus amikacin as empirical treatment of FEBRILE NEUTROPENIA in children with cancer.",FEBRILE NEUTROPENIA,CEFTAZIDIME
3491,CEFTAZIDIME treats FEBRILE NEUTROPENIA,treats,0.9878291611472622,"Ariffin H, Arasu A, Mahfuzah M et al. Single daily ceftriaxone plus amikacin versus thrice daily CEFTAZIDIME plus amikacin as empirical treatment of FEBRILE NEUTROPENIA in children with cancer.",FEBRILE NEUTROPENIA,CEFTAZIDIME
3492,CEFTAZIDIME treats FEBRILE NEUTROPENIA,treats,0.9878291611472622,"Ariffin H, Arasu A, Mahfuzah M et al. Single daily ceftriaxone plus amikacin versus thrice daily CEFTAZIDIME plus amikacin as empirical treatment of FEBRILE NEUTROPENIA in children with cancer.",FEBRILE NEUTROPENIA,CEFTAZIDIME
3493,AMPHOTERICIN B treats NEUTROPENIA,treats,0.99654575824488,"CONCLUSION  In patients with cancer, itraconazole was as effective as AMPHOTERICIN B for eliminating fever and NEUTROPENIA and led to fewer adverse events.",NEUTROPENIA,AMPHOTERICIN B
3494,AMPHOTERICIN B treats NEUTROPENIA,treats,0.99654575824488,"CONCLUSION  In patients with cancer, itraconazole was as effective as AMPHOTERICIN B for eliminating fever and NEUTROPENIA and led to fewer adverse events.",NEUTROPENIA,AMPHOTERICIN B
3495,AMPHOTERICIN B treats NEUTROPENIA,treats,0.99654575824488,"CONCLUSION  In patients with cancer, itraconazole was as effective as AMPHOTERICIN B for eliminating fever and NEUTROPENIA and led to fewer adverse events.",NEUTROPENIA,AMPHOTERICIN B
3496,no_relation,treats,0.99654575824488,"CONCLUSION  In patients with cancer, itraconazole was as effective as AMPHOTERICIN B for eliminating fever and NEUTROPENIA and led to fewer adverse events.",NEUTROPENIA,AMPHOTERICIN B
3497,AMPHOTERICIN B treats NEUTROPENIA,treats,0.99654575824488,"CONCLUSION  In patients with cancer, itraconazole was as effective as AMPHOTERICIN B for eliminating fever and NEUTROPENIA and led to fewer adverse events.",NEUTROPENIA,AMPHOTERICIN B
3498,NEUTROPENIA treats AMPHOTERICIN B,treats,0.99654575824488,"CONCLUSION  In patients with cancer, itraconazole was as effective as AMPHOTERICIN B for eliminating fever and NEUTROPENIA and led to fewer adverse events.",NEUTROPENIA,AMPHOTERICIN B
3499,NEUTROPENIA treats AMPHOTERICIN B,treats,0.99654575824488,"CONCLUSION  In patients with cancer, itraconazole was as effective as AMPHOTERICIN B for eliminating fever and NEUTROPENIA and led to fewer adverse events.",NEUTROPENIA,AMPHOTERICIN B
3500,no_relation,treats,0.4472135954999579,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
3501,HEMOTHERAPY INDUCED NEUTROPENIA treats EUTROPENIA I,treats,0.4472135954999579,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
3502,no_relation,treats,0.4472135954999579,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
3503,no_relation,treats,0.4472135954999579,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
3504,no_relation,treats,0.4472135954999579,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
3505,HEMOTHERAPY INDUCED NEUTROPENIA treats EUTROPENIA I,treats,0.4472135954999579,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
3506,no_relation,treats,0.4472135954999579,1   Reduces duration and severity of nEUTROPENIA In patients with cHEMOTHERAPY INDUCED NEUTROPENIA..,EUTROPENIA I,HEMOTHERAPY INDUCED NEUTROPENIA
3507,EPOETIN ALFA treats ANEMIA,treats,0.938314863256837,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
3508,EPOETIN ALFA treats ANEMIA,treats,0.938314863256837,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
3509,EPOETIN ALFA treats ANEMIA,treats,0.938314863256837,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
3510,no_relation,treats,0.938314863256837,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
3511,no_relation,treats,0.938314863256837,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
3512,EPOETIN ALFA treats ANEMIA,treats,0.938314863256837,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
3513,no_relation,treats,0.938314863256837,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA
3514,ANTICONVULSANT treats EPILEPSY,treats,0.9901475429766742,Some [ANTICONVULSANT]s have shown antiepileptogenic effects in animal models of [EPILEPSY].,EPILEPSY,ANTICONVULSANT
3515,no_relation,treats,0.9901475429766742,Some [ANTICONVULSANT]s have shown antiepileptogenic effects in animal models of [EPILEPSY].,EPILEPSY,ANTICONVULSANT
3516,ANTICONVULSANT treats EPILEPSY,treats,0.9901475429766742,Some [ANTICONVULSANT]s have shown antiepileptogenic effects in animal models of [EPILEPSY].,EPILEPSY,ANTICONVULSANT
3517,ANTICONVULSANT treats EPILEPSY,treats,0.9901475429766742,Some [ANTICONVULSANT]s have shown antiepileptogenic effects in animal models of [EPILEPSY].,EPILEPSY,ANTICONVULSANT
3518,ANTICONVULSANT treats EPILEPSY,treats,0.9901475429766742,Some [ANTICONVULSANT]s have shown antiepileptogenic effects in animal models of [EPILEPSY].,EPILEPSY,ANTICONVULSANT
3519,ANTICONVULSANT treats EPILEPSY,treats,0.9901475429766742,Some [ANTICONVULSANT]s have shown antiepileptogenic effects in animal models of [EPILEPSY].,EPILEPSY,ANTICONVULSANT
3520,no_relation,treats,0.9901475429766742,Some [ANTICONVULSANT]s have shown antiepileptogenic effects in animal models of [EPILEPSY].,EPILEPSY,ANTICONVULSANT
3521,PERMETHRIN 5% CREAM treats NEONATAL SCABIES,treats,1.0,NEONATAL SCABIES treated with PERMETHRIN 5% CREAM.,NEONATAL SCABIES,PERMETHRIN 5% CREAM
3522,PERMETHRIN 5% CREAM treats NEONATAL SCABIES,treats,1.0,NEONATAL SCABIES treated with PERMETHRIN 5% CREAM.,NEONATAL SCABIES,PERMETHRIN 5% CREAM
3523,PERMETHRIN 5% CREAM treats NEONATAL SCABIES,treats,1.0,NEONATAL SCABIES treated with PERMETHRIN 5% CREAM.,NEONATAL SCABIES,PERMETHRIN 5% CREAM
3524,PERMETHRIN 5% CREAM treats NEONATAL SCABIES,treats,1.0,NEONATAL SCABIES treated with PERMETHRIN 5% CREAM.,NEONATAL SCABIES,PERMETHRIN 5% CREAM
3525,PERMETHRIN 5% CREAM treats NEONATAL SCABIES,treats,1.0,NEONATAL SCABIES treated with PERMETHRIN 5% CREAM.,NEONATAL SCABIES,PERMETHRIN 5% CREAM
3526,PERMETHRIN 5% CREAM treats NEONATAL SCABIES,treats,1.0,NEONATAL SCABIES treated with PERMETHRIN 5% CREAM.,NEONATAL SCABIES,PERMETHRIN 5% CREAM
3527,PERMETHRIN 5% CREAM treats NEONATAL SCABIES,treats,1.0,NEONATAL SCABIES treated with PERMETHRIN 5% CREAM.,NEONATAL SCABIES,PERMETHRIN 5% CREAM
3528,AMPHOTERICIN B treats OSTEOARTICULAR SPOROTRICHOSIS,treats,0.99654575824488,"429  AMPHOTERICIN B (a lipid formulation) in patients with OSTEOARTICULAR SPOROTRICHOSIS: 3 5 mg/kg daily or until a response is obtained, followed by oral itraconazole for a total treatment duration of at least 12 months.",OSTEOARTICULAR SPOROTRICHOSIS,AMPHOTERICIN B
3529,AMPHOTERICIN B treats OSTEOARTICULAR SPOROTRICHOSIS,treats,0.99654575824488,"429  AMPHOTERICIN B (a lipid formulation) in patients with OSTEOARTICULAR SPOROTRICHOSIS: 3 5 mg/kg daily or until a response is obtained, followed by oral itraconazole for a total treatment duration of at least 12 months.",OSTEOARTICULAR SPOROTRICHOSIS,AMPHOTERICIN B
3530,AMPHOTERICIN B treats OSTEOARTICULAR SPOROTRICHOSIS,treats,0.99654575824488,"429  AMPHOTERICIN B (a lipid formulation) in patients with OSTEOARTICULAR SPOROTRICHOSIS: 3 5 mg/kg daily or until a response is obtained, followed by oral itraconazole for a total treatment duration of at least 12 months.",OSTEOARTICULAR SPOROTRICHOSIS,AMPHOTERICIN B
3531,AMPHOTERICIN B treats OSTEOARTICULAR SPOROTRICHOSIS,treats,0.99654575824488,"429  AMPHOTERICIN B (a lipid formulation) in patients with OSTEOARTICULAR SPOROTRICHOSIS: 3 5 mg/kg daily or until a response is obtained, followed by oral itraconazole for a total treatment duration of at least 12 months.",OSTEOARTICULAR SPOROTRICHOSIS,AMPHOTERICIN B
3532,AMPHOTERICIN B treats OSTEOARTICULAR SPOROTRICHOSIS,treats,0.99654575824488,"429  AMPHOTERICIN B (a lipid formulation) in patients with OSTEOARTICULAR SPOROTRICHOSIS: 3 5 mg/kg daily or until a response is obtained, followed by oral itraconazole for a total treatment duration of at least 12 months.",OSTEOARTICULAR SPOROTRICHOSIS,AMPHOTERICIN B
3533,AMPHOTERICIN B treats OSTEOARTICULAR SPOROTRICHOSIS,treats,0.99654575824488,"429  AMPHOTERICIN B (a lipid formulation) in patients with OSTEOARTICULAR SPOROTRICHOSIS: 3 5 mg/kg daily or until a response is obtained, followed by oral itraconazole for a total treatment duration of at least 12 months.",OSTEOARTICULAR SPOROTRICHOSIS,AMPHOTERICIN B
3534,AMPHOTERICIN B treats OSTEOARTICULAR SPOROTRICHOSIS,treats,0.99654575824488,"429  AMPHOTERICIN B (a lipid formulation) in patients with OSTEOARTICULAR SPOROTRICHOSIS: 3 5 mg/kg daily or until a response is obtained, followed by oral itraconazole for a total treatment duration of at least 12 months.",OSTEOARTICULAR SPOROTRICHOSIS,AMPHOTERICIN B
3535,DULOXETINE treats STRESS URINARY INCONTINENCE,treats,0.993883734673619,"According to Lenzer, four completed suicides also occurred in the trials of [DULOXETINE] for [STRESS URINARY INCONTINENCE] .",STRESS URINARY INCONTINENCE,DULOXETINE
3536,DULOXETINE treats STRESS URINARY INCONTINENCE,treats,0.993883734673619,"According to Lenzer, four completed suicides also occurred in the trials of [DULOXETINE] for [STRESS URINARY INCONTINENCE] .",STRESS URINARY INCONTINENCE,DULOXETINE
3537,DULOXETINE treats STRESS URINARY INCONTINENCE,treats,0.993883734673619,"According to Lenzer, four completed suicides also occurred in the trials of [DULOXETINE] for [STRESS URINARY INCONTINENCE] .",STRESS URINARY INCONTINENCE,DULOXETINE
3538,DULOXETINE treats STRESS URINARY INCONTINENCE,treats,0.993883734673619,"According to Lenzer, four completed suicides also occurred in the trials of [DULOXETINE] for [STRESS URINARY INCONTINENCE] .",STRESS URINARY INCONTINENCE,DULOXETINE
3539,DULOXETINE treats STRESS URINARY INCONTINENCE,treats,0.993883734673619,"According to Lenzer, four completed suicides also occurred in the trials of [DULOXETINE] for [STRESS URINARY INCONTINENCE] .",STRESS URINARY INCONTINENCE,DULOXETINE
3540,DULOXETINE treats STRESS URINARY INCONTINENCE,treats,0.993883734673619,"According to Lenzer, four completed suicides also occurred in the trials of [DULOXETINE] for [STRESS URINARY INCONTINENCE] .",STRESS URINARY INCONTINENCE,DULOXETINE
3541,DULOXETINE treats STRESS URINARY INCONTINENCE,treats,0.993883734673619,"According to Lenzer, four completed suicides also occurred in the trials of [DULOXETINE] for [STRESS URINARY INCONTINENCE] .",STRESS URINARY INCONTINENCE,DULOXETINE
3542,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM[20],treats,0.9950371902099888,Corticosteroids and colchicine can be used in severe refractory cases.[17][18][19] THALIDOMIDE has been used successfully in the treatment of ERYTHEMA NODOSUM LEPROSUM[20] and it was approved by the U.S. FDA for this use in July 1998.[21.,ERYTHEMA NODOSUM LEPROSUM[20],THALIDOMIDE
3543,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM[20],treats,0.9950371902099888,Corticosteroids and colchicine can be used in severe refractory cases.[17][18][19] THALIDOMIDE has been used successfully in the treatment of ERYTHEMA NODOSUM LEPROSUM[20] and it was approved by the U.S. FDA for this use in July 1998.[21.,ERYTHEMA NODOSUM LEPROSUM[20],THALIDOMIDE
3544,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM[20],treats,0.9950371902099888,Corticosteroids and colchicine can be used in severe refractory cases.[17][18][19] THALIDOMIDE has been used successfully in the treatment of ERYTHEMA NODOSUM LEPROSUM[20] and it was approved by the U.S. FDA for this use in July 1998.[21.,ERYTHEMA NODOSUM LEPROSUM[20],THALIDOMIDE
3545,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM[20],treats,0.9950371902099888,Corticosteroids and colchicine can be used in severe refractory cases.[17][18][19] THALIDOMIDE has been used successfully in the treatment of ERYTHEMA NODOSUM LEPROSUM[20] and it was approved by the U.S. FDA for this use in July 1998.[21.,ERYTHEMA NODOSUM LEPROSUM[20],THALIDOMIDE
3546,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM[20],treats,0.9950371902099888,Corticosteroids and colchicine can be used in severe refractory cases.[17][18][19] THALIDOMIDE has been used successfully in the treatment of ERYTHEMA NODOSUM LEPROSUM[20] and it was approved by the U.S. FDA for this use in July 1998.[21.,ERYTHEMA NODOSUM LEPROSUM[20],THALIDOMIDE
3547,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM[20],treats,0.9950371902099888,Corticosteroids and colchicine can be used in severe refractory cases.[17][18][19] THALIDOMIDE has been used successfully in the treatment of ERYTHEMA NODOSUM LEPROSUM[20] and it was approved by the U.S. FDA for this use in July 1998.[21.,ERYTHEMA NODOSUM LEPROSUM[20],THALIDOMIDE
3548,ERYTHEMA NODOSUM LEPROSUM[20] treats THALIDOMIDE,treats,0.9950371902099888,Corticosteroids and colchicine can be used in severe refractory cases.[17][18][19] THALIDOMIDE has been used successfully in the treatment of ERYTHEMA NODOSUM LEPROSUM[20] and it was approved by the U.S. FDA for this use in July 1998.[21.,ERYTHEMA NODOSUM LEPROSUM[20],THALIDOMIDE
3549,CEFACLOR treats BRONCHITIS,treats,1.0,"Chirurgi VA, Edelstein H, Oster SE et al. Ceftibuten versus CEFACLOR for the treatment of BRONCHITIS",BRONCHITIS,CEFACLOR
3550,CEFACLOR treats BRONCHITIS,treats,1.0,"Chirurgi VA, Edelstein H, Oster SE et al. Ceftibuten versus CEFACLOR for the treatment of BRONCHITIS",BRONCHITIS,CEFACLOR
3551,CEFACLOR treats BRONCHITIS,treats,1.0,"Chirurgi VA, Edelstein H, Oster SE et al. Ceftibuten versus CEFACLOR for the treatment of BRONCHITIS",BRONCHITIS,CEFACLOR
3552,CEFACLOR treats BRONCHITIS,treats,1.0,"Chirurgi VA, Edelstein H, Oster SE et al. Ceftibuten versus CEFACLOR for the treatment of BRONCHITIS",BRONCHITIS,CEFACLOR
3553,CEFACLOR treats BRONCHITIS,treats,1.0,"Chirurgi VA, Edelstein H, Oster SE et al. Ceftibuten versus CEFACLOR for the treatment of BRONCHITIS",BRONCHITIS,CEFACLOR
3554,CEFACLOR treats BRONCHITIS,treats,1.0,"Chirurgi VA, Edelstein H, Oster SE et al. Ceftibuten versus CEFACLOR for the treatment of BRONCHITIS",BRONCHITIS,CEFACLOR
3555,CEFACLOR treats BRONCHITIS,treats,1.0,"Chirurgi VA, Edelstein H, Oster SE et al. Ceftibuten versus CEFACLOR for the treatment of BRONCHITIS",BRONCHITIS,CEFACLOR
3556,AZA treats ULCERATIVE COLITIS,treats,0.961074462327142,"107 , 108  ULCERATIVE COLITIS   Both controlled trials with AZA and uncontrolled series with 6 MP have supported the role of purine analogues for the long term (maintenance) therapy of UC.",ULCERATIVE COLITIS,AZA
3557,AZA treats ULCERATIVE COLITIS,treats,0.961074462327142,"107 , 108  ULCERATIVE COLITIS   Both controlled trials with AZA and uncontrolled series with 6 MP have supported the role of purine analogues for the long term (maintenance) therapy of UC.",ULCERATIVE COLITIS,AZA
3558,AZA treats ULCERATIVE COLITIS,treats,0.961074462327142,"107 , 108  ULCERATIVE COLITIS   Both controlled trials with AZA and uncontrolled series with 6 MP have supported the role of purine analogues for the long term (maintenance) therapy of UC.",ULCERATIVE COLITIS,AZA
3559,AZA treats ULCERATIVE COLITIS,treats,0.961074462327142,"107 , 108  ULCERATIVE COLITIS   Both controlled trials with AZA and uncontrolled series with 6 MP have supported the role of purine analogues for the long term (maintenance) therapy of UC.",ULCERATIVE COLITIS,AZA
3560,AZA treats ULCERATIVE COLITIS,treats,0.961074462327142,"107 , 108  ULCERATIVE COLITIS   Both controlled trials with AZA and uncontrolled series with 6 MP have supported the role of purine analogues for the long term (maintenance) therapy of UC.",ULCERATIVE COLITIS,AZA
3561,AZA treats ULCERATIVE COLITIS,treats,0.961074462327142,"107 , 108  ULCERATIVE COLITIS   Both controlled trials with AZA and uncontrolled series with 6 MP have supported the role of purine analogues for the long term (maintenance) therapy of UC.",ULCERATIVE COLITIS,AZA
3562,AZA treats ULCERATIVE COLITIS,treats,0.961074462327142,"107 , 108  ULCERATIVE COLITIS   Both controlled trials with AZA and uncontrolled series with 6 MP have supported the role of purine analogues for the long term (maintenance) therapy of UC.",ULCERATIVE COLITIS,AZA
3563,CLONAZEPAM treats PANIC DISORDER,treats,1.0,"Kutcher SP, MacKenzie S. Successful CLONAZEPAM treatment of adolescents with PANIC DISORDER",PANIC DISORDER,CLONAZEPAM
3564,CLONAZEPAM treats PANIC DISORDER,treats,1.0,"Kutcher SP, MacKenzie S. Successful CLONAZEPAM treatment of adolescents with PANIC DISORDER",PANIC DISORDER,CLONAZEPAM
3565,CLONAZEPAM treats PANIC DISORDER,treats,1.0,"Kutcher SP, MacKenzie S. Successful CLONAZEPAM treatment of adolescents with PANIC DISORDER",PANIC DISORDER,CLONAZEPAM
3566,CLONAZEPAM treats PANIC DISORDER,treats,1.0,"Kutcher SP, MacKenzie S. Successful CLONAZEPAM treatment of adolescents with PANIC DISORDER",PANIC DISORDER,CLONAZEPAM
3567,CLONAZEPAM treats PANIC DISORDER,treats,1.0,"Kutcher SP, MacKenzie S. Successful CLONAZEPAM treatment of adolescents with PANIC DISORDER",PANIC DISORDER,CLONAZEPAM
3568,CLONAZEPAM treats PANIC DISORDER,treats,1.0,"Kutcher SP, MacKenzie S. Successful CLONAZEPAM treatment of adolescents with PANIC DISORDER",PANIC DISORDER,CLONAZEPAM
3569,CLONAZEPAM treats PANIC DISORDER,treats,1.0,"Kutcher SP, MacKenzie S. Successful CLONAZEPAM treatment of adolescents with PANIC DISORDER",PANIC DISORDER,CLONAZEPAM
3570,[INSULIN GLARGINE] treats [SEVERE NOCTURNAL HYPOGLYCAEMIA],treats,0.993127066322842,[INSULIN GLARGINE] reduces the risk of [SEVERE NOCTURNAL HYPOGLYCAEMIA],[SEVERE NOCTURNAL HYPOGLYCAEMIA],[INSULIN GLARGINE]
3571,[INSULIN GLARGINE] treats [SEVERE NOCTURNAL HYPOGLYCAEMIA],treats,0.993127066322842,[INSULIN GLARGINE] reduces the risk of [SEVERE NOCTURNAL HYPOGLYCAEMIA],[SEVERE NOCTURNAL HYPOGLYCAEMIA],[INSULIN GLARGINE]
3572,no_relation,treats,0.993127066322842,[INSULIN GLARGINE] reduces the risk of [SEVERE NOCTURNAL HYPOGLYCAEMIA],[SEVERE NOCTURNAL HYPOGLYCAEMIA],[INSULIN GLARGINE]
3573,[INSULIN GLARGINE] treats [SEVERE NOCTURNAL HYPOGLYCAEMIA],treats,0.993127066322842,[INSULIN GLARGINE] reduces the risk of [SEVERE NOCTURNAL HYPOGLYCAEMIA],[SEVERE NOCTURNAL HYPOGLYCAEMIA],[INSULIN GLARGINE]
3574,[INSULIN GLARGINE] treats [SEVERE NOCTURNAL HYPOGLYCAEMIA],treats,0.993127066322842,[INSULIN GLARGINE] reduces the risk of [SEVERE NOCTURNAL HYPOGLYCAEMIA],[SEVERE NOCTURNAL HYPOGLYCAEMIA],[INSULIN GLARGINE]
3575,[INSULIN GLARGINE] treats [SEVERE NOCTURNAL HYPOGLYCAEMIA],treats,0.993127066322842,[INSULIN GLARGINE] reduces the risk of [SEVERE NOCTURNAL HYPOGLYCAEMIA],[SEVERE NOCTURNAL HYPOGLYCAEMIA],[INSULIN GLARGINE]
3576,[INSULIN GLARGINE] treats [SEVERE NOCTURNAL HYPOGLYCAEMIA],treats,0.993127066322842,[INSULIN GLARGINE] reduces the risk of [SEVERE NOCTURNAL HYPOGLYCAEMIA],[SEVERE NOCTURNAL HYPOGLYCAEMIA],[INSULIN GLARGINE]
3577,ORAL AMPHOTERICIN B treats FUNGAL INFECTION,treats,0.99654575824488,"Menichetti F, Del Favero A, Martino P et al. Preventing FUNGAL INFECTION in neutropenic patients with acute leukemia: fluconazole compared with ORAL AMPHOTERICIN B.",FUNGAL INFECTION,ORAL AMPHOTERICIN B
3578,ORAL AMPHOTERICIN B treats FUNGAL INFECTION,treats,0.99654575824488,"Menichetti F, Del Favero A, Martino P et al. Preventing FUNGAL INFECTION in neutropenic patients with acute leukemia: fluconazole compared with ORAL AMPHOTERICIN B.",FUNGAL INFECTION,ORAL AMPHOTERICIN B
3579,ORAL AMPHOTERICIN B treats FUNGAL INFECTION,treats,0.99654575824488,"Menichetti F, Del Favero A, Martino P et al. Preventing FUNGAL INFECTION in neutropenic patients with acute leukemia: fluconazole compared with ORAL AMPHOTERICIN B.",FUNGAL INFECTION,ORAL AMPHOTERICIN B
3580,ORAL AMPHOTERICIN B treats FUNGAL INFECTION,treats,0.99654575824488,"Menichetti F, Del Favero A, Martino P et al. Preventing FUNGAL INFECTION in neutropenic patients with acute leukemia: fluconazole compared with ORAL AMPHOTERICIN B.",FUNGAL INFECTION,ORAL AMPHOTERICIN B
3581,FUNGAL INFECTION treats ORAL AMPHOTERICIN B,treats,0.99654575824488,"Menichetti F, Del Favero A, Martino P et al. Preventing FUNGAL INFECTION in neutropenic patients with acute leukemia: fluconazole compared with ORAL AMPHOTERICIN B.",FUNGAL INFECTION,ORAL AMPHOTERICIN B
3582,ORAL AMPHOTERICIN B treats FUNGAL INFECTION,treats,0.99654575824488,"Menichetti F, Del Favero A, Martino P et al. Preventing FUNGAL INFECTION in neutropenic patients with acute leukemia: fluconazole compared with ORAL AMPHOTERICIN B.",FUNGAL INFECTION,ORAL AMPHOTERICIN B
3583,no_relation,treats,0.99654575824488,"Menichetti F, Del Favero A, Martino P et al. Preventing FUNGAL INFECTION in neutropenic patients with acute leukemia: fluconazole compared with ORAL AMPHOTERICIN B.",FUNGAL INFECTION,ORAL AMPHOTERICIN B
3584,[WARM COMPRESSES] treats [HYGIENE],treats,0.522232967867094,Treatment normally consists in maintaining a good [HYGIENE] of the eye and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[HYGIENE],[WARM COMPRESSES]
3585,[WARM COMPRESSES] treats [HYGIENE],treats,0.522232967867094,Treatment normally consists in maintaining a good [HYGIENE] of the eye and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[HYGIENE],[WARM COMPRESSES]
3586,no_relation,treats,0.522232967867094,Treatment normally consists in maintaining a good [HYGIENE] of the eye and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[HYGIENE],[WARM COMPRESSES]
3587,no_relation,treats,0.522232967867094,Treatment normally consists in maintaining a good [HYGIENE] of the eye and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[HYGIENE],[WARM COMPRESSES]
3588,no_relation,treats,0.522232967867094,Treatment normally consists in maintaining a good [HYGIENE] of the eye and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[HYGIENE],[WARM COMPRESSES]
3589,[WARM COMPRESSES] treats [HYGIENE],treats,0.522232967867094,Treatment normally consists in maintaining a good [HYGIENE] of the eye and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[HYGIENE],[WARM COMPRESSES]
3590,no_relation,treats,0.522232967867094,Treatment normally consists in maintaining a good [HYGIENE] of the eye and holding [WARM COMPRESSES] on the affected eyelid to remove the crusts.,[HYGIENE],[WARM COMPRESSES]
3591,no_relation,treats,0.384900179459751,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
3592,no_relation,treats,0.384900179459751,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
3593,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,treats,0.384900179459751,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
3594,no_relation,treats,0.384900179459751,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
3595,no_relation,treats,0.384900179459751,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
3596,no_relation,treats,0.384900179459751,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
3597,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A treats DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,treats,0.384900179459751,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
3598,OMEPRAZOLE treats PEPTIC ESOPHAGITIS,treats,1.0,"1]  Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe PEPTIC ESOPHAGITIS after treatment with OMEPRAZOLE",PEPTIC ESOPHAGITIS,OMEPRAZOLE
3599,OMEPRAZOLE treats PEPTIC ESOPHAGITIS,treats,1.0,"1]  Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe PEPTIC ESOPHAGITIS after treatment with OMEPRAZOLE",PEPTIC ESOPHAGITIS,OMEPRAZOLE
3600,OMEPRAZOLE treats PEPTIC ESOPHAGITIS,treats,1.0,"1]  Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe PEPTIC ESOPHAGITIS after treatment with OMEPRAZOLE",PEPTIC ESOPHAGITIS,OMEPRAZOLE
3601,OMEPRAZOLE treats PEPTIC ESOPHAGITIS,treats,1.0,"1]  Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe PEPTIC ESOPHAGITIS after treatment with OMEPRAZOLE",PEPTIC ESOPHAGITIS,OMEPRAZOLE
3602,OMEPRAZOLE treats PEPTIC ESOPHAGITIS,treats,1.0,"1]  Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe PEPTIC ESOPHAGITIS after treatment with OMEPRAZOLE",PEPTIC ESOPHAGITIS,OMEPRAZOLE
3603,OMEPRAZOLE treats PEPTIC ESOPHAGITIS,treats,1.0,"1]  Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe PEPTIC ESOPHAGITIS after treatment with OMEPRAZOLE",PEPTIC ESOPHAGITIS,OMEPRAZOLE
3604,OMEPRAZOLE treats PEPTIC ESOPHAGITIS,treats,1.0,"1]  Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe PEPTIC ESOPHAGITIS after treatment with OMEPRAZOLE",PEPTIC ESOPHAGITIS,OMEPRAZOLE
3605,IBUPROFEN treats FEVER,treats,1.0,"SEE:   epilepsy  TREATMENT: Appropriate therapy, such as acetaminophen or IBUPROFEN should be instituted to reduce the FEVER",FEVER,IBUPROFEN
3606,IBUPROFEN treats FEVER,treats,1.0,"SEE:   epilepsy  TREATMENT: Appropriate therapy, such as acetaminophen or IBUPROFEN should be instituted to reduce the FEVER",FEVER,IBUPROFEN
3607,FEVER treats IBUPROFEN,treats,1.0,"SEE:   epilepsy  TREATMENT: Appropriate therapy, such as acetaminophen or IBUPROFEN should be instituted to reduce the FEVER",FEVER,IBUPROFEN
3608,IBUPROFEN treats FEVER,treats,1.0,"SEE:   epilepsy  TREATMENT: Appropriate therapy, such as acetaminophen or IBUPROFEN should be instituted to reduce the FEVER",FEVER,IBUPROFEN
3609,IBUPROFEN treats FEVER,treats,1.0,"SEE:   epilepsy  TREATMENT: Appropriate therapy, such as acetaminophen or IBUPROFEN should be instituted to reduce the FEVER",FEVER,IBUPROFEN
3610,IBUPROFEN treats FEVER,treats,1.0,"SEE:   epilepsy  TREATMENT: Appropriate therapy, such as acetaminophen or IBUPROFEN should be instituted to reduce the FEVER",FEVER,IBUPROFEN
3611,IBUPROFEN treats FEVER,treats,1.0,"SEE:   epilepsy  TREATMENT: Appropriate therapy, such as acetaminophen or IBUPROFEN should be instituted to reduce the FEVER",FEVER,IBUPROFEN
3612,no_relation,treats,0.42426406871192895,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
3613,no_relation,treats,0.42426406871192895,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
3614,TOPICAL PILOCARPINE treats PHARMACOLOGIC MYDRIASIS,treats,0.42426406871192895,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
3615,no_relation,treats,0.42426406871192895,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
3616,TOPICAL PILOCARPINE treats PHARMACOLOGIC MYDRIASIS,treats,0.42426406871192895,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
3617,PHARMACOLOGIC MYDRIASIS treats TOPICAL PILOCARPINE,treats,0.42426406871192895,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
3618,TOPICAL PILOCARPINE treats PHARMACOLOGIC MYDRIASIS,treats,0.42426406871192895,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE
3619,CEFTAZIDIME treats URINARY TRACT INFECTION,treats,1.0,"Preheim LC, Childs SJ, Rajfer J et al. Randomized, double blind comparison of cefepime and CEFTAZIDIME therapy for URINARY TRACT INFECTION",URINARY TRACT INFECTION,CEFTAZIDIME
3620,CEFTAZIDIME treats URINARY TRACT INFECTION,treats,1.0,"Preheim LC, Childs SJ, Rajfer J et al. Randomized, double blind comparison of cefepime and CEFTAZIDIME therapy for URINARY TRACT INFECTION",URINARY TRACT INFECTION,CEFTAZIDIME
3621,CEFTAZIDIME treats URINARY TRACT INFECTION,treats,1.0,"Preheim LC, Childs SJ, Rajfer J et al. Randomized, double blind comparison of cefepime and CEFTAZIDIME therapy for URINARY TRACT INFECTION",URINARY TRACT INFECTION,CEFTAZIDIME
3622,CEFTAZIDIME treats URINARY TRACT INFECTION,treats,1.0,"Preheim LC, Childs SJ, Rajfer J et al. Randomized, double blind comparison of cefepime and CEFTAZIDIME therapy for URINARY TRACT INFECTION",URINARY TRACT INFECTION,CEFTAZIDIME
3623,CEFTAZIDIME treats URINARY TRACT INFECTION,treats,1.0,"Preheim LC, Childs SJ, Rajfer J et al. Randomized, double blind comparison of cefepime and CEFTAZIDIME therapy for URINARY TRACT INFECTION",URINARY TRACT INFECTION,CEFTAZIDIME
3624,no_relation,treats,1.0,"Preheim LC, Childs SJ, Rajfer J et al. Randomized, double blind comparison of cefepime and CEFTAZIDIME therapy for URINARY TRACT INFECTION",URINARY TRACT INFECTION,CEFTAZIDIME
3625,CEFTAZIDIME treats URINARY TRACT INFECTION,treats,1.0,"Preheim LC, Childs SJ, Rajfer J et al. Randomized, double blind comparison of cefepime and CEFTAZIDIME therapy for URINARY TRACT INFECTION",URINARY TRACT INFECTION,CEFTAZIDIME
3626,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9797958971132712,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
3627,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9797958971132712,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
3628,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9797958971132712,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
3629,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9797958971132712,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
3630,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9797958971132712,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
3631,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9797958971132712,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
3632,PANCREATIC ISLETS treats STREPTOZOTOCIN INDUCED DIABETES,treats,0.9797958971132712,The ability of PANCREATIC ISLETS implanted into abdominal muscle to effect a recovery from STREPTOZOTOCIN INDUCED DIABETES was compared with that of i.p implants.,PANCREATIC ISLETS,STREPTOZOTOCIN INDUCED DIABETES
3633,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8834522085987719,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
3634,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8834522085987719,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
3635,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8834522085987719,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
3636,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8834522085987719,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
3637,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8834522085987719,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
3638,DACARBAZINE treats METASTATIC MALIGNANT MELANOMA,treats,0.8834522085987719,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
3639,METASTATIC MALIGNANT MELANOMA treats DACARBAZINE,treats,0.8834522085987719,"Phase III study of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alfa 2b versus cisplatin, vinblastine, and DACARBAZINE alone in patients with METASTATIC MALIGNANT MELANOMA (summary last modified 10/1999.",METASTATIC MALIGNANT MELANOMA,DACARBAZINE
3640,CHANCROID treats AZITHROMYCIN,treats,0.9918365981,The CDC recommendation for [CHANCROID] is a single oral dose of [AZITHROMYCIN] or a single IM dose of Ceftriaxone or oral Erythromycin for seven days.,CHANCROID,AZITHROMYCIN
3641,no_relation,treats,0.9918365981,The CDC recommendation for [CHANCROID] is a single oral dose of [AZITHROMYCIN] or a single IM dose of Ceftriaxone or oral Erythromycin for seven days.,CHANCROID,AZITHROMYCIN
3642,AZITHROMYCIN treats CHANCROID,treats,0.9918365981,The CDC recommendation for [CHANCROID] is a single oral dose of [AZITHROMYCIN] or a single IM dose of Ceftriaxone or oral Erythromycin for seven days.,CHANCROID,AZITHROMYCIN
3643,AZITHROMYCIN treats CHANCROID,treats,0.9918365981,The CDC recommendation for [CHANCROID] is a single oral dose of [AZITHROMYCIN] or a single IM dose of Ceftriaxone or oral Erythromycin for seven days.,CHANCROID,AZITHROMYCIN
3644,no_relation,treats,0.9918365981,The CDC recommendation for [CHANCROID] is a single oral dose of [AZITHROMYCIN] or a single IM dose of Ceftriaxone or oral Erythromycin for seven days.,CHANCROID,AZITHROMYCIN
3645,AZITHROMYCIN treats CHANCROID,treats,0.9918365981,The CDC recommendation for [CHANCROID] is a single oral dose of [AZITHROMYCIN] or a single IM dose of Ceftriaxone or oral Erythromycin for seven days.,CHANCROID,AZITHROMYCIN
3646,AZITHROMYCIN treats CHANCROID,treats,0.9918365981,The CDC recommendation for [CHANCROID] is a single oral dose of [AZITHROMYCIN] or a single IM dose of Ceftriaxone or oral Erythromycin for seven days.,CHANCROID,AZITHROMYCIN
3647,FACTOR VII (RFVIIA) treats HEMOPHILIA A,treats,1.0,"FACTOR VIIA  Recombinant activated FACTOR VII (RFVIIA) was approved in 1999 for the treatment of bleeding episodes in patients with HEMOPHILIA A or B who have antibodies (inhibitors) to factor VIII or IX, respectively.",HEMOPHILIA A,FACTOR VII (RFVIIA)
3648,FACTOR VII (RFVIIA) treats HEMOPHILIA A,treats,1.0,"FACTOR VIIA  Recombinant activated FACTOR VII (RFVIIA) was approved in 1999 for the treatment of bleeding episodes in patients with HEMOPHILIA A or B who have antibodies (inhibitors) to factor VIII or IX, respectively.",HEMOPHILIA A,FACTOR VII (RFVIIA)
3649,FACTOR VII (RFVIIA) treats HEMOPHILIA A,treats,1.0,"FACTOR VIIA  Recombinant activated FACTOR VII (RFVIIA) was approved in 1999 for the treatment of bleeding episodes in patients with HEMOPHILIA A or B who have antibodies (inhibitors) to factor VIII or IX, respectively.",HEMOPHILIA A,FACTOR VII (RFVIIA)
3650,FACTOR VII (RFVIIA) treats HEMOPHILIA A,treats,1.0,"FACTOR VIIA  Recombinant activated FACTOR VII (RFVIIA) was approved in 1999 for the treatment of bleeding episodes in patients with HEMOPHILIA A or B who have antibodies (inhibitors) to factor VIII or IX, respectively.",HEMOPHILIA A,FACTOR VII (RFVIIA)
3651,FACTOR VII (RFVIIA) treats HEMOPHILIA A,treats,1.0,"FACTOR VIIA  Recombinant activated FACTOR VII (RFVIIA) was approved in 1999 for the treatment of bleeding episodes in patients with HEMOPHILIA A or B who have antibodies (inhibitors) to factor VIII or IX, respectively.",HEMOPHILIA A,FACTOR VII (RFVIIA)
3652,FACTOR VII (RFVIIA) treats HEMOPHILIA A,treats,1.0,"FACTOR VIIA  Recombinant activated FACTOR VII (RFVIIA) was approved in 1999 for the treatment of bleeding episodes in patients with HEMOPHILIA A or B who have antibodies (inhibitors) to factor VIII or IX, respectively.",HEMOPHILIA A,FACTOR VII (RFVIIA)
3653,FACTOR VII (RFVIIA) treats HEMOPHILIA A,treats,1.0,"FACTOR VIIA  Recombinant activated FACTOR VII (RFVIIA) was approved in 1999 for the treatment of bleeding episodes in patients with HEMOPHILIA A or B who have antibodies (inhibitors) to factor VIII or IX, respectively.",HEMOPHILIA A,FACTOR VII (RFVIIA)
3654,no_relation,treats,0.838627869377535,Alternate therapies include α INTERFERON (with addition of ribavirin if creatinine clearance is > 50 mL/min) for hepatitis C virus associated disease and plasmapheresis with corticosteroids for concomitant severe CRYOGLOBULINEMIA or rapidly progressive GN.,CRYOGLOBULINEMIA,INTERFERON
3655,INTERFERON treats CRYOGLOBULINEMIA,treats,0.838627869377535,Alternate therapies include α INTERFERON (with addition of ribavirin if creatinine clearance is > 50 mL/min) for hepatitis C virus associated disease and plasmapheresis with corticosteroids for concomitant severe CRYOGLOBULINEMIA or rapidly progressive GN.,CRYOGLOBULINEMIA,INTERFERON
3656,INTERFERON treats CRYOGLOBULINEMIA,treats,0.838627869377535,Alternate therapies include α INTERFERON (with addition of ribavirin if creatinine clearance is > 50 mL/min) for hepatitis C virus associated disease and plasmapheresis with corticosteroids for concomitant severe CRYOGLOBULINEMIA or rapidly progressive GN.,CRYOGLOBULINEMIA,INTERFERON
3657,INTERFERON treats CRYOGLOBULINEMIA,treats,0.838627869377535,Alternate therapies include α INTERFERON (with addition of ribavirin if creatinine clearance is > 50 mL/min) for hepatitis C virus associated disease and plasmapheresis with corticosteroids for concomitant severe CRYOGLOBULINEMIA or rapidly progressive GN.,CRYOGLOBULINEMIA,INTERFERON
3658,no_relation,treats,0.838627869377535,Alternate therapies include α INTERFERON (with addition of ribavirin if creatinine clearance is > 50 mL/min) for hepatitis C virus associated disease and plasmapheresis with corticosteroids for concomitant severe CRYOGLOBULINEMIA or rapidly progressive GN.,CRYOGLOBULINEMIA,INTERFERON
3659,INTERFERON treats CRYOGLOBULINEMIA,treats,0.838627869377535,Alternate therapies include α INTERFERON (with addition of ribavirin if creatinine clearance is > 50 mL/min) for hepatitis C virus associated disease and plasmapheresis with corticosteroids for concomitant severe CRYOGLOBULINEMIA or rapidly progressive GN.,CRYOGLOBULINEMIA,INTERFERON
3660,INTERFERON treats CRYOGLOBULINEMIA,treats,0.838627869377535,Alternate therapies include α INTERFERON (with addition of ribavirin if creatinine clearance is > 50 mL/min) for hepatitis C virus associated disease and plasmapheresis with corticosteroids for concomitant severe CRYOGLOBULINEMIA or rapidly progressive GN.,CRYOGLOBULINEMIA,INTERFERON
3661,BEVACIZUMAB treats ABNORMAL GROWTH,treats,0.99654575824488,"This [ABNORMAL GROWTH] is caused by VEGF, so [BEVACIZUMAB] has been successfully used to inhibit VEGF and slow this growth.",ABNORMAL GROWTH,BEVACIZUMAB
3662,BEVACIZUMAB treats ABNORMAL GROWTH,treats,0.99654575824488,"This [ABNORMAL GROWTH] is caused by VEGF, so [BEVACIZUMAB] has been successfully used to inhibit VEGF and slow this growth.",ABNORMAL GROWTH,BEVACIZUMAB
3663,BEVACIZUMAB treats ABNORMAL GROWTH,treats,0.99654575824488,"This [ABNORMAL GROWTH] is caused by VEGF, so [BEVACIZUMAB] has been successfully used to inhibit VEGF and slow this growth.",ABNORMAL GROWTH,BEVACIZUMAB
3664,BEVACIZUMAB treats ABNORMAL GROWTH,treats,0.99654575824488,"This [ABNORMAL GROWTH] is caused by VEGF, so [BEVACIZUMAB] has been successfully used to inhibit VEGF and slow this growth.",ABNORMAL GROWTH,BEVACIZUMAB
3665,BEVACIZUMAB treats ABNORMAL GROWTH,treats,0.99654575824488,"This [ABNORMAL GROWTH] is caused by VEGF, so [BEVACIZUMAB] has been successfully used to inhibit VEGF and slow this growth.",ABNORMAL GROWTH,BEVACIZUMAB
3666,no_relation,treats,0.99654575824488,"This [ABNORMAL GROWTH] is caused by VEGF, so [BEVACIZUMAB] has been successfully used to inhibit VEGF and slow this growth.",ABNORMAL GROWTH,BEVACIZUMAB
3667,no_relation,treats,0.99654575824488,"This [ABNORMAL GROWTH] is caused by VEGF, so [BEVACIZUMAB] has been successfully used to inhibit VEGF and slow this growth.",ABNORMAL GROWTH,BEVACIZUMAB
3668,EPOETIN ALFA treats ANEMIA,treats,0.9970544855015808,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
3669,EPOETIN ALFA treats ANEMIA,treats,0.9970544855015808,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
3670,EPOETIN ALFA treats ANEMIA,treats,0.9970544855015808,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
3671,EPOETIN ALFA treats ANEMIA,treats,0.9970544855015808,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
3672,EPOETIN ALFA treats ANEMIA,treats,0.9970544855015808,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
3673,EPOETIN ALFA treats ANEMIA,treats,0.9970544855015808,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
3674,EPOETIN ALFA treats ANEMIA,treats,0.9970544855015808,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
3675,no_relation,treats,1.0,"Whether VITAMIN E protects against cardiovascular disorders, ALZHEIMER'S DISEASE tardive dyskinesia, and prostate cancer among smokers is controversial.",ALZHEIMER'S DISEASE,VITAMIN E
3676,VITAMIN E treats ALZHEIMER'S DISEASE,treats,1.0,"Whether VITAMIN E protects against cardiovascular disorders, ALZHEIMER'S DISEASE tardive dyskinesia, and prostate cancer among smokers is controversial.",ALZHEIMER'S DISEASE,VITAMIN E
3677,VITAMIN E treats ALZHEIMER'S DISEASE,treats,1.0,"Whether VITAMIN E protects against cardiovascular disorders, ALZHEIMER'S DISEASE tardive dyskinesia, and prostate cancer among smokers is controversial.",ALZHEIMER'S DISEASE,VITAMIN E
3678,no_relation,treats,1.0,"Whether VITAMIN E protects against cardiovascular disorders, ALZHEIMER'S DISEASE tardive dyskinesia, and prostate cancer among smokers is controversial.",ALZHEIMER'S DISEASE,VITAMIN E
3679,no_relation,treats,1.0,"Whether VITAMIN E protects against cardiovascular disorders, ALZHEIMER'S DISEASE tardive dyskinesia, and prostate cancer among smokers is controversial.",ALZHEIMER'S DISEASE,VITAMIN E
3680,no_relation,treats,1.0,"Whether VITAMIN E protects against cardiovascular disorders, ALZHEIMER'S DISEASE tardive dyskinesia, and prostate cancer among smokers is controversial.",ALZHEIMER'S DISEASE,VITAMIN E
3681,ALZHEIMER'S DISEASE treats VITAMIN E,treats,1.0,"Whether VITAMIN E protects against cardiovascular disorders, ALZHEIMER'S DISEASE tardive dyskinesia, and prostate cancer among smokers is controversial.",ALZHEIMER'S DISEASE,VITAMIN E
3682,no_relation,treats,0.314485451016576,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3683,no_relation,treats,0.314485451016576,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3684,no_relation,treats,0.314485451016576,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3685,B MALLEI treats GLANDERS,treats,0.314485451016576,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3686,no_relation,treats,0.314485451016576,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3687,no_relation,treats,0.314485451016576,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3688,no_relation,treats,0.314485451016576,"280 ,   281 ,   283 ,   285  Altenative for treatment of GLANDERS   +    caused by  B MALLEI",GLANDERS,B MALLEI
3689,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3690,HYPERTENSION treats PROPRANOLOL,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3691,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3692,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3693,no_relation,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3694,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3695,PROPRANOLOL treats HYPERTENSION,treats,0.963086824686154,"van Schaik BAM, Geyskes GG, Kettner N et al. Comparison of enalapril and PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
3696,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3697,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3698,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3699,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3700,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3701,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3702,HYPERTHERMIA treats HEPATOCELLULAR CARCINOMA,treats,0.975900072948533,This anecdotal case supports previous experimental evidence suggesting that TNF plus HYPERTHERMIA may be effective for treating unresectable HEPATOCELLULAR CARCINOMA,HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
3703,SOTALOL treats SVT,treats,0.986393923832144,SVT that does not involve the AV node may respond to other anti arrhythmic drugs such as SOTALOL or amiodarone.,SVT,SOTALOL
3704,SVT treats SOTALOL,treats,0.986393923832144,SVT that does not involve the AV node may respond to other anti arrhythmic drugs such as SOTALOL or amiodarone.,SVT,SOTALOL
3705,SOTALOL treats SVT,treats,0.986393923832144,SVT that does not involve the AV node may respond to other anti arrhythmic drugs such as SOTALOL or amiodarone.,SVT,SOTALOL
3706,SOTALOL treats SVT,treats,0.986393923832144,SVT that does not involve the AV node may respond to other anti arrhythmic drugs such as SOTALOL or amiodarone.,SVT,SOTALOL
3707,SOTALOL treats SVT,treats,0.986393923832144,SVT that does not involve the AV node may respond to other anti arrhythmic drugs such as SOTALOL or amiodarone.,SVT,SOTALOL
3708,no_relation,treats,0.986393923832144,SVT that does not involve the AV node may respond to other anti arrhythmic drugs such as SOTALOL or amiodarone.,SVT,SOTALOL
3709,SOTALOL treats SVT,treats,0.986393923832144,SVT that does not involve the AV node may respond to other anti arrhythmic drugs such as SOTALOL or amiodarone.,SVT,SOTALOL
3710,BUPRENORPHINE HYDROCHLORIDE treats POST OPERATIVE PAIN,treats,0.753778361444409,"Dobkin AB, Esposito B, Philbin C. Double blind evaluation of BUPRENORPHINE HYDROCHLORIDE for POST OPERATIVE PAIN",POST OPERATIVE PAIN,BUPRENORPHINE HYDROCHLORIDE
3711,BUPRENORPHINE HYDROCHLORIDE treats POST OPERATIVE PAIN,treats,0.753778361444409,"Dobkin AB, Esposito B, Philbin C. Double blind evaluation of BUPRENORPHINE HYDROCHLORIDE for POST OPERATIVE PAIN",POST OPERATIVE PAIN,BUPRENORPHINE HYDROCHLORIDE
3712,BUPRENORPHINE HYDROCHLORIDE treats POST OPERATIVE PAIN,treats,0.753778361444409,"Dobkin AB, Esposito B, Philbin C. Double blind evaluation of BUPRENORPHINE HYDROCHLORIDE for POST OPERATIVE PAIN",POST OPERATIVE PAIN,BUPRENORPHINE HYDROCHLORIDE
3713,BUPRENORPHINE HYDROCHLORIDE treats POST OPERATIVE PAIN,treats,0.753778361444409,"Dobkin AB, Esposito B, Philbin C. Double blind evaluation of BUPRENORPHINE HYDROCHLORIDE for POST OPERATIVE PAIN",POST OPERATIVE PAIN,BUPRENORPHINE HYDROCHLORIDE
3714,BUPRENORPHINE HYDROCHLORIDE treats POST OPERATIVE PAIN,treats,0.753778361444409,"Dobkin AB, Esposito B, Philbin C. Double blind evaluation of BUPRENORPHINE HYDROCHLORIDE for POST OPERATIVE PAIN",POST OPERATIVE PAIN,BUPRENORPHINE HYDROCHLORIDE
3715,BUPRENORPHINE HYDROCHLORIDE treats POST OPERATIVE PAIN,treats,0.753778361444409,"Dobkin AB, Esposito B, Philbin C. Double blind evaluation of BUPRENORPHINE HYDROCHLORIDE for POST OPERATIVE PAIN",POST OPERATIVE PAIN,BUPRENORPHINE HYDROCHLORIDE
3716,no_relation,treats,0.753778361444409,"Dobkin AB, Esposito B, Philbin C. Double blind evaluation of BUPRENORPHINE HYDROCHLORIDE for POST OPERATIVE PAIN",POST OPERATIVE PAIN,BUPRENORPHINE HYDROCHLORIDE
3717,DIMETHYLGLYCINE treats AUTISTIC BEHAVIOR,treats,0.997458699830735,"[DIMETHYLGLYCINE] is hypothesized to improve speech and reduce [AUTISTIC BEHAVIOR]s, and is a commonly used supplement.",AUTISTIC BEHAVIOR,DIMETHYLGLYCINE
3718,DIMETHYLGLYCINE treats AUTISTIC BEHAVIOR,treats,0.997458699830735,"[DIMETHYLGLYCINE] is hypothesized to improve speech and reduce [AUTISTIC BEHAVIOR]s, and is a commonly used supplement.",AUTISTIC BEHAVIOR,DIMETHYLGLYCINE
3719,DIMETHYLGLYCINE treats AUTISTIC BEHAVIOR,treats,0.997458699830735,"[DIMETHYLGLYCINE] is hypothesized to improve speech and reduce [AUTISTIC BEHAVIOR]s, and is a commonly used supplement.",AUTISTIC BEHAVIOR,DIMETHYLGLYCINE
3720,DIMETHYLGLYCINE treats AUTISTIC BEHAVIOR,treats,0.997458699830735,"[DIMETHYLGLYCINE] is hypothesized to improve speech and reduce [AUTISTIC BEHAVIOR]s, and is a commonly used supplement.",AUTISTIC BEHAVIOR,DIMETHYLGLYCINE
3721,DIMETHYLGLYCINE treats AUTISTIC BEHAVIOR,treats,0.997458699830735,"[DIMETHYLGLYCINE] is hypothesized to improve speech and reduce [AUTISTIC BEHAVIOR]s, and is a commonly used supplement.",AUTISTIC BEHAVIOR,DIMETHYLGLYCINE
3722,DIMETHYLGLYCINE treats AUTISTIC BEHAVIOR,treats,0.997458699830735,"[DIMETHYLGLYCINE] is hypothesized to improve speech and reduce [AUTISTIC BEHAVIOR]s, and is a commonly used supplement.",AUTISTIC BEHAVIOR,DIMETHYLGLYCINE
3723,no_relation,treats,0.997458699830735,"[DIMETHYLGLYCINE] is hypothesized to improve speech and reduce [AUTISTIC BEHAVIOR]s, and is a commonly used supplement.",AUTISTIC BEHAVIOR,DIMETHYLGLYCINE
3724,LOSARTAN treats HYPERTENSION,treats,0.970142500145332,"• The LIFE study prospectively randomized >9000 patients 55 to 80 years of age with HYPERTENSION and left ventricular hypertrophy to the angiotensin receptor blocker LOSARTAN or the β blocker atenolol, with additional therapy using a diuretic of a calcium channel blocker as needed to control BP.",HYPERTENSION,LOSARTAN
3725,LOSARTAN treats HYPERTENSION,treats,0.970142500145332,"• The LIFE study prospectively randomized >9000 patients 55 to 80 years of age with HYPERTENSION and left ventricular hypertrophy to the angiotensin receptor blocker LOSARTAN or the β blocker atenolol, with additional therapy using a diuretic of a calcium channel blocker as needed to control BP.",HYPERTENSION,LOSARTAN
3726,no_relation,treats,0.970142500145332,"• The LIFE study prospectively randomized >9000 patients 55 to 80 years of age with HYPERTENSION and left ventricular hypertrophy to the angiotensin receptor blocker LOSARTAN or the β blocker atenolol, with additional therapy using a diuretic of a calcium channel blocker as needed to control BP.",HYPERTENSION,LOSARTAN
3727,LOSARTAN treats HYPERTENSION,treats,0.970142500145332,"• The LIFE study prospectively randomized >9000 patients 55 to 80 years of age with HYPERTENSION and left ventricular hypertrophy to the angiotensin receptor blocker LOSARTAN or the β blocker atenolol, with additional therapy using a diuretic of a calcium channel blocker as needed to control BP.",HYPERTENSION,LOSARTAN
3728,LOSARTAN treats HYPERTENSION,treats,0.970142500145332,"• The LIFE study prospectively randomized >9000 patients 55 to 80 years of age with HYPERTENSION and left ventricular hypertrophy to the angiotensin receptor blocker LOSARTAN or the β blocker atenolol, with additional therapy using a diuretic of a calcium channel blocker as needed to control BP.",HYPERTENSION,LOSARTAN
3729,LOSARTAN treats HYPERTENSION,treats,0.970142500145332,"• The LIFE study prospectively randomized >9000 patients 55 to 80 years of age with HYPERTENSION and left ventricular hypertrophy to the angiotensin receptor blocker LOSARTAN or the β blocker atenolol, with additional therapy using a diuretic of a calcium channel blocker as needed to control BP.",HYPERTENSION,LOSARTAN
3730,LOSARTAN treats HYPERTENSION,treats,0.970142500145332,"• The LIFE study prospectively randomized >9000 patients 55 to 80 years of age with HYPERTENSION and left ventricular hypertrophy to the angiotensin receptor blocker LOSARTAN or the β blocker atenolol, with additional therapy using a diuretic of a calcium channel blocker as needed to control BP.",HYPERTENSION,LOSARTAN
3731,ORAL TERBINAFINE treats TINEA CAPITIS,treats,0.994936676326182,"55 ,   61 ,   62 ,   63 ,   65 ,   68 ,   75 ,   77  ORAL TERBINAFINE appears to be as effective as oral griseofulvin for treatment of TINEA CAPITIS caused by  Trichophyton , and requires a shorter duration of treatment which may increase compliance.",TINEA CAPITIS,ORAL TERBINAFINE
3732,ORAL TERBINAFINE treats TINEA CAPITIS,treats,0.994936676326182,"55 ,   61 ,   62 ,   63 ,   65 ,   68 ,   75 ,   77  ORAL TERBINAFINE appears to be as effective as oral griseofulvin for treatment of TINEA CAPITIS caused by  Trichophyton , and requires a shorter duration of treatment which may increase compliance.",TINEA CAPITIS,ORAL TERBINAFINE
3733,ORAL TERBINAFINE treats TINEA CAPITIS,treats,0.994936676326182,"55 ,   61 ,   62 ,   63 ,   65 ,   68 ,   75 ,   77  ORAL TERBINAFINE appears to be as effective as oral griseofulvin for treatment of TINEA CAPITIS caused by  Trichophyton , and requires a shorter duration of treatment which may increase compliance.",TINEA CAPITIS,ORAL TERBINAFINE
3734,ORAL TERBINAFINE treats TINEA CAPITIS,treats,0.994936676326182,"55 ,   61 ,   62 ,   63 ,   65 ,   68 ,   75 ,   77  ORAL TERBINAFINE appears to be as effective as oral griseofulvin for treatment of TINEA CAPITIS caused by  Trichophyton , and requires a shorter duration of treatment which may increase compliance.",TINEA CAPITIS,ORAL TERBINAFINE
3735,ORAL TERBINAFINE treats TINEA CAPITIS,treats,0.994936676326182,"55 ,   61 ,   62 ,   63 ,   65 ,   68 ,   75 ,   77  ORAL TERBINAFINE appears to be as effective as oral griseofulvin for treatment of TINEA CAPITIS caused by  Trichophyton , and requires a shorter duration of treatment which may increase compliance.",TINEA CAPITIS,ORAL TERBINAFINE
3736,TINEA CAPITIS treats ORAL TERBINAFINE,treats,0.994936676326182,"55 ,   61 ,   62 ,   63 ,   65 ,   68 ,   75 ,   77  ORAL TERBINAFINE appears to be as effective as oral griseofulvin for treatment of TINEA CAPITIS caused by  Trichophyton , and requires a shorter duration of treatment which may increase compliance.",TINEA CAPITIS,ORAL TERBINAFINE
3737,ORAL TERBINAFINE treats TINEA CAPITIS,treats,0.994936676326182,"55 ,   61 ,   62 ,   63 ,   65 ,   68 ,   75 ,   77  ORAL TERBINAFINE appears to be as effective as oral griseofulvin for treatment of TINEA CAPITIS caused by  Trichophyton , and requires a shorter duration of treatment which may increase compliance.",TINEA CAPITIS,ORAL TERBINAFINE
3738,AMPHOTERICIN B treats PRESUMPTIVE BLASTOMYCOSIS,treats,0.9970544855015808,"36 ,   49 ,   50 ,   51 ,   52 ,   436  IV AMPHOTERICIN B is preferred for initial treatment of severe blastomycosis, especially infections involving the CNS  51 ,   52 ,   55 ,   56 ,   50 ,   51 ,   52 ,   53 ,   54 ,   61 ,   424 ,   436   and for initial treatment of PRESUMPTIVE BLASTOMYCOSIS in immunocompromised patients, including HIV infected individuals.",PRESUMPTIVE BLASTOMYCOSIS,AMPHOTERICIN B
3739,AMPHOTERICIN B treats PRESUMPTIVE BLASTOMYCOSIS,treats,0.9970544855015808,"36 ,   49 ,   50 ,   51 ,   52 ,   436  IV AMPHOTERICIN B is preferred for initial treatment of severe blastomycosis, especially infections involving the CNS  51 ,   52 ,   55 ,   56 ,   50 ,   51 ,   52 ,   53 ,   54 ,   61 ,   424 ,   436   and for initial treatment of PRESUMPTIVE BLASTOMYCOSIS in immunocompromised patients, including HIV infected individuals.",PRESUMPTIVE BLASTOMYCOSIS,AMPHOTERICIN B
3740,AMPHOTERICIN B treats PRESUMPTIVE BLASTOMYCOSIS,treats,0.9970544855015808,"36 ,   49 ,   50 ,   51 ,   52 ,   436  IV AMPHOTERICIN B is preferred for initial treatment of severe blastomycosis, especially infections involving the CNS  51 ,   52 ,   55 ,   56 ,   50 ,   51 ,   52 ,   53 ,   54 ,   61 ,   424 ,   436   and for initial treatment of PRESUMPTIVE BLASTOMYCOSIS in immunocompromised patients, including HIV infected individuals.",PRESUMPTIVE BLASTOMYCOSIS,AMPHOTERICIN B
3741,AMPHOTERICIN B treats PRESUMPTIVE BLASTOMYCOSIS,treats,0.9970544855015808,"36 ,   49 ,   50 ,   51 ,   52 ,   436  IV AMPHOTERICIN B is preferred for initial treatment of severe blastomycosis, especially infections involving the CNS  51 ,   52 ,   55 ,   56 ,   50 ,   51 ,   52 ,   53 ,   54 ,   61 ,   424 ,   436   and for initial treatment of PRESUMPTIVE BLASTOMYCOSIS in immunocompromised patients, including HIV infected individuals.",PRESUMPTIVE BLASTOMYCOSIS,AMPHOTERICIN B
3742,AMPHOTERICIN B treats PRESUMPTIVE BLASTOMYCOSIS,treats,0.9970544855015808,"36 ,   49 ,   50 ,   51 ,   52 ,   436  IV AMPHOTERICIN B is preferred for initial treatment of severe blastomycosis, especially infections involving the CNS  51 ,   52 ,   55 ,   56 ,   50 ,   51 ,   52 ,   53 ,   54 ,   61 ,   424 ,   436   and for initial treatment of PRESUMPTIVE BLASTOMYCOSIS in immunocompromised patients, including HIV infected individuals.",PRESUMPTIVE BLASTOMYCOSIS,AMPHOTERICIN B
3743,AMPHOTERICIN B treats PRESUMPTIVE BLASTOMYCOSIS,treats,0.9970544855015808,"36 ,   49 ,   50 ,   51 ,   52 ,   436  IV AMPHOTERICIN B is preferred for initial treatment of severe blastomycosis, especially infections involving the CNS  51 ,   52 ,   55 ,   56 ,   50 ,   51 ,   52 ,   53 ,   54 ,   61 ,   424 ,   436   and for initial treatment of PRESUMPTIVE BLASTOMYCOSIS in immunocompromised patients, including HIV infected individuals.",PRESUMPTIVE BLASTOMYCOSIS,AMPHOTERICIN B
3744,AMPHOTERICIN B treats PRESUMPTIVE BLASTOMYCOSIS,treats,0.9970544855015808,"36 ,   49 ,   50 ,   51 ,   52 ,   436  IV AMPHOTERICIN B is preferred for initial treatment of severe blastomycosis, especially infections involving the CNS  51 ,   52 ,   55 ,   56 ,   50 ,   51 ,   52 ,   53 ,   54 ,   61 ,   424 ,   436   and for initial treatment of PRESUMPTIVE BLASTOMYCOSIS in immunocompromised patients, including HIV infected individuals.",PRESUMPTIVE BLASTOMYCOSIS,AMPHOTERICIN B
3745,MAGNESIUM SULPHATE treats PRE ECLAMPSIA,treats,0.948683298050514,2007 03 01  The Magpie Trial: a randomised trial comparing MAGNESIUM SULPHATE with placebo for PRE ECLAMPSIA,PRE ECLAMPSIA,MAGNESIUM SULPHATE
3746,MAGNESIUM SULPHATE treats PRE ECLAMPSIA,treats,0.948683298050514,2007 03 01  The Magpie Trial: a randomised trial comparing MAGNESIUM SULPHATE with placebo for PRE ECLAMPSIA,PRE ECLAMPSIA,MAGNESIUM SULPHATE
3747,MAGNESIUM SULPHATE treats PRE ECLAMPSIA,treats,0.948683298050514,2007 03 01  The Magpie Trial: a randomised trial comparing MAGNESIUM SULPHATE with placebo for PRE ECLAMPSIA,PRE ECLAMPSIA,MAGNESIUM SULPHATE
3748,MAGNESIUM SULPHATE treats PRE ECLAMPSIA,treats,0.948683298050514,2007 03 01  The Magpie Trial: a randomised trial comparing MAGNESIUM SULPHATE with placebo for PRE ECLAMPSIA,PRE ECLAMPSIA,MAGNESIUM SULPHATE
3749,MAGNESIUM SULPHATE treats PRE ECLAMPSIA,treats,0.948683298050514,2007 03 01  The Magpie Trial: a randomised trial comparing MAGNESIUM SULPHATE with placebo for PRE ECLAMPSIA,PRE ECLAMPSIA,MAGNESIUM SULPHATE
3750,no_relation,treats,0.948683298050514,2007 03 01  The Magpie Trial: a randomised trial comparing MAGNESIUM SULPHATE with placebo for PRE ECLAMPSIA,PRE ECLAMPSIA,MAGNESIUM SULPHATE
3751,no_relation,treats,0.948683298050514,2007 03 01  The Magpie Trial: a randomised trial comparing MAGNESIUM SULPHATE with placebo for PRE ECLAMPSIA,PRE ECLAMPSIA,MAGNESIUM SULPHATE
3752,no_relation,treats,0.583459965991578,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
3753,no_relation,treats,0.583459965991578,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
3754,no_relation,treats,0.583459965991578,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
3755,no_relation,treats,0.583459965991578,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
3756,no_relation,treats,0.583459965991578,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
3757,no_relation,treats,0.583459965991578,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
3758,AND B VIRUS INFECTIONS treats A OR B VIRUS IN ADULTS,treats,0.583459965991578,"Prevention of Seasonal Influenza A AND B VIRUS INFECTIONS  Prevention of illness caused by influenza A OR B VIRUS IN ADULTS adolescents, and children ≥1 year of age.",AND B VIRUS INFECTIONS,A OR B VIRUS IN ADULTS
3759,TOPIRAMATE treats DIABETIC NEUROPATHY,treats,0.737209780774486,"[TOPIRAMATE] has not been studied in [DIABETIC NEUROPATHY], but has the beneficial side effect of causing mild anorexia and weight loss, and is anecdotally beneficial.",DIABETIC NEUROPATHY,TOPIRAMATE
3760,TOPIRAMATE treats DIABETIC NEUROPATHY,treats,0.737209780774486,"[TOPIRAMATE] has not been studied in [DIABETIC NEUROPATHY], but has the beneficial side effect of causing mild anorexia and weight loss, and is anecdotally beneficial.",DIABETIC NEUROPATHY,TOPIRAMATE
3761,TOPIRAMATE treats DIABETIC NEUROPATHY,treats,0.737209780774486,"[TOPIRAMATE] has not been studied in [DIABETIC NEUROPATHY], but has the beneficial side effect of causing mild anorexia and weight loss, and is anecdotally beneficial.",DIABETIC NEUROPATHY,TOPIRAMATE
3762,no_relation,treats,0.737209780774486,"[TOPIRAMATE] has not been studied in [DIABETIC NEUROPATHY], but has the beneficial side effect of causing mild anorexia and weight loss, and is anecdotally beneficial.",DIABETIC NEUROPATHY,TOPIRAMATE
3763,no_relation,treats,0.737209780774486,"[TOPIRAMATE] has not been studied in [DIABETIC NEUROPATHY], but has the beneficial side effect of causing mild anorexia and weight loss, and is anecdotally beneficial.",DIABETIC NEUROPATHY,TOPIRAMATE
3764,TOPIRAMATE treats DIABETIC NEUROPATHY,treats,0.737209780774486,"[TOPIRAMATE] has not been studied in [DIABETIC NEUROPATHY], but has the beneficial side effect of causing mild anorexia and weight loss, and is anecdotally beneficial.",DIABETIC NEUROPATHY,TOPIRAMATE
3765,DIABETIC NEUROPATHY treats TOPIRAMATE,treats,0.737209780774486,"[TOPIRAMATE] has not been studied in [DIABETIC NEUROPATHY], but has the beneficial side effect of causing mild anorexia and weight loss, and is anecdotally beneficial.",DIABETIC NEUROPATHY,TOPIRAMATE
3766,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,0.99654575824488,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
3767,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,0.99654575824488,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
3768,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,0.99654575824488,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
3769,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,0.99654575824488,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
3770,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,0.99654575824488,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
3771,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,0.99654575824488,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
3772,DEFERIPRONE AND DEFEROXAMINE (DFO) treats MYOCARDIAL IRON OVERLOAD,treats,0.99654575824488,"Regarding iron chelation treatment, patients receiving combined therapy with DEFERIPRONE AND DEFEROXAMINE (DFO) significantly reduced MYOCARDIAL IRON OVERLOAD during the 4 yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",MYOCARDIAL IRON OVERLOAD,DEFERIPRONE AND DEFEROXAMINE (DFO)
3773,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
3774,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
3775,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
3776,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
3777,no_relation,treats,1.0,"Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
3778,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
3779,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,1.0,"Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with CHLORAMBUCIL as primary therapy for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
3780,WARFARIN treats STROKES,treats,0.9615239476408228,"Anticoagulation with warfarin in patients with atrial fibrillation significantly reduces the risk of stroke; in one meta analysis, patients receiving WARFARIN had a third as many STROKES as did control subjects.",STROKES,WARFARIN
3781,WARFARIN treats STROKES,treats,0.9615239476408228,"Anticoagulation with warfarin in patients with atrial fibrillation significantly reduces the risk of stroke; in one meta analysis, patients receiving WARFARIN had a third as many STROKES as did control subjects.",STROKES,WARFARIN
3782,WARFARIN treats STROKES,treats,0.9615239476408228,"Anticoagulation with warfarin in patients with atrial fibrillation significantly reduces the risk of stroke; in one meta analysis, patients receiving WARFARIN had a third as many STROKES as did control subjects.",STROKES,WARFARIN
3783,no_relation,treats,0.9615239476408228,"Anticoagulation with warfarin in patients with atrial fibrillation significantly reduces the risk of stroke; in one meta analysis, patients receiving WARFARIN had a third as many STROKES as did control subjects.",STROKES,WARFARIN
3784,no_relation,treats,0.9615239476408228,"Anticoagulation with warfarin in patients with atrial fibrillation significantly reduces the risk of stroke; in one meta analysis, patients receiving WARFARIN had a third as many STROKES as did control subjects.",STROKES,WARFARIN
3785,WARFARIN treats STROKES,treats,0.9615239476408228,"Anticoagulation with warfarin in patients with atrial fibrillation significantly reduces the risk of stroke; in one meta analysis, patients receiving WARFARIN had a third as many STROKES as did control subjects.",STROKES,WARFARIN
3786,WARFARIN treats STROKES,treats,0.9615239476408228,"Anticoagulation with warfarin in patients with atrial fibrillation significantly reduces the risk of stroke; in one meta analysis, patients receiving WARFARIN had a third as many STROKES as did control subjects.",STROKES,WARFARIN
3787,[COMBINATION THERAPY] treats [INFLUENZA],treats,0.996815278536125,A 1984 study on complicated influenza had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for [INFLUENZA].,[INFLUENZA],[COMBINATION THERAPY]
3788,[COMBINATION THERAPY] treats [INFLUENZA],treats,0.996815278536125,A 1984 study on complicated influenza had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for [INFLUENZA].,[INFLUENZA],[COMBINATION THERAPY]
3789,[COMBINATION THERAPY] treats [INFLUENZA],treats,0.996815278536125,A 1984 study on complicated influenza had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for [INFLUENZA].,[INFLUENZA],[COMBINATION THERAPY]
3790,[COMBINATION THERAPY] treats [INFLUENZA],treats,0.996815278536125,A 1984 study on complicated influenza had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for [INFLUENZA].,[INFLUENZA],[COMBINATION THERAPY]
3791,[COMBINATION THERAPY] treats [INFLUENZA],treats,0.996815278536125,A 1984 study on complicated influenza had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for [INFLUENZA].,[INFLUENZA],[COMBINATION THERAPY]
3792,[COMBINATION THERAPY] treats [INFLUENZA],treats,0.996815278536125,A 1984 study on complicated influenza had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for [INFLUENZA].,[INFLUENZA],[COMBINATION THERAPY]
3793,[COMBINATION THERAPY] treats [INFLUENZA],treats,0.996815278536125,A 1984 study on complicated influenza had found levamisole to be an effective inducer of interferon and had recommended its use in [COMBINATION THERAPY] for [INFLUENZA].,[INFLUENZA],[COMBINATION THERAPY]
3794,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,0.99654575824488,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
3795,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,0.99654575824488,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
3796,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,0.99654575824488,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
3797,no_relation,treats,0.99654575824488,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
3798,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,0.99654575824488,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
3799,PHENYTOIN treats POST-TRAUMATIC EPILEPSY,treats,0.99654575824488,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
3800,no_relation,treats,0.99654575824488,The use of PHENYTOIN in headache syndromes and in prevention of POST-TRAUMATIC EPILEPSY is discussed,POST-TRAUMATIC EPILEPSY,PHENYTOIN
3801,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
3802,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
3803,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
3804,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
3805,INFLAMMATION treats HYDROCORTISONE,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
3806,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
3807,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
3808,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
3809,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
3810,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
3811,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
3812,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
3813,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
3814,KETOPROFEN treats RHEUMATOID ARTHRITIS,treats,1.0,"El-Ghobarey AF, Rennie JAN, Hadidi T et al. A comparative trial of large doses of KETOPROFEN and indomethacin in the treatment of RHEUMATOID ARTHRITIS",RHEUMATOID ARTHRITIS,KETOPROFEN
3815,MEPERIDINE treats CHRONIC PAIN,treats,0.956182887467515,"• A study of MEPERIDINE used for postoperative or CHRONIC PAIN found a high incidence of neuroexcitatory effects including nervousness, twitches, myoclonus, and seizures, as well as adverse mood alterations in patients with and without renal dysfunction.",CHRONIC PAIN,MEPERIDINE
3816,MEPERIDINE treats CHRONIC PAIN,treats,0.956182887467515,"• A study of MEPERIDINE used for postoperative or CHRONIC PAIN found a high incidence of neuroexcitatory effects including nervousness, twitches, myoclonus, and seizures, as well as adverse mood alterations in patients with and without renal dysfunction.",CHRONIC PAIN,MEPERIDINE
3817,MEPERIDINE treats CHRONIC PAIN,treats,0.956182887467515,"• A study of MEPERIDINE used for postoperative or CHRONIC PAIN found a high incidence of neuroexcitatory effects including nervousness, twitches, myoclonus, and seizures, as well as adverse mood alterations in patients with and without renal dysfunction.",CHRONIC PAIN,MEPERIDINE
3818,MEPERIDINE treats CHRONIC PAIN,treats,0.956182887467515,"• A study of MEPERIDINE used for postoperative or CHRONIC PAIN found a high incidence of neuroexcitatory effects including nervousness, twitches, myoclonus, and seizures, as well as adverse mood alterations in patients with and without renal dysfunction.",CHRONIC PAIN,MEPERIDINE
3819,MEPERIDINE treats CHRONIC PAIN,treats,0.956182887467515,"• A study of MEPERIDINE used for postoperative or CHRONIC PAIN found a high incidence of neuroexcitatory effects including nervousness, twitches, myoclonus, and seizures, as well as adverse mood alterations in patients with and without renal dysfunction.",CHRONIC PAIN,MEPERIDINE
3820,MEPERIDINE treats CHRONIC PAIN,treats,0.956182887467515,"• A study of MEPERIDINE used for postoperative or CHRONIC PAIN found a high incidence of neuroexcitatory effects including nervousness, twitches, myoclonus, and seizures, as well as adverse mood alterations in patients with and without renal dysfunction.",CHRONIC PAIN,MEPERIDINE
3821,no_relation,treats,0.956182887467515,"• A study of MEPERIDINE used for postoperative or CHRONIC PAIN found a high incidence of neuroexcitatory effects including nervousness, twitches, myoclonus, and seizures, as well as adverse mood alterations in patients with and without renal dysfunction.",CHRONIC PAIN,MEPERIDINE
3822,no_relation,treats,0.488677777425221,"Antimicrobial therapy should be changed to an active drug when in vitro resistance is noted even though the patient may appear to be improving Blood tests (CBC, ESR, CRP, electrolytes, BUN, creatinine, GLUCOSE pregnancy test, cultures)         To determine the severity of infection and underlying conditions such as renal failure, DEHYDRATION diabetes, and pregnancy.",DEHYDRATION,GLUCOSE
3823,no_relation,treats,0.488677777425221,"Antimicrobial therapy should be changed to an active drug when in vitro resistance is noted even though the patient may appear to be improving Blood tests (CBC, ESR, CRP, electrolytes, BUN, creatinine, GLUCOSE pregnancy test, cultures)         To determine the severity of infection and underlying conditions such as renal failure, DEHYDRATION diabetes, and pregnancy.",DEHYDRATION,GLUCOSE
3824,no_relation,treats,0.488677777425221,"Antimicrobial therapy should be changed to an active drug when in vitro resistance is noted even though the patient may appear to be improving Blood tests (CBC, ESR, CRP, electrolytes, BUN, creatinine, GLUCOSE pregnancy test, cultures)         To determine the severity of infection and underlying conditions such as renal failure, DEHYDRATION diabetes, and pregnancy.",DEHYDRATION,GLUCOSE
3825,GLUCOSE treats DEHYDRATION,treats,0.488677777425221,"Antimicrobial therapy should be changed to an active drug when in vitro resistance is noted even though the patient may appear to be improving Blood tests (CBC, ESR, CRP, electrolytes, BUN, creatinine, GLUCOSE pregnancy test, cultures)         To determine the severity of infection and underlying conditions such as renal failure, DEHYDRATION diabetes, and pregnancy.",DEHYDRATION,GLUCOSE
3826,GLUCOSE treats DEHYDRATION,treats,0.488677777425221,"Antimicrobial therapy should be changed to an active drug when in vitro resistance is noted even though the patient may appear to be improving Blood tests (CBC, ESR, CRP, electrolytes, BUN, creatinine, GLUCOSE pregnancy test, cultures)         To determine the severity of infection and underlying conditions such as renal failure, DEHYDRATION diabetes, and pregnancy.",DEHYDRATION,GLUCOSE
3827,GLUCOSE treats DEHYDRATION,treats,0.488677777425221,"Antimicrobial therapy should be changed to an active drug when in vitro resistance is noted even though the patient may appear to be improving Blood tests (CBC, ESR, CRP, electrolytes, BUN, creatinine, GLUCOSE pregnancy test, cultures)         To determine the severity of infection and underlying conditions such as renal failure, DEHYDRATION diabetes, and pregnancy.",DEHYDRATION,GLUCOSE
3828,no_relation,treats,0.488677777425221,"Antimicrobial therapy should be changed to an active drug when in vitro resistance is noted even though the patient may appear to be improving Blood tests (CBC, ESR, CRP, electrolytes, BUN, creatinine, GLUCOSE pregnancy test, cultures)         To determine the severity of infection and underlying conditions such as renal failure, DEHYDRATION diabetes, and pregnancy.",DEHYDRATION,GLUCOSE
3829,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING],treats,0.920574617898323,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING] properties.",[TUMOR SHRINKING],[CAFFEIC ACID PHENETHYL ESTER]
3830,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING],treats,0.920574617898323,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING] properties.",[TUMOR SHRINKING],[CAFFEIC ACID PHENETHYL ESTER]
3831,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING],treats,0.920574617898323,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING] properties.",[TUMOR SHRINKING],[CAFFEIC ACID PHENETHYL ESTER]
3832,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING],treats,0.920574617898323,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING] properties.",[TUMOR SHRINKING],[CAFFEIC ACID PHENETHYL ESTER]
3833,[CAFFEIC ACID PHENETHYL ESTER] treats [TUMOR SHRINKING],treats,0.920574617898323,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING] properties.",[TUMOR SHRINKING],[CAFFEIC ACID PHENETHYL ESTER]
3834,no_relation,treats,0.920574617898323,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING] properties.",[TUMOR SHRINKING],[CAFFEIC ACID PHENETHYL ESTER]
3835,[TUMOR SHRINKING] treats [CAFFEIC ACID PHENETHYL ESTER],treats,0.920574617898323,"Caffeic acid and its derivative, [CAFFEIC ACID PHENETHYL ESTER] have shown [TUMOR SHRINKING] properties.",[TUMOR SHRINKING],[CAFFEIC ACID PHENETHYL ESTER]
3836,GANCICLOVIR PROPHYLAXIS treats CMV INFECTION,treats,0.971285862357264,"GANCICLOVIR PROPHYLAXIS beginning at the time of engraftment can prevent the development of CMV INFECTION in most patients, but ganciclovir causes significant marrow suppression in at least 30% of patients.",CMV INFECTION,GANCICLOVIR PROPHYLAXIS
3837,GANCICLOVIR PROPHYLAXIS treats CMV INFECTION,treats,0.971285862357264,"GANCICLOVIR PROPHYLAXIS beginning at the time of engraftment can prevent the development of CMV INFECTION in most patients, but ganciclovir causes significant marrow suppression in at least 30% of patients.",CMV INFECTION,GANCICLOVIR PROPHYLAXIS
3838,GANCICLOVIR PROPHYLAXIS treats CMV INFECTION,treats,0.971285862357264,"GANCICLOVIR PROPHYLAXIS beginning at the time of engraftment can prevent the development of CMV INFECTION in most patients, but ganciclovir causes significant marrow suppression in at least 30% of patients.",CMV INFECTION,GANCICLOVIR PROPHYLAXIS
3839,GANCICLOVIR PROPHYLAXIS treats CMV INFECTION,treats,0.971285862357264,"GANCICLOVIR PROPHYLAXIS beginning at the time of engraftment can prevent the development of CMV INFECTION in most patients, but ganciclovir causes significant marrow suppression in at least 30% of patients.",CMV INFECTION,GANCICLOVIR PROPHYLAXIS
3840,no_relation,treats,0.971285862357264,"GANCICLOVIR PROPHYLAXIS beginning at the time of engraftment can prevent the development of CMV INFECTION in most patients, but ganciclovir causes significant marrow suppression in at least 30% of patients.",CMV INFECTION,GANCICLOVIR PROPHYLAXIS
3841,GANCICLOVIR PROPHYLAXIS treats CMV INFECTION,treats,0.971285862357264,"GANCICLOVIR PROPHYLAXIS beginning at the time of engraftment can prevent the development of CMV INFECTION in most patients, but ganciclovir causes significant marrow suppression in at least 30% of patients.",CMV INFECTION,GANCICLOVIR PROPHYLAXIS
3842,GANCICLOVIR PROPHYLAXIS treats CMV INFECTION,treats,0.971285862357264,"GANCICLOVIR PROPHYLAXIS beginning at the time of engraftment can prevent the development of CMV INFECTION in most patients, but ganciclovir causes significant marrow suppression in at least 30% of patients.",CMV INFECTION,GANCICLOVIR PROPHYLAXIS
3843,no_relation,treats,0.9258200997725508,"Certain spermicides and contraceptive creams can kill [L ACIDOPHILUS] in the vagina, clearing the path to possible [YEAST INFECTIONS].",[YEAST INFECTIONS],[L ACIDOPHILUS]
3844,[YEAST INFECTIONS] treats [L ACIDOPHILUS],treats,0.9258200997725508,"Certain spermicides and contraceptive creams can kill [L ACIDOPHILUS] in the vagina, clearing the path to possible [YEAST INFECTIONS].",[YEAST INFECTIONS],[L ACIDOPHILUS]
3845,no_relation,treats,0.9258200997725508,"Certain spermicides and contraceptive creams can kill [L ACIDOPHILUS] in the vagina, clearing the path to possible [YEAST INFECTIONS].",[YEAST INFECTIONS],[L ACIDOPHILUS]
3846,no_relation,treats,0.9258200997725508,"Certain spermicides and contraceptive creams can kill [L ACIDOPHILUS] in the vagina, clearing the path to possible [YEAST INFECTIONS].",[YEAST INFECTIONS],[L ACIDOPHILUS]
3847,no_relation,treats,0.9258200997725508,"Certain spermicides and contraceptive creams can kill [L ACIDOPHILUS] in the vagina, clearing the path to possible [YEAST INFECTIONS].",[YEAST INFECTIONS],[L ACIDOPHILUS]
3848,no_relation,treats,0.9258200997725508,"Certain spermicides and contraceptive creams can kill [L ACIDOPHILUS] in the vagina, clearing the path to possible [YEAST INFECTIONS].",[YEAST INFECTIONS],[L ACIDOPHILUS]
3849,no_relation,treats,0.9258200997725508,"Certain spermicides and contraceptive creams can kill [L ACIDOPHILUS] in the vagina, clearing the path to possible [YEAST INFECTIONS].",[YEAST INFECTIONS],[L ACIDOPHILUS]
3850,CLOZAPINE treats SCHIZOPHRENIA,treats,0.993127066322842,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3851,CLOZAPINE treats SCHIZOPHRENIA,treats,0.993127066322842,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3852,CLOZAPINE treats SCHIZOPHRENIA,treats,0.993127066322842,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3853,CLOZAPINE treats SCHIZOPHRENIA,treats,0.993127066322842,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3854,CLOZAPINE treats SCHIZOPHRENIA,treats,0.993127066322842,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3855,no_relation,treats,0.993127066322842,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3856,CLOZAPINE treats SCHIZOPHRENIA,treats,0.993127066322842,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE
3857,EPIDRIN treats MIGRAINE,treats,0.9712858624,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including [EPIDRIN] and Midrin.",MIGRAINE,EPIDRIN
3858,EPIDRIN treats MIGRAINE,treats,0.9712858624,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including [EPIDRIN] and Midrin.",MIGRAINE,EPIDRIN
3859,EPIDRIN treats MIGRAINE,treats,0.9712858624,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including [EPIDRIN] and Midrin.",MIGRAINE,EPIDRIN
3860,EPIDRIN treats MIGRAINE,treats,0.9712858624,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including [EPIDRIN] and Midrin.",MIGRAINE,EPIDRIN
3861,EPIDRIN treats MIGRAINE,treats,0.9712858624,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including [EPIDRIN] and Midrin.",MIGRAINE,EPIDRIN
3862,EPIDRIN treats MIGRAINE,treats,0.9712858624,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including [EPIDRIN] and Midrin.",MIGRAINE,EPIDRIN
3863,EPIDRIN treats MIGRAINE,treats,0.9712858624,"In combination with paracetamol and isometheptene, it is the active ingredient of medications for [MIGRAINE] and vascular headaches, including [EPIDRIN] and Midrin.",MIGRAINE,EPIDRIN
3864,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
3865,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
3866,no_relation,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
3867,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
3868,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
3869,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
3870,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
3871,no_relation,treats,0.676123403782813,It is approved as monotherapy or adjunctive treatment for the LENNOX GASTAUT SYNDROME (absence variant) and for akinetic and myoclonic SEIZURES,SEIZURES,LENNOX GASTAUT SYNDROME
3872,no_relation,treats,0.676123403782813,It is approved as monotherapy or adjunctive treatment for the LENNOX GASTAUT SYNDROME (absence variant) and for akinetic and myoclonic SEIZURES,SEIZURES,LENNOX GASTAUT SYNDROME
3873,no_relation,treats,0.676123403782813,It is approved as monotherapy or adjunctive treatment for the LENNOX GASTAUT SYNDROME (absence variant) and for akinetic and myoclonic SEIZURES,SEIZURES,LENNOX GASTAUT SYNDROME
3874,LENNOX GASTAUT SYNDROME treats SEIZURES,treats,0.676123403782813,It is approved as monotherapy or adjunctive treatment for the LENNOX GASTAUT SYNDROME (absence variant) and for akinetic and myoclonic SEIZURES,SEIZURES,LENNOX GASTAUT SYNDROME
3875,no_relation,treats,0.676123403782813,It is approved as monotherapy or adjunctive treatment for the LENNOX GASTAUT SYNDROME (absence variant) and for akinetic and myoclonic SEIZURES,SEIZURES,LENNOX GASTAUT SYNDROME
3876,no_relation,treats,0.676123403782813,It is approved as monotherapy or adjunctive treatment for the LENNOX GASTAUT SYNDROME (absence variant) and for akinetic and myoclonic SEIZURES,SEIZURES,LENNOX GASTAUT SYNDROME
3877,LENNOX GASTAUT SYNDROME treats SEIZURES,treats,0.676123403782813,It is approved as monotherapy or adjunctive treatment for the LENNOX GASTAUT SYNDROME (absence variant) and for akinetic and myoclonic SEIZURES,SEIZURES,LENNOX GASTAUT SYNDROME
3878,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
3879,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
3880,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
3881,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
3882,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
3883,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
3884,CHOLECALCIFEROL treats OSTEOPOROSIS,treats,1.0,Alendronate is used alone or in fixed combination with CHOLECALCIFEROL (vitamin D 3 ) for treatment of OSTEOPOROSIS in postmenopausal women,OSTEOPOROSIS,CHOLECALCIFEROL
3885,MORPHINE treats DYSPNEA,treats,0.880450906325624,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
3886,MORPHINE treats DYSPNEA,treats,0.880450906325624,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
3887,MORPHINE treats DYSPNEA,treats,0.880450906325624,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
3888,MORPHINE treats DYSPNEA,treats,0.880450906325624,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
3889,MORPHINE treats DYSPNEA,treats,0.880450906325624,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
3890,MORPHINE treats DYSPNEA,treats,0.880450906325624,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
3891,MORPHINE treats DYSPNEA,treats,0.880450906325624,"Low dose MORPHINE may blunt the medullary response to CO 2  retention or O 2  decline, reducing DYSPNEA and decreasing anxiety without causing significant respiratory depression.",DYSPNEA,MORPHINE
3892,LIPOSOMAL AMPHOTERICIN B GROUP treats FUNGAL INFECTIONS,treats,0.8219949365267859,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
3893,LIPOSOMAL AMPHOTERICIN B GROUP treats FUNGAL INFECTIONS,treats,0.8219949365267859,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
3894,LIPOSOMAL AMPHOTERICIN B GROUP treats FUNGAL INFECTIONS,treats,0.8219949365267859,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
3895,LIPOSOMAL AMPHOTERICIN B GROUP treats FUNGAL INFECTIONS,treats,0.8219949365267859,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
3896,no_relation,treats,0.8219949365267859,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
3897,LIPOSOMAL AMPHOTERICIN B GROUP treats FUNGAL INFECTIONS,treats,0.8219949365267859,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
3898,no_relation,treats,0.8219949365267859,"Success rates were similar between treatment groups, but there were fewer documented breakthrough FUNGAL INFECTIONS in the LIPOSOMAL AMPHOTERICIN B GROUP ( 215.",FUNGAL INFECTIONS,LIPOSOMAL AMPHOTERICIN B GROUP
3899,[BACLOFEN] treats [SPACE SURROUNDING THE SPINAL CORD],treats,0.569209978830308,The pump delivers [BACLOFEN] via a catheter to the thecal [SPACE SURROUNDING THE SPINAL CORD],[SPACE SURROUNDING THE SPINAL CORD],[BACLOFEN]
3900,[BACLOFEN] treats [SPACE SURROUNDING THE SPINAL CORD],treats,0.569209978830308,The pump delivers [BACLOFEN] via a catheter to the thecal [SPACE SURROUNDING THE SPINAL CORD],[SPACE SURROUNDING THE SPINAL CORD],[BACLOFEN]
3901,[BACLOFEN] treats [SPACE SURROUNDING THE SPINAL CORD],treats,0.569209978830308,The pump delivers [BACLOFEN] via a catheter to the thecal [SPACE SURROUNDING THE SPINAL CORD],[SPACE SURROUNDING THE SPINAL CORD],[BACLOFEN]
3902,no_relation,treats,0.569209978830308,The pump delivers [BACLOFEN] via a catheter to the thecal [SPACE SURROUNDING THE SPINAL CORD],[SPACE SURROUNDING THE SPINAL CORD],[BACLOFEN]
3903,[BACLOFEN] treats [SPACE SURROUNDING THE SPINAL CORD],treats,0.569209978830308,The pump delivers [BACLOFEN] via a catheter to the thecal [SPACE SURROUNDING THE SPINAL CORD],[SPACE SURROUNDING THE SPINAL CORD],[BACLOFEN]
3904,[BACLOFEN] treats [SPACE SURROUNDING THE SPINAL CORD],treats,0.569209978830308,The pump delivers [BACLOFEN] via a catheter to the thecal [SPACE SURROUNDING THE SPINAL CORD],[SPACE SURROUNDING THE SPINAL CORD],[BACLOFEN]
3905,[BACLOFEN] treats [SPACE SURROUNDING THE SPINAL CORD],treats,0.569209978830308,The pump delivers [BACLOFEN] via a catheter to the thecal [SPACE SURROUNDING THE SPINAL CORD],[SPACE SURROUNDING THE SPINAL CORD],[BACLOFEN]
3906,DIURETIC treats FLUID RETENTION,treats,0.986393923832144,"Diazoxide can cause [FLUID RETENTION] requiring concomitant use of a [DIURETIC], and prolonged use causes hypertrichosis.",FLUID RETENTION,DIURETIC
3907,DIURETIC treats FLUID RETENTION,treats,0.986393923832144,"Diazoxide can cause [FLUID RETENTION] requiring concomitant use of a [DIURETIC], and prolonged use causes hypertrichosis.",FLUID RETENTION,DIURETIC
3908,DIURETIC treats FLUID RETENTION,treats,0.986393923832144,"Diazoxide can cause [FLUID RETENTION] requiring concomitant use of a [DIURETIC], and prolonged use causes hypertrichosis.",FLUID RETENTION,DIURETIC
3909,DIURETIC treats FLUID RETENTION,treats,0.986393923832144,"Diazoxide can cause [FLUID RETENTION] requiring concomitant use of a [DIURETIC], and prolonged use causes hypertrichosis.",FLUID RETENTION,DIURETIC
3910,no_relation,treats,0.986393923832144,"Diazoxide can cause [FLUID RETENTION] requiring concomitant use of a [DIURETIC], and prolonged use causes hypertrichosis.",FLUID RETENTION,DIURETIC
3911,FLUID RETENTION treats DIURETIC,treats,0.986393923832144,"Diazoxide can cause [FLUID RETENTION] requiring concomitant use of a [DIURETIC], and prolonged use causes hypertrichosis.",FLUID RETENTION,DIURETIC
3912,DIURETIC treats FLUID RETENTION,treats,0.986393923832144,"Diazoxide can cause [FLUID RETENTION] requiring concomitant use of a [DIURETIC], and prolonged use causes hypertrichosis.",FLUID RETENTION,DIURETIC
3913,[IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.9113223768657672,"Intra arterial [IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[IODINE 131 LIPIODOL]
3914,[IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.9113223768657672,"Intra arterial [IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[IODINE 131 LIPIODOL]
3915,[IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.9113223768657672,"Intra arterial [IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[IODINE 131 LIPIODOL]
3916,[IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.9113223768657672,"Intra arterial [IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[IODINE 131 LIPIODOL]
3917,[IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.9113223768657672,"Intra arterial [IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[IODINE 131 LIPIODOL]
3918,[IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.9113223768657672,"Intra arterial [IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[IODINE 131 LIPIODOL]
3919,[IODINE 131 LIPIODOL] treats [VEIN THROMBUS],treats,0.9113223768657672,"Intra arterial [IODINE 131 LIPIODOL] administration Efficacy demonstrated in unresectable patients, those with portal [VEIN THROMBUS]",[VEIN THROMBUS],[IODINE 131 LIPIODOL]
3920,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,Low molecular weight heparin vs HEPARIN in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
3921,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,Low molecular weight heparin vs HEPARIN in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
3922,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,Low molecular weight heparin vs HEPARIN in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
3923,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,Low molecular weight heparin vs HEPARIN in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
3924,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,Low molecular weight heparin vs HEPARIN in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
3925,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,Low molecular weight heparin vs HEPARIN in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
3926,HEPARIN treats PULMONARY EMBOLISM,treats,1.0,Low molecular weight heparin vs HEPARIN in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
3927,MSM treats HAYFEVER,treats,0.99654575824488,Seasonal Allergic Rhinitis: Barrager et al. evaluated the efficacy of [MSM] for [HAYFEVER].,HAYFEVER,MSM
3928,MSM treats HAYFEVER,treats,0.99654575824488,Seasonal Allergic Rhinitis: Barrager et al. evaluated the efficacy of [MSM] for [HAYFEVER].,HAYFEVER,MSM
3929,MSM treats HAYFEVER,treats,0.99654575824488,Seasonal Allergic Rhinitis: Barrager et al. evaluated the efficacy of [MSM] for [HAYFEVER].,HAYFEVER,MSM
3930,MSM treats HAYFEVER,treats,0.99654575824488,Seasonal Allergic Rhinitis: Barrager et al. evaluated the efficacy of [MSM] for [HAYFEVER].,HAYFEVER,MSM
3931,MSM treats HAYFEVER,treats,0.99654575824488,Seasonal Allergic Rhinitis: Barrager et al. evaluated the efficacy of [MSM] for [HAYFEVER].,HAYFEVER,MSM
3932,MSM treats HAYFEVER,treats,0.99654575824488,Seasonal Allergic Rhinitis: Barrager et al. evaluated the efficacy of [MSM] for [HAYFEVER].,HAYFEVER,MSM
3933,MSM treats HAYFEVER,treats,0.99654575824488,Seasonal Allergic Rhinitis: Barrager et al. evaluated the efficacy of [MSM] for [HAYFEVER].,HAYFEVER,MSM
3934,no_relation,treats,0.8551861104941371,<ref> ICAAC: N[OVEL ANTIBIO]tic Stops Travel[ERS' DIAR]rhea.,[ERS' DIAR],[OVEL ANTIBIO]
3935,[OVEL ANTIBIO] treats [ERS' DIAR],treats,0.8551861104941371,<ref> ICAAC: N[OVEL ANTIBIO]tic Stops Travel[ERS' DIAR]rhea.,[ERS' DIAR],[OVEL ANTIBIO]
3936,no_relation,treats,0.8551861104941371,<ref> ICAAC: N[OVEL ANTIBIO]tic Stops Travel[ERS' DIAR]rhea.,[ERS' DIAR],[OVEL ANTIBIO]
3937,[OVEL ANTIBIO] treats [ERS' DIAR],treats,0.8551861104941371,<ref> ICAAC: N[OVEL ANTIBIO]tic Stops Travel[ERS' DIAR]rhea.,[ERS' DIAR],[OVEL ANTIBIO]
3938,no_relation,treats,0.8551861104941371,<ref> ICAAC: N[OVEL ANTIBIO]tic Stops Travel[ERS' DIAR]rhea.,[ERS' DIAR],[OVEL ANTIBIO]
3939,[OVEL ANTIBIO] treats [ERS' DIAR],treats,0.8551861104941371,<ref> ICAAC: N[OVEL ANTIBIO]tic Stops Travel[ERS' DIAR]rhea.,[ERS' DIAR],[OVEL ANTIBIO]
3940,[OVEL ANTIBIO] treats [ERS' DIAR],treats,0.8551861104941371,<ref> ICAAC: N[OVEL ANTIBIO]tic Stops Travel[ERS' DIAR]rhea.,[ERS' DIAR],[OVEL ANTIBIO]
3941,no_relation,treats,0.371390676354104,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
3942,no_relation,treats,0.371390676354104,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
3943,no_relation,treats,0.371390676354104,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
3944,no_relation,treats,0.371390676354104,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
3945,no_relation,treats,0.371390676354104,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
3946,UNILATERAL HEMIFACIAL MICROSOMIA treats BILATERAL MANDIBULAR HYPOPLASIA,treats,0.371390676354104,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
3947,no_relation,treats,0.371390676354104,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
3948,no_relation,treats,0.668153104781061,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
3949,no_relation,treats,0.668153104781061,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
3950,no_relation,treats,0.668153104781061,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
3951,no_relation,treats,0.668153104781061,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
3952,no_relation,treats,0.668153104781061,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
3953,METASTATIC LESION treats METASTASES,treats,0.668153104781061,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
3954,no_relation,treats,0.668153104781061,"In cases of known METASTASES surgical resection of the kidney ('cytoreductive nephrectomy') may improve survival,[43] as well as resection of a solitary METASTATIC LESION...",METASTATIC LESION,METASTASES
3955,[SYSTEMIC MONTELUKAST] treats [OCULAR ITCHING],treats,0.997176464952738,"However, [SYSTEMIC MONTELUKAST] as expected, provided better relief for symptoms distant from the nasal cavity such as [OCULAR ITCHING] and throat/palate itching.",[OCULAR ITCHING],[SYSTEMIC MONTELUKAST]
3956,[SYSTEMIC MONTELUKAST] treats [OCULAR ITCHING],treats,0.997176464952738,"However, [SYSTEMIC MONTELUKAST] as expected, provided better relief for symptoms distant from the nasal cavity such as [OCULAR ITCHING] and throat/palate itching.",[OCULAR ITCHING],[SYSTEMIC MONTELUKAST]
3957,[SYSTEMIC MONTELUKAST] treats [OCULAR ITCHING],treats,0.997176464952738,"However, [SYSTEMIC MONTELUKAST] as expected, provided better relief for symptoms distant from the nasal cavity such as [OCULAR ITCHING] and throat/palate itching.",[OCULAR ITCHING],[SYSTEMIC MONTELUKAST]
3958,[SYSTEMIC MONTELUKAST] treats [OCULAR ITCHING],treats,0.997176464952738,"However, [SYSTEMIC MONTELUKAST] as expected, provided better relief for symptoms distant from the nasal cavity such as [OCULAR ITCHING] and throat/palate itching.",[OCULAR ITCHING],[SYSTEMIC MONTELUKAST]
3959,[SYSTEMIC MONTELUKAST] treats [OCULAR ITCHING],treats,0.997176464952738,"However, [SYSTEMIC MONTELUKAST] as expected, provided better relief for symptoms distant from the nasal cavity such as [OCULAR ITCHING] and throat/palate itching.",[OCULAR ITCHING],[SYSTEMIC MONTELUKAST]
3960,[SYSTEMIC MONTELUKAST] treats [OCULAR ITCHING],treats,0.997176464952738,"However, [SYSTEMIC MONTELUKAST] as expected, provided better relief for symptoms distant from the nasal cavity such as [OCULAR ITCHING] and throat/palate itching.",[OCULAR ITCHING],[SYSTEMIC MONTELUKAST]
3961,[SYSTEMIC MONTELUKAST] treats [OCULAR ITCHING],treats,0.997176464952738,"However, [SYSTEMIC MONTELUKAST] as expected, provided better relief for symptoms distant from the nasal cavity such as [OCULAR ITCHING] and throat/palate itching.",[OCULAR ITCHING],[SYSTEMIC MONTELUKAST]
3962,no_relation,treats,0.9970544855015808,DRUG THERAPY  Introduction  Administer FACTOR VIII or factor IX replacement in patients with HEMOPHILIA A OR B for treatment of or prophylaxis against bleeding.,HEMOPHILIA A OR B,FACTOR VIII
3963,no_relation,treats,0.9970544855015808,DRUG THERAPY  Introduction  Administer FACTOR VIII or factor IX replacement in patients with HEMOPHILIA A OR B for treatment of or prophylaxis against bleeding.,HEMOPHILIA A OR B,FACTOR VIII
3964,no_relation,treats,0.9970544855015808,DRUG THERAPY  Introduction  Administer FACTOR VIII or factor IX replacement in patients with HEMOPHILIA A OR B for treatment of or prophylaxis against bleeding.,HEMOPHILIA A OR B,FACTOR VIII
3965,FACTOR VIII treats HEMOPHILIA A OR B,treats,0.9970544855015808,DRUG THERAPY  Introduction  Administer FACTOR VIII or factor IX replacement in patients with HEMOPHILIA A OR B for treatment of or prophylaxis against bleeding.,HEMOPHILIA A OR B,FACTOR VIII
3966,FACTOR VIII treats HEMOPHILIA A OR B,treats,0.9970544855015808,DRUG THERAPY  Introduction  Administer FACTOR VIII or factor IX replacement in patients with HEMOPHILIA A OR B for treatment of or prophylaxis against bleeding.,HEMOPHILIA A OR B,FACTOR VIII
3967,FACTOR VIII treats HEMOPHILIA A OR B,treats,0.9970544855015808,DRUG THERAPY  Introduction  Administer FACTOR VIII or factor IX replacement in patients with HEMOPHILIA A OR B for treatment of or prophylaxis against bleeding.,HEMOPHILIA A OR B,FACTOR VIII
3968,FACTOR VIII treats HEMOPHILIA A OR B,treats,0.9970544855015808,DRUG THERAPY  Introduction  Administer FACTOR VIII or factor IX replacement in patients with HEMOPHILIA A OR B for treatment of or prophylaxis against bleeding.,HEMOPHILIA A OR B,FACTOR VIII
3969,no_relation,treats,0.597614304667197,[ALGINIC ACID] may coat the mucosa as well as [INCREASE PH] and decrease reflux.,INCREASE PH,ALGINIC ACID
3970,no_relation,treats,0.597614304667197,[ALGINIC ACID] may coat the mucosa as well as [INCREASE PH] and decrease reflux.,INCREASE PH,ALGINIC ACID
3971,no_relation,treats,0.597614304667197,[ALGINIC ACID] may coat the mucosa as well as [INCREASE PH] and decrease reflux.,INCREASE PH,ALGINIC ACID
3972,no_relation,treats,0.597614304667197,[ALGINIC ACID] may coat the mucosa as well as [INCREASE PH] and decrease reflux.,INCREASE PH,ALGINIC ACID
3973,no_relation,treats,0.597614304667197,[ALGINIC ACID] may coat the mucosa as well as [INCREASE PH] and decrease reflux.,INCREASE PH,ALGINIC ACID
3974,ALGINIC ACID treats INCREASE PH,treats,0.597614304667197,[ALGINIC ACID] may coat the mucosa as well as [INCREASE PH] and decrease reflux.,INCREASE PH,ALGINIC ACID
3975,ALGINIC ACID treats INCREASE PH,treats,0.597614304667197,[ALGINIC ACID] may coat the mucosa as well as [INCREASE PH] and decrease reflux.,INCREASE PH,ALGINIC ACID
3976,DISOPYRAMIDE treats COUPLET,treats,0.997458699830735,"Compared with [DISOPYRAMIDE] and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, [COUPLET]s, and nonsustained ventricular tachycardia.",COUPLET,DISOPYRAMIDE
3977,no_relation,treats,0.997458699830735,"Compared with [DISOPYRAMIDE] and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, [COUPLET]s, and nonsustained ventricular tachycardia.",COUPLET,DISOPYRAMIDE
3978,DISOPYRAMIDE treats COUPLET,treats,0.997458699830735,"Compared with [DISOPYRAMIDE] and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, [COUPLET]s, and nonsustained ventricular tachycardia.",COUPLET,DISOPYRAMIDE
3979,DISOPYRAMIDE treats COUPLET,treats,0.997458699830735,"Compared with [DISOPYRAMIDE] and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, [COUPLET]s, and nonsustained ventricular tachycardia.",COUPLET,DISOPYRAMIDE
3980,DISOPYRAMIDE treats COUPLET,treats,0.997458699830735,"Compared with [DISOPYRAMIDE] and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, [COUPLET]s, and nonsustained ventricular tachycardia.",COUPLET,DISOPYRAMIDE
3981,DISOPYRAMIDE treats COUPLET,treats,0.997458699830735,"Compared with [DISOPYRAMIDE] and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, [COUPLET]s, and nonsustained ventricular tachycardia.",COUPLET,DISOPYRAMIDE
3982,DISOPYRAMIDE treats COUPLET,treats,0.997458699830735,"Compared with [DISOPYRAMIDE] and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, [COUPLET]s, and nonsustained ventricular tachycardia.",COUPLET,DISOPYRAMIDE
3983,MALATHION treats HEAD LICE,treats,1.0,MALATHION for treatment of HEAD LICE,HEAD LICE,MALATHION
3984,MALATHION treats HEAD LICE,treats,1.0,MALATHION for treatment of HEAD LICE,HEAD LICE,MALATHION
3985,MALATHION treats HEAD LICE,treats,1.0,MALATHION for treatment of HEAD LICE,HEAD LICE,MALATHION
3986,MALATHION treats HEAD LICE,treats,1.0,MALATHION for treatment of HEAD LICE,HEAD LICE,MALATHION
3987,MALATHION treats HEAD LICE,treats,1.0,MALATHION for treatment of HEAD LICE,HEAD LICE,MALATHION
3988,MALATHION treats HEAD LICE,treats,1.0,MALATHION for treatment of HEAD LICE,HEAD LICE,MALATHION
3989,MALATHION treats HEAD LICE,treats,1.0,MALATHION for treatment of HEAD LICE,HEAD LICE,MALATHION
3990,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.964901281354015,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3991,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.964901281354015,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3992,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.964901281354015,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3993,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.964901281354015,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3994,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.964901281354015,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3995,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.964901281354015,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3996,LOVASTATIN treats HYPERCHOLESTEROLEMIA,treats,0.964901281354015,"Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus lovastatin, pravastatin, LOVASTATIN and fluvastatin in patients with HYPERCHOLESTEROLEMIA (the CURVES study.",HYPERCHOLESTEROLEMIA,LOVASTATIN
3997,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.966736489045664,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
3998,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.966736489045664,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
3999,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.966736489045664,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
4000,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.966736489045664,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
4001,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.966736489045664,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
4002,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.966736489045664,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
4003,CLINDAMYCIN treats SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,treats,0.966736489045664,161  For pyrimethamine dosages of 25 50 mg once daily (given with CLINDAMYCIN or sulfadiazine for SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS): 10 25 mg once daily.,SECONDARY PROPHYLAXIS OF TOXOPLASMOSIS,CLINDAMYCIN
4004,ALEMTUZUMAB treats CELL CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.99654575824488,"2]  Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: ALEMTUZUMAB as single agent treatment for B CELL CHRONIC LYMPHOCYTIC LEUKEMIA",CELL CHRONIC LYMPHOCYTIC LEUKEMIA,ALEMTUZUMAB
4005,ALEMTUZUMAB treats CELL CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.99654575824488,"2]  Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: ALEMTUZUMAB as single agent treatment for B CELL CHRONIC LYMPHOCYTIC LEUKEMIA",CELL CHRONIC LYMPHOCYTIC LEUKEMIA,ALEMTUZUMAB
4006,ALEMTUZUMAB treats CELL CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.99654575824488,"2]  Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: ALEMTUZUMAB as single agent treatment for B CELL CHRONIC LYMPHOCYTIC LEUKEMIA",CELL CHRONIC LYMPHOCYTIC LEUKEMIA,ALEMTUZUMAB
4007,ALEMTUZUMAB treats CELL CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.99654575824488,"2]  Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: ALEMTUZUMAB as single agent treatment for B CELL CHRONIC LYMPHOCYTIC LEUKEMIA",CELL CHRONIC LYMPHOCYTIC LEUKEMIA,ALEMTUZUMAB
4008,ALEMTUZUMAB treats CELL CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.99654575824488,"2]  Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: ALEMTUZUMAB as single agent treatment for B CELL CHRONIC LYMPHOCYTIC LEUKEMIA",CELL CHRONIC LYMPHOCYTIC LEUKEMIA,ALEMTUZUMAB
4009,ALEMTUZUMAB treats CELL CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.99654575824488,"2]  Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: ALEMTUZUMAB as single agent treatment for B CELL CHRONIC LYMPHOCYTIC LEUKEMIA",CELL CHRONIC LYMPHOCYTIC LEUKEMIA,ALEMTUZUMAB
4010,ALEMTUZUMAB treats CELL CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.99654575824488,"2]  Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: ALEMTUZUMAB as single agent treatment for B CELL CHRONIC LYMPHOCYTIC LEUKEMIA",CELL CHRONIC LYMPHOCYTIC LEUKEMIA,ALEMTUZUMAB
4011,[NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.99654575824488,Ziconotide is a non opioid and non [NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NSAID ANALGESIC AGENT]
4012,[NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.99654575824488,Ziconotide is a non opioid and non [NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NSAID ANALGESIC AGENT]
4013,[NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.99654575824488,Ziconotide is a non opioid and non [NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NSAID ANALGESIC AGENT]
4014,no_relation,treats,0.99654575824488,Ziconotide is a non opioid and non [NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NSAID ANALGESIC AGENT]
4015,[NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.99654575824488,Ziconotide is a non opioid and non [NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NSAID ANALGESIC AGENT]
4016,[NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.99654575824488,Ziconotide is a non opioid and non [NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NSAID ANALGESIC AGENT]
4017,[NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,0.99654575824488,Ziconotide is a non opioid and non [NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NSAID ANALGESIC AGENT]
4018,RIBAVIRIN treats CHRONIC HEPATITIS C VIRUS (HCV INFECTION),treats,0.9918365981341752,b  Treatment of CHRONIC HEPATITIS C VIRUS (HCV INFECTION)  >    Concomitant Therapy with Interferon Alfa 2b (Intron ®  A) and RIBAVIRIN  Sub Q:  Children ≥3 years of age: Interferon alfa 2b 3 million units 3 times weekly.,CHRONIC HEPATITIS C VIRUS (HCV INFECTION),RIBAVIRIN
4019,RIBAVIRIN treats CHRONIC HEPATITIS C VIRUS (HCV INFECTION),treats,0.9918365981341752,b  Treatment of CHRONIC HEPATITIS C VIRUS (HCV INFECTION)  >    Concomitant Therapy with Interferon Alfa 2b (Intron ®  A) and RIBAVIRIN  Sub Q:  Children ≥3 years of age: Interferon alfa 2b 3 million units 3 times weekly.,CHRONIC HEPATITIS C VIRUS (HCV INFECTION),RIBAVIRIN
4020,RIBAVIRIN treats CHRONIC HEPATITIS C VIRUS (HCV INFECTION),treats,0.9918365981341752,b  Treatment of CHRONIC HEPATITIS C VIRUS (HCV INFECTION)  >    Concomitant Therapy with Interferon Alfa 2b (Intron ®  A) and RIBAVIRIN  Sub Q:  Children ≥3 years of age: Interferon alfa 2b 3 million units 3 times weekly.,CHRONIC HEPATITIS C VIRUS (HCV INFECTION),RIBAVIRIN
4021,RIBAVIRIN treats CHRONIC HEPATITIS C VIRUS (HCV INFECTION),treats,0.9918365981341752,b  Treatment of CHRONIC HEPATITIS C VIRUS (HCV INFECTION)  >    Concomitant Therapy with Interferon Alfa 2b (Intron ®  A) and RIBAVIRIN  Sub Q:  Children ≥3 years of age: Interferon alfa 2b 3 million units 3 times weekly.,CHRONIC HEPATITIS C VIRUS (HCV INFECTION),RIBAVIRIN
4022,RIBAVIRIN treats CHRONIC HEPATITIS C VIRUS (HCV INFECTION),treats,0.9918365981341752,b  Treatment of CHRONIC HEPATITIS C VIRUS (HCV INFECTION)  >    Concomitant Therapy with Interferon Alfa 2b (Intron ®  A) and RIBAVIRIN  Sub Q:  Children ≥3 years of age: Interferon alfa 2b 3 million units 3 times weekly.,CHRONIC HEPATITIS C VIRUS (HCV INFECTION),RIBAVIRIN
4023,RIBAVIRIN treats CHRONIC HEPATITIS C VIRUS (HCV INFECTION),treats,0.9918365981341752,b  Treatment of CHRONIC HEPATITIS C VIRUS (HCV INFECTION)  >    Concomitant Therapy with Interferon Alfa 2b (Intron ®  A) and RIBAVIRIN  Sub Q:  Children ≥3 years of age: Interferon alfa 2b 3 million units 3 times weekly.,CHRONIC HEPATITIS C VIRUS (HCV INFECTION),RIBAVIRIN
4024,RIBAVIRIN treats CHRONIC HEPATITIS C VIRUS (HCV INFECTION),treats,0.9918365981341752,b  Treatment of CHRONIC HEPATITIS C VIRUS (HCV INFECTION)  >    Concomitant Therapy with Interferon Alfa 2b (Intron ®  A) and RIBAVIRIN  Sub Q:  Children ≥3 years of age: Interferon alfa 2b 3 million units 3 times weekly.,CHRONIC HEPATITIS C VIRUS (HCV INFECTION),RIBAVIRIN
4025,no_relation,treats,0.994134846772434,Premedication with [CORTICOSTEROID]s is recommended before each administration of docetaxel to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,CORTICOSTEROID
4026,CORTICOSTEROID treats FLUID RETENTION,treats,0.994134846772434,Premedication with [CORTICOSTEROID]s is recommended before each administration of docetaxel to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,CORTICOSTEROID
4027,CORTICOSTEROID treats FLUID RETENTION,treats,0.994134846772434,Premedication with [CORTICOSTEROID]s is recommended before each administration of docetaxel to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,CORTICOSTEROID
4028,CORTICOSTEROID treats FLUID RETENTION,treats,0.994134846772434,Premedication with [CORTICOSTEROID]s is recommended before each administration of docetaxel to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,CORTICOSTEROID
4029,CORTICOSTEROID treats FLUID RETENTION,treats,0.994134846772434,Premedication with [CORTICOSTEROID]s is recommended before each administration of docetaxel to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,CORTICOSTEROID
4030,CORTICOSTEROID treats FLUID RETENTION,treats,0.994134846772434,Premedication with [CORTICOSTEROID]s is recommended before each administration of docetaxel to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,CORTICOSTEROID
4031,CORTICOSTEROID treats FLUID RETENTION,treats,0.994134846772434,Premedication with [CORTICOSTEROID]s is recommended before each administration of docetaxel to reduce [FLUID RETENTION] and hypersensitive reactions.,FLUID RETENTION,CORTICOSTEROID
4032,ASENAPINE treats ACUTE MANIA,treats,0.933256525257383,Organon Continues With The Development Of [ASENAPINE] For Schizophrenia And [ACUTE MANIA] Associated With Bipolar I Disorder.,ACUTE MANIA,ASENAPINE
4033,ASENAPINE treats ACUTE MANIA,treats,0.933256525257383,Organon Continues With The Development Of [ASENAPINE] For Schizophrenia And [ACUTE MANIA] Associated With Bipolar I Disorder.,ACUTE MANIA,ASENAPINE
4034,ASENAPINE treats ACUTE MANIA,treats,0.933256525257383,Organon Continues With The Development Of [ASENAPINE] For Schizophrenia And [ACUTE MANIA] Associated With Bipolar I Disorder.,ACUTE MANIA,ASENAPINE
4035,ASENAPINE treats ACUTE MANIA,treats,0.933256525257383,Organon Continues With The Development Of [ASENAPINE] For Schizophrenia And [ACUTE MANIA] Associated With Bipolar I Disorder.,ACUTE MANIA,ASENAPINE
4036,ASENAPINE treats ACUTE MANIA,treats,0.933256525257383,Organon Continues With The Development Of [ASENAPINE] For Schizophrenia And [ACUTE MANIA] Associated With Bipolar I Disorder.,ACUTE MANIA,ASENAPINE
4037,no_relation,treats,0.933256525257383,Organon Continues With The Development Of [ASENAPINE] For Schizophrenia And [ACUTE MANIA] Associated With Bipolar I Disorder.,ACUTE MANIA,ASENAPINE
4038,ASENAPINE treats ACUTE MANIA,treats,0.933256525257383,Organon Continues With The Development Of [ASENAPINE] For Schizophrenia And [ACUTE MANIA] Associated With Bipolar I Disorder.,ACUTE MANIA,ASENAPINE
4039,TRANSDERMAL FENTANYL treats CHRONIC PAIN,treats,1.0,"For CHRONIC PAIN long acting preparations (eg, TRANSDERMAL FENTANYL oxycodone, oxymorphone) are usually best.",CHRONIC PAIN,TRANSDERMAL FENTANYL
4040,TRANSDERMAL FENTANYL treats CHRONIC PAIN,treats,1.0,"For CHRONIC PAIN long acting preparations (eg, TRANSDERMAL FENTANYL oxycodone, oxymorphone) are usually best.",CHRONIC PAIN,TRANSDERMAL FENTANYL
4041,TRANSDERMAL FENTANYL treats CHRONIC PAIN,treats,1.0,"For CHRONIC PAIN long acting preparations (eg, TRANSDERMAL FENTANYL oxycodone, oxymorphone) are usually best.",CHRONIC PAIN,TRANSDERMAL FENTANYL
4042,TRANSDERMAL FENTANYL treats CHRONIC PAIN,treats,1.0,"For CHRONIC PAIN long acting preparations (eg, TRANSDERMAL FENTANYL oxycodone, oxymorphone) are usually best.",CHRONIC PAIN,TRANSDERMAL FENTANYL
4043,TRANSDERMAL FENTANYL treats CHRONIC PAIN,treats,1.0,"For CHRONIC PAIN long acting preparations (eg, TRANSDERMAL FENTANYL oxycodone, oxymorphone) are usually best.",CHRONIC PAIN,TRANSDERMAL FENTANYL
4044,TRANSDERMAL FENTANYL treats CHRONIC PAIN,treats,1.0,"For CHRONIC PAIN long acting preparations (eg, TRANSDERMAL FENTANYL oxycodone, oxymorphone) are usually best.",CHRONIC PAIN,TRANSDERMAL FENTANYL
4045,TRANSDERMAL FENTANYL treats CHRONIC PAIN,treats,1.0,"For CHRONIC PAIN long acting preparations (eg, TRANSDERMAL FENTANYL oxycodone, oxymorphone) are usually best.",CHRONIC PAIN,TRANSDERMAL FENTANYL
4046,RECOMBINANT ALPHA A INTERFERON treats HAIRY CELL LEUKEMIA,treats,0.9897433186107868,"Holmes R, Whiteside MG, Schwarz MA et al. Treatment of HAIRY CELL LEUKEMIA with increasing doses of RECOMBINANT ALPHA A INTERFERON",HAIRY CELL LEUKEMIA,RECOMBINANT ALPHA A INTERFERON
4047,RECOMBINANT ALPHA A INTERFERON treats HAIRY CELL LEUKEMIA,treats,0.9897433186107868,"Holmes R, Whiteside MG, Schwarz MA et al. Treatment of HAIRY CELL LEUKEMIA with increasing doses of RECOMBINANT ALPHA A INTERFERON",HAIRY CELL LEUKEMIA,RECOMBINANT ALPHA A INTERFERON
4048,HAIRY CELL LEUKEMIA treats RECOMBINANT ALPHA A INTERFERON,treats,0.9897433186107868,"Holmes R, Whiteside MG, Schwarz MA et al. Treatment of HAIRY CELL LEUKEMIA with increasing doses of RECOMBINANT ALPHA A INTERFERON",HAIRY CELL LEUKEMIA,RECOMBINANT ALPHA A INTERFERON
4049,RECOMBINANT ALPHA A INTERFERON treats HAIRY CELL LEUKEMIA,treats,0.9897433186107868,"Holmes R, Whiteside MG, Schwarz MA et al. Treatment of HAIRY CELL LEUKEMIA with increasing doses of RECOMBINANT ALPHA A INTERFERON",HAIRY CELL LEUKEMIA,RECOMBINANT ALPHA A INTERFERON
4050,RECOMBINANT ALPHA A INTERFERON treats HAIRY CELL LEUKEMIA,treats,0.9897433186107868,"Holmes R, Whiteside MG, Schwarz MA et al. Treatment of HAIRY CELL LEUKEMIA with increasing doses of RECOMBINANT ALPHA A INTERFERON",HAIRY CELL LEUKEMIA,RECOMBINANT ALPHA A INTERFERON
4051,RECOMBINANT ALPHA A INTERFERON treats HAIRY CELL LEUKEMIA,treats,0.9897433186107868,"Holmes R, Whiteside MG, Schwarz MA et al. Treatment of HAIRY CELL LEUKEMIA with increasing doses of RECOMBINANT ALPHA A INTERFERON",HAIRY CELL LEUKEMIA,RECOMBINANT ALPHA A INTERFERON
4052,RECOMBINANT ALPHA A INTERFERON treats HAIRY CELL LEUKEMIA,treats,0.9897433186107868,"Holmes R, Whiteside MG, Schwarz MA et al. Treatment of HAIRY CELL LEUKEMIA with increasing doses of RECOMBINANT ALPHA A INTERFERON",HAIRY CELL LEUKEMIA,RECOMBINANT ALPHA A INTERFERON
4053,[ARTEMISININ BASED] treats [STRAINS OF P FALCIPARUM],treats,0.9594032236002472,Usage declined in the 1980s as piperaquine resistant [STRAINS OF P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[STRAINS OF P FALCIPARUM],[ARTEMISININ BASED]
4054,[ARTEMISININ BASED] treats [STRAINS OF P FALCIPARUM],treats,0.9594032236002472,Usage declined in the 1980s as piperaquine resistant [STRAINS OF P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[STRAINS OF P FALCIPARUM],[ARTEMISININ BASED]
4055,[ARTEMISININ BASED] treats [STRAINS OF P FALCIPARUM],treats,0.9594032236002472,Usage declined in the 1980s as piperaquine resistant [STRAINS OF P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[STRAINS OF P FALCIPARUM],[ARTEMISININ BASED]
4056,[ARTEMISININ BASED] treats [STRAINS OF P FALCIPARUM],treats,0.9594032236002472,Usage declined in the 1980s as piperaquine resistant [STRAINS OF P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[STRAINS OF P FALCIPARUM],[ARTEMISININ BASED]
4057,[ARTEMISININ BASED] treats [STRAINS OF P FALCIPARUM],treats,0.9594032236002472,Usage declined in the 1980s as piperaquine resistant [STRAINS OF P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[STRAINS OF P FALCIPARUM],[ARTEMISININ BASED]
4058,[ARTEMISININ BASED] treats [STRAINS OF P FALCIPARUM],treats,0.9594032236002472,Usage declined in the 1980s as piperaquine resistant [STRAINS OF P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[STRAINS OF P FALCIPARUM],[ARTEMISININ BASED]
4059,[ARTEMISININ BASED] treats [STRAINS OF P FALCIPARUM],treats,0.9594032236002472,Usage declined in the 1980s as piperaquine resistant [STRAINS OF P FALCIPARUM] arose and [ARTEMISININ BASED] antimalarials became available.,[STRAINS OF P FALCIPARUM],[ARTEMISININ BASED]
4060,AGGRESSIVE CLINICAL COURSE treats PLASMA CELL LEUKAEMIA,treats,0.42426406871192895,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
4061,no_relation,treats,0.42426406871192895,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
4062,no_relation,treats,0.42426406871192895,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
4063,no_relation,treats,0.42426406871192895,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
4064,PLASMA CELL LEUKAEMIA treats AGGRESSIVE CLINICAL COURSE,treats,0.42426406871192895,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
4065,no_relation,treats,0.42426406871192895,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
4066,no_relation,treats,0.42426406871192895,"The diagnosis of PLASMA CELL LEUKAEMIA a rare disorder with an AGGRESSIVE CLINICAL COURSE and poor prognosis, is not always straightforward and may be dependent on the results of immunophenotyping.",AGGRESSIVE CLINICAL COURSE,PLASMA CELL LEUKAEMIA
4067,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION treats CUSHING'S SYNDROME,treats,0.5,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
4068,no_relation,treats,0.5,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
4069,no_relation,treats,0.5,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
4070,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION treats CUSHING'S SYNDROME,treats,0.5,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
4071,no_relation,treats,0.5,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
4072,no_relation,treats,0.5,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
4073,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION treats CUSHING'S SYNDROME,treats,0.5,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
4074,RAMIPRIL treats ANGIOEDEMA,treats,0.3665083331,The results revealed that telmisartan was as effective as [RAMIPRIL] but with lower rates of cough and [ANGIOEDEMA] which led to fewer discontinuations.,ANGIOEDEMA,RAMIPRIL
4075,RAMIPRIL treats ANGIOEDEMA,treats,0.3665083331,The results revealed that telmisartan was as effective as [RAMIPRIL] but with lower rates of cough and [ANGIOEDEMA] which led to fewer discontinuations.,ANGIOEDEMA,RAMIPRIL
4076,no_relation,treats,0.3665083331,The results revealed that telmisartan was as effective as [RAMIPRIL] but with lower rates of cough and [ANGIOEDEMA] which led to fewer discontinuations.,ANGIOEDEMA,RAMIPRIL
4077,RAMIPRIL treats ANGIOEDEMA,treats,0.3665083331,The results revealed that telmisartan was as effective as [RAMIPRIL] but with lower rates of cough and [ANGIOEDEMA] which led to fewer discontinuations.,ANGIOEDEMA,RAMIPRIL
4078,RAMIPRIL treats ANGIOEDEMA,treats,0.3665083331,The results revealed that telmisartan was as effective as [RAMIPRIL] but with lower rates of cough and [ANGIOEDEMA] which led to fewer discontinuations.,ANGIOEDEMA,RAMIPRIL
4079,no_relation,treats,0.3665083331,The results revealed that telmisartan was as effective as [RAMIPRIL] but with lower rates of cough and [ANGIOEDEMA] which led to fewer discontinuations.,ANGIOEDEMA,RAMIPRIL
4080,RAMIPRIL treats ANGIOEDEMA,treats,0.3665083331,The results revealed that telmisartan was as effective as [RAMIPRIL] but with lower rates of cough and [ANGIOEDEMA] which led to fewer discontinuations.,ANGIOEDEMA,RAMIPRIL
4081,CHLORDIAZEPOXIDE treats FIRST TRIMESTER OF PREGNANCY,treats,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
4082,CHLORDIAZEPOXIDE treats FIRST TRIMESTER OF PREGNANCY,treats,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
4083,CHLORDIAZEPOXIDE treats FIRST TRIMESTER OF PREGNANCY,treats,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
4084,CHLORDIAZEPOXIDE treats FIRST TRIMESTER OF PREGNANCY,treats,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
4085,no_relation,treats,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
4086,CHLORDIAZEPOXIDE treats FIRST TRIMESTER OF PREGNANCY,treats,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
4087,no_relation,treats,0.35921060405355,"b ,   c ,   d ,   e  Fetal/Neonatal Morbidity  Some retrospective studies suggest increased risk of congenital malformations in infants of mothers who received CHLORDIAZEPOXIDE during the FIRST TRIMESTER OF PREGNANCY",FIRST TRIMESTER OF PREGNANCY,CHLORDIAZEPOXIDE
4088,VALPROIC ACID treats BIPOLAR DISORDER,treats,1.0,"Macritchie KAN, Geddes JR, Scott J et alVALPROIC ACID valproate and divalproex in the maintenance treatment of BIPOLAR DISORDER (Cochrane Review.",BIPOLAR DISORDER,VALPROIC ACID
4089,VALPROIC ACID treats BIPOLAR DISORDER,treats,1.0,"Macritchie KAN, Geddes JR, Scott J et alVALPROIC ACID valproate and divalproex in the maintenance treatment of BIPOLAR DISORDER (Cochrane Review.",BIPOLAR DISORDER,VALPROIC ACID
4090,VALPROIC ACID treats BIPOLAR DISORDER,treats,1.0,"Macritchie KAN, Geddes JR, Scott J et alVALPROIC ACID valproate and divalproex in the maintenance treatment of BIPOLAR DISORDER (Cochrane Review.",BIPOLAR DISORDER,VALPROIC ACID
4091,VALPROIC ACID treats BIPOLAR DISORDER,treats,1.0,"Macritchie KAN, Geddes JR, Scott J et alVALPROIC ACID valproate and divalproex in the maintenance treatment of BIPOLAR DISORDER (Cochrane Review.",BIPOLAR DISORDER,VALPROIC ACID
4092,VALPROIC ACID treats BIPOLAR DISORDER,treats,1.0,"Macritchie KAN, Geddes JR, Scott J et alVALPROIC ACID valproate and divalproex in the maintenance treatment of BIPOLAR DISORDER (Cochrane Review.",BIPOLAR DISORDER,VALPROIC ACID
4093,VALPROIC ACID treats BIPOLAR DISORDER,treats,1.0,"Macritchie KAN, Geddes JR, Scott J et alVALPROIC ACID valproate and divalproex in the maintenance treatment of BIPOLAR DISORDER (Cochrane Review.",BIPOLAR DISORDER,VALPROIC ACID
4094,VALPROIC ACID treats BIPOLAR DISORDER,treats,1.0,"Macritchie KAN, Geddes JR, Scott J et alVALPROIC ACID valproate and divalproex in the maintenance treatment of BIPOLAR DISORDER (Cochrane Review.",BIPOLAR DISORDER,VALPROIC ACID
4095,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
4096,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
4097,SCHIZOPHRENIA treats CLOZAPINE,treats,0.9,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
4098,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
4099,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
4100,no_relation,treats,0.9,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
4101,CLOZAPINE treats SCHIZOPHRENIA,treats,0.9,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
4102,SLE treats PERICARDITIS,treats,0.338061701891407,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
4103,SLE treats PERICARDITIS,treats,0.338061701891407,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
4104,no_relation,treats,0.338061701891407,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
4105,no_relation,treats,0.338061701891407,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
4106,SLE treats PERICARDITIS,treats,0.338061701891407,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
4107,no_relation,treats,0.338061701891407,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
4108,no_relation,treats,0.338061701891407,"Treatment  To simplify therapy, SLE should be classified as mild (eg, fever, arthritis, pleurisy, PERICARDITIS headache, rash) or severe (eg, hemolytic anemia, thrombocytopenic purpura, massive pleural and pericardial involvement, significant renal damage, acute vasculitis of the extremities or GI tract, florid CNS involvement.",PERICARDITIS,SLE
4109,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
4110,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
4111,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
4112,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
4113,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
4114,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
4115,DOXEPIN treats DEPRESSION,treats,0.8427009716003839,"Dunner DL, Cohn JB, Walshe T et al. Two combined, multicenter double blind studies of paroxetine and DOXEPIN in geriatric patients with major DEPRESSION",DEPRESSION,DOXEPIN
4116,PROPRANOLOL treats ESSENTIAL TREMOR,treats,0.9494253265550828,"Teravainen H, Fogelholm R, Larsen A. Effect of PROPRANOLOL on ESSENTIAL TREMOR",ESSENTIAL TREMOR,PROPRANOLOL
4117,PROPRANOLOL treats ESSENTIAL TREMOR,treats,0.9494253265550828,"Teravainen H, Fogelholm R, Larsen A. Effect of PROPRANOLOL on ESSENTIAL TREMOR",ESSENTIAL TREMOR,PROPRANOLOL
4118,PROPRANOLOL treats ESSENTIAL TREMOR,treats,0.9494253265550828,"Teravainen H, Fogelholm R, Larsen A. Effect of PROPRANOLOL on ESSENTIAL TREMOR",ESSENTIAL TREMOR,PROPRANOLOL
4119,no_relation,treats,0.9494253265550828,"Teravainen H, Fogelholm R, Larsen A. Effect of PROPRANOLOL on ESSENTIAL TREMOR",ESSENTIAL TREMOR,PROPRANOLOL
4120,PROPRANOLOL treats ESSENTIAL TREMOR,treats,0.9494253265550828,"Teravainen H, Fogelholm R, Larsen A. Effect of PROPRANOLOL on ESSENTIAL TREMOR",ESSENTIAL TREMOR,PROPRANOLOL
4121,PROPRANOLOL treats ESSENTIAL TREMOR,treats,0.9494253265550828,"Teravainen H, Fogelholm R, Larsen A. Effect of PROPRANOLOL on ESSENTIAL TREMOR",ESSENTIAL TREMOR,PROPRANOLOL
4122,PROPRANOLOL treats ESSENTIAL TREMOR,treats,0.9494253265550828,"Teravainen H, Fogelholm R, Larsen A. Effect of PROPRANOLOL on ESSENTIAL TREMOR",ESSENTIAL TREMOR,PROPRANOLOL
4123,CIPROFLOXACIN treats BONE INFECTIONS,treats,1.0,"Nix DE, Cumbo TJ, Kuritzky P et al. Oral CIPROFLOXACIN in the treatment of serious soft tissue and BONE INFECTIONS: efficacy, safety, and pharmacokinetics.",BONE INFECTIONS,CIPROFLOXACIN
4124,CIPROFLOXACIN treats BONE INFECTIONS,treats,1.0,"Nix DE, Cumbo TJ, Kuritzky P et al. Oral CIPROFLOXACIN in the treatment of serious soft tissue and BONE INFECTIONS: efficacy, safety, and pharmacokinetics.",BONE INFECTIONS,CIPROFLOXACIN
4125,CIPROFLOXACIN treats BONE INFECTIONS,treats,1.0,"Nix DE, Cumbo TJ, Kuritzky P et al. Oral CIPROFLOXACIN in the treatment of serious soft tissue and BONE INFECTIONS: efficacy, safety, and pharmacokinetics.",BONE INFECTIONS,CIPROFLOXACIN
4126,CIPROFLOXACIN treats BONE INFECTIONS,treats,1.0,"Nix DE, Cumbo TJ, Kuritzky P et al. Oral CIPROFLOXACIN in the treatment of serious soft tissue and BONE INFECTIONS: efficacy, safety, and pharmacokinetics.",BONE INFECTIONS,CIPROFLOXACIN
4127,CIPROFLOXACIN treats BONE INFECTIONS,treats,1.0,"Nix DE, Cumbo TJ, Kuritzky P et al. Oral CIPROFLOXACIN in the treatment of serious soft tissue and BONE INFECTIONS: efficacy, safety, and pharmacokinetics.",BONE INFECTIONS,CIPROFLOXACIN
4128,CIPROFLOXACIN treats BONE INFECTIONS,treats,1.0,"Nix DE, Cumbo TJ, Kuritzky P et al. Oral CIPROFLOXACIN in the treatment of serious soft tissue and BONE INFECTIONS: efficacy, safety, and pharmacokinetics.",BONE INFECTIONS,CIPROFLOXACIN
4129,no_relation,treats,1.0,"Nix DE, Cumbo TJ, Kuritzky P et al. Oral CIPROFLOXACIN in the treatment of serious soft tissue and BONE INFECTIONS: efficacy, safety, and pharmacokinetics.",BONE INFECTIONS,CIPROFLOXACIN
4130,no_relation,treats,0.301511344577764,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
4131,no_relation,treats,0.301511344577764,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
4132,no_relation,treats,0.301511344577764,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
4133,no_relation,treats,0.301511344577764,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
4134,no_relation,treats,0.301511344577764,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
4135,ASCITES FLUID treats HEPATOMA,treats,0.301511344577764,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
4136,no_relation,treats,0.301511344577764,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
4137,[SKIN DIETARY PROANTHOCYANIDINS] treats [CARCINOGENESIS],treats,1.0,ultraviolet damage to [SKIN DIETARY PROANTHOCYANIDINS] may protect against [CARCINOGENESIS] and provide supplementation for sunscreen protection.,[CARCINOGENESIS],[SKIN DIETARY PROANTHOCYANIDINS]
4138,no_relation,treats,1.0,ultraviolet damage to [SKIN DIETARY PROANTHOCYANIDINS] may protect against [CARCINOGENESIS] and provide supplementation for sunscreen protection.,[CARCINOGENESIS],[SKIN DIETARY PROANTHOCYANIDINS]
4139,no_relation,treats,1.0,ultraviolet damage to [SKIN DIETARY PROANTHOCYANIDINS] may protect against [CARCINOGENESIS] and provide supplementation for sunscreen protection.,[CARCINOGENESIS],[SKIN DIETARY PROANTHOCYANIDINS]
4140,no_relation,treats,1.0,ultraviolet damage to [SKIN DIETARY PROANTHOCYANIDINS] may protect against [CARCINOGENESIS] and provide supplementation for sunscreen protection.,[CARCINOGENESIS],[SKIN DIETARY PROANTHOCYANIDINS]
4141,[SKIN DIETARY PROANTHOCYANIDINS] treats [CARCINOGENESIS],treats,1.0,ultraviolet damage to [SKIN DIETARY PROANTHOCYANIDINS] may protect against [CARCINOGENESIS] and provide supplementation for sunscreen protection.,[CARCINOGENESIS],[SKIN DIETARY PROANTHOCYANIDINS]
4142,[SKIN DIETARY PROANTHOCYANIDINS] treats [CARCINOGENESIS],treats,1.0,ultraviolet damage to [SKIN DIETARY PROANTHOCYANIDINS] may protect against [CARCINOGENESIS] and provide supplementation for sunscreen protection.,[CARCINOGENESIS],[SKIN DIETARY PROANTHOCYANIDINS]
4143,[SKIN DIETARY PROANTHOCYANIDINS] treats [CARCINOGENESIS],treats,1.0,ultraviolet damage to [SKIN DIETARY PROANTHOCYANIDINS] may protect against [CARCINOGENESIS] and provide supplementation for sunscreen protection.,[CARCINOGENESIS],[SKIN DIETARY PROANTHOCYANIDINS]
4144,METFORMIN treats TYPE 2 DIABETES MELLITUS,treats,0.9838699100999068,"TYPE 2 DIABETES MELLITUS who were treated with bedtime insulin plus metformin did not gain weight, had fewer hypoglycemic episodes, and had better glycemic control than those treated with bedtime insulin plus glyburide, METFORMIN and glyburide, or morning insulin.",TYPE 2 DIABETES MELLITUS,METFORMIN
4145,METFORMIN treats TYPE 2 DIABETES MELLITUS,treats,0.9838699100999068,"TYPE 2 DIABETES MELLITUS who were treated with bedtime insulin plus metformin did not gain weight, had fewer hypoglycemic episodes, and had better glycemic control than those treated with bedtime insulin plus glyburide, METFORMIN and glyburide, or morning insulin.",TYPE 2 DIABETES MELLITUS,METFORMIN
4146,no_relation,treats,0.9838699100999068,"TYPE 2 DIABETES MELLITUS who were treated with bedtime insulin plus metformin did not gain weight, had fewer hypoglycemic episodes, and had better glycemic control than those treated with bedtime insulin plus glyburide, METFORMIN and glyburide, or morning insulin.",TYPE 2 DIABETES MELLITUS,METFORMIN
4147,METFORMIN treats TYPE 2 DIABETES MELLITUS,treats,0.9838699100999068,"TYPE 2 DIABETES MELLITUS who were treated with bedtime insulin plus metformin did not gain weight, had fewer hypoglycemic episodes, and had better glycemic control than those treated with bedtime insulin plus glyburide, METFORMIN and glyburide, or morning insulin.",TYPE 2 DIABETES MELLITUS,METFORMIN
4148,METFORMIN treats TYPE 2 DIABETES MELLITUS,treats,0.9838699100999068,"TYPE 2 DIABETES MELLITUS who were treated with bedtime insulin plus metformin did not gain weight, had fewer hypoglycemic episodes, and had better glycemic control than those treated with bedtime insulin plus glyburide, METFORMIN and glyburide, or morning insulin.",TYPE 2 DIABETES MELLITUS,METFORMIN
4149,no_relation,treats,0.9838699100999068,"TYPE 2 DIABETES MELLITUS who were treated with bedtime insulin plus metformin did not gain weight, had fewer hypoglycemic episodes, and had better glycemic control than those treated with bedtime insulin plus glyburide, METFORMIN and glyburide, or morning insulin.",TYPE 2 DIABETES MELLITUS,METFORMIN
4150,METFORMIN treats TYPE 2 DIABETES MELLITUS,treats,0.9838699100999068,"TYPE 2 DIABETES MELLITUS who were treated with bedtime insulin plus metformin did not gain weight, had fewer hypoglycemic episodes, and had better glycemic control than those treated with bedtime insulin plus glyburide, METFORMIN and glyburide, or morning insulin.",TYPE 2 DIABETES MELLITUS,METFORMIN
4151,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.9761870601839532,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
4152,no_relation,treats,0.9761870601839532,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
4153,no_relation,treats,0.9761870601839532,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
4154,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.9761870601839532,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
4155,no_relation,treats,0.9761870601839532,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
4156,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.9761870601839532,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
4157,no_relation,treats,0.9761870601839532,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
4158,no_relation,treats,0.92998111,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
4159,FASTING BLOOD GLUCOSE treats NOCTURNAL HYPOGLYCEMIA,treats,0.92998111,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
4160,no_relation,treats,0.92998111,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
4161,no_relation,treats,0.92998111,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
4162,no_relation,treats,0.92998111,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
4163,no_relation,treats,0.92998111,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
4164,NOCTURNAL HYPOGLYCEMIA treats FASTING BLOOD GLUCOSE,treats,0.92998111,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
4165,INSULIN treats DIABETES TYPE I AND II,treats,0.9491579958,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
4166,INSULIN treats DIABETES TYPE I AND II,treats,0.9491579958,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
4167,DIABETES TYPE I AND II treats INSULIN,treats,0.9491579958,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
4168,no_relation,treats,0.9491579958,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
4169,INSULIN treats DIABETES TYPE I AND II,treats,0.9491579958,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
4170,INSULIN treats DIABETES TYPE I AND II,treats,0.9491579958,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
4171,INSULIN treats DIABETES TYPE I AND II,treats,0.9491579958,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
4172,no_relation,treats,0.6432675209000001,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
4173,ISOTRETINOIN treats ACNE,treats,0.6432675209000001,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
4174,ISOTRETINOIN treats ACNE,treats,0.6432675209000001,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
4175,no_relation,treats,0.6432675209000001,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
4176,ISOTRETINOIN treats ACNE,treats,0.6432675209000001,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
4177,no_relation,treats,0.6432675209000001,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
4178,ISOTRETINOIN treats ACNE,treats,0.6432675209000001,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
4179,no_relation,treats,0.6509445549,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
4180,no_relation,treats,0.6509445549,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
4181,CYCLOPHOSPHAMIDE treats RHABDOMYOSARCOMA,treats,0.6509445549,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
4182,no_relation,treats,0.6509445549,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
4183,no_relation,treats,0.6509445549,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
4184,no_relation,treats,0.6509445549,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
4185,no_relation,treats,0.6509445549,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
4186,INSULIN treats HYPERGLYCEMIA,treats,0.8164965809,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
4187,no_relation,treats,0.8164965809,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
4188,INSULIN treats HYPERGLYCEMIA,treats,0.8164965809,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
4189,INSULIN treats HYPERGLYCEMIA,treats,0.8164965809,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
4190,INSULIN treats HYPERGLYCEMIA,treats,0.8164965809,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
4191,no_relation,treats,0.8164965809,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
4192,no_relation,treats,0.8164965809,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
4193,METFORMIN treats NIDDM,treats,0.5494422558,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
4194,no_relation,treats,0.5494422558,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
4195,no_relation,treats,0.5494422558,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
4196,METFORMIN treats NIDDM,treats,0.5494422558,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
4197,METFORMIN treats NIDDM,treats,0.5494422558,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
4198,no_relation,treats,0.5494422558,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
4199,METFORMIN treats NIDDM,treats,0.5494422558,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
4200,INSULIN treats TYPE 2 DIABETES,treats,0.9733285268,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
4201,INSULIN treats TYPE 2 DIABETES,treats,0.9733285268,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
4202,no_relation,treats,0.9733285268,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
4203,no_relation,treats,0.9733285268,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
4204,INSULIN treats TYPE 2 DIABETES,treats,0.9733285268,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
4205,INSULIN treats TYPE 2 DIABETES,treats,0.9733285268,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
4206,INSULIN treats TYPE 2 DIABETES,treats,0.9733285268,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
4207,THALIDOMIDE treats HANSEN'S DISEASE,treats,0.9138115486,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
4208,THALIDOMIDE treats HANSEN'S DISEASE,treats,0.9138115486,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
4209,no_relation,treats,0.9138115486,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
4210,THALIDOMIDE treats HANSEN'S DISEASE,treats,0.9138115486,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
4211,THALIDOMIDE treats HANSEN'S DISEASE,treats,0.9138115486,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
4212,THALIDOMIDE treats HANSEN'S DISEASE,treats,0.9138115486,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
4213,THALIDOMIDE treats HANSEN'S DISEASE,treats,0.9138115486,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
4214,no_relation,treats,0.6681531048,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
4215,no_relation,treats,0.6681531048,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
4216,no_relation,treats,0.6681531048,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
4217,no_relation,treats,0.6681531048,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
4218,no_relation,treats,0.6681531048,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
4219,no_relation,treats,0.6681531048,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
4220,Q WAVE MYOCARDIAL INFARCTION treats STANDARD HEPARIN,treats,0.6681531048,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
4221,PREDNISONE treats INFLAMMATION,treats,0.9332565253,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
4222,PREDNISONE treats INFLAMMATION,treats,0.9332565253,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
4223,PREDNISONE treats INFLAMMATION,treats,0.9332565253,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
4224,PREDNISONE treats INFLAMMATION,treats,0.9332565253,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
4225,PREDNISONE treats INFLAMMATION,treats,0.9332565253,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
4226,PREDNISONE treats INFLAMMATION,treats,0.9332565253,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
4227,PREDNISONE treats INFLAMMATION,treats,0.9332565253,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
4228,ANAKINRA treats RHEUMATOID ARTHRITIS,treats,0.3015113446,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis  1 , 11  Concomitant use not recommended  1 , 11 , 15    Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS  1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
4229,ANAKINRA treats RHEUMATOID ARTHRITIS,treats,0.3015113446,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis  1 , 11  Concomitant use not recommended  1 , 11 , 15    Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS  1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
4230,ANAKINRA treats RHEUMATOID ARTHRITIS,treats,0.3015113446,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis  1 , 11  Concomitant use not recommended  1 , 11 , 15    Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS  1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
4231,ANAKINRA treats RHEUMATOID ARTHRITIS,treats,0.3015113446,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis  1 , 11  Concomitant use not recommended  1 , 11 , 15    Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS  1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
4232,ANAKINRA treats RHEUMATOID ARTHRITIS,treats,0.3015113446,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis  1 , 11  Concomitant use not recommended  1 , 11 , 15    Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS  1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
4233,ANAKINRA treats RHEUMATOID ARTHRITIS,treats,0.3015113446,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis  1 , 11  Concomitant use not recommended  1 , 11 , 15    Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS  1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
4234,ANAKINRA treats RHEUMATOID ARTHRITIS,treats,0.3015113446,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis  1 , 11  Concomitant use not recommended  1 , 11 , 15    Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS  1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
4235,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9138115486,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
4236,no_relation,treats,0.9138115486,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
4237,no_relation,treats,0.9138115486,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
4238,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9138115486,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
4239,no_relation,treats,0.9138115486,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
4240,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9138115486,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
4241,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9138115486,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
4242,no_relation,treats,0.35921060409999994,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
4243,no_relation,treats,0.35921060409999994,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
4244,no_relation,treats,0.35921060409999994,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
4245,no_relation,treats,0.35921060409999994,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
4246,no_relation,treats,0.35921060409999994,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
4247,no_relation,treats,0.35921060409999994,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
4248,no_relation,treats,0.35921060409999994,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
4249,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.9237604307,"BC  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
4250,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.9237604307,"BC  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
4251,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.9237604307,"BC  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
4252,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.9237604307,"BC  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
4253,no_relation,treats,0.9237604307,"BC  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
4254,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.9237604307,"BC  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
4255,TRICYCLIC ANTIDEPRESSANTS treats DEPRESSION,treats,0.9237604307,"BC  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
4256,NIDDM treats INSULIN INJECTION TREATMENT GROUP,treats,0.9712858624,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
4257,INSULIN INJECTION TREATMENT GROUP treats NIDDM,treats,0.9712858624,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
4258,INSULIN INJECTION TREATMENT GROUP treats NIDDM,treats,0.9712858624,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
4259,INSULIN INJECTION TREATMENT GROUP treats NIDDM,treats,0.9712858624,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
4260,no_relation,treats,0.9712858624,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
4261,INSULIN INJECTION TREATMENT GROUP treats NIDDM,treats,0.9712858624,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
4262,INSULIN INJECTION TREATMENT GROUP treats NIDDM,treats,0.9712858624,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
4263,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9897433186,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
4264,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9897433186,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
4265,no_relation,treats,0.9897433186,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
4266,no_relation,treats,0.9897433186,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
4267,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9897433186,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
4268,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9897433186,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
4269,WARFARIN treats ATRIAL FIBRILLATION,treats,0.9897433186,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
